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Abstract 
Dietary restriction (DR) can increase lifespan across evolutionarily distinct species, from yeast to 
rodents. The NAD
+
-dependent (class III) histone deacetylase SIRT1 in mammals, and its ortholog in 
other species, may play a major role in this response, but may affect ‘healthspan’ (number of years of 
good health), rather than lifespan per se. Ageing is accompanied by changes in genome methylation, 
which may be causal in the ageing process. Since histones are one of the many substrates that are 
deacetylated by SIRT1, we hypothesised that epigenetic effects of SIRT1 activity – and specifically 
effects on DNA methylation, which is associated closely with histone acetylation – mediate some of 
the beneficial effects of DR that contribute to increased healthspan. We also propose that dietary 
polyphenols may act at the cellular level in a similar way. 
 
To test this hypothesis, we first investigated effects of altering SIRT1 expression, by overexpression of 
a transgene or siRNA-mediated knockdown, on global DNA methylation (methylation of the LINE-1 
element) in the human intestinal cell line, Caco-2. We also measured effects on global DNA 
methylation of dietary isoflavones and resveratrol, under control conditions as well as conditions of 
SIRT1 overexpression. Measured effects on global DNA methylation revealed possible complex 
interactions between SIRT1 and these dietary polyphenols but were dependent on the assay used to 
measure methylation at the LINE-1 element (COBRA or pyrosequencing), so were not considered to 
be robust observations. 
  
We investigated factors that may affect SIRT1 expression – specifically we examined SIRT1 promoter 
activity in response to polyphenols, effects of promoter methylation and effects of age. Treatment of 
Caco-2 cells with dietary polyphenols had no effect on the SIRT1 promoter in a promoter-reporter 
construct. In contrast, methylation of the SIRT1 promoter reduced reporter gene expression in this 
model. Age did not appear to change the levels of SIRT1 protein expressed in mouse intestinal tissue 
when comparing young and older mice.  
 
An in silico analysis was carried out to investigate if overlaps between groups of genes compiled from 
published and publically-available data found to i) associate with SIRT1, ii) show altered expression 
in response to DR, and iii) show altered methylation with ageing were greater than expected by 
chance, which would support the hypothesis, and provided targets to investigate possible site-specific 
effects of SIRT1 on DNA methylation. Ten genes were found to fit into the ‘three way’ overlap, which 
was statistically greater than expected by chance. Pyrosequencing assays could be optimised for only 8 
of these 10 genes, so we focused further investigations on this sub-set. Significant effects of SIRT1 
overexpression and/or knockdown on methylation were observed on at least one CpG site in the 
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promoters of six of these genes (CDC7, EIF5, IRX3, KLF3, PTPRG, TBX3) and expression at the 
mRNA level of all of the eight genes (also PCYT1A and SLC39A4) was affected significantly. 
 
To gain a more comprehensive view of the extent to which DNA methylation at specific loci may be 
affected by SIRT1 expression levels microarray-based analysis of the methylation pattern across the 
genome in Caco-2 cells was carried out under conditions where SIRT1 was overexpressed or where 
expression was reduced by siRNA. In parallel, we measured the response to expressing SIRT1 at 
different levels at the level of the transcriptome. Overlaps that were statistically greater than expected 
by chance between these data and the lists of genes compiled from published and publically-available 
data used for the in silico analysis were found to exist between the complied list of genes reported to 
respond to dietary restriction and the set of genes we found to show altered expression in response to 
changing the level of SIRT1 expression and the set of genes we found to be differentially-methylated 
in response to reducing the level of SIRT1 expression. This observation is in broad support of our 
overarching hypothesis.  
 
The findings of this study indicate that effects of SIRT1 on methylation of specific genes may 
correspond with altered expression under conditions of dietary restriction. The data reveal a large 
number of gene targets for which causal links between these modifications roles in modulating the 
ageing process could be investigated. 
. 
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1 Introduction 
This research project addresses an overarching hypothesis concerning a proposed mechanism through 
which some of the effects of dietary restriction (DR), which increases lifespan, are mediated. The 
sirtuin Sir2 in yeast, and its homologue SIRT1 in mammals, appear pivotal in extending lifespan in 
response to DR. SIRT1 deacetylates many cellular substrates, including histone proteins. We propose 
that histone deacetylation by SIRT1 affects DNA methylation, because these two tiers of epigenetic 
modifications are linked. DNA methylation patterns alter with ageing and these changes may be causal 
in the ageing process. Thus, we propose that SIRT1-mediated histone deacetylation underlies some of 
the beneficial effects of DR on ageing/lifespan through maintenance of DNA methylation. We also 
propose that specific dietary factors may bring about similar epigenetic consequences and so mimic 
beneficial effects of DR. The following sections will introduce in detail the elements of this hypothesis 
– DR, sirtuins and epigenetic modifications (particularly in the context of ageing) – then consider 
evidence that diet, and in particular specific dietary components, can affect epigenetic modifications. 
1.1 Dietary restriction 
Dietary restriction extends lifespan in evolutionarily-distinct species including Saccharomyces 
cerevisiae, Caenorhabditis elegans, Drosophila melanogaster and mammals. DR is a reduction in 
dietary intake without compromising the nutrition of the organism. In this introductory section the 
term DR is used to cover dietary restriction (which is often used as the interchangeable or overarching 
definition of the reduction of total nutrient intake and/or specific nutrient intake) and calorie restriction 
(CR - defined as the reduction of energy intake). This section will discuss the phenotypic effects of 
DR in higher and lower eukaryotes. The proposed mechanisms by which DR affects lifespan are 
discussed in Section 1.1.3. 
1.1.1 DR in lower eukaryotes 
The single celled budding yeast S. cerevisiae provides a simple model with which to study the effects 
of DR on both chronological and replicative lifespan. DR in yeast, and the associated increase in 
chronological or replicative lifespan, is frequently achieved through either dilution of the glucose 
concentration within the yeast medium from 2 % to 0.5 %, which has produced a 75 % increase in 
lifespan (Kaeberlein et al., 2005b; Lin et al., 2000) or starvation, where yeast cells are switched from 
standard yeast medium to water, producing a reported 300 % increase in lifespan (Wei et al., 2008). 
Lifespan extension through DR in the multi-cellular worm C. elegans has been elicited through 
multiple interventions, including mutations in the Eat genes, which prevent correct pharyngeal 
pumping (Lakowski and Hekimi, 1998), manipulation of the bacterial food source through decreased 
bactopeptone (Hosono et al., 1989), bacterial dilution (Chen et al., 2009) or synthetic alternatives to 
bacteria (Houthoofd et al., 2002) in the media. Such interventions have increased lifespan by up to 85 
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%. Many decades of study into D. melanogaster, including the comprehensive mapping of conserved 
genes to higher eukaryotes and the presence of two distinct genders, make it a well-established and 
complex bilaterally symmetric metazoan model. DR in flies is most commonly achieved through a 
reduction in yeast (Kapahi et al., 2004) or a dilution of media (Giannakou et al., 2008), yielding 
reported increases of up to 66 % in lifespan. 
1.1.2 DR in higher eukaryotes 
Studies of DR in the mammalian models provided by rodents and primates allow for physiological 
comparisons with humans, which augment the genetic and nutritional comparisons provided by lower 
eukaryotes. In rodents, restriction of energy intake by 25–50 % compared with ad libitum levels has 
been observed consistently to increase lifespan by up to 50 % (Weindruch et al., 1986; Weindruch and 
Walford, 1982; Yu et al., 1982; Ross, 1961). Since the 1930s a plethora of DR studies using rodents 
have suggested that this overall increase in lifespan is due, at least in part, to the modulation of 
multiple factors that decrease the prevalence of age-associated diseases such as diabetes, osteoporosis, 
cardiovascular disease, kidney disease, respiratory diseases and cancer (Masoro, 2002). 
 
Studies in long-lived mammals, such as non-human primates, are still at a relatively early stage to 
obtain data on the effects of DR on lifespan; however, data from ongoing studies in rhesus monkeys 
(Macaca mulatta) have mirrored the metabolic and physiological changes demonstrated in rodents in 
response to DR. These observations include reduction in body mass and total body fat (Colman et al., 
1999), reduced core body temperature (Lane et al., 1996) and resting energy expenditure (Blanc et al., 
2003), as well as observations that may implicate a beneficial effect on age-related diseases such as 
cardiovascular disease and diabetes, which include reduced blood pressure, reduced plasma glucose 
and insulin concentrations, increased insulin sensitivity (Gresl et al., 2001; Lane et al., 1999), 
decreased levels of inflammatory mediators (Kim et al., 1997) and a reduction in oxidative damage in 
skeletal muscle (Zainal et al., 2000). The most recent report into the effects of long term DR in rhesus 
monkeys observes that after 2 decades monkeys subjected to 30 % DR showed a reduction in age-
associated muscle wasting, maintained control of glucose homeostasis, had a reduction in neoplasia 
and cardiovascular disease and a preservation of grey matter associated with a decrease in age-related 
brain atrophy compared with controls. Although data allowing either the maximum or average lifespan 
of the rhesus monkeys to be established has yet to been obtained in this study, current survival of those 
monkeys on DR at the time of reporting stood at 80 %, compared with 50 % survival of the controls. 
Conclusions on effects of DR on overall lifespan in primates are therefore yet to emerge (Colman et 
al., 2009). 
 
In humans, DR studies are based on cohorts of willing volunteers who are practicing self-regulated DR 
or where DR has occurred due to external events creating a nutrient rich but calorie poor diet. 
Members of CR Society International have provided researchers with a model to study the effects of 
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between 15-30 % DR (from the recommended adult calorie intake of 2500 for men and 2000 for 
women) on the physiological outcomes of reduced dietary intake in humans. A comparison of 
individuals who had been practicing dietary restriction for at least 6 years compared to age- and sex- 
matched controls on a typical Western diet showed a reduction in percentage body fat, reduced 
cholesterol, fasting insulin and glucose, a reduction in inflammatory markers (Fontana et al., 2004) 
and beneficial effects on cardiovascular function (including a reduction in blood pressure and 
myocardial fibrosis) in subjects undertaking DR (Meyer et al., 2006). The Comprehensive Assessment 
of Long-term Effects of Reducing Intake of Energy (CALERIE) study investigated the effects of DR 
alone (25 %) or in combination with exercise (12.5 % DR and 12.5 % increased exercise) over 6 
months. Both interventions caused a reduction in blood pressure and cholesterol associated with 
reduced cardiovascular disease (Lefevre et al., 2009). A study with similar levels of DR over 3 months 
also showed positive effects on memory function in individuals over 50 years of age (Witte et al., 
2009). 
 
The Okinawa Centenarian Study is one of the most cited centenarian studies, due to the large number 
of individuals reaching ages exceeding 100 years relative to the overall population (Willcox et al., 
2008a). The Okinawan population stands out from other centenarian studies as, although this 
generation is known to have been subjected to poverty-induced food shortages, the composition of the 
local Japanese diet uniquely mimics the qualities of DR. This low calorie diet has been implicated in 
the delay or absence of age-related diseases such as cardiovascular disease, stroke and cancer in those 
over 100 in the Okinawa population (Willcox et al., 2008b). Other centenarian studies, including 
longitudinal studies, have been running globally for many years comparing various measures with 
contrasting groups including survival of groups with natural diets aligned to some elements of DR or 
other lifestyle factors or exposures. Of particular note with regard to the potential role of diet on 
lifespan is the correlation of the Mediterranean diet and moderate exercise with the large Italian 
centenarian population (Tafaro et al., 2009). 
 
In 1991, an experiment to explore the interactions between humans and the environment in an 
enclosed space, known as Biosphere 2, was established. The poor yield of crop and high demand of 
physical labour demanded of the crew led to a state of 20 % dietary restriction and 15-20 % weight 
loss and resulted over two years in reduced blood pressure, fasting glucose, cholesterol and insulin 
levels, thus mimicking effects observed in DR rodents or rhesus monkeys (Walford et al., 2002). 
1.1.3 Mechanisms through which DR may extend healthy lifespan 
Several biological pathways have been proposed through which DR may extend healthy lifespan. 
Many of these mechanisms involve processes involved in nutrient-sensing and positive data have been 
reported in many instances suggesting that multiple pathways play a role in the response to DR. Key 
observations made in this regard are noted below. 
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The insulin signalling pathway is crucial in regulating glucose metabolism. Mutations in the 
insulin/insulin-like growth factor signalling (IIS) pathway have been shown to extend lifespan in 
model organisms. Mutations in the insulin-like receptor Daf2 (Kenyon et al., 1993) and Age-1, the 
downstream target of Daf2 (Johnson, 1990), have extended life in worms. Similarly in flies the 
deletion of the insulin receptor substrate chico (Clancy et al., 2001) or the insulin receptor (InR) itself 
(Tatar et al., 2001) have increased lifespan by up to 48 % and 85 % respectively. However, flies 
lacking expression of the downstream IIS pathway target Foxo (forkhead box type o), which have 
reduced lifespan, still showed an increase in lifespan when subjected to DR (Giannakou et al., 2008), 
suggesting that other pathways – additional to the IIS pathway – are also required for the effects of DR 
on lifespan. In mice, heterozygous knockout (Holzenberger et al., 2003) and adipose-specific 
homozygous knockout (Blüher et al., 2003) of the insulin-like growth receptor IGF-1 increased the 
lifespan of mice compared with controls, as did knockout of the insulin receptor substrate (Taguchi et 
al., 2007). In humans, variations in the FOXO genes have been implicated in several age-related 
diseases and lifespan. For example, the FOXO1 haplotype 3 ‘TCA’ was associated with increased 
levels of glycosylated haemoglobin (HbA1c), a marker of diabetes risk, and myocardial infarction. 
This haplotype predisposed carriers to an increase in mortality. Similarly, the FOXO3 haplotype 2 
‘GAGC’ was associated with an increased risk of stroke and therefore also an increase in mortality 
(Kuningas et al., 2007). 
 
Restriction of amino acids and mutations in the amino acid-sensing target of rapamycin (TOR) 
signalling pathway have both shown a conserved increase in lifespan in yeast (Powers et al., 2006). 
Deletion of nutrient-responsive kinases Tor and Sch9, which regulate the stress response 
serine/threonine kinase Rim15, led to an increase in yeast replicative lifespan (Kaeberlein et al., 
2005b). An increase in chronological lifespan was also observed in response to inhibition of Tor and 
Sch9. Rim15 was additionally found to be activated in another nutrient-sensing pathway – 
Ras/cAMP/PKA – through deletion combinations with the Ras gene (Wei et al., 2008). Deletion of all 
three stress resistance transcription factors downstream of Rim15 regulation – Gis-1 in the TOR 
pathway and Msn2/4 in the Ras pathway – reversed the lifespan-extension effects of DR, suggesting 
that these factors are intermediates in the response of Rim15 to DR (Wei et al., 2008). In worms, a 
deletion of the Tor kinase (Vellai et al., 2003) and downstream target Hif-1 (Chen et al., 2009) and in 
flies, a reduction in the amounts of amino acids through casein restriction (Min and Tatar, 2006), 
overexpression of TOR inhibitors Tsc1 and Tsc2 and deletion of components of the TOR pathway 
TOR and S6K (the fly and mammalian homologue of Sch9) (Kapahi et al., 2004) have been shown to 
extend lifespan. A diet deficient in the amino acid methionine (Miller et al., 2005) has also been 
reported to extend lifespan in mice. AKT activation by phosphoinositide 3 kinase (PI3K – the fly and 
mammalian homologue of Age-1) in the IIS pathway to inhibit TSC1 and TSC2 in the TOR pathway 
(Inoki et al., 2002) and negative feedback of the TOR downstream target S6K in the TOR pathway by 
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phosphorylation of insulin receptor substrate 1 (IRS-1) in the IIS pathway (Shah and Hunter, 2006) 
connects these two pathways. 
 
Yeast models have indicated that the silent information regulator protein, Sir2, has an important role in 
lifespan extension in DR. The exact mechanism through which Sir2 has a role in increasing lifespan 
(chronological or replicative) is unclear; however, upon addition or deletion of a copy of the SIR2 
gene in yeast, lifespan was extended or shortened, respectively (Kaeberlein, 1999). Addition or 
deletion of the Sir2 homologue in worms increased or decreased lifespan respectively and functions 
upstream of Daf-16, the fly homologue of the FOXO transcription factor (Wang and Tissenbaum, 
2006; Tissenbaum and Guarente, 2001), and deletion of Sir2 in flies prevented increased lifespan with 
DR (Rogina and Helfand, 2004). These observations have led to the investigation of the role of SIRT1, 
the mammalian homologue of Sir2, in the longevity response to DR in mammals. There is some 
evidence, though inconsistent, that DR increases SIRT1 expression in several rodent tissues (Barger et 
al., 2008; Kanfi et al., 2008; Nisoli et al., 2005; Brunet et al., 2004), suggesting that SIRT1 is 
regulated by dietary intake. In SIRT1 transgenic mouse models, overexpression of SIRT1 in several 
tissues led to reduced body weight, reduced fasting levels of insulin, glucose and cholesterol and 
improved glucose homeostasis, mimicking effects seen in DR mice (Bordone et al., 2007), and SIRT1 
knockout mice subject to DR showed a reduction in physical activity compared with wild type DR 
mice, suggesting the increase in physical activity observed in DR mice requires the SIRT1 gene (Chen 
et al., 2005a). In addition, DR has also been observed to increase SIRT1 mRNA levels in the skeletal 
muscle of human subjects (Civitarese et al., 2007). In human and mouse cell lines, SIRT1 was found 
to associate with TSC2, an upstream inhibitor of the TOR pathway, to negatively regulate TOR 
signalling (Ghosh et al., 2010) and in human cell lines SIRT1 was found to interact with, and 
represses, the FOXO transcription factors, reducing the rate of apoptosis but increasing resistance to 
stress (Brunet et al., 2004; Motta et al., 2004). These findings interconnect the response of SIRT1 to 
DR with the above mentioned TOR and IIS pathways.  
 
With the introduction of microarray technology, allowing the assay of thousands of genes and their 
expression in a single experiment, it has been possible to examine gene expression changes induced by 
DR in multiple tissues, predominately in mice. Vast amounts of data have now been generated, listing 
genes whose expression changes upon DR; these datasets confirm studies relying on physiological and 
metabolic observations, highlighting up-regulation of groups of genes involved in fatty acid 
metabolism, cellular transport and gluconeogenesis and down-regulation of gene groups involved in 
lipid biosynthesis, cell proliferation and protein building and development (Selman et al., 2006), 
emphasising the switch in gene expression from energy expenditure to energy conservation that is 
associated with DR.  
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Figure 1.1. Conserved pathways associated with longevity in different species. The conserved TOR signalling 
pathway (green), IIS pathway (orange), and actions of the silent information regulator (blue), all of which have 
been shown to increase healthy lifespan upon manipulation, are shown in yeast, worms, flies and mammals 
where applicable. SIRT1/Sir2 is represented in an upregulated state in response to DR. The Ras/cAMP/PKA 
pathway (yellow) another nutrient-sensing pathway which interacts with downstream components of the TOR 
signalling pathway in yeast, is also shown. Inhibition of TOR signalling during conditions of DR leads to the 
inhibition or activation of transcription factors required for mediation of the increase in healthy lifespan. 
Inhibition of the IIS pathway during conditions of DR prevents the inhibition of the Daf-16/FOXO transcription 
factor to mediate effects on longevity. Sir2/SIRT1 is activated under conditions of DR; only those interactions 
relevant to the TOR or IIS pathways are shown. Many other downstream targets of SIRT1 are likely to play a 
role in the longevity response to DR. The proteins that reside on the same plane in the same colour (green, 
orange or blue) in the species-specific pathways are homologues of one another. Those proteins in purple are 
transcription factor targets of the upstream nutrient-sensing pathways. Downstream inhibition or activation of a 
component is represented by an arrow or flat line respectively. For simplicity, and excluding SIRT1/Sir2, 
mammalian nomenclature has been used. Adapted from (Fontana et al., 2010).  
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1.1.4 DR involving restriction of selected nutrients 
Effects on lifespan of forms of DR involving limiting availability/intake of only selected nutrients 
have also been investigated. 
 
In flies, lowering levels of dietary casein, the primary source of amino acids, caused an extension in 
lifespan and reduction in fecundity similar to that observed in DR (Min and Tatar, 2006). Addition of 
the amino acid methionine back into the diet was sufficient to reverse the effects on fecundity without 
reducing lifespan (Grandison et al., 2009). A lifelong low level of methionine in rats without any 
change in body weight-corrected energy intake caused a 30 % increase in lifespan (Orentreich et al., 
1993). A further study went on to test whether the effects of methionine restriction were conserved 
amongst rodents by administering a low methionine-deficient diet to mice. Reduction in the levels of 
dietary methionine again caused an increase in lifespan as well as reducing glucose and insulin levels 
and increasing stress resistance, traits also associated with DR and healthy ageing (Miller et al., 2005). 
In the particular context of our hypothesis, it may be reasonable to speculate that some of the effects of 
a methionine-deficient diet are through the reduced levels available for synthesis of S-
adenosylmethionine, the methyl donor substrate required in methylation of DNA, the maintenance of 
which is required for correct gene expression. 
 
The effect on lifespan of the ratio of carbohydrate to protein in the diet, in the form of yeast and 
sucrose respectively, has also been explored in flies. A higher ratio of carbohydrates to protein 
increased lifespan (Lee et al., 2008), suggesting that, in some instances, the balance of macronutrients 
rather than overall energy content, can bring about lifespan extension in response to DR in flies (Mair 
et al., 2005). Lifespan extension in response to DR in flies was abrogated when water was available ad 
libitum, further suggesting that regulation of the response to DR in flies is different from that of 
mammals; studies in the latter have typically allowed ad libitum access to water (Ja et al., 2009). 
Protein restriction alone extended lifespan in rats (Yu et al., 1985) and also reduced oxidative damage 
(Youngman et al., 1992). 
1.1.5 Periodic DR 
Long term dietary restriction studies have been complemented by studies using severe, but 
intermittent, fasting (IF), for example where food is available ad libitum every other day. Extensive 
study of IF in mice has led to recorded effects that parallel those of DR, such as an increase in glucose 
metabolism, cerebrovascular (Anson et al., 2003) and cardiovascular (Ahmet et al., 2005) protection 
and an increase in resistance to cancer (Descamps et al., 2005), despite overall energy intake being 
matched with non-IF controls. To our knowledge, rigorous studies in humans have not been carried 
out to investigate effects of intermittent fasting. Another aspect of food intake periodicity that may 
have effects on lifespan is the time during the daily cycle at which meals are taken. Time of day when 
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food is available has been shown to affect the expression of circadian genes involved in the 
mammalian circadian clock, which responds to levels of light to regulate metabolic pathways (Froy et 
al., 2009). The dysregulation of circadian genes has been associated with premature ageing and 
reduced lifespan (Penev et al., 1998).  
 
Studies on specific nutrient deficiencies suggest that although the overall response to DR – possibly 
even the multiple mechanisms by which it increases lifespan – are similar, the conditions under which 
divergent species trigger these downstream responses differ. 
1.2 Sirtuins, focusing on SIRT1 
Histone deacetylases (HDAC) are a family of enzymes that catalyse the deacetylation of histone 
substrates through removal of the acetyl group from the ε-N-acetyl lysine histone tail. The HDAC 
family consists of three classes. Class III HDACs include the sirtuin subfamily, which are, unlike 
classes I and II, nicotinamide adenine dinucleotide
 
(NAD
+
)- dependent lysine deacetylases. The first 
identification of a sirtuin gene, the S. cerevisiae gene silent information regulator 2 (Sir2) (Klar, 
1979), was followed by the discovery of a host of homologues from many other organisms, including 
mammals.  
 
The catalytic core domain is conserved through all five classes of sirtuins, which have been identified 
through phylogenetic analysis (summarised in Figure 1.2). Class I is composed of three subclasses, all 
of which contain only eukaryotic sirtuins. The mammalian sirtuin SIRT1 and the yeast homologue 
Sir2 are in Class Ia. Class Ib contains the mammalian SIRT2 and SIRT3 and Class Ic groups 
eukaryotic sirtuins from yeast and fungi. Class II bands bacterial sirtuins as well as eukaryotic sirtuins 
including mammalian SIRT4. Class III includes archaeal, eubacteria and eukaryotic sirtuins, including 
mammalian Sirt5. Class IV, similar to Class I, only bands eukaryotic sirtuins, including mammalian 
SIRT6 and SIRT7, which reside in subclasses a and b respectively. Finally all unclassified sirtuins are 
banded along with gram positive eubacteria Sir2 homologues in Class U (Frye, 2000).
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Figure 1.2. Sirtuin classification. Five families of sirtuins I-IV and U. Human sirtuins are specified individually 
in the relevant class in bold upper case lettering. Sirtuins from other organisms are not specified, but the 
families in which they occur are indicated. Adapted from (Michan and Sinclair, 2007). 
 
The mammalian homologues SIRT1-7, which are represented throughout the five sirtuin subclasses, 
all share a conserved 275 amino acid catalytic core domain that acts as a NAD
+
-dependent lysine 
deacetylase and cleaves the glycosidic bond of NAD
+
 that lies between the nicotinamide and ADP-
ribose groups. This core domain is flanked at the N- and/or C-termini by sequences unique to the 
individual sirtuin (Grubisha, 2005; Frye, 1999). NAD
+ 
is involved in many essential roles in cellular 
metabolism, and the reliance of the sirtuin family on NAD
+
 indicates that they too may be involved in 
metabolic processes, as suggested by the proposed role of SIRT1 in DR. There is currently no crystal 
structure of SIRT1 available, but a 3D comparative model of amino acids 244-498 based on the 
backbone of human sirtuin SIRT2 has revealed information about ligand interactions in the active site. 
The use of a number of indoles to observe docking at the SIRT1 active site elucidated a complex H-
bond network and its importance in SIRT1 substrate binding. Additionally, a binding model for a 
SIRT1 inhibitor - 1000-fold more potent than nicotinamide - has been proposed (Huhtiniemi et al., 
2006). 
 
SIRT1 has remained the main focus of studies after homologues exhibited lifespan extension 
properties in many species; however other members of the sirtuin family have been shown to be 
involved in processes that can be linked with healthy ageing. 
 
SIRT2 is localised to the microtubules in the cytoplasm, where it deacetylates α-tubulin (North et al., 
2003) and through this action plays a role inhibition of oligodendroglial differentiation, perhaps 
preventing overdifferentiation in the central nervous system (Li et al., 2007). SIRT2 has been shown to 
shuttle to the nucleus to deacetylate H4K16 (Vaquero et al., 2006). Levels of SIRT2 are increased 
during mitosis controlling exit from the cell cycle (Dryden et al., 2003). Adipocyte differentiation is 
regulated by SIRT2-dependent deacetylation of FOXO1, preventing export of the peroxisome 
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proliferator-activated receptor gamma (PPARγ) repressor from the nucleus and therefore regulating 
glucose metabolism and storage of fatty acids (Jing et al., 2007). 
 
The mitochondrial sirtuins SIRT3 (Schwer et al., 2006), SIRT4 (Haigis et al., 2006) and SIRT5 
(Nakagawa et al., 2009) contain a specific N-terminal sequence that targets the sirtuins for 
translocation into the mitochondria matrix. SIRT3 increases acetyl-coenzyme A (acetyl-CoA) 
synthesis, a substrate in the energy-producing citric acid cycle in the mitochondria, by deacetylation 
and subsequent activation of lysine 642 of acetyl-CoA synthetase 2 (AceCS2) (Schwer et al., 2006). 
The expression of AceCS2 is also induced with fasting; deacetylation by SIRT3 activates oxidation of 
long chain fatty acids into acetyl-CoA and fasting of SIRT3 knockout mice resulted in an 
accumulation of intermediate products in the liver (Hirschey et al., 2010). SIRT4 is an ADP-
ribosyltransferase that uses NAD
+
 in ADP-ribosylation and inhibits the mitochondrial glutamate 
dehydrogenase (GDH), which in turn prevents insulin secretion in pancreatic β cells (Haigis et al., 
2006). siRNA mediated knockdown of SIRT4 in mouse hepatocytes caused an increase in fatty acid 
oxidation regulated through a increase in SIRT1 levels (Nasrin et al., 2010).  
 
The urea cycle prevents failure of the liver through metabolism of toxic ammonia build up, which can 
occur during fasting. Carbamoyl phosphate synthetase 1 (CPS-1) is required to catalyse the first and 
rate limiting step of the urea cycle. SIRT5 activates CPS-1 through deacetylation. Knockout of SIRT5 
in mice caused a decrease in CPS-1 activity (Nakagawa et al., 2009) and SIRT5 overexpression 
increased CPS-1 activity, measured by blood ammonia levels. SIRT5 mRNA was upregulated during 
fasting in the heart and liver of the transgenic mice (Ogura et al., 2010). 
 
SIRT6 knockout mice die at 4 weeks from symptoms that mimic many aspects of premature ageing, 
including increased blood glucose (Xiao et al., 2010), lowered immune system activity, and loss of 
subcutaneous fat (Mostoslavsky et al., 2006). Further investigation revealed that the premature cellular 
senescence and genomic instability seen in SIRT6 deficiency is the result of telomere dysfunction due 
to the lack of H3K9 deacetylation of telomeric chromatin (Michishita et al., 2008). Deletion of SIRT6 
in mouse liver increased fatty liver formation caused by upregulation of triglyceride synthesis and 
glycolysis, adding weight to the view that SIRT6 plays a critical role in metabolism. This study also 
showed that SIRT1 positively regulated SIRT6, both of which are upregulated during nutrient 
deprivation, through interaction with the transcription factors FOXO3a and NRF-1 at the SIRT6 
promoter (Kim et al., 2010). 
 
SIRT7 has been shown to localise to the nucleolus and interact with RNA polymerase I through 
immunofluorescence assays and co-immunoprecipitation respectively. SIRT7 positively regulates 
RNA polymerase I-mediated transcription of ribosomal DNA, which encodes the ribosomal subunits 
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required for protein translation (Ford et al., 2006). It is not clear if SIRT7 has a role in lifespan and/or 
ageing. SIRT7 knockout mice displayed a premature ageing phenotype characterised by reduced 
lifespan indicative of a role for SIRT7 in preserving a normal ageing trajectory. In apparent 
discordance with such a role, however, overexpression of SIRT7 in mouse embryonic fibroblasts 
inhibited cell growth and proliferation (Vakhrusheva et al., 2008). 
1.2.1 Substrates for SIRT1 deacetylation 
A large number of cellular substrates undergo SIRT1-mediated deacetylation (Figure 1.3) and have a 
potential role in ageing, identifying multiple pathways through which DR may affect longevity via 
SIRT1 activation. Notable examples of SIRT1 substrates include: p53, which may mediate cell 
survival through reducing cellular senescence (Langley et al., 2002); PPAR-γ coactivator 1 alpha 
(PGC-1α), an important regulator of mitochondrial biogenesis (Wu et al., 1999) that may contribute to 
healthy ageing through the maintenance of the mitochondria and thereby energy production and 
related oxidative stress (Lopez-Lluch et al., 2008); the FOXO transcription factors (Brunet et al., 2004; 
Motta et al., 2004), which regulate a variety of genes involved in glucose metabolism, apoptosis, cell 
cycle arrest, reactive oxygen species (ROS) detoxification and DNA repair; Ku70, which is required in 
double strand break repair and telomere maintenance and complexes with the proapoptotic factor 
Bcl2-assocated X (Bax) to prevent localisation of Bax to the mitochondria to induce programmed cell 
death (Cohen et al., 2004); the histone subunits H1, H3 and H4, which have been implicated in 
initiation of heterochromatin formation (Vaquero et al., 2004). In addition, SIRT1 regulates insulin 
secretion through a deacetylation-independent mechanism that may also have effects on lifespan. 
SIRT1 brings about its effect on insulin secretion by binding to and repressing the promoter of the 
mitochondrial uncoupling protein 2 gene (UCP2) to enhance glucose-stimulated insulin release 
(Bordone et al., 2006). 
 
 
 
Figure 1.3. Deacetylation by sirtuins enzymatic action. Deacetylation occurs through cleavage of the glycosidic 
bond between the nicotinamide and ADP-ribose groups of NAD
+
 to produce 2’-O-Acetyl-ADP ribose, 
nicotinamide and the deacetylated product. 
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1.2.2 Regulation of SIRT1 
As a deacetylase of multiple proteins SIRT1 has a crucial role in endogenous and stress response 
regulation within the cell. Since increases in expression of SIRT1 (or its homologues in lower 
eukaryotes) are linked with increased lifespan/healthspan it is of relevance to consider age-dependent 
or ageing-related effects on its expression. In mammals, levels of SIRT1 mRNA expression in the 
hypothalamus are higher in young compared to old mice (Lafontaine-Lacasse et al., 2010). 
Additionally, levels of SIRT1 mRNA and protein expression were shown to decrease as cells 
progressed into a senescent state, and in lung, heart and fat tissues of old compared with young mice. 
Increased SIRT1 deacetylase activity was associated with resistance to senescence. The very many 
cellular processes in which SIRT1 plays a regulatory role invokes a need for tight regulation of SIRT1 
expression and activity. This need is perhaps reflected by the many identified mechanism through 
which SIRT1 is regulated, allowing levels of expression and activity to be sensitive to many different 
perturbations in cellular status. 
1.2.2.1 Transcriptional regulation of the SIRT1 gene 
Several transcription factors have been shown to modulate transcription of SIRT1 under conditions of 
oxidative stress and interactions with the translated SIRT1 protein suggest feedback loops in which 
normal homeostasis of SIRT1 expression and therefore cellular responses to stress are controlled, 
primarily through p53-regulated growth arrest and apoptosis. The transcriptional suppressor 
Hypermethylated in cancer 1 (HIC-1), together with p53, suppresses age-related cancer formation. 
HIC1 forms a complex with SIRT1, which then binds to the promoter of, and suppresses the 
transcription of, SIRT1 under conditions of oxidative stress. The suppression of SIRT1 prevents 
deacetylation and subsequent deactivation of p53-dependent apoptotic responses, inhibiting SIRT1-
mediated stress resistance (Chen et al., 2005b). The nuclear transcription factor EVI-1 is required for 
embryogenesis and has been identified as aberrantly expressed in some leukaemias due to a 
chromosomal rearrangement; SIRT1 levels have also been shown to be increased in chronic myeloid 
leukaemia cases positive for EVI-1. Binding of EVI-1 to the promoter region of SIRT1 causes 
transcriptional upregulation of the gene. Deacetylation of EVI-1 by SIRT1 protein then allows 
ubiquitin-mediated proteosomal degradation in a negative feedback loop. The mechanism behind the 
imbalance of SIRT1 in EVI-1 positive diseases is unclear (Pradhan et al., 2011). E2F-1 activates the 
transcription of genes within the apoptosis pathway and control of the cell cycle. In a mechanism 
independent of p53, E2F-1 targets the SIRT1 promoter under conditions of oxidative stress and 
upregulates SIRT1 gene expression, again invoking a negative feedback loop in which SIRT1 inhibits 
the action of E2F-1 regulating stress resistance (Wang et al., 2006).  
 
Nutrient availability is also a strong regulator of SIRT1 transcription. The increased SIRT1 mRNA 
levels due to nutrient deprivation were abrogated when FOXO3a was knocked down in a human cell 
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line model (Nemoto et al., 2004). Similar increases in SIRT1 mRNA have also been observed with the 
interaction of FOXO1 at the SIRT1 promoter (Xiong et al., 2010). As well as the aforementioned 
response of HIC-1 to oxidative stress, SIRT1 transcription is induced under conditions of nutrient 
deprivation where levels of the HIC-1 co-repressor C-terminal binding protein (CtBP) are diminished 
(Zhang et al., 2007). Under conditions of nutrient deprivation, the cyclic adenosine monophosphate 
(cAMP) response element binding protein (CREB), responsible for glucose production, is activated 
and has been shown to upregulate SIRT1 expression via binding to the promoter region. This action is 
reversed through suppression at the SIRT1 promoter by the carbohydrate response element binding 
protein (ChREBP) responsible for promoting energy storage with increased nutrient availability 
(Noriega et al., 2011). After initiation of adipogenesis the CCAAT/enhancer binding protein (C/EBPα) 
increases the levels of SIRT1 expression to inhibit further differentiation in homeostatic control of the 
adipose tissue (Jin et al., 2010).  
 
Peroxisome proliferator-activated receptor gamma (PPARγ), which induces cellular senescence via 
cell cycle arrest, negatively regulates SIRT1 under normal physiological conditions, allowing PPARγ 
to promote ageing (Han et al., 2010). 
1.2.2.2 Posttranscriptional regulation of SIRT1 mRNA 
HuR, an RNA binding protein that associates with the 3’ UTR of the SIRT1 mRNA in a stabilising 
manner, increases protein expression. Chk2, a cell cycle check point kinase phosphorylates HuR under 
conditions of oxidative stress, resulting in the degradation of the SIRT1 mRNA (Abdelmohsen et al., 
2007). 
 
RNA interference (RNAi) involves the loss of gene function by the processing of double stranded 
RNA dioligonulceotides by an enzyme known as dicer into smaller ~21 nucleotide length microRNAs 
(miRNAs). The miRNA antisense strand is then loaded into the RNA-induced silencing complex 
(RISC) allowing recognition and cleavage of the target mRNA sequence by the complex. The cleaved 
mRNA sequencing is then targeted for degradation and ultimately leads to the prevention of protein 
expression. An miRNA can have more than one target mRNA sequence and similarly an mRNA 
sequence can be targeted by more than one miRNA. A cursory literature search indicates the extent to 
which miRNAs (denoted with miR accessions) have been observed to influence SIRT1 regulation to 
date. MiRNAs account for, but are by no means limited to: SIRT1 downregulation in endothelial cells 
leading to cellular senescence (miR-217; (Menghini et al., 2009) and in endothelial progenitor cells 
leading to inhibition of angiogenesis (miR-34a; (Zhao et al., 2010); SIRT1 downregulation and 
associated apoptosis protection in cardiomyocytes (miR-195; (Zhu et al., 2011) and downregulation of 
the high embryonic mouse stem cell SIRT1 levels after differentiation (miR-9; miR-135a; miR-199b; 
miR-204; miR-181a and b; (Saunders et al., 2010). Conversely, epigenetic silencing of miRNAs has 
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been associated with upregulation of SIRT1 in the transformation of mammary epithelial cells in 
breast cancer (miR-200a; (Eades et al., 2011),  
. 
The presence of UAGG motifs characteristic of exon skipping within exon 8 of the SIRT1 mRNA led 
to identification of a splice variant of the full length SIRT1. Under irradiation stress the levels of the 
SIRT1-ΔExon8 mRNA were increased compared with the full length SIRT1 mRNA. The SIRT1-
ΔExon8 protein exhibited altered deacetylase activity due to partial deletion of the catalytic domain by 
splicing. These observations suggest alternative splicing as another possible mechanism by which the 
functional potential of SIRT1 can be increased (Lynch et al., 2010).  
1.2.2.3 Posttranslational regulation of the SIRT1 protein 
Posttranslational modifications of the SIRT1 protein include sumoylation and phosphorylation. 
Sumoylation of the SIRT1 protein at K734 within the Ψ-K-X-D/E consensus sequence by small 
ubiquitin-related modifiers (SUMOs) activates SIRT1 under normal physiological conditions, 
increasing stress resistance through deacetylation and thus inhibition of proapoptotic substrates. The 
desumoylase SENP1 inactivates SIRT1 during acute DNA damage allowing entry of the cell into the 
apoptotic pathway (Yang et al., 2007). Multiple phosphorylation sites have been identified at threonine 
and serine residues within the SIRT1 protein sequence that could potentially activate the deacetylase 
activity (Sasaki et al., 2008). Phosphorylation of the SIRT1 protein by CK2 has been reported at S154, 
S649, S651 and S683 (Kang et al., 2009; Zschoernig and Mahlknecht, 2009). Phosphorylation by CK2 
resulted in SIRT1 activation and increased substrate binding in response to DNA damage induced by 
genotoxic stress, for example inhibiting p53-mediated apoptosis (Kang et al., 2009). The dual-
specificity tyrosine phosphorylation-regulated kinases DYRK1A and DYRK3 regulate body growth 
and normal brain development and cell proliferation and apoptosis respectively. Both tyrosine kinases 
have been shown to phosphorylate SIRT1 at T522 under conditions of genotoxic stress (Guo et al., 
2010). Finally, JNK1 and JNK2, members of the c-Jun N-terminal kinase (JNK) family, which induce 
signalling cascades in response to cellular stress, also phosphorylate SIRT1. JNK1 phosphorylates 
SIRT1 at S47 and T530 promoting resistance to cellular stress (Nasrin et al., 2009). JNK2 
phosphorylates SIRT1 at S27 and stabilises the protein (Gao et al., 2011; Ford et al., 2008). 
Interestingly, after many interactions with JNK1, phosphorylation leads to ubiquitination and 
degradation of the SIRT1 protein, in line with observations that JNK1 activation is upregulated in 
obesity while SIRT1 is inhibited (Gao et al., 2011). 
 
Subcellular localisation is another mechanism through which SIRT1 is regulated, providing a means of 
control over whether substrates for deacetylation encounter the enzyme. Initially thought to only exist 
in the nucleus (Michishita et al., 2005), SIRT1 was identified in the first instance as an enzyme able to 
deacetylate histones. As other substrates for deacetylation by SIRT1 began to emerge, so did the 
evidence for cytosolic localisation, where SIRT1 has been found to stimulate apoptosis (Jin et al., 
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2007). The location of SIRT1 was also found to be dependent on the tissue and cell type, and possibly 
regulated through the PI3K pathway (Tanno et al., 2007). Active PI3K sequesters SIRT1 in the 
cytoplasm, possibly allowing deacetylation and therefore deactivation of the PI3K inhibitor and SIRT1 
target PTEN (Byles et al., 2010), which has been linked with the aberrant cell growth observed when 
PI3K is constitutively active. 
 
The search for proteins that regulate SIRT1 deacetylase activity through complex formation led to the 
discovery of active regulator of SIRT1 (AROS) and deleted in breast cancer-1 (DBC-1), which 
activate and reduce SIRT1 deacetylase activity respectively. The AROS protein interacts directly with 
amino acids 114 – 217 in the SIRT1 protein to enhance deacetylation activity as measured by SIRT1-
dependent p53 suppression (Kim et al., 2007). It remains to be seen whether AROS is also implicated 
in the deacetylation of other SIRT1 substrates. DBC-1 binds at amino acids 243-268, a region in the 
catalytic core of the SIRT1 protein, to confer reduced deacetylase activity, observed as an increase in 
p53 activity and cell death (Kim et al., 2008; Zhao et al., 2008). 
 
The dependence of SIRT1 on the availability of the NAD
+
 cofactor means that changes in the cellular 
concentration of NAD
+
 can have profound effects on downstream SIRT1-mediated responses. The 
high-affinity Na
+
-dependent dicarboxylate cotransporter (NaDC3) is required for the transport of 
Krebs’ cycle intermediates so affects the NAD+/NADH ratio within the cell. Overexpression of 
NaDC3, increasing Krebs’ cycle intermediates and decreasing NAD+, caused downregulation of 
(NAD
+
-dependent) SIRT1 activity and associated cellular senescence in embryonic lung fibroblasts 
(Liu et al., 2010). Similarly, in transgenic mice with increased nicotinamide mononucleotide 
adenylyltransferase 1 (NMNAT-1) activity and therefore increased NAD
+
 biosynthesis a SIRT1-
mediated increase in axonal protection was observed (Araki et al., 2004). 
1.2.2.4 Regulation of SIRT1 by lifestyle factors 
Intensive exercise was found to increase the levels of SIRT1 protein within rat (Suwa et al., 2008) and 
human (Guerra et al., 2010) skeletal muscle though the mechanism by which this is mediated remains 
unclear. Notable with respect to regulation of SIRT1 by dietary factors is the controversial evidence 
that the plant polyphenol resveratrol is a SIRT1 activator. This topic is discussed in detail in Section 
1.4. Vitamin B3, of which the NAD
+
 precursors nicotinamide and nicotinic acid are both forms, has 
also been proposed as a potential regulator of SIRT1 activity, but has yet to be investigated 
thoroughly. 
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Figure 1.4. Regulation of SIRT1, from gene to protein. At the level of transcription, up- or downregulation of 
the SIRT1 gene is represented by an arrow or a closed square respectively. The stage in transcription under 
cellular stress at which the SIRT1 protein, through a negative feedback loop, suppresses further SIRT1 gene 
transcription is shown. HIC-1 is a repressor of SIRT1 transcription and binds as a complex with SIRT1. EVI-1 
and E2F-1 are activators of SIRT1 transcription and form a complex with SIRT1, as shown, which no longer can 
bind to the SIRT1 promoter. At the level of translation, the activation state of the SIRT1 protein is indicated 
around the protein in response to the post-translational event shown. miRNA – microRNA; Sumo – sumoylation; 
P – phosphorylation; Ub – ubiquitiation.   
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1.2.3 Current debate concerning a role for SIRT1 in lifespan extension 
The many relevant processes and pathways that include substrates that are deacetylated by SIRT1, 
coupled with the factors found to regulate SIRT1, can be linked in multiple ways to provide plausible 
mechanisms through which SIRT1 may increase lifespan. Moreover, as already noted, there is a body 
of evidence based on transgenic models of Sir2 overexpression or ablation in model organisms that 
link the protein directly with increased lifespan. More recent evidence based on similar genetic 
approaches in model organisms however, challenge the view that SIRT1 plays a fundamental role in 
determining lifespan. In particular, longevity in two long lived worm lines with overexpression of Sir2 
was abrogated on backcrossing to wild-type, without reduction in Sir2 expression, and Sir2 
knockdown by siRNA had no effect on lifespan (Burnett et al; Nature, 2011; in press). 
1.3 Epigenetic modifications 
Post-translational modifications of histone proteins by acetylation, methylation and phosphorylation, 
alongside methylation of the DNA at cytosine residues in CpG dinucleotide sites, form the major 
components of epigenetic marking that create changes in gene expression without affecting the 
underlying DNA sequence. 
1.3.1 Histone acetylation 
Histone acetylation is the covalent addition of an acetyl group to the ε-N of lysine in the histone tail 
catalysed by histone acetyltransferase (HAT) enzymes (Vidali et al., 1968). The removal of this acetyl 
group is by the histone deacetylase (HDAC) group of enzymes, which includes the sirtuin family 
(Figure 1.2). The HAT and HDAC enzymes together modulate histone acetylation status throughout 
the genome (Grozinger and Schreiber, 2002; Roth et al., 2001). Acetylation of the positively charged 
lysine residues on the histone tails by HAT neutralises the histone charge. This modification, in turn, 
repels the negatively charged DNA wrapped around the histone core making it more transcriptionally 
accessible, further enhanced by the creation of specific binding sites for transcription factors. Removal 
of the acetyl groups through histone deacetylation reinstates the positive charge of the lysine residues 
inducing a conformational change of the chromatin around the histones, which becomes condensed, 
highly compacted and transcriptionally-repressed. Therefore, the SIRT1 histone deacetylase may 
potentially influence epigenetic status, and hence gene expression, through its histone deacetylase 
activity. This view is substantiated through studies on the epigenetic effects of SIRT1. Evidence 
includes the observation that under conditions of SIRT1 knockdown in human embryonic kidney cells 
there was hyperacetylation of histones and in conditions of SIRT1 overexpression there was reduced 
histone acetylation of an exogenous target (Vaquero et al., 2007). SIRT1 knockdown or inhibition led 
to reactivation of aberrantly silenced, hypermethylated tumour suppressor genes associated with an 
increase in histone acetylation in the corresponding gene promoter region (Pruitt et al., 2006).  
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1.3.2 DNA methylation 
DNA methylation involves DNA methyltransferase catalysing the covalent addition of a methyl group 
from S-adenosylmethionine to the 5’ carbon of the nucleotide cytosine forming 5-methylcytosine. 
Upon donating the methyl group S-adenosylmethionine converts to S-adenosylhomocysteine (Figure 
1.5).
 
 
 
Figure 1.5. Methylation of the nucleotide cytosine. The methyl group is donated by S-adenosylmethionine, 
catalysed by DNA methyltransferase, to the 5’ carbon of cytosine forming 5-methylcytosine. 
 
DNA methylation is associated with transcriptional suppression. Methylated cytosines occur in CpG 
dinucleotide pairs; around 70 % of CpG sites across the genome are methylated. The remaining 
unmethylated CpG sites are found predominately in CpG islands - areas of the genome that are GC 
rich (Bird et al., 1985). Many mammalian gene promoters include a CpG island, which may include 
binding sites for transcription factors (Saxonov et al., 2006). A relatively new concept to emerge from 
the study of CpG distribution throughout the genome is the description of CpG shores, defined as 
regulatory regions within 2000 bp of CpG islands, whose methylation status correlates with the 
expression of the associated gene (Irizarry et al., 2009). 
 
The presence of epigenetic modifications explains how genetically identical somatic cells can take up 
diverse functional roles and make up phenotypically distinct tissue types within the body. The current 
dogma is that DNA hypomethylation results in gene expression and hypermethylation results in gene 
suppression, although emerging data now challenge the ubiquity of this idea. Upon methylation of 
CpG sites the methyl CpG binding protein 2 (MeCP2), which contains a methylcytosine binding 
domain and a transcriptional repressor domain, binds to DNA and recruits histone deacetylases and 
mSin3A, a transcriptional repressor, in a repressive multiprotein complex (Figure 1.6) (Nan et al., 
1997). Genome-wide studies have allowed for the investigation and observation of tissue-specific 
DNA methylation patterns at CpG islands in the promoter regions of genes (Illingworth et al., 2008; 
Rakyan et al., 2008; Schilling and Rehli, 2007; Bock et al., 2006). Of particular note is the discovery 
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of the involvement of epigenetics in inter-individual variation (Schneider et al., 2010; Bock et al., 
2008; Flanagan et al., 2006) and the role played by epigenetics in the ageing process (Kwabi-Addo et 
al., 2007; Fraga et al., 2005). 
1.3.3 The link between DNA methylation and histone acetylation 
Evidence that DNA methylation can initiate changes in histone acetylation is robust and includes the 
observation that the MeCP2 transcriptional repressor domain in mouse fibroblasts once bound to 
methylated DNA recruits histone deacetylases (HDACs), mediating repression of chromatin (Nan et 
al., 1998), and that Xenopus laevis oocytes injected with methylated and unmethylated plasmid 
constructs revealed chromatin assembly on the methylated DNA followed by MeCP2 binding and 
recruitment of HDACs (Jones et al., 1998). Similarly, transfection of mouse fibroblasts with an 
unmethylated thymidine kinase gene construct or an equivalent methylated construct, followed by 
immunoprecipitation of the acetylated fraction, revealed the acetylated fraction to be associated 
predominantly with the unmethylated construct (Eden et al., 2003). All of these studies highlight the 
importance of DNA methylation and of the MeCP2 complex to induce changes in histone acetylation 
and, therefore, gene expression.  
 
In contrast, evidence supporting the view that histone acetylation status can influence DNA 
methylation status is less well represented within the literature. It is proposed that histone acetylation 
confers protection of the adjacent DNA preventing methylation. Insulator elements are known to exist 
within chromatin, defining the boundaries between heterochromatic and euchromatic regions of the 
genome through inhibiting DNA methylation machinery and encouraging acetylation of histones H3 
and H4, allowing the binding of transcription factors (Mutskov et al., 2002). Additional evidence for 
histone acetylation dictating DNA methylation comes from the use of histone deacetylase inhibitors; 
n-butyrate caused global DNA demethylation in mouse splenocytes (Szyf et al., 1985); the histone 
deacetylase inhibitor trichostatin A (TSA) caused selective DNA demethylation in Neurospora 
(Selker, 1998) and in the human embryonic kidney cell line HEK293 (Ou et al., 2007). Treatment with 
TSA also resulted in marked demethylation of transiently-transfected reporter constructs in HEK293 
cells (Cervoni and Szyf, 2001). A successive study observed that overexpression of the oncoprotein 
Set/TAF-1β, an inhibitor of histone acetylation, in HEK293 cells resulted in hypermethylation of 
reporter constructs (Cervoni et al., 2002). Similar consequences for DNA methylation were observed 
with the histone deacetylase inhibitor valproate in mouse brain (Dong et al., 2007) and HEK293 cells 
(Milutinovic et al., 2007). These interactions between DNA methylation and histone acetylation are 
summarised diagrammatically in Figure 1.6. 
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Figure 1.6. The interrelationship between DNA methylation and histone acetylation. DNA methylation leads to 
the assembly of a multiprotein co-repressor complex in which MeCP2 binds to methylated DNA and recruits 
proteins including the transcription repressor mSin3A and histone deacetylases, bringing about changes to 
histone acetylation status. Some evidence suggests these change can be reversed through histone 
acetyltransferase activity and DNA demethylation. 
 
1.3.4 DNA methylation and ageing 
Changes in DNA methylation are associated with the ageing process (Wilson and Jones, 1983) and 
may have effects on gene expression, chromosomal instability and telomere integrity (Gonzalo et al., 
2006; Eden et al., 2003; Richardson, 2003). Inter-individual variation in DNA methylation has been 
implicated in the divergence of disease susceptibility; monozygotic twin studies have shown an 
increasing discordance in the level and distribution of DNA methylation with age (Fraga et al., 2005). 
Demethylation with ageing has been observed in many tissues across many species (Wilson et al., 
1987; Vanyushin et al., 1973), however these early studies measured total methylcytosine content. 
More recently-developed technologies, in particular those utilising downstream array hybridisation or 
that measure site-specific methylation within a sequence of interest, have given a greater insight into 
the role that DNA methylation plays in the ageing process. A study using methylation-sensitive 
restriction digestion followed by array hybridisation showed considerable difference in the 
methylation profile between young and old measured in the mouse small intestine (Maegawa et al., 
2010). Similar divergence with age in methylation patterns has also been observed in multiple human 
tissues, where it was observed that the direction of change in methylation with age at a specific loci 
was dependent upon whether the locus resides in a CpG island (Christensen et al., 2009). Previous 
investigations of site-specific methylation changes with age, have also shown hypermethylation with 
age at CpG islands associated with genes implicated in prostate cancer (Kwabi-Addo et al., 2007) and 
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conversely loci within CpG rich regions associated with pancreatic cancer have show hypomethylation 
with the onset of the age-associated disease (Sato et al., 2003). 
 
With the introduction of whole-genome array technologies the classic view that the genome is 
hypomethylated with ageing, though still apparent at the global level when measuring repetitive 
elements such as Alu (Bollati et al., 2009), has been replaced with an ever growing body of evidence 
suggesting a complex pattern of methylation status within individual tissue types that is dysregulated 
during aging (Maegawa et al., 2010; Rakyan et al., 2010; Teschendorff et al., 2010; Christensen et al., 
2009; Kwabi-Addo et al., 2007).  
1.4 Nutrient-mediated modulation of epigenetic mechanisms 
Substantial inter-individual variation in age-related DNA methylation may be due to different 
environmental and lifestyle factors (Issa, 2002). Comparison of the DNA methylation profiles of pairs 
of monozygotic twins revealed that differences between twin pairs were greater in older individuals 
and that twins who had led different lifestyles and/or lived apart showed greater divergence in DNA 
methylation patterns that twins subject to similar environmental factors, indicating a role of 
environment, and possibly diet, in influencing DNA methylation (Fraga et al., 2005). Numerous 
studies, both in vitro and in vivo, have shown effects of specific dietary components on DNA 
methylation. These factors include folate, a precursor in the synthesis of S-adenosylmethionine, the 
universal methyl donor involved in methylation (Balaghi and Wagner, 1993), selenium (Davis et al., 
2000), and polyphenolic compounds found in plants, such as genistein (Day et al., 2002) and (-)-
epigallocatechin-3-gallate. Epigallocatechin-3-gallate, a polyphenolic compound found in green tea, 
competes for the catalytic domain of DNA methyltransferase I, inhibiting the methylation of cytosine 
(Fang et al., 2003). A screen of ~20,000 molecules for activators of the SIRT1 histone deacetylase 
identified the plant polyphenol resveratrol (Howitz et al., 2003) which, may therefore, through the 
action of SIRT1 deacetylation affect DNA methylation. 
1.4.1 Potential sirtuin-activating polyphenolic compounds 
Dietary compounds naturally derived from various plant sources include polyphenols that potentially 
activate SIRT1. The compounds include resveratrol, noted above for its ability to activate SIRT1, and 
the isoflavones genistein and daidzein (Figure 1.7). 
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Figure 1.7. Chemical structures of selected polyphenols. 
 
1.4.1.1 Resveratrol 
Resveratrol (3, 5, 4’-trihydroxystilbene) is a polyphenolic compound that acts as a phytoalexin 
produced in plants as a response to bacterial and fungal infection. Resveratrol is in the stilbene 
subgroup of the polyphenol family and can be found in a range of fruits and nuts, particularly in the 
skins of red grapes. Resveratrol has been shown to cause an increase in SIRT1 affinity for the NAD
+
 
substrate and the acetylated substrate through allosteric affects and so increases SIRT1 activity 
(Howitz et al., 2003). In lower eukaryotes, resveratrol has been shown to increase lifespan in a Sir2-
dependent manner (Wood et al., 2004; Howitz et al., 2003). The literature includes discordance over 
whether or not Sir2 in lower eukaryotes plays a role in determining lifespan and in particular if 
resveratrol can have effects to extend lifespan through activation of Sir2 (Bass et al., 2007; Gruber et 
al., 2007; Kaeberlein et al., 2005a; Viswanathan et al., 2005; Bauer et al., 2004; Jarolim et al., 2004). 
The main source of controversy surrounding activation of SIRT1 by resveratrol is an in vitro 
fluorescence activity assay used to measure SIRT1 deacetylase activity (Howitz et al., 2003), with 
several groups reporting independently that activation of SIRT1 by resveratrol is only observed when 
SIRT1 is attached to a fluorescent moiety (Pacholec et al., 2010; Beher et al., 2009; Borra et al., 2005; 
Kaeberlein et al., 2005a). Irrespective of whether measures of the effects of resveratrol on SIRT1 
deacetylase have been flawed, a body of evidence indicates that resveratrol may influence lifespan 
and/or healthspan through actions involving SIRT1. At the transcriptional level resveratrol has been 
shown to change levels of SIRT1 mRNA (Csiszar et al., 2009), upregulate transcription factors in a 
SIRT1-dependent manner (Gracia-Sancho et al., 2010) and mediate SIRT1-regulated adipogenesis 
(Picard et al., 2004). Mammalian studies into the potential of dietary resveratrol to mimic some of the 
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beneficial effects of DR in ageing and lifespan-extension include studies of the role of dietary 
resveratrol in protecting against some of the biochemical and physiological effects of a high fat diet in 
mice. Effects of resveratrol included a reversal in increased glucose, insulin and IGF-1 levels and a 
reversal in increased liver size (Baur et al., 2006). In a second study, dietary resveratrol increased 
mitochondrial biogenesis, consistent with a reduction in the acetylation levels of the main regulator of 
mitochondrial production, PGC-1α. This effect was not observed in SIRT1-/- mouse embryonic 
fibroblasts, suggesting that SIRT1 may play a role in mediating this action (Lagouge et al., 2006). 
Evidence that resveratrol can mimic some changes associated with DR were obtained through 
comparison of gene expression profiles between mice fed resveratrol or mice subjected to DR. Both 
treatments showed a high level of similarity in their effect on gene expression and these changes 
opposed age-related changes in gene expression (Barger et al., 2008). This observation was 
corroborated in an independent study (Pearson et al., 2008). However, the resveratrol-fed mice did not 
show an increase of SIRT1 in brain or liver (Barger et al., 2008) and the lifespan extension properties 
of resveratrol have yet to be seen in lean mice (Pearson et al., 2008). 
1.4.1.2 Isoflavones 
The polyphenols genistein (4', 5, 7-trihydroxyisoflavone) and daidzein (4', 7-dihydroxyisoflavone) 
reside in the isoflavone subgroup of the flavonoids and share a degree of structural similarity to 
resveratrol (Figure 1.7). Genistein and daidzein are both found in abundance in soyabeans and have 
been associated with beneficial effects against age-related diseases that include osteoporosis, various 
cancers and cardiovascular disease. The isoflavones have been observed to have both negative and 
positive effects on DNA methylation. These observations include the reversal of DNA 
hypermethylation of the p16
INK4a
, retinoic acid receptor beta (RARβ) and O6-methylguanine DNA 
methyltransferase (MGMT) loci in esophageal squamous carcinoma cells treated with genistein and 
the reversal of hypermethylation and induced mRNA expression of RARβ upon treatment of prostate 
cancer cell lines with genistein. Daidzein treatment of esophageal squamous cell carcinoma cells 
showed similar effects on expression of the RARβ mRNA (Fang et al., 2005). The glutathione S-
transferase gene, GSTP-1 is hypermethylated in prostate cancer; glutathione S-transferase catalyses 
the detoxification of oxidative stress byproducts. Treatment of human prostate cancer cell lines with 
genistein and daidzein induced demethylation of the GSTP-1 promoter region, and was proposed to 
contribute to the lower incidence of prostate cancer within Asian populations whose diet is rich in soy 
polyphenols (Vardi et al., 2010). 
 
Conversely, differential hybridisation to a DNA microarray of methylated and unmethylated mouse 
DNA identified CpG islands that were hypermethylated in response to a genistein-supplemented diet 
(Day et al., 2002). Studies using the agouti variable yellow mouse model, which shows a shift in coat 
colour from yellow to pseudo-agouti in response to methylation of DNA upstream of the Agouti gene, 
revealed increased DNA methylation in response to genistein supplementation (Dolinoy et al., 2006).  
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Isoflavones have mechanisms of action independent of effects on DNA methylation. Of particular 
relevance in the context of our hypothesis, genistein and daidzein were found to increase 
mitochondrial biogenesis in renal proximal tubular cells, in concert with deacetylation and activation 
of the SIRT1 substrate and regulator of mitochondrial biogenesis PGC-1α. It remains unclear if these 
effects were mediated through SIRT1 activation, since only daidzein activated recombinant SIRT1 in 
vitro (Rasbach and Schnellmann, 2008). 
 
The indication that the soyabean isoflavones may, as with resveratrol, mediate cellular effects through 
SIRT1 identifies these dietary agents as potential mimetics of some aspects of the longevity response 
to DR.  
1.5 Techniques employed for analysis of the epigenetic mechanism DNA methylation 
A variety of methods are currently employed to measure DNA methylation status. Many methods 
utilise the sequence recognition properties of restriction enzymes to distinguish between products that 
have, or have not, been deaminated by bisulfite modification, or restriction enzymes whose cleavage is 
hindered by the presence of a methyl group in combination with an isoschizomer that is not. These 
techniques can be refined to measure both global and site-specific DNA methylation. DNA 
methylation detection methods also include the use of chromatin immunoprecipitation with antibodies 
that recognise 5-methylcytosine or proteins that bind to methylated DNA. These methods are now 
regularly followed by hybridisation of the products to a microarray chip. High-throughput next 
generation sequencing, of either bisulfite-modified or immunoprecipitated DNA, is fast becoming the 
state-of-the-art approach to measuring DNA methylation across genomes. The techniques employed in 
this thesis are detailed below. 
1.5.1 Bisulfite Modification 
Bisulfite modification is used in conjunction with a downstream application to distinguish between 
methylated and unmethylated cytosines at the level of a single nucleotide. Genomic DNA is bisulfite 
modified, which involves deamination of unmethylated cytosines to uracil through removal of an 
amino group (Figure 1.8A). This sodium bisulfite treatment effectively fixes the DNA methylation 
pattern within the sample, as the methyl group protects methylated cytosines from deamination, in 
contrast to the unprotected cytosines which when converted to a uracil base are read by DNA 
polymerase in a subsequent PCR reaction as thymine (Clark et al., 1994) (Figure 1.8B). 
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Figure 1.8. Deamination through bisulfite modification. A – Sodium bisulfite catalyses the hydrolytic removal 
of an amino group from cytosine to form uracil. B – Methylated cytosines are protected from deamination.  
1.5.2 Combined Bisulfite Restriction Analysis (COBRA) 
Bisulfite modification of DNA followed by PCR amplification leads to the loss or retention of existing 
methylation-dependent restriction sites, dependent on the methylation status of the cytosine residing in 
the restriction site upon deamination. Combined Bisulfite Restriction Analysis (COBRA) (Xiong and 
Laird, 1997) is a method that exploits the change in restriction sites dependent on methylation status 
through digestion with a restriction enzyme whose recognition sequence contains a cytosine as part of 
a CpG site. 
 
To estimate global DNA methylation the COBRA technique is applied to a repetitive element within 
the genome. The LINE-1 (long interspersed nucleotide element 1) retrotransposons contribute to 
around 21 % of the human genome sequence through the ability to self replicate and reintegrate into 
the genome, making it an ideal surrogate marker of global DNA methylation (Babushok and Kazazian, 
2007). DNA samples are first bisulfite modified, fixing the DNA methylation pattern. COBRA LINE-
1 (Yang et al., 2004) then involves amplification of the bisulfite modified DNA to the LINE-1 
retrotransposon by PCR using specific LINE-1 primers. The PCR product is digested with the 
restriction enzyme HinfI. The HinfI restriction sequence is 5’ -G/ANTC- 3’, so after bisulfite 
modification the enzyme will cleave only PCR product generated from a methylation sequence where 
the cytosine has been protected against deamination. Within the LINE-1 retrotransposon sequence 
there are two such HinfI restriction sites. The methylation at these two CpG sites in a DNA sample is 
expressed as the ratio of uncut to cut PCR product as determined by densitometric quantification of 
SYBR green-stained agarose gels (Figure 1.9). 
 
28 
 
 
 
 
Figure 1.9. Schematic representation of COBRA. Genomic DNA is bisulfite modified to ‘fix’ the DNA 
methylation pattern. Bisulfite modified DNA is then PCR amplified to the LINE-1 sequence and the PCR 
products are digested with the restriction enzyme HinfI. Deamination reaction with by sodium bisulfite of 
unmethylated (and therefore unprotected) CpG sites results in the loss of the HinfI recognition sequence, 
preventing digestion by the enzyme. This procedure produces two sets of fragments – uncut, representing 
unmethylated DNA and cut, representing methylated DNA – the ratio of which can be used to express the 
methylation status within the original sample of the CpG sites within the recognition sequence. 
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1.5.3 Pyrosequencing 
1.5.3.1 Principle of pyrosequencing 
Pyrosequencing is a method of sequencing DNA and analysing methylation status through the release 
and quantification of pyrophosphate by a nucleotide incorporation event. One of the four 
deoxynucleotide triphosphates (dNTPs) is added to the reaction and incorporated by DNA polymerase 
if complementary to the template sequence. As the correct base is incorporated pyrophosphate (PPi) is 
released. PPi and adenosine 5' phosphosulfate (ASP) are converted to adenosine triphosphate (ATP) 
by sulfurylase which drives luciferase to convert luciferin to oxyluciferin. This conversion generates 
light which is detected by a charged coupled device (CCD) camera and produces a signal peak on the 
pyrogram. Apyrase degrades unincorporated dNTPs and excess ATP. Upon completion of degradation 
another of the four dNTPs is added. As each dNTP is added the sequence of the complementary strand 
is elucidated. 
1.5.3.2 Performing the pyrosequencing assay 
To prepare a sample for pyrosequencing, genomic DNA is first bisulfite modified to fix the 
methylation pattern. The bisulfite modified DNA is subjected to two rounds of PCR amplification. 
Primers are designed to a target sequence, focusing on a region containing CpG sites whose DNA 
methylation status is of interest. The first PCR is to a larger region around the target sequence using 
bisulfite-modified genomic DNA as a template and degenerate primers – 50 % C and 50 % T – at the 
site of a CpG location, to avoid bias selection of the methylated or unmethylated sequence. The second 
round of PCR performed is a nested PCR to a smaller region within the target sequence, focusing in on 
the specific CpG sites to be measured. PCR reactions contain HotStarTaq Master Mix, sense primer, 
biotinylated antisense primer and the first PCR reaction to act as a DNA template. Biotinylated 
antisense primer is used at a lower concentration within the reaction to prevent excess biotin and 
reduce primer dimerisation. The size of the PCR product is confirmed by agarose gel electrophoresis 
and used in the pyrosequencing reaction as described above. The primers and sequencing primer used 
in the second PCR are designed using the PyroMark Assay Design Software 2.0 (Qiagen). Percentage 
DNA methylation is then measured at the target CpG sites within the sequence of interest.  
 
The ratio of converted cytosine (thymine) to unconverted cytosine within each CpG site (C/T) is used 
to determine the percentage DNA methylation at each CpG site. An inbuilt control, a cytosine not 
followed by a guanine, acts to assess the efficiency of the bisulfite modification step, as the cytosine 
should not be methylated and so upon bisulfite treatment be fully converted to a thymine following 
PCR. 
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1.5.3.3 Confirmation of linear amplification 
For each target sequence analysed by pyrosequencing the linear amplification of methylated and 
unmethylated sequences is confirmed using a standard curve. Unmethylated DNA template is 
generated through PCR amplification of the target sequence from genomic DNA. Unmethylated PCR 
product is methylated in vitro using CpG SssI methylase. Methylated and unmethylated products are 
bisulfite modified to fix the DNA methylation pattern and combined to give appropriate methylation 
percentages to generate the standard curve (0, 5, 10, 25, 50, 75, 90, 95, 100 % methylated). A non 
linear relationship between standard concentration and percentage DNA methylation indicates biased 
amplification of methylated or unmethylated DNA and requires assays to be redesigned to achieve a 
more reliable result. 
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Figure 1.10. Schematic representation of the pyrosequencing reaction. Upon incorporation of a dNTP by DNA 
polymerase PPi is released. PPi and APS are converted to ATP by sulfurylase. ATP then drives the luciferase-
mediated conversion of luciferin to oxyluciferin (light), which is recorded as a signal peak on the pyrogram. 
dNTP/’N’ – deoxynucleotide triphosphates; PPi – pyrophosphate; APS – adenosine 5' phosphosulfate; ATP – 
adenosine triphosphate; 
m
C – 5’-methyl cytosine. 
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1.5.4 LUminometric Methylation Assay (LUMA) using Pyrosequencing 
The LUminometric Methylation Assay (LUMA) (Karimi et al., 2006) uses methylation-specific 
cleavage by restriction enzymes to determine the methylation status of a cytosine by bioluminometric 
polymerase extension of the resulting overhang. The LUMA assay involves digestion of genomic 
DNA with either EcoRI and MspI restriction enzymes or EcoRI and HpaII restriction enzymes. MspI 
and HpaII are isoschizomers which are CpG methylation insensitive and CpG methylation sensitive, 
respectively, and upon DNA cleavage leave 5’-CG overhangs. The EcoRI enzyme leaves 5’-AATT 
overhangs and provides an inbuilt control for DNA concentration. The products of the two separate 
DNA digestions are then quantified using the pyrosequencer by extending the 5’ overhangs. The 
percentage methylation of the DNA sample is determined by the MspI/HpaII ratio; a ratio of 1.0 
would represent 100 % methylation whereas an MspI/HpaII ratio approaching zero would represent 
unmethylated DNA (Figure 1.11). 
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Figure 1.11. Schematic representation of LUMA assay. Genomic DNA is digested with a combination of either 
EcoRI and MspI or EcoRI and HpaII restriction enzymes. Pyrosequencing (Section 1.5.2) is employed to 
measure the extent of cleavage. EcoRI cleavage is represented by peaks produced upon incorporation of A and T 
(1
st
 and 3
rd
 peaks on the pyrogram). MspI or HpaII cleavage, in the respective reactions, is represented by the 
peak produced upon incorporation of C and G (2
nd
 peak on the pyrogram). The ratio of these peaks is then used 
to calculate the percentage DNA methylation within the sample. The final incorporation event of C and G is an 
internal control to ensure that the previous extension was completed and so therefore any peak generated should 
be close to zero (4
th
 peak on the pyrogram). Adapted from (Karimi et al., 2006). 
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1.5.5 Methylated DNA Immunoprecipitation (MeDIP) 
Methylated DNA Immunoprecipitation (MeDIP) (Weber et al., 2005) is an affinity-based method that 
utilises an antibody to 5-methylcytidine to produce an enriched product to detect methylation status 
across the genome. MeDIP involves sonication of genomic DNA via an ultrasonic homogeniser to 
fragment the DNA into 200 – 1000 bp lengths for immunoprecipitation. The fragmented DNA is 
incubated with a primary anti-5-methylcytidine antibody which binds methylated cytosines within the 
sample DNA sequence. The complex of antibody and methylated DNA is purified by the addition of 
secondary IgG coated superparamagnetic polystyrene beads and capture on a magnetic rack. This 
methylated-enriched fraction can then be co-hybridised to an array chip with a complementary input 
sample or subjected to high throughput sequencing and alignment to a reference genome (Figure 
1.12). 
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Figure 1.12. Schematic representation of methylated DNA immunoprecipitation followed by chip array 
hybridisation (MeDIP-CHIP) or high throughput sequencing (MeDIP-SEQ). Genomic DNA is fragmented by 
sonication. A methylation-enriched fraction is generated through immunoprecipitation of methylated DNA using 
a 5mC Ab. This enriched fraction is then either co-hybridised to an array chip with an input sample (MeDIP-
CHIP) or subjected to high throughput sequencing and alignment to a reference genome (MeDIP-SEQ). 5mC Ab 
– anti-5-methylcytidine antibody; magnetic beads – IgG coated superparamagnetic polystyrene beads.  
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1.6 An investigation of roles for SIRT1 and dietary polyphenols in modulating the 
ageing process through DNA methylation 
 
Our hypothesis is that effects on DNA methylation may contribute to the effects of DR to increase 
healthy lifespan through histone acetylation mediated by SIRT1, and these effects may be mimicked 
by plant derived polyphenolic compounds (Figure 1.13). 
 
 
 
 
Figure 1.13. Diagrammatic representation of the hypothesis. We propose that SIRT1-mediated histone 
deacetylation underlies some of the beneficial effects of dietary restriction (DR) on ageing/lifespan/healthspan 
through maintenance of DNA methylation. We also propose that specific dietary factors may bring about similar 
epigenetic consequences and so mimic beneficial effects of DR.  
38 
 
1.7 Aims and objectives 
This project aimed to investigate a role for SIRT1 and dietary polyphenols in healthy ageing by 
manipulating the expression levels or activity of SIRT1 in cultured human cells, including in 
combination with dietary polyphenols, to investigate if such interventions result in effects on DNA 
methylation, and to identify and investigate new targets whose regulation through SIRT1 may 
contribute to the mechanism of ageing proposed by the hypothesis. The specific objectives were: 
 
i. to identify appropriate human cell lines for the investigation, taking into consideration levels 
of endogenous DNA methylation, ideally to identify cell lines with minimal and maximal 
levels of global DNA methylation to increase assay sensitivity with respect to detecting both 
increases and reductions in DNA methylation; 
ii. to manipulate SIRT1 in a cell line model (human intestinal Caco-2 cells) through changes in 
activity (pharmaceutically) and expression (by overexpression of a transgene or siRNA 
mediated knockdown), and to determine the effect on global and site-specific DNA 
methylation; 
iii. to investigate in the Caco-2 cell line model factors that may affect SIRT1 expression with 
regard to the central themes of the hypothesis: mimetics of dietary restriction, DNA 
methylation and age; 
iv. to utilise an in silico approach to explore overlaps between groups of genes that associate with 
SIRT1, show altered expression in response to DR, and show altered methylation with ageing 
to support their relationship proposed by our hypothesis and identify further targets for in vitro 
investigation; 
v. to investigate directly if methylation and/or expression of genes highlighted in the in silico 
analysis was affected by altering the expression of SIRT1 in the Caco-2 cell line model; 
vi. to investigate on a genome-wide scale the effect on methylation and gene expression of 
altering SIRT1 expression and to explore overlaps between genes affected in these ways and 
genes that respond to DR and/or undergo age-related changes in methylation. 
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2 Materials and Methods 
All chemical compounds were from Sigma Aldrich, UK unless otherwise stated and all water was 
molecular biology grade. 
2.1 Culture of Escherichia coli cells 
2.1.1 Growth 
E. coli strains were grown overnight at 37 °C on Luria Bertoni (LB) agar plates (1 % NaCl, 1 % 
peptone, 0.5 % yeast extract, 15 g/L agar) containing 100 µg/ml ampicillin unless otherwise stated. 
Colonies were selected, grown overnight at 37 °C in 5 ml of LB containing 100 µg/ml ampicillin and, 
where applicable, screened for the corrected plasmid (Section 2.2.2). Where a larger yield of bacteria 
was required for plasmid preparation 1 ml of overnight culture was inoculated into 100 ml of LB 
containing the appropriate antibiotic; usually 100 µg/ml ampicillin and incubated at 37 °C in an orbital 
shaker until an optical density of 0.4 – 0.6 at 600 nm was reached, and plasmid DNA was prepared as 
described in Section 2.2.2. 
2.1.2 Generation of competent cells 
Competent OneShot TOP10 E. coli cells were purchased from Invitrogen for use in transformation. 
2.1.3 Transformation of E. coli with plasmid DNA 
Transformation of OneShot TOP10 E. coli (Invitrogen) with 3 l plasmid DNA was performed on ice 
for 30 minutes, followed by heat shock at 42 °C and addition of 250 l of SOC medium (2 % tryptone, 
0.5 % yeast extract, 10 mM NaCl, 2.4 mM MgCl2, 10 mM MgSO4, 20 mM glucose) then cells were 
incubated shaking at 37 °C for 1 hour. Colonies were grown as described in Section 2.1.1. 
2.1.4 Preparation of E. coli cell stocks 
E. coli strains were cultured to an optical density of 0.4 – 0.6 at 600 nm as described in Section 2.1.1. 
Bacterial culture and 50 % glycerol were mixed in equal volumes, aliquoted into 1.5 ml microtube 
tubes, snap frozen in liquid nitrogen and stored at -80 °C. 
2.2 Generation and manipulation of DNA plasmid constructs 
DNA plasmid constructs were obtained from commercially available sources or generated as required 
within the laboratory. All plasmid are listed in Table 2.1. Plasmid maps are provided in Appendix A. 
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2.2.1 Sub-cloning of DNA into plasmid vectors 
DNA products were cloned directly into pTOPO vectors (Invitrogen). Four microlitres of DNA 
product were incubated with 4 l of vector, 1 l 10x ligation buffer (Invitrogen) and 1 l of ligase 
(Invitrogen) overnight at 16 °C. Three microlitres of the ligation reaction were then transformed with 
competent OneShot TOP10 E. coli as described in Section 2.1.3. 
2.2.2 Preparation of plasmid DNA 
Plasmid DNA from commercially available or laboratory generated clones was prepared using 
QuickLyse MiniPrep kit or EndoFree
®
 MaxiPrep kit (Qiagen) yielding up to 20 and 50 – 250 µg 
respectively. All procedures were carried out according to the manufacturer’s instructions. 
2.2.3 Generation of unmethylated DNA plasmid constructs 
Unmethylated DNA plasmid constructs were generated as outlined below. Plasmids were propagated 
through a specific E. coli strain (K12 ER2925; New England Biolabs) that is dcm
-
 and dam
- 
negative 
therefore is unable to replicate methylation patterns.   
2.2.3.1 Generation of competent K12 ER2925 cells 
Competent E. coli K12 ER2925 cells were generated from a non-competent K12 ER2925 strain (New 
England Biolabs). The non-competent strain was grown as described in Section 2.1.1 with the 
replacement of ampicillin for 34 g/ml chloramphenicol. Cells were pelleted by centrifugation at 
7,000 g for 15 minutes at 4 °C and the pellet was resuspended in 20 ml ice cold 100mM MgCl2. Cells 
were pelleted again by centrifugation at 7,000 g for 15 minutes at 4 °C and the pellet was resuspended 
in 4 ml of ice cold 100 mM CaCl2 and left on ice for 2 hours. Competent cells were stored at -80 °C as 
glycerol stocks prepared as described in Section 2.1.4. 
2.2.3.2 Transformation of competent K12 ER2925 cells 
Competent K12 ER2925 cells were transformed as described in Section 2.1.3 using 250 l of 
competent cells and 34 g/ml chloramphenicol for selection of transformed cells. 
2.2.4 In vitro methylation of DNA 
Methylated DNA was generated by in vitro methylation with CpG SssI methylase (4000 U/ml) (New 
England Biolabs). Reactions typically contained 4 l CpG SssI methylase, 1X NE Buffer 2 (New 
England Biolabs), 160 M S-adenosylmethionine (SAM) (New England Biolabs) and 2 g DNA, in a 
final volume of 25 l. Reactions were incubated overnight at 37 C. An additional 1 l SAM (1:8 
dilution of 200X stock) was added after 3 hours incubation. Mock methylation reactions were identical 
to in vitro methylation reactions except the CpG SssI methylase was omitted. 
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2.2.4.1 Phenol:chloroform purification of DNA 
Methylated DNA or PCR products required for downstream applications were purified by 
phenol:chloroform precipitation. The sample to be purified was made up to a total volume of 200 l 
with water. An equal volume of phenol:chloroform pH8 was added before centrifugation at 13,000 g 
for 15 minutes at 4 ºC. The upper fraction was transfer to a new 1.5 ml microtube and lower fractions 
discarded. One tenth of the initial volume of 3 M sodium acetate and double the initial volume of ice 
cold 100 % ethanol were added to the upper fraction and stored at -20 ºC overnight. The mixture was 
centrifuged at 13,000 g for 15 minutes at 4 ºC and supernatant discarded. The pellet was resuspended 
in 10 l of water and quantified (Section 2.4.4). 
2.2.5 DNA sequencing 
All laboratory-generated plasmids were sequenced by MWG Biotech. 
2.3 Culture of mammalian cells  
2.3.1 Growth and maintenance 
Caco-2, (human epithelial colorectal adenocarcinoma), HeLa (human epithelial cervical 
adenocarcinoma), HepG2 (human liver hepatocellular carcinoma) and MDA (human epithelial breast 
adenocarcinoma) cells were cultured routinely in Dulbecco’s modified Eagle’s medium (GIBCO, 
Invitrogen) containing 10 % (v/v) fetal calf serum, 1 % non-essential amino acids, 60 μg/ml 
gentamycin in 75 cm
3 
tissue culture flasks at 37 °C in an atmosphere of 5 % CO2 in air.  
  
MCF-7 (human epithelial breast adenocarcinoma) cells were routinely cultured in minimum Eagle’s 
medium (GIBCO, Invitrogen) containing 10 % (v/v) fetal calf serum, 1 % sodium pyruvate, 1 % non-
essential amino acids, 60 μg/ml gentamycin in 75 cm3 tissue culture flasks at 37 °C in an atmosphere 
of 5 % CO2 in air.  
 
SW480 (human epithelial colorectal adenocarcinoma) cells were routinely cultured in Leibovitz’s L15 
(GIBCO, Invitrogen) containing 10 % (v/v) fetal calf serum, 1 % non-essential amino acids, 60 μg/ml 
gentamycin in 75 cm
3 
tissue culture flasks at 37 °C in an atmosphere of 0 % CO2 in air. 
 
SH-SY5Y (human epithelial brain neuroblastoma) cells were routinely cultured in a 1:1 ratio of 
Dulbecco’s modified Eagle’s medium and F-12 Nutrient Mixture (Ham) (GIBCO, Invitrogen) 
containing 10 % (v/v) fetal calf serum, 1 % non-essential amino acids, 60 μg/ml gentamycin in 75 cm3 
tissue culture flasks at 37 °C in an atmosphere of 5 % CO2 in air. 
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All cells were subcultured once they had reached 80 % confluence by removing the medium, washing 
the confluent monolayer with 15 ml sterile PBS (pH 7.4), then adding 2 ml trypsin (10 X Solution 
Trypsin-EDTA; Sigma). The cells were incubated at 37 °C for 5 minutes and once passaged were 
resuspended in 10 ml of medium. The cells were centrifuged for 5 minutes at 1500 rpm and the 
supernatant of fluid was removed. Cells were resuspended in 10 ml of medium and 1 ml of this was 
transferred to a new 75 cm
3
 flask. Fifteen millilitres of medium were added and the cells were grown 
at 37 °C. All cell culture medium compositions are listed in Appendix B. 
2.3.2 siRNA transfection of mammalian cells 
For siRNA transfection reactions, once confluent, cells were subcultured onto six well plates at a 
seeding density of 3.5 x 10
5
 cells per well and after 24 hours growth were transfected with validated 
stealth RNAi
™
 siRNA (Invitrogen) using the Lipofectamine
™ 
RNAiMAX transfection reagent 
according to the manufacturer’s instructions (Invitrogen). For each well, 500 μl transfection mixtures 
were prepared containing 100 pmol of siRNA in serum and antibiotic-free medium and 4 μl of 
Lipofectamine
™ 
RNAiMAX. The mixture was added in a dropwise manner. All siRNAs are listed in 
Table 2.2A. 
2.3.3 Transient transfection of mammalian cells 
For transfection reactions, once confluent, cells were subcultured onto six well plates at a seeding 
density of 3.5 x 10
5
 cells per well and after 24 hours’ growth were transfected with endotoxin-free 
plasmid DNA (Qiagen) using the GeneJammer® Transfection Reagent, according to the 
manufacturer’s instructions (Stratagene). For each well, 100 μl transfection mixtures were prepared 
containing 2 µg of DNA in serum and antibiotic-free medium and 5 µl of GeneJammer® Transfection 
Reagent. The mixture was added in a dropwise manner.  
2.3.4 Co-transfection of mammalian cells 
Co-transfection of mammalian cells was conducted as described in Section 2.3.2 with the exception of 
only 1 µg of each DNA plasmid being used. 
2.3.5 Treatment of cells with polyphenols and other chemicals 
Filter-sterilised stock concentrations of the polyphenols genistein (LC Laboratories), daidzein (LC 
Laboratories), and resveratrol and SIRT1 inhibitor sirtinol (10 mM) were prepared in DMSO 
(dimethyl sulfoxide) and tert-butyl hydrogen peroxide (100 mM) was dissolved in ethanol. Twenty 
four hours after transfection, cells were treated with genistein, daidzein, resveratrol, sirtinol, tert-butyl 
hydrogen peroxide or a control of DMSO or ethanol, as appropriate and at the same ratio as present in 
cells reviving treatments (usually 0.1 % v/v). Polyphenol treatments were complimented by the use of 
phenol free medium (Appendix B) to ensure effects were due to polyphenols and not the medium 
component. 
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2.3.6 Preparation of mammalian cell stocks 
Mammalian cell stocks were prepared by trypsinisation as described in Section 2.3.1 and resuspended 
to a density of 3 x 10
6
 cells/ml in 8 ml of complete medium specific to cell type, an additional 10 % 
fetal calf serum and 10 % DMSO. Cell suspensions were aliquoted into 1.8 ml cryovials and frozen 
slowly in isopropanol at -80 ºC. After 24 hours cryovials were transferred to liquid nitrogen storage. 
2.4 DNA/RNA extraction 
2.4.1 Simultaneous DNA/RNA lysate preparation 
Cells were harvested 72 hours after transfection. Cells in each well were washed with 1 ml 1 x PBS 
which was then removed and replaced with 350 µl lysis buffer RLT (Qiagen). Cells were lysed by 
repeated (10x) homogenisation with a needle and syringe. The cell lysate was stored at -80 ºC for 
further analysis. Genomic DNA and total RNA were extracted from Caco-2 cells using the AllPrep 
DNA/RNA Mini Kit (Qiagen) following the manufacturer’s protocol. Where only genomic DNA was 
required the QIAamp
®
 DNA Mini Kit (Qiagen) was used following the manufacturer’s protocol. 
2.4.2 RNA lysate preparation using TRIzol® reagent 
Cells were harvested 24 - 72 hours after transfection with siRNA or endotoxin-free plasmid DNA. 
Cells in each well were washed with 1 ml 1 x PBS which was then removed and replaced with 0.5 ml 
of TRIzol
®
 Reagent (Invitrogen). Total RNA was extracted from Caco-2 cells using the TRIzol
®
 
Reagent protocol (Invitrogen). 
2.4.3 RNA lysate preparation for microarray or qRT-PCR analysis 
Cells were harvested 72 hours after transfection with siRNA or endotoxin-free plasmid DNA. RNA 
lysates were prepared as described in Section 2.4.2, lysates were then further purified using the 
PureLink™ RNA Mini Kit (Invitrogen) following the manufacturer’s protocol. 
2.4.4 Determination of DNA/RNA concentration 
DNA and RNA concentrations were analysed using the Nanodrop 1000 spectrophotometer (Thermo 
Scientific, UK). DNA with an A260/A280 ≥ 1.8 and an A260/A230 ≥ 1.8 and RNA with an A260/A280 ≥ 2.0 
and an A260/A230 ≥ 1.8 was considered suitable for downstream applications. 
2.4.5 Determination of RNA integrity 
RNA integrity was analysed using the Agilent 2100 bioanalyser (Agilent Technologies). A RIN (RNA 
Integrity Number) above the threshold of 7 was required for downstream applications. 
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2.5 Routine techniques for amplification, manipulation and analysis of DNA 
2.5.1 End Point Polymerase chain reaction 
2.5.1.1  Standard PCR 
For amplification of DNA each PCR reaction contained 1 μl DNA, 0.5 μl BIOTAQ™ DNA 
polymerase (Bioline), 2 μl 10x NH4 Buffer (Bioline), 1.2 μl 50 mM MgCl2 (Bioline), 0.3 μl 100 mM 
dNTPs (Bioline), 0.5 μM sense and antisense primers (MWG Biotech) and water to a final volume of 
20 μl. Cycling parameters for BIOTAQ™ DNA polymerase (Bioline) using a Thermohybaid PX2™ was 
as follows: 
 
                                              95˚C   5 minutes initial denaturation 
95˚C   30 seconds denaturation 
35 cycles      *45 - 65˚C  30 seconds annealing 
72˚C   1 minutes elongation 
72˚C   5 minutes 
4˚C hold 
 
* At temperature given in Table 2.2B for specific primer pairs  
PCR primers (MWG Biotech) were designed to be 18-24 bases in length, to optimally have 50 % GC 
content and to preferably terminate at both ends in a G or a C. All primers used are listed in Table 
2.2B. 
2.5.1.2  High specificity hot-start PCR 
For PCR products to be analysed on the Pyrosequencer (Qiagen), HotStarTaq Master Mix (Qiagen) 
was used to ensure higher PCR specificity and reduced non-specific amplification, and required a 15 
minute, 95 °C activation step. Each PCR reaction contained 4 μl DNA, 25 μl HotStarTaq Master Mix, 
0.25 μM sense and antisense primers (0.20 μM if biotinylated) (MWG Biotech) and water to a final 
volume of 50 μl. Cycling parameters for HotStarTaq MasterMix using a Thermohybaid PX2™ was as 
follows: 
 
                                              95˚C   15 minutes initial denaturation 
95˚C   15 seconds denaturation 
*35-50 cycles      *50-55˚C  *30 seconds – 1 minute annealing 
72˚C   *15 seconds – 2 minutes elongation 
72˚C   5 minutes 
4˚C hold 
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* At temperature and duration given in Table 2.2B and C for specific primer pairs  
PCR primers (MWG Biotech) for the amplification of bisulfite modified DNA were designed as 
described in Section 2.5.1.1 using the PyroMark Assay Design Software (Qiagen) to ensure 
compatibility with the pyrosequencing assay. Antisense pyrosequencing primers were designed with a 
5’ biotin label. For assay specific cycling parameters see Table 2.2C. 
2.5.2 Restriction digest 
Typically, DNA was incubated at 37 ºC for 2 hours with 2 μl of 10x restriction enzyme buffer (see 
individual Sections for enzyme specific buffer and manufacturer), 0.2 µl of 10 µg/ml BSA and 0.5 μl 
(5 U) of the restriction endonuclease/s (see individual Sections for manufacturer) and water to a final 
volume of 20 µl. 
2.5.3 Agarose gel electrophoresis 
PCR products and restriction digested DNA were analysed on a 1 % gel prepared by boiling 0.5 g 
Agarose and 50 ml of 1 x TBE buffer diluted from a stock of 10 x TBE buffer (Tris base 108 g, Boric 
Acid 55 g, EDTA 9.3 g, 1 L MQH2O pH 8.3) then 2 µl of 10 mg/ml ethidium bromide were added. 
Eight microlitres of PCR product were mixed with 2 μl loading dye (50 mM Tris-HCl pH 8, 5 mM 
EDTA, 20 % glycerol and 0.1 % Bromophenol Blue) and the sample was loaded onto the gel. A 1000 
bp ladder, (Hyperladder IV; Bioline) or 10000 bp ladder (Hyperladder I; Bioline) were used as size 
markers. The gel was run at 70 V for 30 minutes and DNA bands were visualised under UV light 
using a gel documentation system (Uvitec (model BTS-26M), UK). 
2.5.4 SYBR® Green Agarose Gel Electrophoresis 
Bisulfite modified, HinfI digested, PCR products were analysed on a 3 % gel prepared by boiling 4.5 g 
agarose and 150 ml of 1 x TBE buffer diluted from a stock of 10 x TBE buffer (Tris base 108 g, Boric 
Acid 55 g, EDTA 9.3 g, 1 L MQH2O pH 8.3). Twelve microlitres of PCR product were mixed with 2 
μl loading dye (50 mM Tris-HCl pH 8, 5 mM EDTA, 20 % glycerol and 0.1 % bromophenol blue) and 
the sample was loaded onto the gel. A 1000 bp ladder, (Hyperladder IV; Bioline) was used as a size 
marker. The gel was run at 120 V for 1 hour 30 minutes after which the gel was incubated shaking at 4 
ºC in 20 µl of 10 000 x concentrated SYBR
®
 green stain in DMSO (Invitrogen) diluted in 200 ml of 
TBE. DNA bands were visualised under UV light using a gel documentation system (UVItec (model 
BTS-26M), UK). DNA band intensities were measured using densitometry software (UVItec 
(UVIBand software), UK) on the gel documentation system (UVItec (model BTS-26M), UK).  
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2.6 DNA methylation analysis 
2.6.1 Bisulfite conversion of DNA 
DNA was bisulfite modified using the EZ DNA Methylation-Gold™ Kit (Zymo Research Corp.) to 
convert unmethylated cytosines to uracils following the manufacturer’s protocol.  
2.6.2 Measurement of DNA methylation using the COBRA Assay 
DNA was bisulfite modified as described in Section 2.6.1. The bisulfite modified products were then 
PCR amplified using high specificity HotStarTaq DNA polymerase (Qiagen) (Section 2.5.1.2) with 
primers specific to the LINE-1 retrotransposon (see Table 2.2B) and 10 µl of this PCR product was 
incubated at 37 ºC for 2 hours with 2 μl of 10x RE buffer (Fermentas) and 1 μl (5 U) of HinfI 
(Fermentas) and water to a final volume of 20 µl. Digested PCR products were analyses using SYBR
®
 
Green Agarose Gel Electrophoresis (Section 2.5.4).  
2.6.2.1 Data analysis of COBRA Assay 
DNA methylation was calculated arbitrarily as the ratio of uncut to cut PCR product as determined by 
densitometric quantification of SYBR green-stained agarose gels. Results are shown as means ± 
standard error of the mean (SEM) for all experiments. Statistical analysis was performed using the 
statistical software package InStat (GraphPad), statistical tests used are stated in the figure legends. 
Data was taken to differ significantly at a p value of 0.05 or less.  
2.6.3 Measurement of DNA methylation using Qiagen PyroMark MD System 
2.6.3.1 Primer and assay design 
Pyrosequencing assays and primers were designed using PyroMark Assay Design Software 2.0 
(Qiagen). Biotin (5’)-labelled PCR products were designed to be around 200 nucleotides in length and 
contain no CpG sites within the primer sequences. Sequencing primers were designed to anneal 
upstream of the initial CpG site to be quantified.  
2.6.3.2 Pyrosequencing using Qiagen PyroMark MD system 
Ten microlitres of biotinylated PCR product (Section 2.5.1.2) was purified and the biotinylated strand 
was separated use as a template in the pyrosequencing reaction by incubation with 80 μl binding 
master mix containing 2 μl streptavidin-coated sepharose beads (GE Healthcare), 38 μl binding buffer 
(Qiagen) and 40 μl H2O on a shaker for 10 minutes. The sequencing primer was diluted to 0.3 μmol/L 
in annealing buffer (Qiagen) and 12 μl was added to each well of a Pyromark MD 96 well plate 
(Qiagen). The vacuum tool on the PyroMark Vacuum Prep Workstation (Qiagen) was primed in MQ 
H2O for 30 seconds and then applied to the biotinylated PCR product/binding master mix. A series of 
5 second washes (70 % ethanol, denaturing buffer (0.2 mol/L NaOH solution) and wash buffer 
(Qiagen), respectively) removed contaminants. The vacuum was removed and the purified single-
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stranded PCR products, with primers annealed, were then added to the Pyromark MS 96 well plate 
containing sequencing primer by immersion of the probes, and the beads were shaken off. The 96 well 
plate was then incubated at 80 ºC for two minutes, cooled to room temperature and transferred to the 
PyroMark MD
™
 system (Qiagen). The principle of pyrosequencing is outlined in Section 1.5.3. 
2.6.3.3 Standard Curves 
Standard curves were generated for all sequencing primers to confirm linear amplification of 
methylated and unmethylated DNA controls. Unmethylated template DNA through the removal of 
methyl groups by PCR amplification using primers as specified (see Table 2.2C). Nine microlitres of 
unmethylated control PCR product was methylated in vitro as described in Section 2.2.4. Nine 
microlitres of methylated or 25 µl unmethylated was then bisulfite modified as described in Section 
2.6.1 and reactions were combined to give appropriate methylated percentages (0, 5, 10, 25, 50, 75, 
90, 95, 100 % methylated) in a total volume of 10 µl. PCR reactions for each sequencing primer were 
carried out in duplicate for each methylation percentage and a standard curve was generated. Non 
linear amplification indicated biased amplification of methylated or unmethylated DNA and assays 
deemed unreliable were redesigned. Typical methylation standard curves for each gene analysed are 
shown in Appendix C. 
2.6.3.4 Data analysis 
Data were analysed using PyroMark CpG software 1.0.11 (Qiagen). The ratio of converted cytosine 
(thymine) to unconverted cytosine within each CpG site (C/T) was used to determine the percentage 
DNA methylation at each CpG site. An inbuilt control, a cytosine not followed by a guanine, acts to 
assess the efficiency of the bisulfite modification step, as the cytosine should not be methylated and so 
upon bisulfite treatment be fully converted to a thymine following PCR. Output from the analysis 
using the PyroMark software indicated if reaction met the required quality threshold. 
2.6.4 Measurement of DNA methylation using the CDC7 assay 
Two micrograms of genomic DNA were bisulfite modified. The bisulfite modified DNA was subject 
to two rounds of PCR amplification. Primers were designed to the CDC7 sequence, focusing on a 
region containing CpG sites that could be analysed for DNA methylation. The first PCR was to a 912 
bp region of the CDC7 sequence and performed using HotStar Taq Master Mix, 0.25 μM sense and 
antisense primers (CDC7#1F and CDC7#1R) and 2 μl bisulfite-modified genomic DNA made up to a 
final volume of 50 μl with water. The second round of PCR performed was a nested PCR to a smaller 
301 bp region within the CDC7 sequence focusing in on eight specific CpG sites. PCR reactions 
contain HotStar Taq Master Mix, 0.25 μM sense primer (CDC7#2R), 0.20 μM biotinylated antisense 
primer (CDC7#2F) and 4 μl PCR#1 DNA template made up to a final volume of 50 μl with water. 
Primer annealing sites in the CDC7 sequence are displayed in Figure 6.1 and primer sequences and 
annealing temperatures are outlined in Table 2.2C. PCR product size was confirmed by agarose gel 
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electrophoresis and 5 μl used for pyrosequencing as described in Section 2.6.3. The CDC7 primers and 
sequencing primer (CDC7Seq) used in the second PCR were designed using the PyroMark Assay 
Design Software 2.0 (Qiagen). 
2.6.5 Measurement of DNA methylation using the EIF5 assay 
Two micrograms of genomic DNA were bisulfite modified. The bisulfite modified DNA was subject 
to two rounds of PCR amplification. Primers were designed to the EIF5 sequence, focusing on a 
region containing CpG sites that could be analysed for DNA methylation. The first PCR was to a 949 
bp region of the EIF5 sequence and performed using HotStar Taq Master Mix, 0.25 μM sense and 
antisense primers (EIF5#1F and EIF5#1R) and 2 μl bisulfite-modified genomic DNA made up to a 
final volume of 50 μl with water. The second round of PCR performed was a nested PCR to a smaller 
302 bp region within the EIF5 sequence focusing in on eight specific CpG sites. PCR reactions contain 
HotStar Taq Master Mix, 0.25 μM sense primer (EIF5#2R), 0.20 μM biotinylated antisense primer 
(EIF5#2F) and 4 μl PCR#1 DNA template made up to a final volume of 50 μl with water. Primer 
annealing sites in the EIF5 sequence are displayed in Figure 6.3 and primer sequences and annealing 
temperatures are outlined in Table 2.2C. PCR product size was confirmed by agarose gel 
electrophoresis and 5 μl used for pyrosequencing as described in Section 2.6.3. The EIF5 primers and 
sequencing primer (EIF5Seq) used in the second PCR were designed using the PyroMark Assay 
Design Software 2.0 (Qiagen). 
2.6.6 Measurement of DNA methylation using the IRX3 assay 
Two micrograms of genomic DNA were bisulfite modified. The bisulfite modified DNA was subject 
to two rounds of PCR amplification. Primers were designed to the IRX3 sequence, focusing on a 
region containing CpG sites that could be analysed for DNA methylation. The first PCR was to a 993 
bp region of the IRX3 sequence and performed using HotStar Taq Master Mix, 0.25 μM sense and 
antisense primers (IRX3#1F and IRX3#1R) and 2 μl bisulfite-modified genomic DNA made up to a 
final volume of 50 μl with water. The second round of PCR performed was a nested PCR to a smaller 
437 bp region within the IRX3 sequence focusing in on three specific CpG sites. PCR reactions 
contain HotStar Taq Master Mix, 0.25 μM sense primer (IRX3#2R), 0.20 μM biotinylated antisense 
primer (IRX3#2F) and 4 μl PCR#1 DNA template made up to a final volume of 50 μl with water. 
Primer annealing sites in the IRX3 sequence are displayed in Figure 6.5 and primer sequences and 
annealing temperatures are outlined in Table 2.2C. PCR product size was confirmed by agarose gel 
electrophoresis and 5 μl used for pyrosequencing as described in Section 2.6.3. The IRX3 primers and 
sequencing primer (IRX3Seq) used in the second PCR were designed using the PyroMark Assay 
Design Software 2.0 (Qiagen). 
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2.6.7 Measurement of DNA methylation using the KLF3 assay 
Two micrograms of genomic DNA were bisulfite modified. The bisulfite modified DNA was subject 
to two rounds of PCR amplification. Primers were designed to the KLF3 sequence, focusing on a 
region containing CpG sites that could be analysed for DNA methylation. The first PCR was to a 904 
bp region of the KLF3 sequence and performed using HotStar Taq Master Mix, 0.25 μM sense and 
antisense primers (KLF3#1F and KLF3#1R) and 2 μl bisulfite-modified genomic DNA made up to a 
final volume of 50 μl with water. The second round of PCR performed was a nested PCR to a smaller 
309 bp region within the KLF3 sequence focusing in on six specific CpG sites. PCR reactions contain 
HotStar Taq Master Mix, 0.25 μM sense primer (KLF3#2R), 0.20 μM biotinylated antisense primer 
(KLF3#2F) and 4 μl PCR#1 DNA template made up to a final volume of 50 μl with water. Primer 
annealing sites in the KLF3 sequence are displayed in Figure 6.7 and primer sequences and annealing 
temperatures are outlined in Table 2.2C. PCR product size was confirmed by agarose gel 
electrophoresis and 5 μl used for pyrosequencing as described in Section 2.6.3. The KLF3 primers and 
sequencing primer (KLF3Seq) used in the second PCR were designed using the PyroMark Assay 
Design Software 2.0 (Qiagen). 
2.6.8 Measurement of DNA methylation using the LINE-1 assay 
Two micrograms of genomic DNA were bisulfite modified. The bisulfite modified DNA was subject 
to two rounds of PCR amplification. Primers were designed to the LINE-1 retrotransposon sequence, 
focusing on a region containing CpG sites that could be analysed for DNA methylation. The first PCR 
was to a 529 bp region of the LINE-1 sequence and performed using HotStar Taq Master Mix, 0.25 
μM sense and antisense primers (LINE1#1F and LINE1#1R) and 2 μl bisulfite-modified genomic 
DNA made up to a final volume of 50 μl with water. The second round of PCR performed was a 
nested PCR to a smaller 146 bp region within the LINE-1 sequence focusing in on three specific CpG 
sites. PCR reactions contain HotStar Taq Master Mix, 0.25 μM sense primer (LINE1#2R), 0.20 μM 
biotinylated antisense primer (LINE1#2F) and 4 μl PCR#1 DNA template made up to a final volume 
of 50 μl with water. Primer annealing sites in the LINE-1 retrotransposon sequence are displayed in 
Figure 3.1 and primer sequences and annealing temperatures are outlined in Table 2.2C. PCR product 
size was confirmed by agarose gel electrophoresis and 5 μl used for pyrosequencing as described in 
Section 2.6.3. The LINE-1 primers and sequencing primer (LINE1Seq) used in the second PCR were 
designed using the PyroMark Assay Design Software 2.0 (Qiagen). 
2.6.9 Measurement of DNA methylation using the LUMA assay 
DNA (200 ng) from cells was digested using a combination of EcoRI plus MspI or EcoRI plus HpaII 
(New England Biolabs). Restriction digests were set up in a 96 well format and incubated at 37 ºC for 
4 hours with 2 μl of Tango buffer (New England Biolabs) and 2.5 U of EcoRI or MspI or 5 U of HpaII 
in a final volume of 20 µl. Reactions were then transferred to a 96 well pyrosequencing plate and 20 μl 
of Annealing Buffer (Qiagen) added to each reaction. Pyrosequencing reactions were performed in the 
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PyroMark MD
™
 system (Qiagen). The nucleotide dispensation order was programmed as: ACTCGA. 
Methylation was then quantified using the PyroMark CpG software 1.0.11 (Qiagen) to analyse the 
peak heights at each nucleotide dispensation. The MspI/EcoRI and HpaII/EcoRI ratios were calculated 
by the ratio of ‘C’ peak‘/A’ peak in the two respective digestions. The MspI /HpaII ratio was then 
calculated as (MspI/EcoRI)/(HpaII/EcoRI). The principle of LUMA is outlined in Section 1.5.4. 
2.6.10 Measurement of DNA methylation using the PCYT1A assay 
Two micrograms of genomic DNA were bisulfite modified. The bisulfite modified DNA was subject 
to two rounds of PCR amplification. Primers were designed to the PCYT1A sequence, focusing on a 
region containing CpG sites that could be analysed for DNA methylation. The first PCR was to a 939 
bp region of the PCYT1A sequence and performed using HotStar Taq Master Mix, 0.25 μM sense and 
antisense primers (PCYT1A#1F and PCYT1A#1R) and 2 μl bisulfite-modified genomic DNA made 
up to a final volume of 50 μl with water. The second round of PCR performed was a nested PCR to a 
smaller 433 bp region within the PCYT1A sequence focusing in on two specific CpG sites. PCR 
reactions contain HotStar Taq Master Mix, 0.25 μM sense primer (PCYT1A #2R), 0.20 μM 
biotinylated antisense primer (PCYT1A#2F) and 4 μl PCR#1 DNA template made up to a final 
volume of 50 μl with water. Primer annealing sites in the PCYT1A sequence are displayed in Figure 
6.9 and primer sequences and annealing temperatures are outlined in Table 2.2C. PCR product size 
was confirmed by agarose gel electrophoresis and 5 μl used for pyrosequencing as described in 
Section 2.6.3. The PCYT1A primers and sequencing primer (PCYT1ASeq) used in the second PCR 
were designed using the PyroMark Assay Design Software 2.0 (Qiagen). 
2.6.11 Measurement of DNA methylation using the PTPRG assay 
Two micrograms of genomic DNA were bisulfite modified. The bisulfite modified DNA was subject 
to two rounds of PCR amplification. Primers were designed to the PTPRG sequence, focusing on a 
region containing CpG sites that could be analysed for DNA methylation. The first PCR was to a 917 
bp region of the PTPRG sequence and performed using HotStar Taq Master Mix, 0.25 μM sense and 
antisense primers (PTPRG#1F and PTPRG#1R) and 2 μl bisulfite-modified genomic DNA made up to 
a final volume of 50 μl with water. The second round of PCR performed was a nested PCR to a 
smaller 501 bp region within the PTPRG sequence focusing in on nine specific CpG sites. PCR 
reactions contain HotStar Taq Master Mix, 0.25 μM sense primer (PTPRG#2R), 0.20 μM biotinylated 
antisense primer (PTPRG#2F) and 4 μl PCR#1 DNA template made up to a final volume of 50 μl with 
water. Primer annealing sites in the PTPRG sequence are displayed in Figure 6.11 and primer 
sequences and annealing temperatures are outlined in Table 2.2C. PCR product size was confirmed by 
agarose gel electrophoresis and 5 μl used for pyrosequencing as described in Section 2.6.3. The 
PTPRG primers and sequencing primer (PTPRGSeq) used in the second PCR were designed using the 
PyroMark Assay Design Software 2.0 (Qiagen). 
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2.6.12 Measurement of DNA methylation using the SLC39A4 assay 
Two micrograms of genomic DNA were bisulfite modified. The bisulfite modified DNA was subject 
to two rounds of PCR amplification. Primers were designed to the SLC39A4 sequence, focusing on a 
region containing CpG sites that could be analysed for DNA methylation. The first PCR was to a 900 
bp region of the SLC39A4 sequence and performed using HotStar Taq Master Mix, 0.25 μM sense 
and antisense primers (SLC39A4#1F and SLC39A4#1R) and 2 μl bisulfite-modified genomic DNA 
made up to a final volume of 50 μl with water. The second round of PCR performed was a nested PCR 
to a smaller 282 bp region within the SLC39A4 sequence focusing in on three specific CpG sites. PCR 
reactions contain HotStar Taq Master Mix, 0.25 μM sense primer (SLC39A4#2R), 0.20 μM 
biotinylated antisense primer (SLC39A4#2F), 3 μl 50 mM MgCl2 (Bioline) and 4 μl PCR#1 DNA 
template made up to a final volume of 50 μl with water. Primer annealing sites in the SLC39A4 
sequence are displayed in Figure 6.13 and primer sequences and annealing temperatures are outlined 
in Table 2.2C. PCR product size was confirmed by agarose gel electrophoresis and 5 μl used for 
pyrosequencing as described in Section 2.6.3. The SLC39A4 primers and sequencing primer 
(SLC39A4Seq) used in the second PCR were designed using the PyroMark Assay Design Software 
2.0 (Qiagen). 
2.6.13 Measurement of DNA methylation using the TBX3 assay 
Two micrograms of genomic DNA were bisulfite modified. The bisulfite modified DNA was subject 
to two rounds of PCR amplification. Primers were designed to the TBX3 sequence, focusing on a 
region containing CpG sites that could be analysed for DNA methylation. The first PCR was to a 912 
bp region of the TBX3 sequence and performed using HotStar Taq Master Mix, 0.25 μM sense and 
antisense primers (TBX3#1F and TBX3#1R) and 2 μl bisulfite-modified genomic DNA made up to a 
final volume of 50 μl with water. The second round of PCR performed was a nested PCR to a smaller 
240 bp region within the TBX3 sequence focusing in on three specific CpG sites. PCR reactions 
contain HotStar Taq Master Mix, 0.25 μM sense primer (TBX3#2R), 0.20 μM biotinylated antisense 
primer (TBX3#2F) and 4 μl PCR#1 DNA template made up to a final volume of 50 μl with water. 
Primer annealing sites in the TBX3 sequence are displayed in Figure 6.15 and primer sequences and 
annealing temperatures are outlined in Table 2.2C. PCR product size was confirmed by agarose gel 
electrophoresis and 5 μl used for pyrosequencing as described in Section 2.6.3. The TBX3 primers and 
sequencing primer (TBX3Seq) used in the second PCR were designed using the PyroMark Assay 
Design Software 2.0 (Qiagen). 
2.6.14 Measurement of DNA methylation profile of human genome by Methylated DNA 
Immunoprecipitation (MeDIP) analysis 
2.6.14.1 Preparation of genomic DNA 
Genomic DNA was extracted from Caco-2 cells as described in Section 2.4.1. 
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2.6.14.2 Sonication of genomic DNA 
Genomic DNA was fragmented into 200 – 1000 bp lengths by sonication using an ultrasonic 
homogeniser (4710 Series; Cole Palmer). Fragmented DNA was then purified using the DNA Clean 
and Concentrator 25 kit (Zymo Research) following the manufacturer’s protocol eluting in 50 µl of 
water and quantified (Section 2.4.4). 
2.6.14.3 Preparation of internal controls 
Unmethylated (negative) and methylated (positive) internal controls were generated to spike genomic 
DNA samples to calculate enrichment within the methylated fraction after immunoprecipitation. Two 
different fragments of ~500 bp in length were PCR amplified from Lambda phage dam dcm- genomic 
DNA (Fermentas) using high specificity HotStarTaq DNA polymerase (Qiagen) (Section 2.5.1.2; for 
primers see Table 2.2B) producing unmethylated PCR products. PCR products were purified as 
described in Section 2.2.4.1. Up to 5 µg of one unmethylated PCR product was then methylated in 
vitro as described in Section 2.2.4 and 2.2.4.1 to produce a purified methylated control. Purified 
unmethylated and methylated controls were diluted to a concentration of 10ng/μl with water and 
stored in aliquots at -20 ºC. The methylation status of the unmethylated and methylated controls was 
assessed by restriction digest of DNA (200 ng) with 2.5 U of the methylation sensitive restriction 
enzyme AciI (Fermentas) as described in Section 2.5.2.  
2.6.14.4 Immunoprecipitation of methylated DNA (MeDIP) 
Purified fragmented DNA (4.4 µg) (Section 2.6.14.2) was diluted to 487 µl with water, 4 µl (40 ng) of 
negative and positive internal control (Section 2.6.14.3) were added to each sample. The spiked 
fragmented DNA was denatured at 95 °C for 10 minutes on a heated shaker at 1000 rpm and 
immediately cooled on ice for a further 10 minutes. Forty five microlitres of spiked fragmented DNA 
was transferred to a separate microtube to act as an input and stored at 4 °C. Fifty one microlitres of 
10x Immunoprecipitation Buffer (100 mM Na-Phosphate pH 7.0, 1.4 M NaCl, 0.5 % Triton X-100) 
and 12 µl 5-methylcytidine (5mC) antibody (Eurogentec) was added to the remainder of the spiked 
fragmented DNA and the sample was incubated at 4 °C for 2 hours on a rotating wheel.  
 
During the 2 hour incubation sheep anti-mouse IgG Dynabeads (Invitrogen) were prepared, the 
Dynabeads were vortexed briefly before transferring 48 µl of beads per sample into a microtube. The 
Dynabeads were captured with a magnetic rack (Invitrogen) for 1 minute and the preservative solution 
was discarded. The Dynabeads were then washed twice with 800 µl of 1x Immunoprecipitation Buffer 
for 5 minutes shaking at 500 rpm and captured with the magnetic rack for 1 minute and the was 
solution was discarded. The Dynabeads were then resuspended in 48 µl of 1x Immunoprecipitation 
Buffer per DNA sample.  
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Forty eight microlitres of the Dynabeads suspension was added to each DNA/antibody sample and 
incubated at 4 °C for 2 hours on a rotating wheel. The Dynabeads/DNA were captured with a magnetic 
rack for 1 minute and the solution discard. The Dynabeads/DNA were then washed three times in 700 
µl of 1x Immunoprecipitation buffer for 10 minutes shaking at 1000 rpm, captured with a magnetic 
rack for 1 minute and the solution discard. The Dynabeads/DNA were then resuspended in 250 µl of 
1x Proteinase K Digestion Buffer (50 nM Tris pH8.0, 10 mM EDTA, 0.5 % SDS). Seven microlitres 
of Proteinase K (10 mg/ml stock; Roche) was added per sample to cleave the DNA/5mC antibody 
from the Dynabeads through incubation at 50 °C for 2 hours on heated shaker at 1000 rpm to prevent 
bead sedimentation. The Dynabeads were captured with a magnetic rack for 1 minute and the solution 
containing the DNA and 5mC antibody was transferred to a new microtube. The DNA sample 
enriched with the methylated fraction (hereafter referred to as MeDIP DNA was then purified using 
the DNA Clean and Concentrator 5 kit (Zymo Research) following the manufacturer’s protocol, 
eluting in 15 µl of water, and quantified as single-stranded DNA (Section 2.4.4). Samples were diluted 
to 2 ng/µl with water. 
2.6.14.5 Whole genome amplification of input and MeDIP DNA products 
Eleven microlitres of Input or MeDIP DNA (2 ng/µl) was whole genome amplified using the 
GenomePlex
®
 Complete Whole Genome Amplification kit following the manufacturer’s protocol. 
Whole genome amplified products were then purified using the GenElute
™
 PCR Clean-Up kit 
following the manufacturer’s protocol, eluting in 50 µl of water, and quantified (Section 2.4.4). Three 
hundred nanograms of each whole genome amplification product was analysed by agarose gel 
electrophoresis (Section 2.5.3) to check that DNA was still within the 200 – 1000 bp range. Five 
micrograms of each input and MeDIP whole genome-amplified DNA sample (250 ng/µl) was 
transferred to a new microtube for array hybridisation. The remainder of each whole genome-
amplified DNA sample was diluted to 25 ng/µl with water for enrichment analysis by qPCR. 
2.6.14.6 Enrichment analysis by qPCR 
Reactions using primers to negative and positive controls (see Table 2.2D) were set up as described in 
Section 2.7.2.4 for each input and MeDIP DNA sample. Enrichment for each sample was calculated 
using the CT values generated for each sample and applying the following equation: 
 
2 ^ [MeDIP (CT Positive – CT Negative) – Input (CT Positive – CT Negative)] 
2.6.14.7 Methylome profiling 
The methylation profile of DNA samples was investigated using the DNA Methylation Service 
provided by NimbleGen Roche (Reykjavik, Iceland). After preparation and confirmation of quality 
(Sections 2.6.15.1 – 2.6.15.6), DNA samples were sent for array analysis by NimbleGen Roche. Input 
and MeDIP DNA samples were labelled using the NimbleGen Dual-Colour DNA Labelling Kit with 
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Cy3 and Cy5 respectively. The labelled samples were then co-hybridised to the Human 3x720K CpG 
Island Plus RefSeq Promoter Array using the NimbleGen Hybridisation System. The hybridised arrays 
were then washed with the NimbleGen Wash Buffer Kit, dried with the NimbleGen Microarray Drier 
and signal peak intensities for each probe measured with the NimbleGen MS 200 Microarray Scanner.  
2.6.14.8 Data analysis by microarray 
Data was provided as signal intensity data for each probe and calculate p-values which indicated if 
DNA fragments hybridising to the probe on the array were enriched for the methylated fraction (Cy5 
signal > Cy3 signal). These data were used to detect peaks through manual inspection in Excel 
(Microsoft), accepting positive enrichment being where at least 2 probes met a >2 p-value minimum 
cut off. 
2.7 RNA analysis 
2.7.1 Measurement of mRNA expression analysed by reverse transcriptase PCR 
2.7.1.1 Preparation of RNA 
RNA was extracted from Caco-2 cells as described in 2.4.2. 
2.7.1.2 DNase treatment of RNA 
RNA (4.5 µg) was added to a mixture of 4.5 U DNase (Roche) and 2 µl 10X DNase buffer (Roche) 
with RNase free water to a final volume of 20 µl. The reaction was incubated at 37 °C for 30 minutes 
after which 4 µl of stop solution (EDTA, 20 mM, pH 8.0) was added. A further incubation of the 
sample at 65 °C for 10 minutes was carried out then the RNA was placed on ice if required for use 
immediately or stored at -80°C.  
2.7.1.3 Reverse transcription of RNA 
RNA from Caco-2 cells (5µl) was reverse transcribed to cDNA using Superscript
™
 III RNase H- 
Reverse Transcriptase (Invitrogen). RNA was added to 0.4 µl of 0.5 mM dNTPs (Bioline), 50 ng 
random primers (Promega) and RNase free water to a final volume of 13 µl. The reaction was heated 
at 65 ºC for 5 minutes. One microlitre of RNase Inhibitor (40 U/µl) (Promega), 1 µl Superscript™ III 
RT (200 U/µl), 4 µl 15x First Strand Buffer (250 mM Tris-HCl pH 8.3, 375 mM KCl, 15 mM MgCl2) 
and 0.1 μl 0.1 M DTT were mixed into the reaction by pipetting. The reaction was then heated to 25 
ºC for 5 minutes, 50 ºC for 45 minutes, and then 70 ºC for 15 minutes using a Thermohybaid PX2™ 
thermal cycler. Absence of DNA contamination of the RNA sample or reagents was confirmed with a 
negative control, where the reaction was repeated with the exclusion of the Superscript™ III RT. 
2.7.1.4 PCR amplification of reverse transcribed cDNA 
PCR of reverse transcribed cDNA was as described in Section 2.5.1.1. 
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2.7.2 Measurement of mRNA expression analysed by qRT-PCR 
2.7.2.1 Preparation of RNA 
RNA was extracted from Caco-2 cells as described in 2.4.2. 
2.7.2.2 DNase treatment of RNA 
RNA was DNase treated as described in Section 2.7.1.2 
2.7.2.3 Reverse transcription of RNA 
RNA was reverse transcribed to cDNA as described in Section 2.7.1.3 
2.7.2.4 qPCR using the Roche LightCycler® 480 
PCR reactions were set up in LightCycler
® 96 well plates and contained 1 μl cDNA (diluted 1 in 4 
with water), 10 μl LightCycler® 480 SYBR Green I Master (Roche), 0.5 μM sense and antisense 
primers (MWG Biotech; Table 2.2D) and water to a final volume of 20 μl. Cycling parameters were as 
follows: 
 
                                              95˚C   5 minutes initial denaturation 
95˚C   10 seconds denaturation 
45 cycles      *52 - 60˚C  10 seconds annealing 
72˚C   15 seconds elongation 
 
* At temperature given in Table 2.2D for specific primer pairs.  
Fluorescence was detected for each PCR cycle and the threshold crossing points (CT values) 
determined. A melt curve peak analysis was performed at the end of all reactions to ensure 
amplification of a single product. Each sample was measured in duplicate. Typical amplification 
curves for each gene analysed are shown in Appendix D. 
2.7.2.5 Standard Curves 
Standard curves were generated for all target and reference genes to confirm linear amplification of 
PCR products. Undiluted cDNA extracted from untreated Caco-2 cells was used to create an 8 point 2-
fold dilution series. Dilution concentrations were plotted against CT values to generate a standard 
curve. Each dilution standard was measured in duplicate. A standard curve was run for each qRT-PCR 
analysis. Typical standard curves for each gene analysed are shown in Appendix D. 
2.7.2.6 Data analysis 
Expression of all target and reference genes was calculated for each sample using the gene specific 
standard curve generated during each run and reading off the CT values. Each target cDNA 
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concentration was then normalised to the average value of the reference gene from the sample cDNA 
preparation. 
2.7.3 Measurement of mRNA expression analysis by hybridisation to DNA microarray 
2.7.3.1 Preparation of RNA 
RNA was extracted from Caco-2 cells as described in Section 2.4.3, and quality and integrity was 
checked as described in Sections 2.4.4 and 2.4.5 respectively.  
2.7.3.2 Gene expression profiling 
Gene expression profiling of RNA samples was investigated using the Illumina Gene Expression 
Service provided by Service XS (Leiden, The Netherlands). RNA samples were reverse transcribed to 
produce a cDNA template that was then amplified by in vitro transcription, incorporating biotin-
labelled nucleotides. This labelled RNA sample was then hybridised to the HumanHT-12 v4 
Expression BeadChip (Illumina), the signal developed with Streptavidin-Cy3 and the BeadChip 
scanned. After scanning the Illumina Whole-genome Gene Expression For BeadStation system 
extracted gene expression data from the scan images and the intensity value for each probe was 
calculated.  
2.7.3.3 Data analysis 
Raw data generated from the microarray was imported into GeneSpring GX 11 (Agilent) for 
visualisation. Hierarchical clustering was used to assess the similarity of biological replicates. Probes 
were considered further if the detection p-value was >0.6 in all samples in a replicate group. 
RankProducts (Breitling et al., 2004) analysis was used to determine differential expression between 
groups using the RankProd (Hong et al., 2006) package from BioConductor (Gentleman et al., 2004) 
to report probes with a p.f.p of <0.05 over 100 permutations of the class labels with a resulting fold 
change of >1.5. 
2.8 Protein analysis 
2.8.1 Western blotting 
2.8.1.1 Tissue preparation 
Tissue samples were ground with a pestle and mortar in the presence of liquid nitrogen and added to 
500 µl of protein buffer (100 mM NaCl, 10 mM Tris HCl, 1 mM EDTA, 1 % NP-40 and 1 protease 
inhibitor tablet per 10 ml of protein buffer). Tissues were further lysed by repeated (10x) 
homogenisation with a needle and syringe. The tissue lysate was centrifuged at 13,000 g for 15 
minutes at 4 ºC and the supernatant fluid was transferred to a new 1.5 ml microtube tube and stored at 
-80 ºC for further analysis. 
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2.8.1.2 Whole cell lysate preparation 
Cells were harvested 96 hours after transfection. Cells in each well were washed with 1 ml of 1 x PBS, 
which was then removed and replaced with 1 ml ice cold 1 x PBS plus 1 protease inhibitor tablet 
(Roche) per 10 ml of PBS. Cells were collected using a cell scraper (Greiner) and transferred to a new 
1.5 ml microtube tube. Cells were then centrifuged at 13,000 g for 15 minutes at 4 ºC. Supernatant 
fluid was discarded and the pellet was stored at -80 ºC for further analysis. For further analysis the 
pellet was resuspended in 50 µl of suspension buffer (100 mM NaCl, 10 mM Tris HCl, 1 mM EDTA 
and 1 protease inhibitor tablet per 10 ml of suspension buffer). 
2.8.1.3 Histone lysate preparation 
Cells were harvested 96 hours after transfection. Two millilitres of cold lysis buffer (10 mM Tris, 50 
mM sodium bisulfite, 1 % Triton X-100, 10 mM MgCl2 8.6 % sucrose and 1 protease inhibitor tablet 
per 10 ml of cold lysis buffer) were added to cells in each well. Cells were collected using a cell 
scraper and transferred to a new 20 ml tube. Cells were then centrifuged at 1900 rpm (700 g) for 15 
minutes. The pellet formed was then washed with 1 ml of cold lysis buffer and centrifuged at 1900 
rpm (700 g) for a further 15 minutes. The supernatant fluid was discarded and the cell pellet was 
stored at -20 ºC for further analysis. 
 
Histone proteins were extracted from pellets of lysed Caco-2 cells. Each pellet was resuspended in 100 
µl of water and then 100 µl of 0.4M H2SO4 was then added in a dropwise manner. The resuspended 
pellet was then incubated over night at 4 ºC. The resuspended pellet was then transferred to a 1.5 ml 
microtube tube and centrifuged at 10,000 g for 15 minutes. The supernatant was transferred to a new 
1.5 ml microtube tube and 1 ml of acetone (Sigma, UK) was added before being incubated over night 
at -20 ºC. Following this step, the acetone was removed and the sample was air dried for 5 minutes. 
Ten microlitres of 2M NaOH and 10 µl of water were added to the sample. 
2.8.1.4 Determination of protein concentration 
A Bradford assay was carried out to determine the histone protein concentration of each intestinal 
epithelial cell lysate. Standards of 0, 20, 40, 60, 80 and 100 μM were made in triplicate using a 100 
μg/ml bovine serum albumin standard solution and 50 μl of each were pipetted into a 96 well plate 
(SLS Ltd, UK). Intestinal epithelial cell lysates were diluted 1 in 50 for analysis and 50 μl was used in 
the assay. Biorad dye reagent concentrate (Biorad, UK) was diluted 1 in 5 from the stock with MQH2O 
and 200 μl was added to the 96 well plate on top of the standards and samples and the absorbance was 
measured at 595 nm on a plate reader (ThermoLab Systems Multiscan Acent). 
2.8.1.5 Electrophoresis of protein 
Protein samples were separated by SDS-PAGE. A 12.5 % separating gel was made up with 2.19 ml 40 
% Acrylamide/Bis Acrylamide Stock solution (37.5:1), 2.8 ml 2.5x separating gel buffer (1.875M Tris 
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base pH8.9 0.25 % SDS), 1.94 ml H2O. Six microlitres of N,N,N’,N’-Tetramethylethylenediamine 
(TEMED) diluted in water and 0.1 % (w/v) ammonium persulphate (from a 10 % stock solution) was 
added to polymerase the gel. A 5 % stacking gel containing the comb was placed on top of the 
separating gel. This gel was made up with 12.4 % (v/v) of 40 % Acrylamide/Bis Acrylamide (37.5:1), 
20 % (v/v) stacking gel buffer (0.3M Trisphosphate, 0.5 % SDS, pH6.7). Two and a half microlitres of 
N,N,N’,N’-Tetramethylethylenediamine (TEMED) diluted in water and 0.1 % (w/v) ammonium 
persulphate was added to set the gel. The gel was run in protein electrophoresis buffer (0.1 M Tris 
base, 0.384M glycine and 0.1 % SDS). Coloured protein ladders (high range markers (Sigma)) were 
run in parallel with the protein samples to determine the size of proteins detected. The ladder and 
samples were run in a vertical gel electrophoresis chamber (Atto, GRI, UK) at 120V until the blue dye 
reached the bottom of the gel. 
2.8.1.6 Blotting and detection of protein 
The proteins were transferred from the gel to a polyvinylidene difluride (PVDF) membrane (Roche, 
UK), by a semi-dry transfer method. The membrane was hydrated before transfer by incubating in 100 
% methanol (Fisher Scientific) for 30 seconds followed by 2 minutes in deionised water, and finally 
placed in transfer buffer (2.5 mM Tris base, 150 mM glycine, 10 % (w/v) methanol, pH 8.3 without 
adjustment) until use. Three layers of Grade 3 mm Whatman
®
 chromatography paper were soaked in 
transfer buffer and placed on the bottom electrode of the transfer apparatus (Atto, GRI, UK). Any air 
bubbles present between the layers of paper were removed before the membrane was laid on top of 
them. The SDS-PAGE gel was placed on top of the membrane followed by three more sheets of 
Whatman
®
 paper soaked in transfer buffer, followed by the removal of any air bubbles. The top 
electrode was positioned and transfer was carried out at 15V for 1 hour. 
 
After transfer of protein, the membrane was blocked to prevent non-specific binding of the antibodies 
to the membrane. The membrane was blocked with 5 % (w/v) dried milk powder (Marvel) in PBS 
containing 0.05 % (v/v) Tween 20, with over night shaking at 4 ºC. Primary antibodies (Table 2.3) 
were diluted in 5 % (w/v) dried milk powder in PBS containing 0.05 % (v/v) Tween 20 and were 
incubated with shaking for 1 hour. Bound unspecific primary antibody was removed by washing the 
membrane in PBS containing 0.05 % (v/v) Tween 20. The membrane was washed for 4 x 10 minute 
washes. After the washes the secondary antibodies (Table 2.3) were diluted in 5 % (w/v) dried milk 
powder in PBS and 0.5 % (v/v) Tween 20, and incubated with the membrane for 1 hour with shaking. 
Bound unspecific secondary antibody was removed by washing the membrane in PBS containing 0.05 
% (v/v) Tween 20 for 5 x 10 minute washes. 
 
The membrane was visualised using the Enhanced Chemiluminescence PLUS kit (Amersham 
Bioscience). This was followed by exposure of the membrane in a dark room with Kodak Biomax 
XAR film in a Hypercassette™ (Amersham Bioscience) for between 10 seconds and 5 minutes 
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(depending on the density of the signal). The films were developed in Kodak GBX developer followed 
by Kodak GBX fixer (Sigma).  
2.8.1.7 Staining of protein 
To assess loading efficiency of proteins when a house keeping antibody could not be used, SDS-
PAGE gels were stained with a colloidal blue staining kit (Invitrogen) according to the manufacturer’s 
instructions. Gels were incubated with shaking in 100 ml colloidal blue stain overnight. The following 
day the gel was incubated in 200 ml of deionised water until the background became clear. 
2.8.1.8 Band quantification by densitometry 
Protein band intensities were measured using densitometry software (UVItec (UVIBand software), 
UK) on a gel documentation system (UVItec (model BTS-26M), UK). 
2.8.2 Reporter gene assay 
The beta-galactosidase activity assay was used to measure the ability of a gene promoter region to 
drive the expression of the lacZ gene encoding beta-galactosidase. 
2.8.2.1  Total cell lysate preparation 
Cells were harvested 96 hours after transfection. Cells in each well were washed with 1 ml 1 x PBS 
which was then removed and replaced with 100 µl of lysis buffer (0.25 M Tris pH7.4, 0.25 % (v/v) 
NP-40, 2.5 mM EDTA). Cells were frozen at -20 ºC for a minimum of 30 minutes and then thawed at 
room temperature. Cells were collected using a cell scraper and transferred to a 1.5 ml microtube tube. 
Cell lysate was then centrifuged at 12,000 g for 5 minutes at 4 ºC. The supernatant fluid was 
transferred to a new 1.5 ml microtube tube. Pelleted cell debris was discarded. 
2.8.2.2 Determination of protein concentration 
Protein concentration was determined by Bradford assay as described in Section 2.8.1.4. 
2.8.2.3 Beta-galactosidase reporter assay 
The beta-galactosidase reporter assay is based on the conversion of chlorophenol red-β-D-
galactopyranoside (CPRG) to galactose and chlorophenol red in the presence of beta-galactosidase 
enzyme expression and is seen as a colour change from yellow to red. One hundred and thirty 
microlitres of 1.2 ng/ml CPRG (in a buffer containing 100 mM NaCl, 25 mM MOPS & 10 mM 
MgCl2 pH7.5) was added to a 96 well plate containing 20 µl of cell lysate (Section 2.8.2.1) to give a 
final volume of 150 µl. The reactions were timed upon incubated at 37 ºC until a colour change was 
observed. The reactions were stopped with the addition of 50 µl of 0.5 M Na2CO3. Absorbance was 
measured at 560 nm on a plate reader (Thermo LabsSystems Multiskan Acent). 
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2.8.2.4 Data analysis 
Beta-galactosidase activity was calculated as nmoles of chlorophenol red formed per minute per mg of 
total protein. Results are shown as means ± standard error of the mean (SEM) for all experiments. 
Statistical analysis was performed using the statistical software package InStat (GraphPad), statistical 
tests used are stated in the figure legends. Data were taken to differ significantly at a p value of 0.05 or 
less.  
2.8.3 Fluor de Lys™ fluorescent activity assay 
The Fluor de Lys™ fluorescent activity assay was used to measure the ability of endogenous SIRT1 to 
deacetylate the Fluor de Lys-SIRT1 substrate, comprising of the p53 sequence Arg-His-Lys. The 
procedure was carried out in accordance with the manufacturer’s instructions; with 
modifications/details as below 
2.8.3.1 Whole cell lysate preparation 
Whole cell lysate was prepared as described in Section 2.8.2.1. 
2.8.3.2 Determination of protein concentration 
Protein concentration was determined by Bradford assay as described in Section 2.8.1.4. 
2.8.3.3 Sirt1 fluorescent activity assay 
The SIRT1 fluorescent activity assay (BIOMOL
®
 International) is based on the deacetylation and 
sensitisation of the Fluor de Lys-SIRT1 substrate upon incubation of cell lysate containing 
endogenous SIRT1 together with the co-substrate NAD
+
. Upon treatment with the Fluor de Lys 
Developer II, a detectable fluorophore is produced. Twenty five microlitres of cell lysate was added to 
a 96 well plate containing 25 µl of 2x substrate solution (3 mM NAD
+
, 100 uM Fluor de Lys-SIRT1) 
and incubated at 37 ºC for 30 minutes after which 50 µl of stop solution (1 x Fluor de Lys Developer 
II, 2 mM Nicotinamide) was added to each reaction. Fluorescence emission was measured at 460 nm 
with an excitation wavelength of 355 nm, at 10 second intervals using the FLUOStar OPTIMA (BMG 
Labtechnologies) until readings plateaued. 
2.8.3.4 Data analysis 
SIRT1 activity was calculated as fluorophore fluorescence generated per minute per mg of total 
protein.  
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2.9 In silico bioinformatic analysis 
2.9.1 Gene identifier conversion 
To compare lists all gene identifiers were converted to the equivalent Ensembl identifier using the 
Ensembl Biomart Gene Conversion Tool at www.ensembl.org/biomart.  
2.9.2 Gene overlaps 
Gene lists converted into Ensembl identifiers were compared and duplicates identified using the 
Advanced Filter > Unique Records option in Excel (Microsoft). 
2.9.2.1 Data analysis of gene overlaps  
The representation factor for gene overlaps indicates whether the number of genes common between 
lists is more or less than expected from independent groups and was calculated by applying the 
following equation: 
 
X / [ ( n x D ) / N] 
 
Where X was the number of genes common between groups, n was the number of genes in one list, D 
the number of genes in the other list and N the total number of genes. A representation factor of >1 
indicated more overlap than would be expected in two independent groups. 
 
The cumulative hypergeometric probability indicates the probability that an n-trial hypergeometric 
experiment (number of genes on one list) results in greater than or equal to X overlaps, when the total 
gene lists consist of N items, D of which are the number of genes on the other list. Cumulative 
hypogeometric probability was calculated by applying the following equation: 
 
h ( ≥ X; N, n, D ) = [ DCX ] [ N-DCn-X ] / [ NCn ] 
 
Where X was the number of genes common between groups, n was the number of genes in one list, D 
the number of genes in the other list, N the total number of genes and DCX is the number of 
combinations of D things, taken X at a time. Cumulative hypogeometric probability was calculated 
using the StatTrek hypogeometric calculator at http://stattrek.com.  
 
2.9.3 Identification of CpG islands within gene promoter sequences 
The presence of a CpG island, typically located within the promoter region, in a target gene was 
investigated using an algorithm to analyse the promoter sequence of the gene for typical CpG Island 
features. 
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2.9.3.1 Determination of gene promoter sequence using Genomatix Gene2Promoter 
Gene promoter sequences were retrieved in FASTA format using the Gene2Promoter Software 
(Genomatix, Germany). All proposed promoter sequences were checked against the genomic 
transcript to ensure the promoter lay upstream of the start of transcription of the specific gene and in 
the correct orientation. 
2.9.3.2 CpG Island prediction using CpG Island Explorer 
Gene promoter sequences generated as described in Section 2.9.3.1 were analysed for the presence of 
CpG Islands using the CpGIE2.0 software based on (Wang and Leung, 2004) and parameters set to 50 
% GC content, 0.60 CpG observed/expected ratio and 200 bp minimum length.  
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2.10 Plasmids, Oligos and Antibodies 
Table 2.1. Plasmids 
 
Plasmid Source Insert 
   
pCMV6-Neo Origene Random Sequence 
pCMV6-ENTRYSIRT1 Origene Human SIRT1 ORF 
pBlue-TOPO Invitrogen  
   
 
Table 2.2. Oligos 
A 
siRNA Sequence 5'-3' 
  
SIRT1 siRNA #1 GCAACAGCAUCUUGCCUGAUUUGUA 
SIRT1 siRNA #2 UCAUAGAGCCAUGAAGUAUGACAAA 
  
 
B 
End Point Primer Name Sequence 5'-3' Length (bp) Annealing °C 
    
SIRT1F GGCAAAGGAGCAGATTAGTAGG 22 55 
SIRT1R CATCAGGCTCATCTTCTAAGCC 22 55 
    
RTPCR18sF AGGAATTGACGGAAGGGCACCAC 23 55 
RTPCR18sR GTGCAGCCCCGGACATCTAAGG 22 55 
    
LINE1COBRAF TTGAGTTGTGGTGGGTTTTATTTAG 25  
LINE1COBRAR TCATCTCACTAAAAAATACCAAACA 25  
    
SLC30A5PromoterF GGCCATGAAGTTTCGCACGTG 21 55 
SLC30A5PromoterR CGGCTCCGGCTCACTAGCACACAC 24 55 
    
pBlueTOPOR CATTTGCTGTCCACCAGTCATGC 23 55 
    
SIRT1PromoterF GGAAGGGCTTTCCACTAAGC 20 55 
SIRT1PromoterR CTTCCAACTGCCTCTCTGG 19 55 
    
GAPDHPromoterF GAGCCTCGAGGAGAAGTTCC 20 60 
GAPDHPromoterR AAGAAGATGCGGCTGACTGT 20 60 
    
λM#1F AGCAACCAACAAGAAAACACT 21 60 
λM#1R TCATCCTCGGCAAACTCTTT  21 60 
    
λUM#1F GTGAGGTGAATGTGGTGAAGT  22 60 
λUM#1R TCGCAGAGATAAAACACGCT 20 60 
    
  
  
C 
Pyrosequencing Primer Name Sequence 5'-3' Length (bp) Annealing °C Annealing Time Elongation Time Cycle # 
       
CDC7F#1 CACTATGCTTCCCCCACACT 20 54 
30 sec 2 min 
35 
CDC7R#1 ACAAACCGTCGGAAACTCAC 20 54 
CDC7YF#1 TATTATGTTTTTTTTATATT 20 48 
1 min 1 min 
CDC7YR#1 AACAAACCYTCYAAAACTCA 20 48 
CDC7F#2 Bio-AGGGATGTGTTAGTATTTGAGATT 24 54 
50 
CDC7R#2 TCTCCAAAAAATCCCCACCTA 21 54 
CDC7Seq CCCTACCCAACACTTC 16 n/a n/a n/a n/a 
       
EIF5F#1 TGCCCACTAGGAGAAAGGTG 20 54 
30 sec 2 min 
35 
EIF5R#1 CGGACTCACCTCTGGAATGT 20 54 
EIF5YF#1 TGTTTATTAGGAGAAAGGTG 20 48 
1 min 1 min 
EIF5YR#1 CCYAACTCACCTCTAAAATAT 21 48 
EIF5F#2 Bio-GAGGGAGGGGATTAATTATTATTT 24 58 
50 
EIF5R#2 CCTCACTACCCATTAACTAAAAA 23 58 
EIF5Seq ACTAAAAACCTACCACAACT 20 n/a n/a n/a n/a 
       
IRX3F#1 CGTCCCCTTTGTCCTGTAGA 20 54 
30 sec 2 min 
35 
IRX3R#1 AACGTGTCTGCCTTTGTGTG 20 54 
IRX3YF#1 YGTTTTTTTTGTTTTGTAGA 20 40 
1 min 1 min 
IRX3YR#1 AACYTATCTACCTTTATA 18 40 
IRX3F#2 Bio-AATGGGGAAGAAGGGAGTGA 20 54 
50 
IRX3R#2 ACTATAACCCCCCTATCTACCCC 23 54 
IRX3Seq CCCCTATCTACCCCCT 16 n/a n/a n/a n/a 
       
KLF3F#1 AGAAAGAGCGCGCCTACAG 19 54 
30 sec 2 min 
35 
KLF3R#1 GCTCCTGGCACCAACTCC 18 54 
KLF3YF#1 AGAAAGAGYGYGTTTATAG 19 48 
1 min 1 min 
KLF3YR#1 ACTCCTAACACCAACTCC 18 48 
KLF3F#2 GGGAATAATGAGTGTTTGTTAGGT 24 54 
50 
KLF3R#2 Bio-CCAACTCCCAACAATCACATAAC 23 54 
KLF3Seq AAGTGGGTGGGGATT 15 n/a n/a n/a n/a 
  
Continued…       
       
LINE1#1F AGAAATGTAGAAATTATT 18 55 
30 sec 2 min 
35 
LINE1#1R GAGGTTATTGTTGTTTTTT 19 55 
LINE1YF#1 AGAAGACYGGTGATTTCT 18 55 
1 min 1 min 
LINE1YR#1 GAGGTTACTGCTGTCTTTT 19 55 
LINE1#2F Bio-TTTTGAGTTAGGTGTGGGATATA 23 50 
50 
LINE1#2R AAAATCAAAAAATTCCCTTTC 21 50 
LINE1Seq GGGTGGGAGTGAT 13 n/a n/a n/a n/a 
       
PCYT1AF#1 GAGGGACAGAGGTCAAGGTG 20 54 
30 sec 2 min 
35 
PCYT1AR#1 ACATCACTCACCCACACGAA 20 54 
PCYT1AYF#1 GAGGGATAGAGGTTAAGGTG 20 48 
1 min 1 min 
PCYT1AYR#1 ACATCACTCACCCACACYAA 20 48 
PCYT1AF#2 Bio-TTTTATGGATTTTATTGGGTTTAA 24 51 
50 
PCYT1AR#2 CCCCCCAAAAACTTTATTTCA 21 51 
PCYT1ASeq ATTATCATTTTCATTAAT 18 n/a n/a n/a n/a 
       
PTPRGF#1 CTCCAGAGAAGCTGCGAGTT 20 54 
30 sec 2 min 
35 
PTPRGR#1 GGAAACGGAGGAAAACACAA 20 54 
PTPRGYF#1 TTTTAGAGAAGTTGYGAGTT 20 40 
1 min 1 min 
PTPRGYR#1 AAAAACYAAAAAAAACACAA 20 40 
PTPRGF#2 Bio-TTGTAAATGTTAGGGTAGTGAAGT 24 54 
50 
PTPRGR#2 ACCATACCTCCATACAAAAAATA 23 54 
PTPRGSeq AGATTTTTTTTTAGTAGTTA 20 n/a n/a n/a n/a 
       
SLC39A4F#1 GGTGCCTGTAATCCCAGCTA 20 54 
30 sec 2 min 
35 
SLC39A4R#1 GATCCCACACCTCACAAACC 20 54 
SLC39A4YF#1 GGTGTTTGTAATTTTAGTTA 20 48 
1 min 1 min 
SLC39A4YR#1 AATCCCACACCTCACAAACC 20 48 
SLC39A4F#2 Bio-TGATTTTTGTTTGGGGATAGGTT 27 54 
50 
SLC39A4R#2 ACCCCAATCCCAACTCCAATAA 22 54 
SLC39A4Seq CTCAACTAAAAAAAAACAAT 20 n/a n/a n/a n/a 
       
       
  
Continued…       
       
TBX3F#1 TCGCGTGACACAGCTAAGTT 20 54 
30 sec 2 min 
35 
TBX3R#1 TTGAATTGGTGCCTGCCTAT 20 54 
TBX3YF#1 TYGYGTGATATAGTTAAGTT 20 48 
1 min 1 min 
TBX3YR#1 TTAAATTAATACCTACCTAT 20 48 
TBX3F#2 Bio-GTAAGGGATTTTTGTTTTTAGTTT 24 51 
50 
TBX3R#2 CCCCTCTCTTTAAAACATCACTAA 24 51 
TBX3Seq AAATTTACCCCCTTCC 16 n/a n/a n/a n/a 
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D 
qPCR Primer Name Sequence 5'-3' Length (bp) Annealing °C 
    
BACTINF TGTTACAGGAAGTCCCTTGCCATC 24 60 
BACTINR CTCCCCTGTGTGGACTTGGG 20 60 
    
CDC7F TTTGGCCACAGCACAGTTAC 20 52 
CDC7R CAAAAACGACTCATGCTCCA 20 52 
    
EIF5F TCCAACGTATCCCACCAAAT 20 52 
EIF5R GCTTCTTTGGATTGACATGC 20 52 
    
H19F GAGCCGCACCAGATCTTCAG 20 60 
H19R TTGGTGGAACACACTGTGATCA 22 60 
    
IRX3F CGCGCAGTATGAGCTGAAG 19 52 
IRX3R CTGGTGCTCTCCCTGGTG 18 52 
    
KLF3F CAGCCTCTCATGGTCTCCTT 20 52 
KLF3R GGGGTGACATTTCTTCAGGA 20 52 
    
L1.2F CTGAGTCAAAGAAAGGGGTGA  22 60 
L1.2R GGATATAGTCTCGTGGTGCG  21 60 
    
PCYT1AF ACTCCTTGTGAGCGACCTGT 20 52 
PCYT1AR CACCGTGAAGCCTTTGAAGT 20 52 
    
PTPRGF ACCCGTACTGGGCCTACTCT 20 52 
PTPRGR GCGACTGTTTTCCCTGTGTT 20 52 
    
SIRT1F GGCAAAGGAGCAGATTAGTAGG 22 55 
SIRT1R CATCAGGTCATCTTCTAAGCC 21 55 
    
SLC39A4F CAAGACGGCCTGCGTAGATA 20 52 
SLC39A4R TGCTGCTGGAACACAAAGTC 20 52 
    
TBX3F ACTGGGGAACAGTGGATGTC 20 52 
TBX3R GAATTCAGTTTCGGGGAACA 20 52 
    
UBE2BF CTCAGGGGTGGATTGTTGAC 20 60 
UBE2BR TGTGGATTCAAAGACCACGA  21 60 
    
WNT11F TGACCTCAAGACCCGATACC 20 52 
WNT11R GCTTCCGTTGGATGTCTTGT 20 52 
    
λM#2F TACAGAAAGACGGACGAAGG 20 60 
λM#2R TGGTGGGCGTTTTCATACAT  21 60 
    
λUM#2F TTCGTGATATTCCGTCGCTG  21 60 
λUM#2R AGTTTTTTGCCGCTTTACCG  21 60 
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Table 2.3. Antibodies 
 
1° Antibody Source Dilution 
   
Rabbit Anti-Human SIRT1 AbCam 1 in 200 
Rabbit Anti-AlphaTubulin AbCam 1 in 5000 
Mouse Anti-Mouse SIRT1 AbCam 1 in 1000 
   
   
   
2° Antibody Source Dilution 
   
Goat Anti-Rabbit IgG - Peroxidase Sigma 1 in 5000 
Goat Anti-Mouse IgG - Peroxidase Sigma 1 in 10000 
   
 
69 
 
3 Effect of SIRT1 manipulation and dietary polyphenols on global DNA 
methylation in Caco-2 cells 
3.1 Outline 
The beneficial effects of dietary restriction (DR) to delay the ageing process and increase lifespan in 
model systems are well established but the underlying mechanisms are unclear. The yeast NAD
+
-
dependent deacetylase, Sir2, was the first of the sirtuin family to be implicated in DR and lifespan 
extension. Research into mammalian sirtuins has expanded due to their potential as targets for anti-
ageing interventions or therapies. There are many cellular substrates of the mammalian homologue 
SIRT1, whose deacetylation activity may contribute to, or be responsible for, the apparent ability of 
sirtuins to increase lifespan. We propose that these effects may be exerted either directly or indirectly 
through changes in DNA methylation patterns via the deacetylation activity of SIRT1 on histone 
proteins. DNA methylation is potentially causal in the ageing process as age-associated changes in the 
DNA methylation state of the genome can result in genome instability, inappropriate gene expression 
or silencing so it is within reason to suggest correct maintenance of DNA methylation plays a role in 
the effects of lifespan extension seen with DR. A number of naturally occurring polyphenolic 
compounds, obtained though the diet from various plant sources, may activate SIRT1 mimicking DR 
and its beneficial effects. Experiments in lower eukaryotes have demonstrated that resveratrol, a 
polyphenol naturally found in a variety of fruits and nuts, increased lifespan in a Sir2-dependent 
manner (Baur et al., 2006; Lagouge et al., 2006). The ability of resveratrol to delay some aspects of 
ageing raises the question as to whether other polyphenolic compounds have similar properties and act 
through similar mechanisms. 
 
Global DNA methylation levels in the Caco-2 cell line were measured by COBRA and the 
pyrosequencing assays LUMA and LINE-1 to investigate if changes in SIRT1 expression or exposure 
to dietary polyphenols had any effect at this level. The Caco-2 cell line was selected from a variety of 
cell lines on the basis of measurements of baseline levels of global DNA methylation. The SIRT1 
inhibitor Sirtinol had no affect on DNA methylation when measured by COBRA or the LUMA 
pyrosequencing assay. SIRT1 manipulation by transfection was then achieved with either a transgene 
to overexpress SIRT1 or SIRT1-targetting siRNAs. Effects of these treatments on SIRT1 expression 
was confirmed at the mRNA level by RT-PCR or RT-qPCR and at the protein level by western blot. 
Dietary polyphenols were then tested alone and in combination with SIRT1 manipulation to determine 
if they affected global DNA methylation and if any such effects were mediated through SIRT1.  
70 
 
3.2 Selection of appropriate cell lines for the investigation of DNA methylation 
A range of human cell lines derived from a variety of tissues were screened to find those with the 
minimum and maximum levels of endogenous DNA methylation, with the aim of maximising any 
observed effects of the experimental treatments on both hyper- and hypo-methylation of DNA. Cell 
lines for measurements of endogenous DNA methylation were chosen based on availability in the 
laboratory and included Caco-2, HeLa, HEPG2, MCF-7, MDA-MB321, SH-SY5Y, and SW480. 
These cell lines were grown in 75 cm
2
 flasks and, on reaching confluency, were lysed and DNA was 
extracted as described in Section 2.3. Methylation status of the extracted DNA from each cell line was 
analysed by two different methods.  
 
The first method involved assaying DNA methylation at the LINE-1 retrotransposon by 
pyrosequencing as described in Section 1.5.3 and 2.6.3. Percentage DNA methylation was measured at 
the three consecutive CpG sites within the LINE-1 element, occurring at 252 bp, 256 bp and 270 bp 
into the LINE-1 sequence (Figure 3.1 and Section 2.6.8). Briefly, the LINE-1 pyrosequencing assay 
consisted of a two stage PCR reaction. The first PCR generated a 595 bp product, and contained 25 μl 
HotStar Taq MasterMix (Qiagen), 0.25 μM sense and antisense primers (LINE1YF#1 and 
LINE1YR#1) using 4 μl of bisulfite modified genomic DNA (Section 2.6.1) as a template. Primer 
sequences and annealing temperatures are outlined in Table 2.2C. This reaction was followed by a 
second, nested PCR, generating a 146 bp product, and contained 25 μl HotStar Taq MasterMix 
(Qiagen), 0.25 μM sense primer and 0.20 μM antisense biotinylated primer (LINE1F#2 and 
LINE1R#2) using 4 μl of the first PCR reaction as a template. Primer sequences and annealing 
temperatures are outlined in Table 2.2C. Pyrosequencing using the LINE-1 sequencing primer was 
carried out in duplicate for each sample (Figure 3.2A). 
 
Standard curves were generated to confirm linear amplification of methylated and unmethylated 
LINE-1 sequences. Unmethylated LINE-1 DNA template was generated through the removal of 
methyl groups by PCR amplification of a 529 bp region (LINE1F#1 and LINE1R#1) of the LINE-1 
sequence from genomic DNA as described above. Primer sequences and annealing temperatures are 
outlined in Table 2.2C. Nine microlitres of unmethylated LINE-1 PCR product was methylated in 
vitro as described in Section 2.2.4. Nine microlitres of methylated or 25 µl unmethylated LINE-1 PCR 
product was then bisulfite modified as described in Section 2.6.1. Nested PCR using primers to 
produce a smaller product focusing in on the specific CpG sites for analysis was then performed as 
described above. Primer sequences and annealing temperatures are outlined in Table 2.2C. Reactions 
were combined to give appropriate percentages of methylated DNA (0, 5, 10, 25, 50, 75, 90, 95, and 
100 %) in a total volume of 10 µl. Pyrosequencing using the LINE-1 sequencing primer was carried 
out in duplicate. Methylation standard curves for LINE-1 can be found in Appendix C.   
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Figure 3.1. The LINE-1 sequence and related primers. The LINE-1 sequence taken from NCBI (accession 
number: X58075) is shown. Primers were designed for PCR to a region in the LINE-1 sequence (LINE1YF#1 - 
light blue and LINE1YR#1 - dark blue) and a nested PCR (LINE1F#2 - light green and LINE1R#2 - dark green) 
to focus in on four specific CpG sites (pink) within the LINE-1 sequence. A sequencing primer was designed for 
use in the pyrosequencing reaction (LINE1Seq - orange). Primers and annealing temperatures are given in 
Table 2.2C.  
LINE-1 Sequence 
Accession number: X58075  
 
+1   gggggaggag ccaagatggc cgaataggaa cagctccggt ctacagctcc  
50   cagcgtgagc gacgcagaag acgggtgatt tctgcatttc catctgaggt  
100  accgggttca tctcactagg gagtgccaga cagtgggcgc aggccactgt  
150  gtgcgcgcac cgtgcgcgag ccgaagcagg gcgaggcatt gcctcacctg  
200  ggaagcgcaa ggggtcaggg agttcccttt ccgagtcaaa gaaaggggtg  
250  acggacgcac ctggaaaatc gggtcactcc cacccgaata ttgcgctttt  
300  cagaccggct taagaaacgg cgcaccacga gactatatcc cacacctggc  
350  tcagagggtc ctacgcccac ggaatctcgc tgattgctag cacagcagtc  
400  tgagatcaaa ctgcaaggcg gcaacgaggc tgggggaggg gcgcccgcca  
450  ttgcccaggc ttgcttaggt aaacaaagca gccgggaagc tcgaactggg  
500  tggagcccac cacagctcaa ggaggcctac ctgcctctgt aggctccacc  
550  tctgggggca gggcacagac aaacaaaaag acagcagtaa cctctgcaga  
600  cttaagtgtc cctgtctgac agctttgaag agagcagtgg ttctcccagc  
650  acgcagctgg agatctgaga acgggcagac tgcctcctca agtgggtccc  
700  tgacccctga cccccgagca gcctaactgg gaggcacccc ccagcagggc  
750  acactgacac ctcacacggc agggtattcc aacagacctg cagctgaggg  
800  tcctgtctgt tagaaggaaa actaacaacc agaaaggaca tctacacgaa  
850  aacccatctg tacatcacca tcatcaaaga ccaaaagtag ataaaaccac  
900  aaagatgggg aaaaaacaga acagaaaaac tggaaactct aaaacgcaga  
950  ggccctctcc tcctccaaag gaacgcagtt cctcaccagc aacagaacaa  
1000 agctggatgg agaatgattt tgacgagctg agagaagaag gcttcagacg  
1050 atcaaattac tctgagctac aggaggacat tcaaaccaaa ggcaaagaag  
1100 ttgaaaactt tgaaaaaaat ttagaagaat gtataactag aataacc  
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The second method for assessing the methylation status of the extracted DNA used LUMA, as 
described in Section 1.5.4 and 2.6.9. Two hundred nanograms of genomic DNA were digested with 
either EcoRI and MspI restriction enzymes or EcoRI and HpaII restriction enzymes. The percentage 
methylation of the DNA sample was determined by the MspI/HpaII ratio. 
 
Results of the LINE-1 and LUMA assays did not correlate (Figure 3.2C), but this observation is not 
necessarily surprising since the two assays interrogate different CpG sites across the genome and it is 
completely feasible that methylation at these sites differs. Based on the observation that the range of 
methylation values for the different cell lines was smaller when methylation was measured using the 
LUMA assay, it may be argued that measurement of methylation at the LINE-1 element is a more 
sensitive measure of global DNA methylation. 
 
No significant difference in DNA methylation in the cell lines tested was observed (Figure 3.2), thus 
the human intestinal Caco-2 cell line was selected as the model for this study, based on the fact that 
there was extensive experience in the laboratory in the culture, transfection and manipulation of this 
cell line. A second reason was that a model of the intestinal response to DR would allow for testing the 
effects of potential dietary mimetics of DR – specifically the polyphenol resveratrol, along with the 
isoflavones genistein and daidzein – using the (readily available) parent compounds, to which the 
intestinal mucosa would be exposed as a result of dietary intake; effects of such compounds on other 
tissues would have to take account of effects of metabolites (often unavailable commercially), rather 
than the parent compound. 
 
The Caco-2 human epithelial colorectal adenocarcinoma cell line was derived from a carcinoma 
within the large intestine of a 72 year old Caucasian male (Fogh et al., 1977). The parental Caco-2 cell 
line from the American Tissue Culture Collection (ATCC) has a heterogeneous quality that may have 
led to divergence in published results based on this model as well as the emergence of homogenous 
subpopulations of clonal cell lines with specific differentiation characteristics. Key factors in 
maintaining a culture true to the parental cell line include passage number, seeding density and 
medium composition. Various functional traits of the Caco-2 cell line are affected after 35 or more 
passages in culture such as multi-layering (Briske-Anderson et al., 1997), metabolic (Nakumura et al., 
2003) and transport activities (Bravo et al., 2004). Maintaining a consistent seeding density and time 
of passage to achieve a comparative confluency, and therefore stage of differentiation, over each 
experiment time course avoids variable differentiation-related traits. Additionally, composition of the 
cell culture medium should be taken into consideration (Papaconstantinou et al., 2000). It is therefore 
crucial to ensure a uniform approach to the culture of the Caco-2 parental cell line to generate 
reproducible results.  
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Figure 3.2. Comparison of LINE-1 (A) and LUMA (B) assay results for measurement of endogenous levels of 
DNA methylation in Caco-2, SW480, HeLa, SH-SY5Y, HepG2, MCF-7 and MDA cell lines. A – The LINE-1 
assay measured percentage DNA methylation at three CpG sites within the LINE-1 retrotransposon element and 
showed no statistically significant difference between endogenous DNA methylation at CpG sites in the range of 
cell lines tested (p > 0.05 by one way ANOVA followed by Bonferroni’s multiple comparisons test). B – The 
LUMA assay used methylation sensitive and insensitive isoschizomers to produce a global ratio of methylated to 
unmethylated DNA and showed no statistical differences between the DNA methylation levels in the range of cell 
lines tested (p > 0.05 by one way ANOVA followed by Bonferroni’s multiple comparisons test); n = 2. C – 
Relationship between LINE-1 CpG site % DNA methylation (y axis) and LUMA global DNA methylation (x axis). 
The colour representing each cell line is indicated in the key, CpG sites 1, 2 and 3 are represented as a diamond 
(♦), triangle (▲) and square (■) respectively. No correlation was found by Spearman rank correlation (sr) 
between the three CpG sites in the LINE-1 assay and the data from the LUMA assay; LUMA and CpG1 sr = 
0.2500, p = 0.59, LUMA and CpG2 sr = 0.2500, p = 0.59, LUMA and CpG3 sr = 0.5357, p = 0.2357. There was 
strong correlation between all three CpG sites within the cell lines; CpG1 and CpG2 sr = 1.000, p = 0.0004, 
CpG2 and CpG3 sr = 0.8929, p = 0.0123, CpG1 and CpG3 sr = 0.8929, p = 0.0123. All data are mean ± SEM 
for n = 9. 
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3.3 Effects on genomic DNA methylation of treating Caco-2 cells with the SIRT1 
inhibitor Sirtinol 
Sirtinol was identified as an inhibitor of the yeast Sir2p NAD
+
-dependent deacetylase activity through 
a high-throughput cell-based screen of compounds (Grozinger et al., 2001) and later used to inhibit 
SIRT1 activity in the plant cell model Arabidopsis thaliana and a variety of human cell lines. Moieties 
on the aromatic ring of Sirtinol (Figure 3.3A) are proposed to interact with hydrophobic residues in the 
SIRT1 binding site that interacts with the adenosine base in the NAD
+
 substrate (Trapp et al., 2006), a 
feature that prevents off-target inhibition of Class I and II HDACs (Bedalov et al., 2001; Grozinger et 
al., 2001). Concentrations of 10 - 100 μM Sirtinol have been used in SIRT1 inhibition experiments 
with the half maximal inhibitory concentration (IC50) for Sir2/SIRT1 in yeast and human being 40 – 
70 μM. At 10 μM Sirtinol inhibition of SIRT1 in white blood cells led to an increase in MMP9 levels, 
a matrix metalloproteinase involved in degradation of the extracellular matrix in age-related diseases 
(Nakamaru et al., 2009). At a 10-fold greater concentration (100 μM), Sirtinol was shown to induce 
senescence-like growth arrest in breast and lung cancer cell lines, as measured by senescence-
associated β-galactosidase and increased plasminogen activator inhibitor 1 expression. This 
observation suggests that at high concentrations Sirtinol acts in a similar way to chemotherapeutic 
agents to arrest the growth of cancerous cells (Ota et al., 2005). 
 
Caco-2 cells seeded 24 hours previously at 3.5 x 10
5
 cells/well in a six well plate (area = 9.6 cm
2
/well) 
were treated with 10, 40, 70 or 100 μM Sirtinol (in 0.1 % v/v DMSO) or a control of 0.1 % v/v DMSO 
as described in Section 2.3.5. The concentrations of Sirtinol used were to reflect the minimum and 
maximum amounts used in published work as well as cover the IC50 range. After an additional 48 
hours cells were lysed and DNA was extracted as described in Section 2.4.1. DNA from cells treated 
with Sirtinol was assessed by two different methods for levels of DNA methylation at two CpG sites 
in the LINE-1 retrotransposon within two HinfI restriction enzyme sites, using the gel-based 
Combined Bisulfite Restriction Analysis (COBRA) as described in Sections 1.5.2 and 2.6.2 and at 
four CpG sites by pyrosequencing as described in Sections 1.5.3 and 2.6.8. 
 
COBRA involved amplification of bisulfite modified DNA to the LINE-1 retrotransposon by PCR 
with primers specific to the LINE-1 retrotransposon (LINE1COBRAF and LINE1COBRAR – See 
Table 2.1B). Ten microlitres of the PCR product was digested with HinfI. Within the LINE-1 
retrotransposon sequence there are two HinfI restriction sites both containing a CpG site. The 
methylation at these two CpG sites in a DNA sample was expressed as the ratio of uncut to cut PCR 
product as determined by densitometric quantification of SYBR green-stained agarose gels. 
 
Based on measurement by pyrosequencing, LINE-1 methylation was expressed as the percentage of 
unmethylated cytosines converted to thymines as a result of bisulfite modification. To compare results 
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obtained using the two techniques more accurately the assay was modified and extended to assess a 
fourth CpG site. This site occurred 232 bp into the LINE-1 sequence and was within the second HinfI 
restriction site. 
 
No significant difference in DNA methylation in response to Sirtinol treatment was detected when 
measured by COBRA (Figure 3.3B) or the LINE-1 pyrosequencing assay (Figure 3.3C). This 
observation may indicate either that Sirtinol did not effectively inhibit SIRT1 activity under the 
experimental conditions (it was not possible to measure SIRT1 activity directly – see Section 4.5) or 
that SIRT1 inhibition had no effect on methylation of DNA at the LINE-1 retrotransposon.  
 
An alternative approach to inhibit protein function is through short interference RNA (siRNA) 
knockdown, the targeted cleavage and degradation of an mRNA by a specific siRNA preventing the 
translation into a protein. Using siRNA to achieve total mRNA and therefore protein knockdown 
provides a tool for SIRT1 manipulation whose efficacy can be measured (by RT-qPCR and western 
blotting) and may be a more effective way to assess the effects of reduced levels of SIRT1 on DNA 
methylation levels within a cell population. 
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Figure 3.3. Effect on genomic DNA methylation in Caco-2 cells of Sirtinol, the SIRT1 deacetylase activity 
inhibitor. A – Chemical structure of Sirtinol. B – COBRA showed no statistical differences between DNA 
methylation levels in Caco-2 cells treated with Sirtinol over a range of concentrations when compared with the 
control (p > 0.05 by one way ANOVA followed by Bonferroni’s multiple comparisons test). C – The LINE-1 
pyrosequencing assay showed no statistical differences between DNA methylation levels in Caco-2 cells treated 
with Sirtinol over a range of concentrations (10, 40, 70 and 100 μM – light blue to green respectively) when 
compared with the control (dark blue) (p > 0.05 by one way ANOVA followed by Bonferroni’s multiple 
comparisons test). All data are mean ± SEM for n = 3 – 12. 
  
79 
 
3.4 Effects on genomic DNA methylation of manipulated SIRT1 expression levels 
Level of SIRT1 increased in the brain, kidney, visceral fat pads and liver of DR mice (Cohen et al., 
2004). To achieve comparable levels of SIRT1 overexpression to that observed in response to DR 
Caco-2 cells were manipulated with the use of a SIRT1 overexpression construct, and the approach 
was complemented with use of SIRT1-targeting siRNAs to investigate if changes in expression of 
SIRT1 in human cells can influence DNA methylation, consistent with such a mechanism contributing 
to SIRT1-mediated effects of DR to increase lifespan.  
3.4.1 Effects on genomic DNA methylation of knockdown of SIRT1 expression levels 
The mechanism by which synthetic microRNAs known as short interference RNAs (siRNA) act upon 
a target mRNA sequence for degradation has recently become an effective tool to knockdown gene 
function within mammalian cells. RNA interference (RNAi) involves the loss of gene function by the 
processing of dsRNA dioligonulceotides by an enzyme known as dicer into smaller ~21 nucleotide 
length siRNAs. The siRNA antisense strand is then loaded into the RNA-induced silencing complex 
(RISC) allowing recognition and cleavage of the target mRNA sequence by the complex. The cleaved 
mRNA sequence is then targeted for degradation and ultimately leads to the prevention of protein 
expression. Synthetic molecules can be engineered to represent siRNA processed by dicer; with a 
better understanding of the RNAi pathway synthetic siRNAs have improved specificity and stability 
for use in cell culture as well as a reduction in off-target effects and innate immune responses. To 
achieve SIRT1 knockdown in the Caco-2 cell line, two non-overlapping validated Stealth RNAi
™
 
siRNAs targeting SIRT1 mRNA were purchased from Invitrogen. Knockdown was assessed at 24, 48 
and 72 hours after transfection to ascertain the most effective incubation time. 
 
Caco-2 cells seeded 24 hours previously at 3.5 x 10
5
 cells/well in a six well plate (area = 9.6 cm
2
/well) 
were transfected transiently with 100 pmol SIRT1-targeting siRNA or with 100 pmol of a Stealth 
RNAi
™
 siRNA negative control of similar GC content (Section 2.3.2). After 24, 48 and 72 hours cells 
were lysed and RNA and total cell lysate were extracted from parallel experiments. RNA was used to 
assess SIRT1 knockdown at the mRNA level by RT-PCR as described in Section 2.7.1. Total RNA 
was extracted from Caco-2 cells using the Qiagen AllPrep DNA/RNA Mini Kit (Section 2.4.1). Four 
and a half micrograms of DNase-treated RNA (Section 2.7.1.2) was reverse transcribed using 
Superscript
™
 III RNase H- Reverse Transcriptase (Invitrogen) (Section 2.7.1.3). Reverse transcribed 
cDNA was then amplified by PCR (Section 2.5.1.1) using primers specific to a 128 bp region of the 
SIRT1 gene (SIRT1F and SIRT1R) or to a 328 bp region of the reference gene RN18S1 (18s rRNA) 
which acted as a control (18sF and 18sR). Primer sequences and annealing temperatures are specified 
in Table 2.2B. A decreased intensity of the SIRT1-specific band from cells transfected with the SIRT1 
expression construct compared with the band generated from the control cells indicated that SIRT1 
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mRNA knockdown had been achieved. Optimum SIRT1 mRNA knockdown was achieved at 72 hours 
after siRNA transfection into Caco-2 cells (Figure 3.4A).  
 
SIRT1 knockdown at the mRNA level 72 hours after transfection was also assessed by RT-qPCR 
(Figure 3.4B) as described in Section 2.7.2. RNA was extracted, DNase treated and reverse 
transcribed as described above. Reverse transcribed cDNA was then PCR amplified (Section 2.5.1.1) 
using the aforementioned primers specific to a 239 bp region of the SIRT1 gene. Data were normalised 
to the reference gene ACTB (β ACTIN) using primers that amplified a 90 bp region. Primer sequences 
and annealing temperatures are outlined in Table 2.2D.  
 
Reverse transcription-qPCR analysis of SIRT1 and β ACTIN was performed using the Roche 
LightCycler
®
 480 (Section 2.7.2.4). Standard curves were generated for SIRT1 and β ACTIN to 
confirm linear amplification of PCR products and were run in parallel with the experimental samples. 
To generate standard curves undiluted cDNA extracted from untreated Caco-2 cells and reverse 
transcribed was used to create an 8 point 2-fold dilution series (Section 2.7.2.5). Each dilution within 
this series was then used in qPCR amplification for each gene, and each reaction was performed in 
duplicate. Amplification and standard curves for SIRT1 and β ACTIN can be found in Appendix D. 
Relative levels of SIRT1 transcript in the Caco-2 cells transfected with either of the two siRNAs show 
a statistically significant reduction (68 % and 70 % respectively; p < 0.001) in SIRT1 mRNA 
compared with the control siRNA (Figure 3.4B), confirming observations made by the gel-based RT-
PCR analysis.  
 
Total cell lysate was used to assess SIRT1 knockdown at the protein level by western blot as described 
in Section 2.8. Total cell lysate was extracted (Section 2.8.2.2) and protein concentration determined 
by Bradford assay (Section 2.8.1.4). Ten micrograms of total cell lysate was separated by SDS-PAGE 
(Section 2.8.1.5) and blotted onto a polyvinylidene difluride (PVDF) membrane (Section 2.8.1.6), 
which was then probed with antibodies to SIRT1 and the loading control protein alpha tubulin. SIRT1 
protein knockdown was confirmed by a decrease in binding of the SIRT1 antibody in cells transfected 
transiently with the SIRT1-targeting siRNA in comparison to cells transfected transiently with the 
Stealth RNAi
™
 siRNA negative control (Figure 3.4C). This transfection model was continued as a 
means to knockdown SIRT1 within Caco-2 cells in further experiments. 
 
Global methylation status of the extracted DNA from Caco-2 cells transfected with either the SIRT1-
targeting siRNA or with the Stealth RNAi
™
 siRNA negative control was assessed by LINE-1 COBRA 
and the LINE-1 pyrosequencing assay as described in Sections 1.5.2 and 2.6.2 and 1.5.3 and 2.6.8 
respectively. SIRT1 knockdown alone had no apparent effect on LINE-1 methylation measured using 
either technique (p > 0.05) (Figure 3.5A and Figure 3.5B).  
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Figure 3.4. Confirmation of (A) SIRT1 mRNA expression knockdown in transiently transfected Caco-2 cells 
by RT-PCR and (B) RT-qPCR and (C) SIRT1 protein knockdown by western blot. A – RT-PCR products were 
analysed by agarose gel electrophoresis. As indicated, lanes contained products generated from Caco-2 cells 
transiently transfected with either SIRT1-targeting siRNA or with a Stealth RNAi
™
 siRNA negative control of 
similar GC content at either 24, 48 or 72 hours after transfection. Primer pairs (SIRT1 –SIRT1F and SIRT1R or 
18s –18sF and 18sR – see Table 2.2B) were included in the reaction as indicated along with MMLVRT. A 
comparison of band intensity between cells transfected with either SIRT1-targeting siRNA and those transfected 
with the Stealth RNAi
™
 siRNA negative control indicate SIRT1 mRNA knockdown. B – RT products were 
analysed quantitatively for SIRT1 and β ACTIN mRNA expression using the Roche LightCycler® 480, 
LightCycler
®
 480 SYBR Green I Master and primer pairs (SIRT1 –SIRT1F and SIRT1R or 18s –18sF and 18sR – 
see Table 2.2C). Relative levels of SIRT1 expression were calculated in each sample using levels of SIRT1 
expression normalised to β ACTIN. A comparison between SIRT1 mRNA expression levels between cells 
transfected with either of the two SIRT1-targeting siRNAs and those transfected with the control indicates 
statistically significant SIRT1 mRNA knockdown; ***p < 0.001 by one way ANOVA followed by Tukey. All data 
are mean ± SEM for n = 9. C – Protein extracted from Caco-2 cells transiently transfected with either SIRT1-
targeting siRNA or with a Stealth RNAi
™
 siRNA negative control of similar GC content at either 24, 48 or 72 
hours after transfection was separated by SDS-PAGE gel electrophoresis. SIRT1 expression was analysed by 
probing with an antibody to the SIRT1 protein followed by reprobing with an antibody to alpha tubulin as a 
loading control. A comparison of band intensity between cells transfected with either SIRT1-targeting siRNA 
and those transfected with the Stealth RNAi
™
 siRNA negative control indicate SIRT1 mRNA knockdown.  
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Figure 3.5. Effect on genomic DNA methylation of SIRT1 knockdown using (A) COBRA and (B) the LINE-1 
pyrosequencing assay. A – COBRA analysis showed no statistically signification difference between DNA 
methylation levels in Caco-2 cells transfected with SIRT1-targeting siRNA (blue and light blue) for 72 hours 
when compared with a Stealth RNAi
™
 siRNA negative control of similar GC content (dark blue) (p > 0.05 by one 
way ANOVA followed by Bonferroni’s multiple comparisons test). All data are mean ± SEM for n = 6. B – The 
LINE-1 pyrosequencing assay showed no statistically signification difference between DNA methylation levels in 
Caco-2 cells transfected with SIRT1-targeting siRNA (blue and light blue) for 72 hours when compared with a 
Stealth RNAi
™
 siRNA negative control of similar GC content (dark blue) (p > 0.05 by one way ANOVA followed 
by Bonferroni’s multiple comparisons test). All data are mean ± SEM for n = 6. 
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3.4.2 Effects on genomic DNA methylation of overexpression of SIRT1 
To achieve stable SIRT1 overexpression in the Caco-2 cell line, a plasmid comprising the pCMV6-
ENTRY vector containing the SIRT1 open reading frame (ORF) was purchased from Origene. The 
pCMV6-ENTRY-SIRT1 plasmid was propagated through E. coli as described in Section 2.1 and 2.2. 
The presence of SIRT1 within the plasmid construct was confirmed by restriction mapping with BglII 
and MluI (Figure 3.6) and also through sequencing using primers to the SIRT1 sequence (Table 2.2B). 
 
Caco-2 cells seeded 24 hours previously at 3.5 x 10
5
 cells/well in a six well plate (area = 9.6 cm
2
/well) 
were successfully transfected with 2 μg SIRT1 expression construct or with 2 μg control vector 
without a SIRT1 insert, pCMV6-Neo, that also confers resistance to G418 (Section 2.3.3). Cells were 
selected using G418 at a concentration of 750 μg/ml, determined empirically to be the lowest effective 
concentration for cell death. When the G418 treatment had led to cell death in the untransfected 
population, cells transfected with either the SIRT1 expression construct or the control vector were 
lysed and RNA was extracted. RNA was analysed by RT-PCR as described previously (Section 3.4.1) 
to establish if SIRT1 overexpression had been achieved. An increased intensity of the SIRT1-specific 
band from cells transfected with the SIRT1 expression construct compared with the band generated 
from the control cells indicated that SIRT1 mRNA overexpression had been achieved (Figure 3.7A). 
 
SIRT1 overexpression at the protein level was assessed using a total cell lysate preparation from the 
stably-transfected cell lines; the samples were analysed by western blot as previously described 
(Section 3.4.1). Initially, cells transfected with the SIRT1 overexpression construct showed an increase 
in the levels of SIRT1 expression in comparison to the negative control; however in subsequent 
passages there appeared to be a return of SIRT1 expression to an endogenous level similar to that of 
the negative control (Figure 3.7B).   
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Figure 3.6. Confirmation of the presence of the SIRT1 ORF in the recombinant pCMV6-ENTRY-based 
construct through restriction mapping. A – Digestion of the pCMV6-ENTRY vector containing the SIRT1 ORF 
with BglII and MluI. Products (5 kb, 1.3 kb and 900 bp) confirmed the presence of SIRT1. A DNA molecular 
weight marker (Hyperladder I Bioline, sizes indicated) was run in the lane marked ‘M’.  B – Diagrammatic 
representation of the digestion of the SIRT1 expression construct with BglII and MluI, sites indicated. 
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Figure 3.7. Confirmation of (A) SIRT1 mRNA overexpression in stably transfected Caco-2 cells by RT-PCR, 
(B) equal protein loading concentrations by colloidal blue staining and of (C) SIRT1 protein overexpression 
in stably transfected Caco-2 cells by western blot. RT-PCR products were analysed by agarose gel 
electrophoresis. In lane 1 a DNA molecular weight marker (Hyperladder IV, Bioline; sites indicated) was run. 
As indicated, lanes 2 - 9 contained products generated from Caco-2 cells stably transfected with either the 
control vector pCMV6-Neo or the SIRT1 expression construct pCMV6-ENTRYSIRT1. Primer pairs (SIRT1F, 
SIRT1R, 18sF, 18sR – see Table 2.2B) and MMLVRT were included in the reaction as indicated. A comparison 
of band intensity between cells transfected with the SIRT1 expression construct and those transfected with the 
control vector indicate SIRT1 mRNA overexpression. B – Colloidal blue staining of an SDS-PAGE gel was used 
to confirm equal loading of the protein samples. A wide range protein electrophoresis molecular weight marker 
(ColourBurst 8-220 kDa, Sigma) was run in the lane marked ‘M’ (sizes indicated). C – After selection with 
G418, protein extracted from Caco-2 cells containing the SIRT1 overexpressing construct or the negative 
control vector were separated by SDS-PAGE gel electrophoresis and SIRT1 expression was analysed by probing 
with an antibody to the SIRT1 protein followed by reprobing with an antibody to alpha tubulin as an additional 
loading control to the colloidal blue staining (sizes indicated). SIRT1 overexpression was analysed at two 
passages to check reliability of overexpression construct.  
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As SIRT1 overexpression appeared to have been lost quickly in the G418-selected cells over a few 
passages it was reasoned that transient transfection of the same SIRT1 expression construct may be a 
more reliable approach to achieve SIRT1 overexpression during cell experimentation given that time 
was not available for clonal selection following G418 treatment. To verify SIRT1 overexpression from 
the plasmid construct under conditions of transient transfection, Caco-2 cells were transfected with 2 
μg SIRT1 expression construct (pCMV6-ENTRYSIRT1) or with 2 μg control vector without a SIRT1 
insert (pCMV6-Neo). After 72 hours cells were lysed and RNA and total cell lysate were extracted 
from parallel experiments as described previously (Section 3.4.1). RNA was used to assess SIRT1 
overexpression at the mRNA level by RT-PCR as described previously (Section 3.4.1). An increased 
intensity of the SIRT1-specific band from cells transfected with the SIRT1 expression construct 
compared with the band generated from the control cells indicated that SIRT1 mRNA overexpression 
had been achieved (Figure 3.8A). SIRT1 overexpression at the mRNA level was also assessed by RT-
qPCR (Figure 3.8B) as described previously (Section 3.4.1) confirming RT-PCR observations. Total 
cell lysate was used to confirm SIRT1 overexpression at the protein level by western blot (Figure 
3.8C) as described previously (Section 3.4.1). This transfection model was continued as a means to 
overexpress SIRT1 within cells in further experiments. 
 
Global methylation status of the extracted DNA from Caco-2 cells transfected with either the SIRT1 
expression construct or with the control vector was assessed by LINE-1 COBRA and the LINE-1 
pyrosequencing assay as described in Sections 1.5.2 and 2.6.2 and 1.5.3 and 2.6.8 respectively. SIRT1 
overexpression alone had no apparent effect on LINE-1 methylation measured using either technique 
(p > 0.05) (Figures 3.9A and Figure 3.9B). 
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Figure 3.8. Confirmation of (A) SIRT1 mRNA overexpression in transiently transfected Caco-2 cells by RT-
PCR and (B) RT-qPCR and (C) SIRT1 protein overexpression by western blot. A – RT-PCR products were 
analysed by agarose gel electrophoresis. As indicated, lanes contained products generated from Caco-2 cells 
transiently transfected with either the control vector pCMV6-Neo or the SIRT1 expression construct pCMV6-
ENTRY + SIRT1. Primer pairs (RTPCRSIRT1F, RTPCRSIRT1R, RTPCR18sF, RTPCR18sR – see Table 2.2B) 
and MMLVRT were included in the reaction as indicated. A comparison of band intensity between cells 
transfected with the SIRT1 expression construct and those transfected with the control vector indicate SIRT1 
mRNA overexpression. B – RT products were analysed quantitatively for SIRT1 and β ACTIN mRNA expression 
using the Roche LightCycler
®
 480, LightCycler
®
 480 SYBR Green I Master and primer pairs (SIRT1 –SIRT1F 
and SIRT1R or 18s –18sF and 18sR – see Table 2.2D). Relative levels of SIRT1 expression were calculated in 
each sample using levels of SIRT1 expression normalised to β ACTIN. A comparison between SIRT1 mRNA 
expression levels between cells transfected with the SIRT1 expression construct pCMV6-ENTRYSIRT1 and those 
transfected with the control vector pCMV6-Neo indicates statistically significant SIRT1 mRNA overexpression; 
***p < 0.0001 by Student’s unpaired t-test. All data are mean ± SEM for n = 9. C – Protein extracted from 
Caco-2 cells transiently transfected with either the control vector pCMV6-Neo or the SIRT1 expression construct 
pCMV6-ENTRYSIRT1 was separated by SDS-PAGE gel electrophoresis. SIRT1 expression was analysed by 
probing with an antibody to the SIRT1 protein followed by reprobing with an antibody to alpha tubulin as a 
loading control. A comparison of band intensity between cells transfected with either the control vector pCMV6-
Neo or the SIRT1 expression construct pCMV6-ENTRYSIRT1 indicate SIRT1 mRNA overexpression. 
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Figure 3.9. Effect on genomic DNA methylation of SIRT1 overexpression measured using (A) COBRA and 
(B) the LINE-1 pyrosequencing assay. A – COBRA analysis showed no statistically signification difference 
between DNA methylation levels in Caco-2 cells transfected with SIRT1 expression construct pCMV6-
ENTRYSIRT1 (teal) for 72 hours when compared with the control vector pCMV6-Neo (blue) (p > 0.05 by 
student’s t-test). All data are mean ± SEM for n = 21. B – The LINE-1 pyrosequencing assay showed no 
statistically signification difference between DNA methylation levels in Caco-2 cells transfected with SIRT1 
expression construct pCMV6-ENTRYSIRT1 (teal) for 72 hours when compared with the control vector pCMV6-
Neo (blue) (p > 0.05 by student’s t-test). All data are mean ± SEM for n = 12.  
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3.5 Effects on genomic DNA methylation of treating Caco-2 cells with the polyphenols 
genistein, daidzein and resveratrol, in parallel with manipulation of SIRT1 
expression levels 
As previously discussed, substantial inter-individual variation in age-related DNA methylation may be 
due to different environmental and lifestyle factors, including diet (Issa, 2002). The identification of 
the plant polyphenol resveratrol as a possible SIRT1 activator (Howitz et al., 2003) and reported 
observations that the isoflavones genistein and daidzein can have effects on DNA methylation (Fang et 
al., 2005) identifies these dietary agents as potential mimetics of some aspects of the longevity 
response to DR. To test our hypothesis that effects on DNA methylation may contribute to the 
longevity effects of DR through histone acetylation mediated by SIRT1, and that these effects may be 
mimicked by plant polyphenolic compounds, Caco-2 cells were treated with the polyphenols in the 
presence and absence of SIRT1 manipulation and global DNA methylation was measured. Resveratrol 
(10 µM, Sigma), genistein (50 µM, LC Laboratories) and daidzein (50 µM, LC Laboratories) from 10 
mM filter-sterilised stock solutions were prepared in DMSO (Section 2.3.5). For treatment with the 
polyphenols, the cell culture medium was substituted for a phenol red-free equivalent to that ensure 
any effects seen were due to the added polyphenols and not the phenol-red dye. 
 
Caco-2 cells seeded 24 hours previously at 3.5 x 10
5
 cells/well in a six well plate (area = 9.6 cm
2
/well) 
transfected with SIRT1-targeted siRNA (Sections 2.3.2 and 3.4.1) or the SIRT1 overexpression 
construct (Sections 2.3.3 and 3.4.2) and relevant controls were treated after 24 hours with the 
polyphenols resveratrol (10 µM), genistein (50 µM), daidzein (50 µM) or a control of 0.1 % v/v 
DMSO and levels of DNA methylation were assessed by LINE-1 COBRA (Sections 1.5.2 and 2.6.2) 
and the LINE-1 pyrosequencing assay (Sections 1.5.3 and 2.6.8) after a further 72 hours.  
 
An increase in DNA methylation was measured following treatment of Caco-2 cells, transfected with 
vector only (no manipulation of SIRT1 expression), with resveratrol (10µM); this increase in DNA 
methylation at the LINE-1 element was measured only using COBRA (p < 0.001) (Figure 3.10A) and 
was not detected by LINE-1 pyrosequencing (p > 0.05) (Figure 3.11A). When SIRT1 was 
overexpressed, the resveratrol-induced increase in LINE-1 methylation was abrogated. Genistein 
(50µM) and daidzein (50µM) had no effects against the control background (vector only) but in the 
presence of either compound and SIRT1 overexpression reduced LINE-1 methylation measured only 
using COBRA (p < 0.01 and p < 0.05 respectively) (Figure 3.10B and Figure 3.10C) and was not 
detected by LINE-1 pyrosequencing (p > 0.05) (Figure 3.11B and Figure 3.11C). 
 
Resveratrol, genistein or daidzein had no effect on LINE-1 methylation under conditions of SIRT1 
knockdown measured using either technique (Figure 3.12 and Figure 3.13). Notably, the increase seen 
in LINE-1 methylation in response to resveratrol measured in cells transfected with the pCMV6-Neo 
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vector using COBRA (Figure 3.10A and L J Ions, L A Wakeling and D Ford; unpublished 
observations) was not observed when cells were transfected with the control siRNA. 
 
 
 
.  
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Figure 3.10 Effect on genomic DNA methylation of resveratrol, genistein or daidzein treatment in the 
presence of SIRT1 overexpression in Caco-2 cells using COBRA. SIRT1 overexpression (teal) did not affect the 
measured level of LINE-1 DNA methylation compared to the control vector without a SIRT1 insert (blue), but 
treatment of cells with resveratrol resulted in a significant increase (A). Against a background of SIRT1 
overexpression DNA methylation was reduced when Caco-2 cells were treated with (A) resveratrol (red) (RSV; 
10 µM); ***p < 0.001 n = 21 by one way ANOVA then Bonferroni’s multiple comparisons test, (B) genistein 
(green) (GEN; 50 µM); **p < 0.01 n = 9 by Student’s unpaired t-test and (C) daidzein (purple) (DZN; 50 µM); 
*p < 0.05 by Student’s unpaired t-test. All data are mean ± SEM for n = 9 or 21 as indicated.  
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Figure 3.11 Effect on genomic DNA methylation of resveratrol, genistein or daidzein treatment in the 
presence of SIRT1 overexpression in Caco-2 cells using the LINE-1 pyrosequencing assay. The LINE-1 
pyrosequencing assay showed no statistical differences between DNA methylation levels in Caco-2 cells 
transfected with a SIRT1 overexpression construct (teal) and treated with (A) resveratrol (red) (RSV; 10 µM), 
(B) genistein (green) (GEN; 50 µM) or (C) daidzein (purple) (DZN; 50 µM) 24 h after transfection when 
compared to the control (blue) (p > 0.05 by one way ANOVA then Bonferroni’s multiple comparisons test). All 
data are mean ± SEM for n = 12. 
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Figure 3.12 Effect on genomic DNA methylation of SIRT1-targeted siRNA knockdown and resveratrol, 
genistein or daidzein treatment in Caco-2 cells measured using COBRA. No statistically significant differences 
were measured between DNA methylation levels in Caco-2 cells transfected cells transfected with an siRNA 
negative control (dark blue) or either of the two validated non-overlapping SIRT1 siRNAs (blue and light blue) 
and treated with (A) resveratrol (red) (RSV; 10 µM), (B) genistein (green) (GEN; 50 µM) or (C) daidzein 
(purple) (DZN; 50 µM) 24 h after transfection when compared with the control (p > 0.05 by one way ANOVA 
then Bonferroni’s multiple comparisons test). All data are mean ± SEM for n = 3.  
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Figure 3.13 Effect on genomic DNA methylation of SIRT1-targeted siRNA knockdown and resveratrol, 
genistein or daidzein treatment in Caco-2 cells measured using the LINE-1 pyrosequencing assay. The LINE-
1 pyrosequencing assay showed no statistical differences between DNA methylation levels in Caco-2 cells 
transfected with an siRNA negative control (dark blue) or either of the two validated non-overlapping SIRT1 
siRNAs (blue and light blue) and treated with (A) resveratrol (red) (RSV; 10 µM), (B) genistein (green) (GEN; 
50 µM), or (C) daidzein (purple) (DZN; 50 µM) 24 h after transfection when compared with the control (p > 
0.05 by one way ANOVA then Bonferroni’s multiple comparisons test). All data are mean ± SEM for n = 3.  
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3.6 Discussion 
The Caco-2 human epithelial colorectal adenocarcinoma cell line was selected from a screen of cell 
lines representing a range of tissues to investigate DNA methylation. The cell lines tested showed no 
significant difference in global DNA methylation levels as measured by the pyrosequencing of CpG 
sites within the LINE-1 retrotransposon and the LUMA assay. Enterocytes are the predominant cell 
type of the epithelial lining of the mucosa of the intestine and their morphological and physiological 
properties are exhibited by the Caco-2 cell line, which therefore may provide a suitable model for the 
intestinal response to DR or, in the case of this study, potential dietary mimetics of DR whose first 
encounter upon consumption would be with the intestinal cell wall. All cell lines were from tumour 
cell populations and so due to well documented changes in DNA methylation in cancerous tissue 
perhaps did not show a true representation of DNA methylation levels of the corresponding tissue; 
indeed this factor was also the main limitation associated with using the Caco-2 cell line.  
 
Investigating the effects of manipulating SIRT1, through blocking the enzymatic activity of the SIRT1 
protein with Sirtinol, on levels of global DNA methylation as measured through the repetitive LINE-1 
surrogate marker, revealed no significant response. Interpretation of the result of this experiment is 
limited, however, by our inability to measure directly if the Sirtinol treatment was effective in 
reducing SIRT1 activity. Attempts to generate a Caco-2 cell line stably overexpressing SIRT1 failed. 
Depending upon the integration point of the SIRT1 transgene a mixed population of different levels of 
SIRT1 expression would arise within the selected cell line. The loss of SIRT1 overexpression after 
several rounds of passage may indicate that a shift had occurred towards those cells in which the 
SIRT1 transgene, due to the location of integration, was expressed at a lower level. A possible 
approach to overcome this limitation would be the selection of clonal cell lines after transfection, 
measuring the levels of SIRT1 expression within these cell lines and selecting those expressing SIRT1 
at the highest levels. However time constraints did not permit this approach. Manipulating the levels 
of SIRT1 through transient expression from an overexpression plasmid construct and siRNA mediated 
knockdown had no significant effect on levels of LINE-1 DNA methylation. A publication identifying 
sites in the genome to which SIRT1 binds (Oberdoerffer et al., 2008) did not reveal the LINE-1 
element as a site of SIRT1 binding. Perhaps therefore the LINE-1 repetitive element as a measure of 
global methylation is not an appropriate site at which to measure effects of SIRT1 on DNA 
methylation. A recent report investigating the role of SIRT1 in telomere maintenance and repair in 
mice deficient or overexpressing SIRT1 measured DNA methylation in response to SIRT1 
manipulation. SIRT1 manipulation did not have an effect on global DNA methylation when measured 
at the B1-SINE1 element using COBRA as a surrogate marker of global DNA methylation (Palacios et 
al., 2010). Overall, therefore, our own observations and those of other researchers provide no evidence 
that SIRT1 alone can affect global DNA methylation, but a definitive conclusion cannot yet be 
reached as a result of experimental limitations. 
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The effects of the polyphenols resveratrol, genistein and daidzein, alone or in combination with SIRT1 
manipulation, on DNA methylation in the Caco-2 cell line were measured by COBRA and the LINE-1 
pyrosequencing assay. Caco-2 cells were treated with resveratrol, genistein or daidzein with the aim to 
establish whether the plant polyphenols played a role in mimicking some of the beneficial effects of 
DR, potentially through SIRT1 and/or changes in DNA methylation levels. In Caco-2 cells transfected 
with an empty vector, resveratrol (10µM, 48 hours) caused an increase in DNA methylation at the 
LINE-1 element. In Caco-2 cells treated with resveratrol (10 µM, 48 hours), genistein or daidzein (50 
µM, 48 hours) a reduction in LINE-1 DNA methylation in response to SIRT1 overexpression was 
measured using COBRA. However, measurement using pyrosequencing indicated that LINE-1 
methylation was unaffected by all of these treatments. Copies of the LINE-1 retrotransposon 
throughout the genome show sequence variability (Khan et al., 2006). Different primer pairs were 
used for the two assays, so a possible explanation for the discordance between measurements using the 
two methods is, therefore, preferential primer binding to different sequences that are differentially 
affected by the polyphenols tested. The findings demonstrate that choice of assay for measuring DNA 
methylation may have an impact on the conclusions drawn and highlight the potential pitfalls of 
relying on a single approach to detect the fairly subtle effects typical of the actions of dietary 
components on LINE-1 methylation. 
 
Overall, these observations support a general view that SIRT1 can influence DNA methylation in the 
presence of the dietary polyphenols tested and at elevated, but not reduced, levels of SIRT1 expression 
in Caco-2 cells, revealing complex interactions. Moreover, detection of such effects is assay-
dependent. As previously discussed, it is possible that other genome regions may be better markers of 
effects of SIRT1 on global DNA methylation. In addition, measurement of gene-specific DNA 
methylation may be required to identify sites modified by SIRT1, such as investigated in following 
chapters (Chapter 5 and Chapter 6). 
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4 An investigation of factors that may affect SIRT1 expression 
4.1 Outline 
In the previous chapter effects of the manipulation of SIRT1 activity and expression on global DNA 
methylation were investigated. In vivo, effects (for example of DR) on SIRT1 may also be at both the 
level of enzyme activation/inhibition and/or at the level of gene expression. We thus sought to 
improve understanding of how SIRT1 is regulated at both levels.  
 
We hypothesise that some effects of DR may be mimicked by dietary polyphenols. One potential 
mechanism for such effects is through these compounds affecting SIRT1 gene transcription. Such 
effects may, potentially, modify the effects of SIRT1-polyphenol interactions on DNA methylation 
(and of other SIRT1-mediated responses to DR). 
 
It is known that the methylation status of a gene promoter region can affect gene expression. Proposed 
underlying mechanisms include the direct physical prevention of transcription factor binding by the 
methylated CpG site or by proteins that bind to methylated CpG sites (Tate and Bird, 1993). Our 
overarching hypothesis proposes that SIRT1 affects DNA methylation through histone deacetylation 
activity, resulting in altered expression of downstream gene targets. We questioned if the SIRT1 gene 
was subject to regulation by promoter methylation, which may potentially affect levels of expression 
with increased age and/or be a mechanism through which other factors – such as dietary compounds or 
indeed levels of SIRT1 activity itself – may modulate expression. 
 
It is well established that methylation patterns across the genome change with ageing. The majority of 
earlier published work suggested there is an overall decrease in methylation with age (Wilson et al., 
1987; Vanyushin et al., 1973), but emerging evidence reveals site-specific increases, as well as 
reductions, with age (Maegawa et al., 2010; Rakyan et al., 2010; Teschendorff et al., 2010; 
Christensen et al., 2009; Kwabi-Addo et al., 2007). Regardless of the direction of DNA methylation 
change, an effect on the expression of the affected gene is possible. It was of relevance in the context 
of our overarching hypothesis, therefore, to investigate if the expression of SIRT1 itself was changed 
with age.  
 
We thus studied the transcriptional activity of SIRT1 in response to polyphenols, changes in promoter 
methylation and investigated any change in expression with age. 
 
Furthermore, with a view to studying regulation of SIRT1 at the level of enzyme activation/inhibition, 
and also to confirm functional consequences of changes in expression in our experimental cell line 
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models, we attempted to employ a commercially available assay to measure SIRT1 deacetylation 
activity. 
4.2 Effects on SIRT1 transcriptional activity of polyphenols resveratrol, genistein and 
daidzein 
To test the effects of polyphenols on the SIRT1 promoter a SIRT1 promoter-reporter plasmid construct 
was generated comprising the region –1011 to +53 (relative to the start of transcription) of the human 
SIRT1 gene upstream of the β-galactosidase reporter gene in the plasmid pBlue-TOPO (Invitrogen). 
The 1064 bp region of the SIRT1 promoter (Figure 4.1) was PCR amplified (Section 2.5.1.1) and 
subcloned into the pBlue-TOPO
®
 vector (Invitrogen) (Section 2.2.1) to produce this promoter reporter 
plasmid construct. Amplification and subcloning of the required sequence was verified by sequencing 
(Figure 4.2). 
 
A GAPDH promoter-reporter plasmid construct comprising the region –517 to +67 (relative to the 
start of transcription) of the human GAPDH gene upstream of the β-galactosidase reporter gene in the 
plasmid pBlue-TOPO
® 
was used as a control. The 584 bp region of the GAPDH promoter (Figure 4.3) 
was used to produce a promoter reporter plasmid construct as above. Amplification and subcloning of 
the required sequencing was verified by sequencing (Figure 4.4).  
 
A transcriptionally inert pBlue-TOPO
®
 construct containing a segment of DNA sequence known to 
have no promoter activity was used as a negative control (J Tyson, Newcastle University, Personal 
communication). 
 
Caco-2 cells seeded 24 hours previously at 3.5 x 10
5
 cells/well in a six well plate (area = 9.6 cm
2
/well) 
were transfected transiently with the SIRT1 promoter-reporter plasmid construct or the GAPDH 
control. After 24 hours cells were treated with the polyphenols resveratrol (10 µM), genistein (50 µM), 
daidzein (50 µM) or a control of 0.1 % v/v DMSO (vehicle only, at the same concentration as for the 
addition of the test polyphenols) and reporter gene activity was measured after a further 48 hours. 
Total cell lysate was used to measure reporter gene activity (β-galactosidase), as described in Section 
2.8.2. Total cell lysate was extracted (Section 2.8.2.1) and protein concentration determined by 
Bradford assay (Section 2.8.1.4). Twenty microlitres of total cell lysate was incubated at 37 ºC with 
130 µl 1.2 ng/ml chlorophenol red- β-D-galactopyranoside (Section 2.8.2.3). Reporter gene activity 
was expressed as nmoles of chlorophenol red formed per minute per mg of total protein and 
normalised to the reporter gene activity measured in Caco-2 cells grown in control medium.  
 
Resveratrol and genistein, but not daidzein, had an effect on SIRT1 promoter activity in this system 
and reduced reporter gene expression (Figure 4.5A) (p < 0.05 and p < 0.001 respectively). However, 
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though not significant, resveratrol and genistein reduced reporter gene expression also from the 
GAPDH promoter (Figure 4.5B) (p > 0.05), indicating a likely effect on gene transcription that is not 
specific to SIRT1. When measures of reporter gene activity driven by the SIRT1 promoter under the 
different conditions were normalised relative to the measured activity from the GAPDH promoter no 
differences between treatments were observed (Figure 4.5C) (p > 0.05). Thus, we find no evidence for 
effects of the polyphenols tested on SIRT1 gene transcription specifically.  
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Figure 4.1. The SIRT1 promoter region sequence. The -1050 to +100 bp SIRT1 promoter sequence taken from 
the human genome sequence is shown. The genomic region upstream of the start of transcription as identified by 
alignment of the transcript sequence NM_02238 (lowercase) is represented in uppercase letters. Primers were 
designed for amplification by PCR of a 1064 bp region of the SIRT1 sequence (SIRT1PromoterF - light red and 
SIRT1PromoterR - dark red) to generate a PCR product to sub-clone into the pBlue-TOPO
® 
reporter vector. 
Primers and annealing temperatures are given in Table 2.2B.  
SIRT1 Sequence
Chr10+: 69643377 - 69644576
-1050 GAGTCACAGT GTGCCAGAAT TTCAGGGAGA GAGGAAAGTG GAAGGGCTTT 
-1000 CCACTAAGCC TTTTGAACTA CTAGGTACCC CTCGTTTTAC ATCTGGTTAT 
-950  CTCATTTAAA TCTATGACGT TTTAAAATAC TTATTACCAT TTAAGACATG
-900  AGAAAAATTA AGTTTAGAAA CGGCTAGATA GCTCACGCTA GAAAGGAAGG 
-850  ACTCCAAATT TTAACCAAGG GCAGATGTGC ATGGAGGCCA AGTCATTTCC 
-800  TTCCCATGCT CTCATACTGA CCCAACAAAC CCATTCTGCA CGTGAGAAAA
-750  CTGAGGCCCG GAGGAGGGAA TTCACACACG TTTGAAGCCA AGCTGGGGCC
-700  AGAAAGTAGA TCGGCTGATC TCCAAACCTC CACGTCAAAG GTCTTCCCAG 
-650  GAGGACATAT GCCTTCAAGG ATTTTACAAT GTATACCACC CTACAAGTGA 
-600  TGGGAGAGAG GGGAAAAAAG CAACCGACTA AGGAGAAAAG CAAGGAGCAG 
-550  AAAAAGGAGC AAAAGAGGAG CTGTCAGAAC GGTGTGAGGA GAGTGGGAAA 
-500  GGAGCCGCCT CCTTTTGCCT CTCTTCCTAC TTATTAACAA AACAGAACGA 
-450  CTATCCAACG TATTTCAGGG AGCTAAGTCT TAGCCAGCTT CAGCTGTGTT 
-400  TTAACCCTTA GCTAAATATA GACAAGGCTA AGGCAGGCCA GGTGTACACT 
-350  TCAGGAAGAC GTGGAAATTC CCAGGGCGGA CCAAAACTTG AGCTGTTCCG 
-300  GCGGTAGTGA TTTGAGGTCA GTTTGAAAGA GAAGTTGAGA AAGCGGCCGA
-250  GGGGCGAATT TGGCTGCACT ACACGCTCGC CACAAAGAGG AAGGGCCGCC 
-200  GGCCGCCGGG GCCGAGTGCG CTTCCAGCCC AGGCGGAGCG GTAGACGCAA 
-150  CAGCCTCCGC CCGCCACGTG ACCCGTAGTG TTGTGGTCTG GCCCGCGTGG 
-100  GTGGCGGGAG CGCCGAGAGG GCGGGGGCGG CGATGGGGCG GGTCACGTGA 
-50   TGGGGTTTAA ATCTCCCGCA GCCGGAGCCG CGGGGGCGCC AGTGCCGCGC
+1    gtcgagcggg agcagaggag gcgagggagg agggccagag aggcagttgg
+50   aagatggcgg acgaggcggc cctcgccctt cagcccggcg gctccccctc
+100  ggcggcgggg gccgacaggg aggccgcgtc gtcccccgcc ggggagccgc
+150  tccgcaagag gccgcggaga gatggtcccg gcctcgagcg gagcccgggc
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Figure 4.2. The SIRT1 promoter sequence inserted into pBlue-TOPO
®
 and related primers. The region of the 
SIRT1 promoter sequence (non-italicised uppercase and lowercase) inserted into the pBlue-TOPO
®
 vector 
(italicised uppercase) is shown aligned to the original genomic sequence. Primers were designed to sequence the 
SIRT1 region in pBlue-TOPO
®
 (SIRT1PromoterF - light red and SIRT1PromoterR - dark red). A reverse primer 
was designed for PCR to the pBlueTOPO vector (pBlueTOPOR – dark red; italicised uppercase) sequence for 
sequence verification. Primers and annealing temperatures are given in Table 2.2B.  
Aligned SIRT1 Insert Sequence in pBLUE-TOPO
-1050 GAGTCACAGT GTGCCAGAAT TTCAGGGAGA GAGGAAAGTG GAAGGGCTTT
| ||||||||||
-1050 GAGCTCGGAT CCCTAGTCCA GTGTGGTGGA ATTGCCCTTG GAAGGGCTTT
-1000 CCACTAAGCC TTTTGAACTA CTAGGTACCC CTCGTTTTAC ATCTGGTTAT
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-1000 CCACTAAGCC TTTTGAACTA CTAGGTACCC CTCGTTTTAC ATCTGGTTAT
-950  CTCATTTAAA TCTATGACGT TTTAAAATAC TTATTACCAT TTAAGACATG
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-950  CTCATTTAAA TCTATGACGT TTTAAAATAC TTATTACCAT TTAAGACATG
-900  AGAAAAATTA AGTTTAGAAA CGGCTAGATA GCTCACGCTA GAAAGGAAGG
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-900  AGAAAAATTA AGTTTAGAAA CGGCTAGATA GCTCACGCTA GAAAGGAAGG
-850  ACTCCAAATT TTAACCAAGG GCAGATGTGC ATGGAGGCCA AGTCATTTCC
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-850  ACTCCAAATT TTAACCAAGG GCAGATGTGC ATGGAGGCCA AGTCATTTCC
-800  TTCCCATGCT CTCATACTGA CCCAACAAAC CCATTCTGCA CGTGAGAAAA
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-800  TTCCCATGCT CTCATACTGA CCCAACAAAC CCATTCTGCA CGTGAGAAAA
-750  CTGAGGCCCG GAGGAGGGAA TTCACACACG TTTGAAGCCA AGCTGGGGCC
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-750  CTGAGGCCCG GAGGAGGGAA TTCACACACG TTTGAAGCCA AGCTGGGGCC
-700  AGAAAGTAGA TCGGCTGATC TCCAAACCTC CACGTCAAAG GTCTTCCCAG 
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-700  AGAAAGTAGA TCGGCTGATC TCCAAACCTC CACGTCAAAG GTCTTCCCAG
-650  GAGGACATAT GCCTTCAAGG ATTTTACAAT GTATACCACC CTACAAGTGA
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-650  GAGGACATAT GCCTTCAAGG ATTTTACAAT GTATACCACC CTACAAGTGA
-600  TGGGAGAGAG GGGAAAAAAG CAACCGACTA AGGAGAAAAG CAAGGAGCAG
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-600  TGGGAGAGAG GGGAAAAAAG CAACCGACTA AGGAGAAAAG CAAGGAGCAG
-550  AAAAAGGAGC AAAAGAGGAG CTGTCAGAAC GGTGTGAGGA GAGTGGGAAA 
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-550  AAAAAGGAGC AAAAGAGGAG CTGTCAGAAC GGTGTGAGGA GAGTGGGAAA
-500  GGAGCCGCCT CCTTTTGCCT CTCTTCCTAC TTATTAACAA AACAGAACGA 
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-500  GGAGCCGCCT CCTTTTGCCT CTCTTCCTAC TTATTAACAA AACAGAACGA
-450  CTATCCAACG TATTTCAGGG AGCTAAGTCT TAGCCAGCTT CAGCTGTGTT 
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-450  CTATCCAACG TATTTCAGGG AGCTAAGTCT TAGCCAGCTT CAGCTGTGTT
-400  TTAACCCTTA GCTAAATATA GACAAGGCTA AGGCAGGCCA GGTGTACACT 
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-400  TTAACCCTTA GCTAAATATA GACAAGGCTA AGGCAGGCCA GGTGTACACT
-350  TCAGGAAGAC GTGGAAATTC CCAGGGCGGA CCAAAACTTG AGCTGTTCCG 
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-350  TCAGGAAGAC GTGGAAATTC CCAGGGCGGA CCAAAACTTG AGCTGTTCCG
-300  GCGGTAGTGA TTTGAGGTCA GTTTGAAAGA GAAGTTGAGA AAGCGGCCGA
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-300  GCGGTAGTGA TTTGAGGTCA GTTTGAAAGA GAAGTTGAGA AAGCGGCCGA
-250  GGGGCGAATT TGGCTGCACT ACACGCTCGC CACAAAGAGG AAGGGCCGCC 
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-250  GGGGCGAATT TGGCTGCACT ACACGCTCGC CACAAAGAGG AAGGGCCGCC
-200  GGCCGCCGGG GCCGAGTGCG CTTCCAGCCC AGGCGGAGCG GTAGACGCAA 
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-200  GGCCGCCGGG GCCGAGTGCG CTTCCAGCCC AGGCGGAGCG GTAGACGCAA
-150  CAGCCTCCGC CCGCCACGTG ACCCGTAGTG TTGTGGTCTG GCCCGCGTGG 
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-150  CAGCCTCCGC CCGCCACGTG ACCCGTAGTG TTGTGGTCTG GCCCGCGTGG
-100  GTGGCGGGAG CGCCGAGAGG GCGGGGGCGG CGATGGGGCG GGTCACGTGA 
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-100  GTGGCGGGAG CGCCGAGAGG GCGGGGGCGG CGATGGGGCG GGTCACGTGA
-50   TGGGGTTTAA ATCTCCCGCA GCCGGAGCCG CGGGGGCGCC AGTGCCGCGC
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
-50   TGGGGTTTAA ATCTCCCGCA GCCGGAGCCG CGGGGGCGCC AGTGCCGCGC
+1    gtcgagcggg agcagaggag gcgagggagg agggccagag aggcagttgg
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
+1    gtcgagcggg agcagaggag gcgagggagg agggccagag aggcagttgg
+50   aagatggcgg acgaggcggc cctcgccctt cagcccggcg gctccccctc
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
+50   aagAAGGGCA ATTCTGCAGA AAGCTTACCA TGGGGGGTTC TCATCATCAT
+100  ggcggcgggg gccgacaggg aggccgcgtc gtcccccgcc ggggagccgc
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
+100  CATCATCATG GTATGGCTAG CATGACTGGT GGACAGCAAA TGGGTCGGGA
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Figure 4.3 The GAPDH promoter region sequence. The -517 to +67 bp GAPDH promoter sequence taken from 
the human genome sequence is shown. The genomic region upstream of the start of transcription as identified by 
alignment of the transcript sequence NM_002046 (lowercase) is represented in uppercase letters. Primers were 
designed for amplification by PCR of a 584 bp region of the GAPDH sequence (GAPDHPrmomoterF - light red 
and GAPDHPromoterR - dark red) to generate a PCR product to sub-clone into the pBlue-TOPO
® 
reporter 
vector. Primers and annealing temperatures are given in Table 2.2B.  
GAPDH Sequence
Chr12+:6642657 - 6643957
-1000 GGAGGGACTT CCGCCCTCAC GTCCCGCTCT TCGCCCCAGG CTGGATGGAA
-950  TGAAAGGCAC ACTGTCTCTC TCCCTAGGCA GCACAGCCCA CAGGTTTCCA 
-900  GGAGTGCCTT TGTGGGAGGC CTCTGGGCCC CCACCAGCCA TCCTGTCCTC 
-850  CGCCTGGGGC CCCAGCCCGG AGAGAGCCGC TGGTGCACAC AGGGCCGGGA 
-800  TTGTCTGCCC TAATTATCAG GTCCAGGCTA CAGGGCTGCA GGACATCGTG
-750  ACCTTCCGTG CAGAAACCTC CCCCTCCCCC TCAAGCCGCC TCCCGAGCCT 
-700  CCTTCCTCTC CAGGCCCCCA GTGCCCAGTG CCCAGTGCCC AGCCCAGGCC 
-650  TCGGTCCCAG AGATGCCAGG AGCCAGGAGA TGGGGAGGGG GAAGTGGGGG 
-600  CTGGGAAGGA ACCACGGGCC CCCGCCCGAG GCCCATGGGC CCCTCCTAGG 
-550  CCTTTGCCTG AGCAGTCCGG TGTCACTACC GCAGAGCCTC GAGGAGAAGT 
-500  TCCCCAACTT TCCCGCCTCT CAGCCTTTGA AAGAAAGAAA GGGGAGGGGG 
-450  CAGGCCGCGT GCAGCCGCGA GCGGTGCTGG GCTCCGGCTC CAATTCCCCA 
-400  TCTCAGTCGT TCCCAAAGTC CTCCTGTTTC ATCCAAGCGT GTAAGGGTCC 
-350  CCGTCCTTGA CTCCCTAGTG TCCTGCTGCC CACAGTCCAG TCCTGGGAAC 
-300  CAGCACCGAT CACCTCCCAT CGGGCCAATC TCAGTCCCTT CCCCCCTACG 
-250  TCGGGGCCCA CACGCTCGGT GCGTGCCCAG TTGAACCAGG CGGCTGCGGA 
-150  AAAAAAAAAG CGGGGAGAAA GTAGGGCCCG GCTACTAGCG GTTTTACGGG
-100  CGCACGTAGC TCAGGCCTCA AGACCTTGGG CTGGGACTGG CTGAGCCTGG 
-50   CGGGAGGCGG GGTCCGAGTC ACCGCCTGCC GCCGCGCCCC CGGTTTCTAT
+1    aaattgagcc cgcagcctcc cgcttcgctc tctgctcctc ctgttcgaca
+50   gtcagccgca tcttcttttg cgtcgccagg tgaagacggg cggagagaaa
+100  cccgggaggc tagggacggc ctgaaggcgg caggggcggg cgcaggccgg
+150  atgtgttcgc gccgctgcgg ggtgggcccg ggcggcctcc gcattgcagg
+200  ggcgggcgga ggacgtgatg cggcgcgggc tgggcatgga ggcctggtgg
+250  gggaggggag gggaggcgtg tgtgtcggcc ggggccacta ggcgctcact
+300  gttctctccc tccgcgcagc cgagccacat cgctcagaca ccatggggaa
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Figure 4.4 The GAPDH promoter sequence inserted into pBlue-TOPO
®
 and related primers. The region of the 
GAPDH promoter sequence (non-italicised uppercase and lowercase) inserted into the pBlue-TOPO
®
 vector 
(italicised uppercase) is shown aligned to the original genomic sequence. Primers were designed to sequence the 
GAPDH region in pBlue-TOPO
®
 (GAPDHPromoterF - light red and GAPDHPromoterR - dark red). A reverse 
primer was designed for PCR to the pBlueTOPO vector (pBlueTOPOR – dark red; italicised uppercase; part 
shown) sequence for sequence verification. Primers and annealing temperatures are given in Table 2.2B.  
Aligned GAPDH Insert Sequence in pBlue-TOPO
-550  CCTTTGCCTG AGCAGTCCGG TGTCACTACC GCAGAGCCTC GAGGAGAAGT
||||||| ||||||||||
GGATCCCTAG TCCAGTGTGG TGGAATTGCC CTTGAGCCTC GAGGAGAAGT
-500  TCCCCAACTT TCCCGCCTCT CAGCCTTTGA AAGAAAGAAA GGGGAGGGGG
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
TCCCCAACTT TCCCGCCTCT CAGCCTTTGA AAGAAAGAAA GGGGAGGGGG
-450  CAGGCCGCGT GCAGCCGCGA GCGGTGCTGG GCTCCGGCTC CAATTCCCCA
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
CAGGCCGCGT GCAGCCGCGA GCGGTGCTGG GCTCCGGCTC CAATTCCCCA
-400  TCTCAGTCGT TCCCAAAGTC CTCCTGTTTC ATCCAAGCGT GTAAGGGTCC
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
TCTCAGTCGT TCCCAAAGTC CTCCTGTTTC ATCCAAGCGT GTAAGGGTCC
-350  CCGTCCTTGA CTCCCTAGTG TCCTGCTGCC CACAGTCCAG TCCTGGGAAC
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
CCGTCCTTGA CTCCCTAGTG TCCTGCTGCC CACAGTCCAG TCCTGGGAAC
-300  CAGCACCGAT CACCTCCCAT CGGGCCAATC TCAGTCCCTT CCCCCCTACG
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
CAGCACCGAT CACCTCCCAT CGGGCCAATC TCAGTCCCTT CCCCCCTACG
-250  TCGGGGCCCA CACGCTCGGT GCGTGCCCAG TTGAACCAGG CGGCTGCGGA
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
TCGGGGCCCA CACGCTCGGT GCGTGCCCAG TTGAACCAGG CGGCTGCGGA
-150  AAAAAAAAAG CGGGGAGAAA GTAGGGCCCG GCTACTAGCG GTTTTACGGG
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
AAAAAAAAAG CGGGGAGAAA GTAGGGCCCG GCTACTAGCG GTTTTACGGG
-100  CGCACGTAGC TCAGGCCTCA AGACCTTGGG CTGGGACTGG CTGAGCCTGG
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
CGCACGTAGC TCAGGCCTCA AGACCTTGGG CTGGGACTGG CTGAGCCTGG
-50   CGGGAGGCGG GGTCCGAGTC ACCGCCTGCC GCCGCGCCCC CGGTTTCTAT
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
CGGGAGGCGG GGTCCGAGTC ACCGCCTGCC GCCGCGCCCC CGGTTTCTAT
+1    aaattgagcc cgcagcctcc cgcttcgctc tctgctcctc ctgttcgaca
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
aaattgagcc cgcagcctcc cgcttcgctc tctgctcctc ctgttcgaca
+50   gtcagccgca tcttcttttg cgtcgccagg tgaagacggg cggagagaaa
|||||||||| |||||||
gtcagccgca tcttcttAAG GGCAATTCTG CAGAAAGCTT ACCATGGGGG
+100  cccgggaggc tagggacggc ctgaaggcgg caggggcggg cgcaggccgg
GTTCTCATCA TCATCATCAT CATGGTATGG CTAGCATGAC TGGTGGACAG
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Figure 4.5. Effect of dietary polyphenols on activity of the human SIRT1 promoter. Activity of the β-
galactosidase reporter gene was measured 72 h after transfection with a promoter-reporter construct 
comprising either (A) the human SIRT1 promoter region (–1011 to +34, relative to the start of transcription) or 
(B) the human GAPDH promoter region (-517 to +67, relative to the start of transcription) upstream of the β-
galactosidase reporter gene in the plasmid pBlue-TOPO (Invitrogen) or with a corresponding negative control 
construct (‘-ve’), without a promoter sequence insert. Treatment with resveratrol (RSV; 10 µM), genistein 
(GEN; 50 µM) or daidzein (DZN; 50 µM) was 24 h after transfection. Control cells (‘Control’) were treated 
with DMSO vehicle only. All data are mean ± SEM for n = 12-18 and are expressed as a ratio of the protein 
concentration of the cell lysate, normalised to the control condition. (C) Activity of the SIRT1 promoter region 
normalised to the activity of the GAPDH promoter region. *p < 0.05, ***p < 0.001 by one way ANOVA 
followed by Bonferroni’s multiple comparisons test.  
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4.3 Effects of promoter methylation on SIRT1 transcription 
To investigate if levels of SIRT1 expression can themselves be modulated by (potentially SIRT1-
mediated) DNA methylation, Caco-2 cells were transfected with a methylated and unmethylated 
SIRT1 promoter reporter construct; comprising the SIRT1 promoter upstream of the LacZ gene. An 
equivalent construct containing the SLC30A5 (zinc transporter) promoter was used as a positive 
control; previous work in the laboratory had established that SLC30A5 promoter activity is repressed 
by methylation (L J Coneyworth, Newcastle University, PhD Thesis).  
 
The SIRT1 promoter-reporter plasmid construct previously generated (Section 4.2) comprising the 
region –1011 to +53 (relative to the start of transcription) of the human SIRT1 gene upstream of the β-
galactosidase reporter gene in the plasmid pBlue-TOPO was used to assess the effect of methylation 
on SIRT1 transcription. The SLC30A5 promoter reporter plasmid construct comprising the region –
1000 to +100 (relative to the start of transcription) of the human SLC30A5 gene (Figure 4.6) was used 
to produce a positive control promoter reporter plasmid construct (Figure 4.7) as described previously 
(Section 4.2). As before, a transcriptionally inert pBlue-TOPO
®
 construct was used as a negative 
control. 
 
For both SIRT1 and SLC30A5 unmethylated promoter-reporter constructs were generated by the 
propagation of the plasmid through the methylase deficient K12 ER2925 E. coli strain as described in 
Section 2.2.3 and plasmid DNA was prepared as described in Section 2.2.2. Methylated SIRT1 and 
SLC30A5 promoter-reporter constructs were generated through in vitro methylation of 2 μg 
unmethylated plasmid DNA by SssI methylase (New England Biolabs) as described in Section 2.2.4. 
As a control, to ensure that any changes in promoter activity were not due to the enzymatic 
methylation process, ‘mock’ methylation reactions were set up and were identical to in vitro 
methylation reactions except the SssI methylase was omitted. 
 
Caco-2 cells seeded 24 hours previously at 3.5 x 10
5
 cells/well in a six well plate (area = 9.6 cm
2
/well) 
were transfected transiently with either the unmethylated, ‘mock’ methylated or methylated SIRT1 and 
SLC30A5 promoter-reporter plasmid construct or the negative control. After 48 hours cells were lysed 
and reporter gene (β-galactosidase) activity was measured as described in Section 2.8.2. Total cell 
lysate was extracted (Section 2.8.2.1) and protein concentration was determined by Bradford assay 
(Section 2.8.1.4). Twenty microlitres of total cell lysate was incubated at 37 ºC with 130 µl 1.2 ng/ml 
chlorophenol red-β-D-galactopyranoside (Section 2.8.2.3). Reporter gene activity was expressed as 
nmoles of chlorophenol red formed per minute per mg of total protein.   
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Figure 4.6. The SLC30A5 promoter region sequence. The -1000 to +100 bp region of the SLC30A5 promoter 
sequence taken from the human genome sequence is shown. The genomic region upstream of the start of 
transcription as identified by alignment of the transcript sequence NM_022902 (lowercase) is represented in 
uppercase letters. Primers were designed for amplification by PCR of a 1000 bp region of the SLC30A5 
sequence (SLC30A5F#1 - light red and SLC30A5R#1 - dark red) to generate a PCR product to sub-clone into 
the pBlue-TOPO
® 
reporter vector. Primers and annealing temperatures are given in Table 2.2B.  
SLC30A5 Promoter Sequence
Chr5+:68388882 - 68390031
-1000 CTTTAGAAAT CTGGAAATTG CCTTTAGGTT CCCTTAGGAG TAGGAGAGAA
-950  GGCCATGAAG TTTCGCACGT GGTCACTCCT AGAAAATTGC CCTGGGATAG
-900  TTTGCTGAGG AGGCAAATTT TGGTCAATAC TAGTTTCTCC TCTCCAAAGT
-850  CCATCAAAGG CATTGTTCAA AAGAAATGGC CGTACCACTA TTTGTAATTG
-800  ATTCTCTACA GCTTCAAAAA TAGTTATCTC TGGTTGGGGG AAGGGCACGT
-750  GAACTTTTAA GACTTCGGGC CTTCTCATCA CAAAAATGAT CCATACTCAC
-700  AAAAACTTAG AGGCAGAGGG TATGTTAACC TAGATTAAGA ATCTCTAGGC
-650  CGAGTGCGGT GGCTCACTCC TGTAATCGCA GCACTTTGGG AGGCCGAGGT
-600  GGGTGGATCA CCTGAGGTCA GGAGTTCGAG ACCAGCCTGA CCAACATGGA
-550  GAAACCCCGT CTCTACTAAA AATACAAAAT TAGCCAGGTG TGGTGGCACA
-500  TGCCTGTAAT CCCAGCTACT TGGGAGACTG AGGCAGGAGA ATCGCTTGAA
-450  CCTGGGAGGT GGAAGTTGCC GTGAGCCGAG ATCGCGCCAT TGCACTCCAG
-400  CCTGGGCAAC AGGAGCGAAA CTCCATCTCA AAACAAAAAA AAAAAGAATC
-350  CCTAACGCAG AGGAAAAGAT TGGTGAGCTT TGTTTAATCA CACACGCTGT
-300  ACATTTTCCA CGCCCTCCCC CTCTGCCCTA CAGGAATCCG CTGTACTTCT
-250  GACGGCCCAT AGGTGGCACT GTAGGGACAG GTAAGTGCAC AGGGAGCGCC
-200  ACCCGGAGAG GCTGATAGGA GGCGGAGCTT CAATGCGACA CAACGTGGCG
-150  GGAGGAGCCT AAGGGACGAG GAAAGGCGAG TGTTCTGCTT GCGCAGACGC
-100  AAGGCTGGGC ACTCCCCCGG GAGTGAGGGT TGCTGGGCCT GATGACGTGG
-50   CTTGGCAACG TCCCTACCGC CGCTGCTTCC CGGGAACCTG GCGCCGCCGG
+1    aactgatcgc ggcctagtcc cgacgcgtgt gtgctagtga gccggagccg
+50   gcgacggcgg cagtggcggc ccggcctgca ggagcccgac ggggtctctg
+100  ccatggggga gtgacgcgcc tgcacccgct gttccgcggc agcggcgaga
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Figure 4.7. The SLC30A5 promoter sequence inserted into pBlue-TOPO
®
 and related primers. The region of 
the SLC30A5 promoter sequence (non-italicised uppercase) inserted into the pBlue-TOPO
®
 vector (italicised 
uppercase) is shown aligned to the original genomic sequence. Primers were designed for a PCR to a region in 
the SLC30A5 (SLC30A5PromoterF - light red and SLC30A5PromoterR#1 - dark red; non-italicised uppercase) 
sequence. A reverse primer was designed for PCR to the pBlueTOPO vector (pBlueTOPOR – dark red; italicised 
uppercase) sequence for sequence verification. Primers and annealing temperatures are given in Table 2.2B.  
Aligned SLC30A5 Insert Sequence in pBlue-TOPO
-1000 CTTTAGAAAT CTGGAAATTG CCTTTAGGTT CCCTTAGGAG TAGGAGAGAA
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
CTTTAGAAAT CTGGAAATTG CCTTTAGGTT CCCTTAGGAG TAGGAGAGAA
-950  GGCCATGAAG TTTCGCACGT GGTCACTCCT AGAAAATTGC CCTGGGATAG
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
GGCCATGAAG TTTCGCACGT GGTCACTCCT AGAAAATTGC CCTGGGATAG
-900  TTTGCTGAGG AGGCAAATTT TGGTCAATAC TAGTTTCTCC TCTCCAAAGT
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
TTTGCTGAGG AGGCAAATTT TGGTCAATAC TAGTTTCTCC TCTCCAAAGT
-850  CCATCAAAGG CATTGTTCAA AAGAAATGGC CGTACCACTA TTTGTAATTG
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
CCATCAAAGG CATTGTTCAA AAGAAATGGC CGTACCACTA TTTGTAATTG
-800  ATTCTCTACA GCTTCAAAAA TAGTTATCTC TGGTTGGGGG AAGGGCACGT
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
ATTCTCTACA GCTTCAAAAA TAGTTATCTC TGGTTGGGGG AAGGGCACGT
-750  GAACTTTTAA GACTTCGGGC CTTCTCATCA CAAAAATGAT CCATACTCAC
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
GAACTTTTAA GACTTCGGGC CTTCTCATCA CAAAAATGAT CCATACTCAC
-700  AAAAACTTAG AGGCAGAGGG TATGTTAACC TAGATTAAGA ATCTCTAGGC
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
AAAAACTTAG AGGCAGAGGG TATGTTAACC TAGATTAAGA ATCTCTAGGC
-650  CGAGTGCGGT GGCTCACTCC TGTAATCGCA GCACTTTGGG AGGCCGAGGT
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
CGAGTGCGGT GGCTCACTCC TGTAATCGCA GCACTTTGGG AGGCCGAGGT
-600  GGGTGGATCA CCTGAGGTCA GGAGTTCGAG ACCAGCCTGA CCAACATGGA
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
GGGTGGATCA CCTGAGGTCA GGAGTTCGAG ACCAGCCTGA CCAACATGGA
-550  GAAACCCCGT CTCTACTAAA AATACAAAAT TAGCCAGGTG TGGTGGCACA
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
GAAACCCCGT CTCTACTAAA AATACAAAAT TAGCCAGGTG TGGTGGCACA
-500  TGCCTGTAAT CCCAGCTACT TGGGAGACTG AGGCAGGAGA ATCGCTTGAA
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
TGCCTGTAAT CCCAGCTACT TGGGAGACTG AGGCAGGAGA ATCGCTTGAA
-450  CCTGGGAGGT GGAAGTTGCC GTGAGCCGAG ATCGCGCCAT TGCACTCCAG
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
CCTGGGAGGT GGAAGTTGCC GTGAGCCGAG ATCGCGCCAT TGCACTCCAG
-400  CCTGGGCAAC AGGAGCGAAA CTCCATCTCA AAACAAAAAA AAAAAGAATC
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
CCTGGGCAAC AGGAGCGAAA CTCCATCTCA AAACAAAAAA AAAAAGAATC
-350  CCTAACGCAG AGGAAAAGAT TGGTGAGCTT TGTTTAATCA CACACGCTGT
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
CCTAACGCAG AGGAAAAGAT TGGTGAGCTT TGTTTAATCA CACACGCTGT
-300  ACATTTTCCA CGCCCTCCCC CTCTGCCCTA CAGGAATCCG CTGTACTTCT
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
ACATTTTCCA CGCCCTCCCC CTCTGCCCTA CAGGAATCCG CTGTACTTCT
-250  GACGGCCCAT AGGTGGCACT GTAGGGACAG GTAAGTGCAC AGGGAGCGCC
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
GACGGCCCAT AGGTGGCACT GTAGGGACAG GTAAGTGCAC AGGGAGCGCC
-200  ACCCGGAGAG GCTGATAGGA GGCGGAGCTT CAATGCGACA CAACGTGGCG
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
ACCCGGAGAG GCTGATAGGA GGCGGAGCTT CAATGCGACA CAACGTGGCG
-150  GGAGGAGCCT AAGGGACGAG GAAAGGCGAG TGTTCTGCTT GCGCAGACGC
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
GGAGGAGCCT AAGGGACGAG GAAAGGCGAG TGTTCTGCTT GCGCAGACGC
-100  AAGGCTGGGC ACTCCCCCGG GAGTGAGGGT TGCTGGGCCT GATGACGTGG
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
AAGGCTGGGC ACTCCCCCGG GAGTGAGGGT TGCTGGGCCT GATGACGTGG
-50   CTTGGCAACG TCCCTACCGC CGCTGCTTCC CGGGAACCTG GCGCCGCCGG
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
CTTGGCAACG TCCCTACCGC CGCTGCTTCC CGGGAACCTG GCGCCGCCGG
+1    aactgatcgc ggcctagtcc cgacgcgtgt gtgctagtga gccggagccg
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
aactgatcgc ggcctagtcc cgacgcgtgt gtgctagtga gccggagccg
+50   gcgacggcgg cagtggcggc ccggcctgca ggagcccgac ggggtctctg
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
AAGGGCAATT CTGCAGAAAG CTTACCATGG GGGGTTCTCA TCATCATCAT
+100  ccatggggga gtgacgcgcc tgcacccgct gttccgcggc agcggcgaga
|||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
CATCATGGTA TGGCTAGCAT GACTGGTGGA CAGCAAATGG GTCGGGATCT
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As expected, methylation of the SLC30A5 promoter reporter construct resulted in a loss of promoter 
activity (p < 0.001). A comparison of ‘mock’ methylated and unmethylated constructs showed no 
difference in levels of reporter gene expression. The SIRT1 promoter showed a modest reduction in 
activity when methylated (p < 0.01) (Figure 4.8) revealing the potential for any SIRT1-mediated (or 
other) effects on methylation of the SIRT1 promoter to affect SIRT1 expression.  
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Figure 4.8 Effect on SIRT1 transcriptional activity of promoter methylation. Cell lysate extracted from Caco-2 
cells transfected with methylated or unmethylated SIRT1 promoter reporter constructs or control methylated or 
unmethylated ZnT5 promoter reporter constructs were assessed for promoter activity using the beta 
galactosidase activity assay to measure reporter gene expression. As expected, methylated ZnT5 promoter 
reporter constructs had reduced promoter activity in comparison to unmethylated constructs (***p < 0.001 by 
student’s t-test). The methylated SIRT1 promoter reporter construct also showed a decrease in promoter activity 
compared with the unmethylated SIRT1 promoter reporter construct (** p < 0.01 by student’s t-test). All data 
are mean ± SEM for n = 3.  
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4.4 Relationship between SIRT1 levels and ageing in intestinal mouse tissue 
We propose in our hypothesis that the increased levels of SIRT1 seen under DR affect levels of DNA 
methylation to mediate some of the beneficial effects of reduced dietary intake. It is possible that such 
an increase in SIRT1 expression opposes an age-related decline in expression. The literature currently 
available shows a wide variation in the effects of ageing on SIRT1 expression levels in different 
tissues. Of particular note are: an observed increase in SIRT1 skeletal muscle of rats (proposed by the 
authors to potentially compensate for the decreased activity of SIRT1/lower levels of NAD
+
 substrate 
with age) (Koltai et al., 2010); an increase in SIRT1 in monkey heart as a protective affect against 
stress (Alcendor et al., 2007); a decrease in SIRT1 in thymus and heart in mice in response to 
senescence, part of the cellular process of ageing, (Sasaki et al., 2006; Sakamoto et al., 2004); a 
decrease during senescence in human fibroblasts (Michishita et al., 2005). To our knowledge there are 
currently no reports of the levels of SIRT1 in the ageing gut, so SIRT1 expression was measured in 
samples of intestinal tissue from relatively young and older mice.  
 
Protein lysates extracted from the jejunum and ileum tissue of 12 and 38 month old mice were 
assessed for changes in SIRT1 levels in response to ageing by western blot as described in Section 2.8. 
Protein lysate was extracted (Section 2.8.1.1) and protein concentration determined by Bradford assay 
(Section 2.8.1.4). Ten micrograms of tissue lysate extracted from each tissue sample was separated by 
SDS-PAGE (Section 2.8.1.5) and blotted onto a polyvinylidene difluride (PVDF) membrane (Section 
2.8.1.6), which was then probed with antibodies to SIRT1 and the loading control protein alpha 
tubulin. Bands revealed on the blot were quantified by densitometry and the arbitrary values obtained 
for SIRT1 protein expression were expressed as a ratio of the band intensity of the alpha tubulin 
loading control. Figure 4.9A shows a typical western blot assessing the levels of SIRT1 protein in the 
intestinal tissue of a single animal from each age group. Data were then normalised against the 
densitometric signal intensity obtained from the 12 month old mice analysed on the same blot. This 
analysis revealed no difference in the level of SIRT1 expression between young and old mouse 
intestinal tissues (Figure 4.9B). However, the small pool of three mice per age group was probably not 
sufficient to accurately represent the inter-individual differences in SIRT1 and alpha tubulin protein 
expression in the intestinal gut tissues of individual mice, so findings remain inconclusive.  
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Figure 4.9. Relationship between SIRT1 levels and ageing in mouse intestinal tissue. A – Protein extracted 
from 12 month and 38 month jejunum and ileum mouse tissue were separated by SDS-PAGE and SIRT1 
expression was analysed by probing with an antibody to the SIRT1 protein followed by reprobing with an 
antibody to the loading control alpha tubulin. B – The bands revealed on the blot were quantified using 
densitometry. There was no statistically significant difference between the SIRT1 protein levels in the jejunum 
and ileum of young and old mice. p > 0.05 by student’s t-test. All data are mean ± SEM for n = 3.  
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4.5 Attempts of measure SIRT1 activity for use in cell line models and mouse tissues 
In addition to the investigations described above, we also made attempts to optimise the SIRT1 Fluor 
de Lys
™
 fluorescent activity assay (BIOMOL
®
 International) using recombinant SIRT1 (supplied with 
the kit) with the intention of studying the effects of dietary compounds, promoter methylation and age 
on SIRT1 deacetylase activity, as well as providing evidence of increased activity in cells 
overexpressing SIRT1 from plasmid constructs and in response to siRNA knockdown as employed in 
the work described in Chapter 3, Chapter 6 and Chapter 7.  
 
The SIRT1 fluorescence activity assay has been used widely and reported within the literature as a 
means to investigate the effects of potential sirtuin-activating compounds (STACs) on SIRT1 
deacetylase activity and test/identify synthetic STACs (Milne et al., 2007). The assay is based on the 
deacetylation and sensitisation of the Fluor de Lys-SIRT1 substrate upon incubation with cell lysate 
containing endogenous SIRT1 together with the co-substrate NAD
+
. Upon treatment with the Fluor de 
Lys Developer II, a detectable fluorophore is produced (Figure 4.10). To assess SIRT1 activity in 
Caco-2 cells transfected with the SIRT1 overexpression construct, total cell lysate from the 
overexpression experiments replaced the human recombinant SIRT1 provided with the assay, which 
was used as a positive control. Fluorescence was also measured when the recombinant SIRT1 was 
replaced with cell lysate but the apparent reaction rate was independent of the quantity of cells lysate 
added. We therefore tested for fluorescence emission under assay conditions in the absence of any 
added protein and the same rate of fluorescence emission was observed, leading to the deduction that 
the substrate was unstable and that any apparent SIRT1 activity in the lysate was an artefact. 
Additionally, there has been much controversy surrounding the use of this assay in measuring SIRT1 
deacetylase activity, leading to heated discussion within the literature over the authenticity of results. 
Recent research (Pacholec et al., 2010; Beher et al., 2009) backs up earlier claims (Borra et al., 2005; 
Kaeberlein et al., 2005a) questioning the reliability of the fluorescent assay to screen for compounds 
that enhanced SIRT1 deacetylase activity, specifically the use of the fluorescent peptide substrate 
employed within the Fluor de Lys assay. These studies propose that the non-physiological fluorescent 
moiety within the substrate creates experimental artefacts through increased binding affinity of the 
fluorescently labelled peptide irrespective of the presence of the peptide sequence. GlaxoSmithKline 
subsequently addressed these concerns by running further experiments identifying novel compounds 
that did not require the fluorophore for increased activity (Dai et al., 2010). Validation of the STACs 
in this study was through an activity assay employing a different substrate. 
 
Our own observations, along with the uncertainty in the reliability of the assay as reported above, led 
the SIRT1 Fluor de Lys
™
 assay to be dismissed as sufficiently robust for measurements of the 
deacetylase activity of SIRT1 in our experiments. 
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Figure 4.10. Schematic of the SIRT1 Fluorescence Activity Assay. A – The Fluor de Lys-SIRT1 substrate, 
which comprises the p53 sequence Arg-His-Lys-Lys(ε-acetyl), is incubated with the human recombinant SIRT1 
together with the co-substrate NAD
+
 leading to the deacetylation and sensitisation of the Fluor de Lys-SIRT1 
substrate. B - Upon treatment with the Fluor de Lys developer II, a detectable fluorophore is produced.  
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4.6 Discussion 
In this chapter the transcriptional activity of SIRT1 was investigated in the context of changes to 
promoter activity in response to polyphenols, effects of promoter methylation and effects of age. The 
effects of the polyphenols resveratrol, genistein and daidzein on SIRT1 promoter activity were 
investigated using the β-galactosidase activity assay. Caco-2 cells were treated with resveratrol, 
genistein or daidzein in the presence of a promoter-reporter construct containing the promoter region 
of the human SIRT1 gene upstream of the β-galactosidase gene with the aim to establish whether the 
plant polyphenols play a role in modifying SIRT1 promoter activity and therefore deacetylation of 
downstream targets of SIRT1 that may be involved in mimicking some of the beneficial effects of DR 
through SIRT1. In Caco-2 cells transfected with the SIRT1 promoter reporter construct resveratrol (10 
μM, 48 hours) and genistein (50 μM, 48 hours) caused a reduction in the level of SIRT1 promoter 
activity, however once normalised to the response of the reference gene GAPDH these effects were no 
longer apparent, therefore the polyphenols do not appear to effect the transcriptional activity of the 
SIRT1 gene specifically. Both genistein (Akiyama et al., 1987) and resveratrol (Jayatilake et al., 1993) 
might have a general affect on transcription of the reporter constructs through their known ability to 
inhibit tyrosine kinases involved in regulating protein activation via phosphorylation. 
 
The consequences of methylation of the SIRT1 for transcriptional activity of the gene were 
investigated using a methylated promoter-reporter model (Coneyworth et al., 2009). Caco-2 cells were 
transfected with the SIRT1 promoter-reporter construct with the aim to establish if the methylation 
status of the SIRT1 promoter sequence affected the transcriptional activity of the SIRT1 gene. In Caco-
2 cells transfected with the methylated SIRT1 promoter reporter construct, the level of SIRT1 promoter 
activity was reduced compared to the unmethylated control. This observation suggested that SIRT1 
activity can be regulated through the methylation status of the promoter region of the SIRT1 gene.  
 
The expression levels of SIRT1 in young (12 months) and old mice (38 months) were investigated at 
the protein level by probing total cell lysate, extracted from intestinal tissue and resolved by SDS-
PAGE, with an antibody to the SIRT1 protein. No differences were detected between the levels of 
SIRT1 in young compared with old mouse intestinal tissue. Our observation that levels of SIRT1 
expression within the mouse gut did not differ between younger and older mice does not exclude the 
possibility that the cell-type or sub-cellular localisation was unaffected, since only total tissues 
homogeny was used. Furthermore, the availability of only 3 mice per group for this analysis may have 
provided insufficient power to detect a difference in SIRT1 expression. 
 
The Fluor de Lys
™
 activity assay system to measure SIRT1 enzymatic activity has been found to be 
unreliable in other studies as well as through our own observations. There are several other methods 
through which levels of SIRT1 deacetylation may be measured. Promega have recently developed a 
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new SIRT1 activity assay, SIRT-Glo
™
, based on the recognition and deacetylation by SIRT1 of a 
novel substrate that contains a peptide sequence derived from p53 with an acetylated lysine attached to 
aminoluciferin. The deacetylation of this peptide results in the production of a substrate that can be 
cleaved by a developer reagent to release the aminoluciferin, which is then acted upon by luciferase to 
give a measurable luminescence signal (Halley et al., 2011). Advantages include the addition of a 
single reagent mixture that contains all the components required for the reaction, a higher sensitivity 
compared to fluorescent based assays and a steady-state luminescent signal. One of the first 
investigations into validation of the SIRT1 Fluor de Lys
™
 fluorescent activity assay utilised additional 
techniques in parallel to the Fluor de Lys
™ 
system. Coumarin and rhodamine-based fluorescence 
assays, where the Fluor de Lys-SIRT1 substrate (which contains the human p53 sequence from amino 
acids 379 to 382 with the acetylated lysine adjacent to the fluorophore) was replaced by either a p53-
AMC and p53-R110 substrate respectively, showed the same effect of resveratrol to activate SIRT1-
mediated deacetylation. However, when the Fluor de Lys-SIRT1 peptide was replaced by [
3
H]AcH3 
peptide – another deacetylation target for SIRT1 – or an unlabelled p53 peptide, no activation of 
SIRT1 by resveratrol was observed suggesting that the fluorophore and not the peptide sequence 
conferred resveratrol activation (Borra et al., 2005). High performance liquid chromatography (HPLC) 
was utilised to measure the presence of 
14
C labelled NAD
+
 and the deacetylation product nicotinamide 
in the reaction using the fluorophore-free ([3H]AcH3) substrate. This assay would have been another 
possible method to assay SIRT1 deacetylase activity in our own investigations had there not been time 
constraints. 
 
Several factors that may affect SIRT1 expression are investigated through the research presented in 
this chapter, however many aspects of SIRT1 regulation – expression of the pre-mRNA, post-
transcriptional modification and translation of the protein – have not been investigated in any depth by 
our own or other research groups and warrant further investigation. The regulation of expression of the 
SIRT1 gene to produce the primary transcript is known to rely upon the binding of several 
transcription factors under different conditions. We observed a repression of transcriptional activity 
when the SIRT1 promoter region upstream of the LacZ gene was methylated. Further investigations, to 
identify the combination of methylated CpG sites crucial for transcriptional suppression are justifiable 
as downstream experimentation could then determine the effect of the methylation on transcription 
factor binding. The discovery of microRNAs to target mRNA for degradation preventing protein 
expression has added another layer to the central dogma of gene regulation. Several SIRT1-targeting 
microRNAs have now been found and will no doubt play fundamental roles in how and when SIRT1 
is expressed and may also explain some discrepancies between data reported.  
 
Studies of sirtuin regulation should extend to other family members, which have also been observed to 
play fundamental roles in a variety of pathways that may be perturbed during the ageing process. 
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Recent studies have showed that SIRT4 negatively regulates levels of SIRT1 and downstream fatty 
acid oxidation in the liver (Nasrin et al., 2010) and the protective effect of DR against oxidative 
damage in multiple tissues is abolished with DR in SIRT3 knockout mice (Someya et al., 2010) 
suggesting the other sirtuins perhaps work in concert with SIRT1 to produce the lifespan extension 
response to DR. Experiments involving knockdown of multiple sirtuins may go some way to 
addressing the level of the interplay between the seven sirtuins.  
 
In contrast to reports based on analysis of other tissues, we did not observe a change in SIRT1 protein 
levels with age in a small cohort of mouse intestine, based on analysis of six animals. Sub-cellular 
localisation of SIRT1 has been shown to differ between numerous tissue and cell types (Tanno et al., 
2007) suggesting a mechanism with which the deacetylation of both nuclear and cytoplasmic targets of 
SIRT1 can be functionally regulated. Use of immunohistochemistry or fluorescent protein tags to 
visualise the sub-cellular location of SIRT1 in response to age would perhaps reveal other effects of 
age and possibly shed more light on possible influence of age on the functional actions of SIRT1 not 
measurable by levels of expression alone.  
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5 In silico analysis of relationships between loci binding SIRT1, genes 
affected by dietary restriction and genes showing ageing-related 
changes in methylation 
5.1 Outline 
As discussed previously dietary restriction (DR) remains one of the most robust dietary interventions 
proved effective to increase lifespan across evolutionarily distinct species, from yeast to rodents 
(Guarente and Picard, 2005). The NAD
+
-dependent (class III) histone deacetylase SIRT1 in mammals, 
and its ortholog in other species, may be pivotal in mediating the effect of DR to increase lifespan. 
Ageing is associated with changes in genome methylation (e.g.
 
(Maegawa et al., 2010), which may be 
causative in the ageing process. Such observations, in view of the activity of SIRT1 at the level of the 
epigenome, form the basis for the hypothesis that epigenetic affects of SIRT1 activity mediate some of 
the beneficial effects of DR that contribute to lifespan extension. The approach to testing this 
hypothesis in this chapter was to determine, through in silico analysis, the overlap between genes that 
bind SIRT1, those regulated at the mRNA level in response to DR, and those that show an age-related 
change in methylation status, predicated on the principle that overlaps greater than would be expected 
by chance would support the hypothesis.  
 
As the intention was to compare gene lists from a wide variety of sources all genes were converted to 
be represented with the same gene identifier. Ensembl identifiers are one of the most stable and 
extensively used gene identifiers currently in use and provide a comprehensive and up to date gene ID 
set on which to base bioinformatic analysis. The Ensembl Biomart Gene Conversion Tool was used to 
convert genes from their given identifier to the Ensembl format as described in Section 2.9.1. The 
NimbleGen MM5 array was used as the ‘Universe’ against which all genes lists analysed were 
checked to ensure their presence. Genes not represented in the ‘Universe’ were excluded from further 
analysis to ensure that sizes of overlaps obtained through gene list comparisons and their statistical 
analysis were precise and robust. Altogether 17087 genes on the MM5 array could be represented by 
an Ensembl identifier using the Ensembl Biomart Gene Conversion Tool (Appendix E.I). 
5.2 SIRT1-associated genes 
A list of gene loci at which SIRT1 binds to the promoter region in mouse embryonic stem cells (ES 
cells) was obtained from the published data of Oberdoerffer and co-workers (Oberdoerffer et al., 2008) 
based on use of chromatin immunoprecipitation using an anti-SIRT1 antibody. Mouse embryonic stem 
cells were cross linked with 1 % formaldehyde, sonicated, incubated with the antibody and 
immunoprecipitated using an anti-SIRT1 antibody. The immunoprecipitated DNA was co-hybridised 
with input DNA (not enriched for sites of SIRT1 binding) to a NimbleGen MM5 minimal promoter 
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tiling array. A list of all loci corresponding to probes for which there was enrichment in the 
immunoprecipitated DNA fraction was provided as supplementary material. Four hundred and thirty 
annotated gene loci were identified to which SIRT1 bound and that could be represented by an 
Ensembl identifier (Table 5.2 and Appendix E.I).  
5.3 Genes responsive to dietary restriction 
To investigate the extent to which genes that were associated with SIRT1 in mouse embryonic stem 
cells overlapped with those regulated at the mRNA level in response to dietary restriction - also in 
mouse - a literature research was conducted to establish a list for this comparison. Initially, to search 
for relevant publications the online PubMed database which accesses MEDLINE the online Medical 
Literature Analysis and Retrieval System (MEDLARS) was used. PubMed (1950 – 2008) searches 
were conducted using the search terms ‘mouse’ in conjunction with (‘calorie restriction’ OR ‘caloric 
restriction’ OR ‘dietary restriction’ OR ‘energy restriction’) AND (‘gene expression’ OR 
‘transcriptional profiling’ OR ‘microarray’). Relevant references cited in publications and reviews 
(Swindell, 2008; Han and Hickey, 2005) obtained through this search were also included as potential 
sources for gene lists. Studies that did not provide full results of the transcriptional profiling within the 
body of the paper or as easily accessible supplementary material were excluded. This process 
identified eleven studies from which a single gene list, with duplicates excluded, was compiled 
(Sharov et al., 2008; Swindell, 2008; Wu et al., 2008; Dhahbi et al., 2006; Fu et al., 2006; Selman et 
al., 2006; Han and Hickey, 2005; Higami et al., 2004; Massaro et al., 2004; Tsuchiya et al., 2004; Lee 
et al., 2002) (Table 5.1). For each published study the authors’ list of regulated genes was accepted 
using data from any tissues for which it was available; the rationale was that the data available for 
gene loci binding SIRT1 was based on ES cells, so was not tissue-specific. All gene lists were 
converted to Ensembl identifiers as described above and duplicates were eliminated to generate a 
single list of 2613 genes (Appendix E.I) found to respond to DR in mice and also found on the MM5 
array ‘Universe’. 
  
Reference Tissue   Design   Gene Identifier Number of Genes 
   
 
 
  
Dhanbi et al (2006) Heart  Male B6C3F1 were DR for 2 months (17 % 2 weeks then 45 % 6 weeks) from 29 months of age then 
killed at 31 months n = 4 
 
GeneBank 106 
    
 
  
Fu et al (2006) Heart, Hypothalamus, Liver  Male C57BL/6 were 40 % DR for 2.5 - 4.5 months from 1.5 months old then killed at 4 - 6 months of age 
n = 6 per tissue (each pooled from 3 mice) 
GeneBank 1116 
  
    
 
  
Han et al (2005) Anterior Pituitary, 
Cerebellum, Epididymus, 
Gastrolcnemius Muscle, 
Heart, Liver, Lung, 
Neocortex, WAT 
 Gene expression data was collected from 15 published studies; male and female 129/sv, Ames, Ames 
Dwarf, B6C3F1, BALB/c, C3B10RF, C57BL/6 or C57BL/6J were DR. See Han et al 2005 for details of 
each individual study. 
 
GeneBank 167 
    
 
  
Higami et al (2004) WAT  Male C57BL/6 were 41 % DR for 0.75 - 9 months from 1.5 months old then killed at 10 - 11 months of 
age n = 5  
 
GeneBank 109 
    
 
  
Lee et al (2002) Heart  Male B6C3F1 were 41 % DR for 16 months from 14-30 months old then killed at 30 months of age n = 5 
 
GeneBank 831 
    
 
  
Massaro et al (2004) Lung  Male C57BL/6 were 66 % DR for 14 days n = 6 
 
GeneBank 257 
    
 
  
Selman et al (2006) Colon, Gastrolcnemius 
Muscle, Hypothalamus, Liver 
 Male C57BL/6 were 10-30 % DR for 30 days from 3.5-4 months old then killed at 4.03 months of age n 
= 3 per tissue (each pooled from 3.3 mice) 
 
HUGO 2072 
    
 
  
Sharov et al (2008) Ovary, Testis  Male and female C57BL/6 were 40 % DR for 0.75 months from 3.5 months old then killed at 6 - 24 
months of age n = 6 per tissue 
 
HUGO 136 
    
 
  
Swindell (2008) Cochlea, Colon, Heart, 
Hippocampus, Hypothalamus, 
Kidney, Liver, Lung, Muscle, 
WAT 
 Gene expression data was collected from 10 published studies; male and female 129/sv, Ames, B6C3F1, 
B6CBA, C57BL/6, C57BL/6J, or C57BL/6NHsd were DR. See Swindell 2008 for details of each 
individual study. 
 
HUGO 28 
    
 
  
Tsuchiya et al (2004) Liver  Male and female Ames and Ames Dwarf were 30 % DR for 4 months from 2 months old then killed at 6 
months of age n = 8 per mouse strain 
 
GeneBank 77 
    
 
  
Wu et al (2008) Hippocampus  Male B6CBA were 30 % DR for 4 months from 4 months of age then killed at 8 months of age n = 4 
 
GeneBank 146 
 
Table 5.1. Summary of gene profiling studies in dietary restricted mice. Abbreviations: DR – dietary restriction; WAT – white adipose tissue. 
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5.4 Genes with a methylation status changed with age 
Publication of a data set listing genes that showed a change in methylation status with ageing in mouse 
intestine (Maegawa et al., 2010) afforded the opportunity to determine if genes found to associate with 
SIRT1 and/or to respond to DR were also over-represented in this group. Genomic DNA from 
intestinal tissue of 3 or 35 month old C57BL/6 mice was fragmented by methylation-sensitive 
restriction digestion using SmaI to produce blunt end fragments, cutting only when the recognition site 
(CCCGGG) is unmethylated. This digestion was followed by digestion using XmaI, the SmaI 
methylation-insensitive isoschizomer, to cut methylated SmaI sites and produce CCGG overhangs 
allowing adaptor ligation. The fragments produced from this digestion process were PCR amplified 
and samples from young and old mice were co-hybridised to the promoter oligonucleotide array after 
labelling with Cy3 (green) or Cy5 (red).  
 
Using the same criteria as the authors of this study to designate genes as showing differential 
methylation between young (3 month) and old (35 month) tissue, Ensembl identifiers were assigned to 
1040 genes that showed ageing-related changes in methylation status (Appendix E.I) and were 
represented in the list of 17087 genes on the NimbleGen MM5 minimal promoter tiling array for 
which could also be represented by Ensembl identifiers.  
 
5.5 Analysis of overlaps between SIRT1-associated genes, genes responsive to DR and 
genes with a methylation status changed with age. 
Of the 1040 genes that showed ageing-related changes in methylation status, 47 were also in the list of 
genes found to associate with SIRT1 (Table 5.2); the number expected by chance is 26 (i.e. 
1040/17087 (or 6.1 %) of the 430 SIRT1-associated genes). Calculation of cumulative hypergeometric 
probability indicates that the apparent over-representation of genes found to show ageing-related 
changes in methylation status that also associate with SIRT1 (representation factor of 1.81) is 
statistically significant (P = 7.1 x 10
-5
). This analysis indicates that genes to which SIRT1 binds are 
more likely to show changes in methylation status with increased age. This relationship also supports 
the hypothesis that responses to DR include epigenetic effects (specifically effects on DNA 
methylation) resulting from SIRT1 activity. 
 
The 2613 genes identified as responsive to DR represented 15.3 % of the genes interrogated as 
potential SIRT1 targets (i.e. 2613/17087). Eighty-four genes appeared on both the list of SIRT1 targets 
and on the list of genes responsive to DR (Table 5.2). If the proportion of SIRT1-associated genes 
responsive to DR were the same as the proportion of all genes responsive to DR (as would be the case 
if DR-responsiveness and association with SIRT1 were independent variables), then the expected size 
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of this overlap would be 66 genes (i.e. 15.3 % of the 430 SIRT1-associated genes). Calculation of 
cumulative hypergeometric probability indicates that the apparent over-representation of genes 
responsive to DR that also associate with SIRT1 (representation factor of 1.27) is statistically 
significant (P = 0.0095). This analysis indicates that there is an association between genes that respond 
to DR and genes that bind SIRT1, which supports the hypothesis that responses to DR include 
epigenetic effects resulting from SIRT1 activity. 
 
One hundred and ninety one genes appeared on both the lists of genes responsive to DR and found to 
show an age-related change in methylation status. This figure compared with 159 expected by chance 
(i.e. 6.1 % of the 2613 genes found to respond to DR or 15.3 % of the 1040 genes found to show an 
ageing-related change in methylation status), giving a representation factor of 1.20 and cumulative 
hypergeometric probability of 0.0031. This analysis indicates that genes that respond to DR are more 
likely than other genes to show changes in methylation status with ageing (or vice versa), consistent 
with a view that effects of DR include effects on gene methylation status relevant to ageing and 
therefore in agreement with the overall hypothesis. Numbers of genes, observed/expected values, 
representation factors and hypergeometric probability values for the above three pairwise comparisons 
of overlaps are summarised in Table 5.3. 
 
Ten genes fell into the ‘three way’ overlap between the gene lists compiled (Table 5.2 and Appendix 
E.I), compared with an expected number of 4 (i.e. 0.153 x 0.061 x 430), giving a representation factor 
of 2.5 and cumulative hypergeometric probability of 0.0079. This ‘three way’ overlap is represented 
via a Venn diagram in Figure 5.1. Again, the analysis supports the hypothesis that responses to DR 
include epigenetic effects (specifically effects on DNA methylation) resulting from SIRT1 activity.  
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Genes associated with SIRT1 AND responsive to DR 
ENSMUSG00000025964* Adam23* ENSMUSG00000029178 Klf3 ENSMUSG00000019889 Ptprk 
ENSMUSG00000053644  Aldh7a1  ENSMUSG00000026866  Kynu  ENSMUSG00000004127  Rg9mtd2  
ENSMUSG00000020610  Amz2  ENSMUSG00000032193  Ldlr  ENSMUSG00000026360*  Rgs2*  
ENSMUSG00000011958*  Bnip2*  ENSMUSG00000029103*  Lrpap1*  ENSMUSG00000008301  Rnuxa  
ENSMUSG00000055172*  C1r*  ENSMUSG00000018819  Lsp1  ENSMUSG00000012848  Rps5  
ENSMUSG00000024372  C2  ENSMUSG00000008035  Mid1Ip1  ENSMUSG00000031568  Rwdd4a  
ENSMUSG00000029283  Cdc7  ENSMUSG00000059908  Mug1  ENSMUSG00000017707*  Serinc3*  
ENSMUSG00000069089  Cdk7  ENSMUSG00000073832  Mup17  ENSMUSG00000033965  Slc16a2  
ENSMUSG00000056501  Cebpb  ENSMUSG00000020900*  Myh10*  ENSMUSG00000026205  Slc23a3  
ENSMUSG00000028044  Cks1b  ENSMUSG00000061911*  Myt1l*  ENSMUSG00000022664  Slc35a5  
ENSMUSG00000022843  Clcn2  ENSMUSG00000021710  Nln  ENSMUSG00000063354  Slc39a4  
ENSMUSG00000026317  Cln8  ENSMUSG00000027405  Nol5a/NoP56  ENSMUSG00000006641  Slc5a6  
ENSMUSG00000024644  Cndp2  ENSMUSG00000030551  Nr2f2  ENSMUSG00000020027  Socs2  
ENSMUSG00000000326*  Comt*  ENSMUSG00000027852  Nras  ENSMUSG00000039218  Srrm2  
ENSMUSG00000032330  Cox7a2  ENSMUSG00000041827  Oasl1  ENSMUSG00000018167  Stard3  
ENSMUSG00000031446  Cul4a  ENSMUSG00000020131  Pcsk4  ENSMUSG00000047963  Stbd1  
ENSMUSG00000029630  Cyp3a59  ENSMUSG00000005615*  Pcyt1a*  ENSMUSG00000022241  Tars  
ENSMUSG00000003135  D1bwg0212e  ENSMUSG00000025728  Pigq  ENSMUSG00000018604  Tbx3  
ENSMUSG00000046179  E2f8  ENSMUSG00000023452  Pisd  ENSMUSG00000024498  Tcerg1  
ENSMUSG00000022053  Ebf2  ENSMUSG00000014503  Pkd2l2  ENSMUSG00000006335*  Tfpt*  
ENSMUSG00000035530*  Eif1*  ENSMUSG00000031538  Plat  ENSMUSG00000048007  Timm8a1  
ENSMUSG00000021282  Eif5  ENSMUSG00000028691  Prdx1  ENSMUSG00000027801  Tm4sf4  
ENSMUSG00000021364  Elovl2  ENSMUSG00000005161  Prdx2  ENSMUSG00000029723*  Tsc22d4*  
ENSMUSG00000024360  Etf1  ENSMUSG00000039671  Prkcbp1  ENSMUSG00000062380  Tubb3  
ENSMUSG00000055401  Fbxo6  ENSMUSG00000002455  Prpf6  ENSMUSG00000030870  Ubfd1  
ENSMUSG00000025059  Gyk  ENSMUSG00000027566  Psma7  ENSMUSG00000001891  Ugp2  
ENSMUSG00000031734  Irx3  ENSMUSG00000022193  Psmb5  ENSMUSG00000032376  Usp3  
ENSMUSG00000003779  Kif20a  ENSMUSG00000021745  Ptprg  ENSMUSG00000027803*  Wwtr1*  
      
Genes associated with SIRT1 AND showing a change in methylation status with ageing  
ENSMUSG00000030249 Abcc9 ENSMUSG00000028344 Invs  ENSMUSG00000038205 Prkab2 
ENSMUSG00000054808 Actn4 ENSMUSG00000033365 Ipo13 ENSMUSG00000021745 Ptprg 
ENSMUSG00000029094 Afap1 ENSMUSG00000031734 Irx3 ENSMUSG00000025485 Ric8 
ENSMUSG00000052414 Atf7 ENSMUSG00000031738 Irx6 ENSMUSG00000057378 Ryr3 
ENSMUSG00000057914 Cacnb2 ENSMUSG00000054274 Kif26b ENSMUSG00000045092 S1pr1 
ENSMUSG00000015733 Capza2 ENSMUSG00000029178 Klf3 ENSMUSG00000019913 Sim1 
ENSMUSG00000029283 CDC7 ENSMUSG00000032193 Ldlr ENSMUSG00000063354 Slc39a4 
ENSMUSG00000006958 Chrd ENSMUSG00000026890 Lhx6 ENSMUSG00000040247 Tbc1d10c 
ENSMUSG00000045672 Col27a1 ENSMUSG00000038668 Lpar1 ENSMUSG00000000093 Tbx2 
ENSMUSG00000029705* Cux1* ENSMUSG00000045095 Magi1 ENSMUSG00000018604 Tbx3 
ENSMUSG00000030871 Ears2 ENSMUSG00000020900* Myh10* ENSMUSG00000032536* Trak1* 
ENSMUSG00000021282 Eif5 ENSMUSG00000005886 Ncoa2 ENSMUSG00000007805 Twist2 
ENSMUSG00000028664 Ephb2 ENSMUSG00000026525 Opn3 ENSMUSG00000008604 Ubqln4 
ENSMUSG00000059003 Grin2a ENSMUSG00000005615* Pcyt1a* ENSMUSG00000006270 Vax1 
ENSMUSG00000056755 Grm7 ENSMUSG00000056204 Pgpep1 ENSMUSG00000022023 Wbp4 
ENSMUSG00000069308 Hist1h2bp ENSMUSG00000018547 Pip4k2b 
  
      
Genes associated with SIRT1 AND responsive to DR AND showing a change in methylation status with ageing  
ENSMUSG00000029283 Cdc7  ENSMUSG00000032193 Ldlr  ENSMUSG00000021745 Ptprg  
ENSMUSG00000021282 Eif5  ENSMUSG00000020900*  Myh10*  ENSMUSG00000063354 Slc39a4 
ENSMUSG00000031734 Irx3 ENSMUSG00000005615* Pcyt1a* ENSMUSG00000018604 Tbx3 
ENSMUSG00000029178 Klf3 
     
Table 5.2. Lists of SIRT1-associated genes also responsive to DR or showing a change in methylation status 
with ageing or responsive to DR AND showing a change in methylation status with ageing. Both ENSEMBL 
identifiers and gene symbols are stated. *Denotes genes found also to be deregulated with age in mouse 
neocortex.
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Figure 5.1. Diagrammatic representation of the ‘three way’ overlap of genes found to be associated with 
SIRT1 and found to be responsive to DR and found to show an ageing-related change in methylation status. 
‘n’ indicates the number of genes common to both groups; ‘p’ indicates the cumulative hypergeometric 
probability.  
 
 
Table 5.3. Overlaps between genes responsive to DR, genes that SIRT1 binds to and genes that show changes 
in methylation status with ageing, based on in silico analysis. ‘n’ indicates the number of genes common to 
both groups; Observed (OBS) over calculated expected (EXP) values, the representation factor, are shown; ‘p’ 
indicates the cumulative hypergeometric probability.  
Gene set interrogated 
n = 17087 (see Appendix E.I) 
Genes responsive to DR 
n = 2613 (see Appendix E.I) 
Genes showing a change in methylation 
status with ageing 
n = 1040 (see Appendix E.I) 
SIRT1-associated genes 
n = 430 (see Table 5.2) 
OBS/EXP = 84/66 = 1.27 
p = 0.0095 
OBS/EXP = 47/26 = 1.81 
p = 7.1 x 10-5 
Genes showing a change in methylation 
status with ageing 
n = 1040 (see Appendix E.I) 
OBS/EXP = 191/159 = 1.20 
p = 0.0031  
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5.6 Genes identified as targets for SIRT1-binding that responds to DR and undergo an 
age-related change in methylation status. 
Genes falling within the ‘three way’ overlap identified through our in silico analysis may be 
particularly strong candidates for mediating affects of DR on lifespan/healthspan through the SIRT1-
mediated effects on methylation that we propose. Each of these 10 genes is thus considered briefly 
below, noting the nature of the observed response to DR and with emphasis on possible or speculative 
roles in ageing and/or modulation of healthy lifespan. 
5.6.1 Cell division cycle 7 
The Cdc7 gene showed increased expression in response to DR in mouse hippocampus (Wu et al., 
2008) and encodes the conserved cell division cycle 7 kinase, which is required in parallel with the 
cyclin-dependent kinase (CDK) to establish replication forks during DNA replication. During G1 
phase the MCM2-7 (minichromosome maintenance 2-7) DNA helicase complex is loaded onto the 
origin of replication in an inactive form. CDC7 and CDK are essential to activate this replicative 
helicase and also for recruitment of co-factors required for chromosome replication (Labib, 2010). 
Inactivation of CDC7 results in genomic instability (Costanzo et al., 2003) and cell death (Montagnoli 
et al., 2004) so possible links with ageing – through effects on cell survival – are likely though, to our 
knowledge, not established.  
5.6.2 Eukaryotic translation initiation factor 5 
Eukaryotic translation initiation factor 5 (Eif5), which showed increased expression in response to DR 
in mouse liver (Fu et al., 2006) regulates the activity of the conserved guanosine triphosphate (GTP)-
binding eukaryotic translation initiation factor 2 protein eIF2. eIF2 is composed of three subunits (αβγ) 
and initiates eukaryotic protein translation through binding (to the γ subunit) and delivering initiator 
methionyl tRNA (met-tRNA) to the ribosome. eIF2 forms a pre-initiation complex (PIC) with the 40s 
ribosomal subunit and initiation factors eIFs 1, 1A, 3 and 5 (through the β subunit) after binding met-
tRNA. eIF5 acts as a GDP dissociation inhibitor (GDI) and GTPase accelerating protein (GAP) 
regulating the translation initiation process through eIF2 activity via hydrolysis of the eIF2-bound 
GTP required for release of the 40s ribosomal subunit for 60s interaction and transcription initiation. 
eIF5 then later prevents eIF2-bound GDP release, which would result in the downstream reactivation 
of eIF2 and subsequent translation initiations. Mutation of Eif5 results in dysregulation and stalling of 
transcription initiation resulting in slowed cell growth (Jennings and Pavitt, 2010) a process that could 
feasibly alter the ageing trajectory. Additionally, the C. elegans homologue of the human eukaryotic 
translation initiation factor eIF4H, drr-2 has been shown to respond to DR and increase longevity in 
worms, highlighting the importance of transcription initiation in lifespan (Ching et al., 2010). 
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5.6.3 Iroquois related homeobox 3 
The Irx3 gene showed increased expression in response to DR in mouse heart (Lee et al., 2002). 
Translation of the Irx3 gene in progenitor cells during early embryonic development produces the 
Iroquois related homeobox 3 protein, a member of the Iroquois transcription factor family. Irx genes 
are responsible for a variety of developmental processes such as organisation of the heart, eye and, in 
the case of Irx3, the dorso-ventral patterning of neural tube (the precursor to the central nervous 
system) via strict direction of motor neuron generation (Cavodeassi et al., 2001). Although Irx3 is 
required for aspects of embryonic development, other Iroquois transcription factors have been 
implicated in regulation of gene expression in adult cells; most notably, Irx5 has a role in contraction 
of the heart, where it negatively regulates the expression of potassium channels to control 
depolarisation and repolarisation of endocardial (septal base of heart) and epicardial (ventricular apex 
of heart) myocytes (Costantini et al., 2005). It is possible that Irx3 may also have roles in the 
regulation of gene expression in adult cells with functional consequences of relevance to ageing, 
though to our knowledge such factors have not yet been identified.  
5.6.4 Krüppel-like factor 3 
Klf3 showed increased expression in response to DR in mouse liver (Selman et al., 2006). The family 
of Krüppel-like factor (KLF) transcription factors bind DNA, specifically promoters and enhancers of 
genes, through three highly-conserved zinc fingers, which allow the KLF proteins to regulate gene 
expression through activation and repression. The Krüppel-like factor 3 (KLF3) regulates gene 
expression of target sequences through recruitment of the C-terminal binding protein CtBP, binding of 
co-factors including histone methyl transferases and deacetylases, and sumoylation of KLF3 lysines, 
together forming a repressor complex. KLF3 plays roles in i) regulation of adipogenesis by repression 
of the adipogenic genes PPARγ, C/EBPα and β inhibiting fat cell formation, ii) generation of red 
blood cells by binding and repression of embryonic and adult β-globins and iii) differentiation of B 
cells through downstream activation of KLF3 after the activation and initiation of the B cell response. 
Conversely, KLF3 appears to act as an activator in development of muscle cells, binding the muscle 
creatine kinase (MCK) promoter, which mediates the transfer of energy from the mitochondria to 
muscle cells, promoting muscle differentiation (Pearson et al., 2011). Given the wide range of 
biological processes and tissues in which KLF3 functions, it is easy to propose links between 
expression of this transcription factor and factors of ageing, particularly with respect to 
haematopoiesis and the reliance of the human body on this system for immunity; however, to our 
knowledge, such links have not yet been addressed explicitly.  
5.6.5 Low density lipoprotein receptor 
The low density lipoprotein (LDL) receptor (LDLR) is a transmembrane glycoprotein that is expressed 
at the cell surface in a wide variety of tissues within the body - specifically the liver - and acts as the 
main regulator of cholesterol homeostasis within the plasma. The Ldlr showed decreased expression in 
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response to DR in mouse white adipose tissue (Higami et al., 2004). LDLR binds and transports via 
endocytosis the major carrier of cholesterol, LDL, from the plasma into the cell for lysosomal 
degradation. Mutations in Ldlr cause hypercholesterolemia, an increase in blood cholesterol levels that 
can also be caused by environmental factors such as poor diet and obesity and ultimately can lead to 
cardiovascular disease with increasing age. Thus, affecting LDLR expression levels may be a 
mechanism through which DR affects the ageing process. 
5.6.6 Myosin, heavy chain 10 
Myh10 showed decreased expression in response to DR in mouse liver (Selman et al., 2006). The 
myosin motor protein superfamily is essential in cellular processes requiring migration along actin 
filaments, a major cytoskeletal component of the cell. Class II myosin is present in all non muscle 
eukaryotic cells in addition to playing a major role in contraction of cardiac, skeletal and smooth 
muscle. Non muscle myosin II (NM II) has the same structure as muscle myosin; composed of heavy 
and light chains forming bipolar filaments to which actin can then bind, forming the sliding filaments 
of muscle tissue. Myh9, Myh10 and Myh14, encode the NM II heavy chain isoforms A, B and C 
respectively (NMHC IIA-C) and define the NM II isoforms (NM IIA-C). NM IIB (encoded by Myh10) 
gives structure to the centre and rear of the migrating cell, assists with cell adhesion, mediates nuclear 
localisation and establishes Golgi apparatus and microtubule-organising centre positioning, ensuring 
correct migration, adhesion, and polarity of the cell respectively (Vicente-Manzanares et al., 2009). 
Ablation of NMHC IIB in a mouse model results in incorrect myocardialisation of the heart (Tullio et 
al., 1997) and brain architecture (Tullio et al., 2001) in early development. Known roles of this gene 
product, therefore, are of a fundamental nature and while specific functions directly relating to ageing 
have not, to our knowledge, been identified it is feasible that perturbation of function in older 
organisms may contribute to an ageing phenotype and that restriction of function through DR may 
have beneficial consequences. 
5.6.7 Phosphate cytidylyltransferase 1 choline alpha isoform  
Pcyt1a showed increased expression in response to DR in mouse liver (Fu et al., 2006). 
Phosphatidylcholines are a key membrane lipid component of the cell, the biosynthesis of which is 
catalysed by cytidine 5’-triphosphate (CTP):phosphocholine cytidylyltransferase alpha (CTα) 
(Sugimoto et al., 2008). Phosphatidylcholine biosynthesis plays a crucial role as cells divide and an 
increase in membrane phospholipids is required for cells to proceed through G1. Reducing the 
bioavailability of choline in fibroblasts (Tercé et al., 1994) or reducing the activation and expression 
of Pcyt1a (Banchio et al., 2003) greatly impairs the progress of cells through G1 and S phase 
respectively. Dysregulation of such mechanisms facilitating progression of the cell cycle is likely to 
lead to genomic instability and adverse changes such as oncogenesis and other pathological challenges 
related to those of an ageing cell, so it is feasible that beneficial effects of DR may be mediated 
through affects on Pcyt1a expression 
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5.6.8 Protein tyrosine phosphatase receptor type G 
Ptprg showed increased in response to DR in mouse hippocampus (Wu et al., 2008). The protein 
tyrosine phosphatase receptor type G – encoded by Ptprg – transduces signals across the cell 
membrane through removal of phosphate groups from tyrosine residues on proteins. PTPRG has been 
proposed as a tumour suppressor gene due to its location in a frequently deleted section of human 
chromosome 3 associated with renal and lung carcinomas. Additionally, reduction in PTPRG 
expression is associated with chronic myeloid leukaemia characterised by a decrease in methylation at 
gene promoter CpG sites recorded in 55 % of patients assessed (Della Peruta et al., 2010). Such 
observations suggest an important role for correct expression of Ptprg in prevention of cancers, which 
become more prevalent with age, and providing a potential link between effects of DR on expression 
of the gene and ageing-related disease. 
5.6.9 Solute carrier 39, member 4 
Slc39a4 showed decreased expression in response to DR in mouse liver (Selman et al., 2006). Zinc 
availability plays a major role in many cellular processes due to the requirement of zinc in protein 
structure and function. Indeed, up to 10 % of the human genome may code for zinc-associated proteins 
(Andreini et al., 2006). The regulation of zinc homeostasis is dependent upon the expression of genes 
to take up, store and efflux zinc from the cytoplasm. The Slc39 solute carrier family encode the ZIP 
proteins, which transport zinc into the cell or release it from intracellular stores. The zinc transporter 
ZIP4, encoded by Slc39a4, plays an important role in intestinal zinc absorption through the apical 
membrane of enterocytes (Eide, 2004). Mutations in the Slc39a4 gene result in acrodermatitis 
enteropathica, an inherited disorder of dietary zinc absorption (Dufner-Beattie et al., 2003). It remains 
an unproven, yet feasible, hypothesis that altered methylation of Slc39a4 in the ageing gut leads to 
impaired zinc absorption, which may explain zinc-related features of ageing, notably compromised 
immune function (Fairweather-Tait et al., 2008). 
5.6.10 T-box3 transcription factor 
Tbx3 showed decreased expression in response to DR in mouse ovary (Sharov et al., 2008). T-box 
genes code for transcription factors that, through a conserved T-box DNA binding domain, activate or 
repress the promoter or enhancer of genes required in early embryonic development. The T-box 3 
transcription factor - encoded by Tbx3 - is required in limb bud formation, specifically digit 
development. Haploinsufficiency of the Tbx3 gene in development results in ulnar-mammary 
syndrome and congenital malformations (King et al., 2006). Dysregulation of Tbx3 in adult plays a 
role in tumourigenesis through inhibition of senescence via the ARF/MDM2/p53/p21
CIP1
 pathway (Lu 
et al., 2010), providing a link between the function of this transcription factor and the ageing process. 
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5.7 Discussion 
Genes were selected and converted to a common identifier from studies identifying genes that 
associated with SIRT1 (Oberdoerffer et al., 2008), were responsive to DR at the mRNA level (Sharov 
et al., 2008; Swindell, 2008; Wu et al., 2008; Dhahbi et al., 2006; Fu et al., 2006; Selman et al., 2006; 
Han and Hickey, 2005; Higami et al., 2004; Massaro et al., 2004; Tsuchiya et al., 2004; Lee et al., 
2002) or whose methylation changed with ageing (Maegawa et al., 2010) generating three gene lists 
for which overlaps were identified. An overlap of 84 genes between the list of genes identified as sites 
of binding by SIRT1 and the list of genes found to respond to DR was found to be greater than would 
be expected by chance (p = 0.0095). The overlap of 47 genes associated with SIRT1 that also showed 
ageing-related changes in methylation status was also greater than expected by chance (p = 7.1 x 10
-5
). 
An overlap of 191 DR-responsive genes and genes showing a change in methylation with ageing (p = 
0.0031) was also greater than expected by chance. Similarly, the overlap between the three lists of ten 
genes was again greater than would be expected by chance (p = 0.0079). Overall, this in silico analysis 
supported the hypothesis that SIRT1-mediated effects of DR include effects on DNA methylation. 
 
The genes highlighted through this in silico analysis by virtue of appearing on all three lists encode 
proteins involved in a diverse range of cellular processes such as the fundamental regulation of the cell 
cycle (CDC7, EIF5), structure (MYH10, PCYT1A), and signalling (PTPRG), control of gene 
expression in early development (IRX3, TBX3) or general transcriptional regulation (KLF3) and 
regulation of dietary components (LDLR, SLC39A4). To our knowledge, previous studies have 
identified none of these genes as pivotal in determining lifespan or features of ageing, but hypotheses 
can be proposed. Thus, each gene provides a starting point for further investigation into how its 
methylation status may be a factor linking SIRT1, DR and their effects on the ageing cell.  
 
The following chapter describes investigation of these gene loci individually to examine directly if 
SIRT1 expression can influence methylation status and/or expression levels, to attempt to uncover 
further evidence to support the overarching hypothesis and to highlight further if there is a strong 
argument favouring further research on these genes as possible mediators of lifespan or healthspan. 
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6 Gene-targeted in vitro investigation of links between SIRT1 expression, 
gene-specific DNA methylation and gene expression 
6.1 Outline 
This chapter describes investigation of the 10 genes identified by in silico analysis described in 
Chapter 5 to determine if they respond to SIRT1 manipulation, by having altered methylation at CpG 
sites within their promoter regions and/or to show affected gene expression levels.  
 
To investigate if levels of SIRT1 expression can affect DNA methylation, SIRT1 was overexpressed 
and knocked down in the Caco-2 cell line. SIRT1 overexpression and knockdown in Caco-2 cells was 
confirmed at the mRNA level by RT-qPCR and at the protein level by western blot. DNA methylation 
at selected CpG sites was measured by pyrosequencing at CpG dinucleotides immediately upstream of 
the start of transcription in eight of the ten genes (CDC7, EIF5, IRX3, KLF3, PCYT1A, PTPRG, 
SLC39A4, TBX3) highlighted by the in silico analysis. Robust assays were not achieved for the 
measurement of methylation within the LDLR and MYH10 promoter regions. Reverse transcription-
qPCR was used to determine if expression at the mRNA level of the same genes was affected by 
manipulation of SIRT1 expression levels.  
 
6.2 Gene specific DNA methylation and mRNA expression 
To achieve SIRT1 knockdown, Caco-2 cells seeded 24 hours previously at 3.5 x 10
5
 cells/well in a six 
well plate (area = 9.6 cm
2
/well) were transfected transiently with 100 pmol SIRT1-targeting siRNA or 
with 100 pmol of a Stealth RNAi
™
 siRNA negative control of similar GC content. After 72 hours cells 
were lysed and DNA, RNA and total cell lysate were extracted from parallel experiments. Genomic 
DNA and total RNA were used to assess affects of SIRT1 knockdown on DNA methylation levels and 
expression of the target genes, respectively. First, RNA and protein were used to confirm SIRT1 
knockdown at the transcriptional and translational level. RNA was used to assess SIRT1 knockdown 
at the mRNA level by RT-qPCR as described in Section 2.7.2. Total RNA was extracted from Caco-2 
cells using TRIzol
®
 reagent followed by the Invitrogen PureLink
™
 RNA Mini Kit (Section 2.4.3). Four 
and a half micrograms of DNase-treated RNA (Section 2.7.1.2) was reverse transcribed using 
Superscript
™
 III RNase H- Reverse Transcriptase (Invitrogen) (Section 2.7.1.3). Reverse transcribed 
cDNA was then PCR amplified (Section 2.5.1.1) using primers specific to a 128 bp region of the 
SIRT1 gene (SIRT1F and SIRT1R). Measurements were normalised against the reference gene ACTB 
(β ACTIN) using primers that amplified a 90 bp region. Primer sequences and annealing temperatures 
are outlined in Table 2.2B.  
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Reverse transcription-qPCR analysis of SIRT1 and β ACTIN was performed using the Roche 
LightCycler
®
 480 (Section 2.7.2.4). Standard curves were generated for SIRT1 and β ACTIN to 
confirm linear amplification of PCR products and were run in parallel with the experimental samples. 
To generate standard curves undiluted cDNA extracted from untreated Caco-2 cells was used to create 
an 8 point 2-fold dilution series (Section 2.7.2.5), each dilution within this series was then used in 
qPCR amplification for each gene, and each reaction was performed in duplicate. (See Appendix D for 
typical amplification and standard curves for SIRT1 and β ACTIN.) As before, relative levels of 
SIRT1 transcript in the Caco-2 cells transfected with either of the two siRNAs showed a statistically 
significant reduction (~70 %) in SIRT1 mRNA compared with the control siRNA (Figure 3.4B) (p < 
0.001).  
 
Total cell lysate was used to assess SIRT1 knockdown at the protein level by western blot as described 
in Section 2.8. Total cell lysate was extracted (Section 2.8.2.2) and protein concentration determined 
by Bradford assay (Section 2.8.1.4). Ten micrograms of total cell lysate was separated by SDS-PAGE 
(Section 2.8.1.5) and blotted onto a polyvinylidene difluride (PVDF) membrane (Section 2.8.1.6), 
which was then probed with antibodies to SIRT1 and the loading control protein alpha tubulin. SIRT1 
protein knockdown was confirmed by a reduced signal intensity revealed by the SIRT1 antibody in 
cells transfected transiently with the SIRT1-targeting siRNA compared with cells transfected 
transiently with the Stealth RNAi
™
 siRNA negative control. (See Chapter 3 Figure 3.4C for typical 
western blot confirmation of SIRT1 knockdown.) 
 
To achieve SIRT1 overexpression, Caco-2 cells seeded 24 hours previously at 3.5 x 10
5
 cells/well in a 
six well plate (area = 9.6 cm
2/well) were transfected transiently with 2 μg SIRT1 expression construct 
(pCMV6-ENTRYSIRT1) or with 2 μg control vector without a SIRT1 insert (pCMV6-Neo). After 72 
hours cells were lysed and DNA, RNA and total cell lysate were extracted from parallel experiments 
as described above. Genomic DNA and total RNA were used to assess affects of SIRT1 
overexpression on methylation levels and expression of the target genes, respectively. Total RNA and 
cell lysate were used to confirm SIRT1 overexpression at the mRNA level by RT-qPCR and protein 
level by western blot as described above. (See Chapter 3 Figure 3.8B and Figure 3.8C for typical RT-
qPCR and western blot confirmation of SIRT1 overexpression.) 
 
Having obtained DNA and RNA samples with confirmed SIRT1 knockdown and overexpression, 
DNA methylation was measured by pyrosequencing at the CpG sites immediately upstream of the start 
of transcription in eight of the ten genes (CDC7, EIF5, IRX3, KLF3, PCYT1A, PTPRG, SLC39A4, 
TBX3) highlighted by the in silico analysis described in Chapter 5. Primers were designed to amplify 
~1000 bp sequence to cover approximately 900 bp upstream and 100 bp downstream of the start of 
transcription of each gene, representing the classically-defined promoter region. Pyrosequencing 
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assays were designed using the PyroMark Assay Design Software 2.0 (Qiagen) using this ~1000 bp 
sequence as a template. This starting sequence, before being entered into the design software, was 
converted to corresponding bisulfite modified sequence in Microsoft Word by using the ‘Find’ and 
‘Replace All’ functions to first replace ‘CG’ (CpG sites) with ‘C/TG’, then replace ‘C’ with ‘T’ then 
replace ‘T/’ with ‘C/’, to give a sequence where ‘C/T’ represents a site that, depending on the original 
methylation pattern, may or may not have been deaminated by bisulfite treatment. Representing the 
CpG site in this way allows the design software to recognise it as a polymorphism that can then be 
checked by sequencing producing a ratio of ‘C’ vs. ‘T’ and therefore a percentage of cytosines 
protected by a methyl group at this site within the sample population – percentage DNA methylation. 
Upon running the assay design the software generated possible primer sets (‘F#2’, ‘R#2’ and ‘Seq’). 
The set with the best score and widest CpG site coverage was selected for use and uploaded onto the 
PyroMark MD
™
 system (Qiagen). For CDC7, EIF5, IRX3 and PTPRG these CpG dinucleotides were 
within predicted CpG islands (Section 2.9.3). Robust assays were not achieved for the measurement 
by pyrosequencing of methylation within the LDLR and MYH10 promoter regions. In parallel with 
measurements of DNA methylation, RT-qPCR was used to determine if expression at the mRNA level 
of the same genes was affected by manipulation of SIRT1 expression levels. 
 
Pyrosequencing was carried out as described in Section 1.5.3 and 2.6.8. Percentage DNA methylation 
was measured at consecutive CpG sites within the sequence. Each pyrosequencing assay consisted of a 
two stage PCR reaction. The first PCR generated a ~1000 bp product, and contained 25 μl HotStar Taq 
MasterMix (Qiagen), 0.25 μM sense and antisense primers (‘YF#1’ and ‘YR#1’) using 4 μl of 
bisulfite-modified genomic DNA (Section 2.6.1) as a template. This reaction was followed by a 
second, nested PCR generating a ~200 bp product, and contained 25 μl HotStar Taq MasterMix 
(Qiagen), 0.25 μM sense primer and 0.20 μM antisense biotinylated primer (‘F#2’ and ‘R#2’) using 4 
μl of the first PCR reaction as a template. Primer sequences and annealing temperatures are stated in 
Table 2.2C and gene-specific assay details are given in each corresponding following section. 
Pyrosequencing using the gene-specific sequencing primer (‘Seq’) was carried out in duplicate for 
each sample. 
 
Standard curves were generated to confirm linear amplification of methylated and unmethylated 
sequences. Unmethylated DNA template was generated by PCR amplification of a ~1000 bp region 
(‘F#1’ and ‘R#1’) of the target sequence from genomic DNA as described above. Two micrograms of 
unmethylated PCR product was methylated in vitro as described in Section 2.2.4. Nine microlitres of 
methylated or 25 µl unmethylated PCR product was then bisulfite modified as described in Section 
2.6.1. The nested PCR using primers to produce a smaller product focusing in on the specific CpG 
sites was performed as described above. Reactions were combined to give appropriate percentages of 
methylated DNA (0, 5, 10, 25, 50, 75, 90, 95, 100 %) in a total volume of 10 µl. Pyrosequencing using 
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the gene-specific sequencing primer was carried out in duplicate for each standard and a standard 
curve was generated. 
 
Total RNA was used to measure gene expression at the mRNA level by RT-qPCR using primers 
specific to a ~200 bp region of each target gene as described above. Primers were designed to span an 
intron. Values were normalised to the WNT11 gene, which was found to be stably expressed regardless 
of SIRT1 manipulation in microarray analysis (see Chapter 7), using primers that amplified a 214 bp 
region (WNT11F and WNT11R). Primer sequences and annealing temperatures are outlined in Table 
2.2D. Figure 6.3 shows the amplification and standard curve for WNT11; reference to gene-specific 
amplification and standard curves is provided in each relevant subsection below. 
 
Details of the results of pyrosequencing to measure DNA methylation and qRT-PCR to determine 
levels of expression are provided below for each of the individual 8 genes whose response to SIRT1 
manipulation was analysed.  
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6.2.1 Effects of SIRT1 manipulation on CDC7 
Percentage DNA methylation was measured at eight consecutive CpG sites within the PCR amplified 
CDC7 sequence spanning - 248 to + 53, occurring at - 58, - 51, - 49, - 43, - 27, - 10, - 7 and - 4 bp 
relative to the start of transcription of the CDC7 sequence (Figure 6.1 and Section 2.6.4). The first 
PCR generated a 912 bp product (CDC7YF#1 and CDC7YR#1) and the second, nested PCR generated 
a 301 bp product (CDC7F#2 and CDC7R#2). Pyrosequencing was carried out using the CDC7 
sequencing primer (CDC7Seq). Methylation standard curves for CDC7 can be found in Appendix C. 
 
Total RNA was used to assess CDC7 expression at the mRNA level by RT-qPCR using primers 
specific to a 211 bp region of the CDC7 gene (CDC7F and CDC7R) as described above. Primer 
sequences and annealing temperatures are outlined in Table 2.2D. Amplification and standard curves 
for CDC7 can be found in Appendix D. 
 
The 8th CpG site upstream of the CDC7 transcript at position -58 relative to the start of transcription 
showed altered levels of DNA methylation in response to SIRT1 knockdown compared with control 
(Figure 6.2A). Table 6.1 summarises the data for CpG sites at which significant effects of SIRT1 
expression level were measured. CDC7 gene expression was also changed in response to SIRT1 
manipulation. SIRT1 overexpression caused an increase in levels of CDC7 transcript compared with 
the control (p < 0.05) and SIRT1 knockdown elicited the opposite response causing a decrease in 
levels of CDC7 transcript compared with the control (p < 0.05); the data for the two extremes 
(overexpression and knockdown) also showed a statistically significant difference (p < 0.001) (Figure 
6.2B).  
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Figure 6.1. The CDC7 sequence and related primers for use in the CDC7 pyrosequencing assay. The CDC7 
sequence taken from the human genome sequence is shown. Primers were designed for a PCR to a region in the 
CDC7 sequence (CDC7YF#1 – light blue and CDC7YR#1 – dark blue) and a nested PCR (CDC7F#2 – light 
green and CDC7R#2 – dark green) to focus in on eight specific CpG sites (pink) within the CDC7 sequence. A 
sequencing primer was designed for use in the pyrosequencing reaction (CDC7Seq - orange). Primers and 
annealing temperatures are given in Table 2.2C.   
CDC7 Sequence
-1000 CTATTTCCTC TGCTTCCACA CTTGCCCCTC TACAATCCAT TCTCTTCATA 
-950  ACAGATAGAT CATATTACTC CCTTGCTTTA AAACTTTCAA ATAGCTTCCA 
-900  ATTGTACTCA GAACAAACAC TAAACTTCTT ACCCTGGCTT TCAAGGACCC
-850  TGGTCTGGCT TCTGCCTAAC TCTCCACCTT CATCTATCTG GGACTATCTT
-800  GCGGCTCACT CACTATGCTT CCCCCACACT GGCCTTTCCT GCCCTGCCCC
-750  TGCAACATAC CAAGTTCCTC TTTCTCTCTG CATTTGCCCT ATCCTTTCTT
-700  TGCCAGGACA ACAGTCTCCC TACCAGCTCT TTCTCATCCA GGTCTCTTTG
-650  AGAGGGCTTC CCTGACCATC TAGATGCCAC CTTCCTGGTC AGTATTTCCC
-600  TCAAGTAGTA ATCAATGCCG GAAAGAATAC TGTTCATTTA TTCATCCGTT
-550  ATTGTCATCG CTTCATTGGA ATTTAGCTTC CTACAGGGAT GGTGTTTATC
-500  TTGCTCACTA TGATTCCAGC CCCTAGAAAA ACCCACCTAC CTCATAGCCA
-450  AGGGCTCAGT AAATAGTATA CACTGCCTTC CTGCCACTGT GCTAATTTCT
-400 ACTAACACAG CCACAAACAA TCAGCAATTA CATTTTCTGC TTGTTTTTAA
-350 CGGGGAAGTA GGGCACTCAA CGAAAAGGAA ATAAAAGCAG AGTCAAGAAA
-300  GTGCCTTTTA TCCATGGAGT GCCCAATGTG TTGTGCGGCC GGCCACGTAT
-250  ATAGGGATGT GTCAGCACCT GAGATTTTTC CTTCTCTGAG CTAGCTTCTT
-200  TCCTGGAAAT CATGCTGGGC CCTTAGCCTT ATGGTTCACC CTGTTTTTTA
-150  AGATCATCCA CGGGCTTCAT TCCCGTAACC GCTCTTCTAG CTGGCCAAGG
-100  CGGCGGGAAG AAACCCCACC CTCTTGCGCA AACGCCCAGT AGCGGAATCC
-50   GCGGGGTCGA GGGCTTTAGT GTGCGCATGT GCAACCAGAG CGGCGGCGGG
+1 aagtgttgcg caggcgcatc cgatcgactc ggtaggtggg gatctcttgg
+50   agacggcgac ccaggcatct ggggagccac agaagtcgta ctcccttaaa
+100  ccGTGAGTTT CCGACGGTTT GTTCCATGGC GCGGGATTGT GAGGGATTAG 
+150  GAACGAATTC TGGATCGTGA CTTCGGTTTT CTCGCCGTGC AGTTCCTTTT
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Figure 6.2. Effect of SIRT1 overexpression or SIRT1 knockdown by siRNA on A) percentage methylation at 
CpG sites within the CDC7 gene as measured by pyrosequencing and B) mRNA levels for CDC7 as measured 
by RT-qPCR. A – Methylation is expressed as the percentage of unmethylated cytosines converted to thymines as 
a result of bisulfite modification determined by pyrosequencing. Data are medians ± upper and lower quartile 
ranges for each CpG site (n = 9). For the set of data corresponding to each CpG site the first (left-hand-most) 
bar corresponds to SIRT1 overexpression, the second to control and the third to SIRT1 knockdown as indicated 
by the triangular symbols beneath each set to indicate a progressive decrease in SIRT1 expression. Outliers are 
represented by ○. *p < 0.05, compared with control (green) by Kruskal Wallis then Dunn’s multiple comparison. 
B – Gene expression is measured as the PCR cycle number at which the fluorescence signal increases above the 
background threshold (CT values). Data are mean ± SEM (n = 9) normalised to the CT value of the reference 
gene WNT11 measured in the same samples. *p < 0.05, ***p < 0.001 compared with control (green) or SIRT1 
overexpression (blue) by one way ANOVA then Bonferroni's multiple comparison.  
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6.2.2 Effects of SIRT1 manipulation on EIF5 
Percentage DNA methylation was measured at eight consecutive CpG sites within the PCR amplified 
EIF5 sequence spanning - 282 to + 20, occurring at -60, -58, -48, -41, -38, -32, -21 and -17 bp relative 
to the start of transcription of the EIF5 sequence (Figure 6.3 and Section 2.6.5). The first PCR 
generated a 949 bp product (EIF5YF#1 and EIF5YR#1) and the nested PCR generated a 302 bp 
product (EIF5F#2 and EIF5R#2). Pyrosequencing was carried out using the EIF5 sequencing primer 
(EIF5Seq). Standard curves for EIF5 can be found in Appendix C. 
 
Total RNA was used to assess EIF5 expression at the mRNA level by RT-qPCR using primers specific 
to a 200 bp region of the EIF5 gene (EIF5F and EIF5R) as described above. Primer sequences and 
annealing temperatures are outlined in Table 2.2D. Amplification and standard curves for EIF5 can be 
found in Appendix D. 
 
The 1st, 2nd and 4th CpG site upstream of the EIF5 transcript at positions -17, -21 and -38 relative to 
the start of transcription showed altered levels of DNA methylation in response to SIRT1 manipulation 
(Figure 6.4A). Table 6.1 summarises the data for CpG sites at which significant effects of SIRT1 
expression level were measured. EIF5 gene expression was also changed in response to SIRT1 
manipulation. SIRT1 overexpression caused an increase in levels of EIF5 transcript compared with the 
control (p < 0.05) and SIRT1 knockdown elicited the opposite response causing a decrease in levels of 
EIF5 transcript compared with the control (p < 0.05); the data for the two extremes (overexpression 
and knockdown) also showed a statistically significant difference (p < 0.001) (Figure 6.4B).  
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Figure 6.3. The EIF5 sequence and related primers for use in the EIF5 pyrosequencing assay. The EIF5 
sequence taken from the human genome sequence is shown. Primers were designed for a PCR to a region in the 
EIF5 sequence (EIF5YF#1 – light blue and EIF5YR#1 – dark blue) and a nested PCR (EIF5F#2 – light green 
and EIF5R#2 – dark green) to focus in on eight specific CpG sites (pink) within the EIF5 sequence. A 
sequencing primer was designed for use in the pyrosequencing reaction (EIF5Seq - orange). Primers and 
annealing temperatures are given in Table 2.2C.   
EIF5 Sequence
-1000 TCCCAAAGTG CTGGGATTAC AGACGTGAGC CACCGCGACC GGCCTAAATA 
-950  ATAGTAATTT TCAACGGAAT ACATTGGAAT CTCATTATAA ATGCCTGCTC
-900  TGGGCTACGA TTTGCTTATC AAAGAATTCA CAAGTCATAA ACTAGAGGGG 
-850  GTGGACTCGA CGTGATGCCC ACTAGGAGAA AGGTGACAAG AGAAGCACGA 
-800  AGGATAGCGC TTTTCAACCC TGGGAGAGCA GGGAGGCCTT CACCAGAAGG 
-750  TGGGAACCCA CCACGAAGCG CCTTCAGGAG GCCCCAGGAT TCCAAACCAA 
-700  TTAAGGGCCT CCTCTTCCGA AAACGGGAGG CGACGCGCTG AGCTAAGCGC 
-650  GCAGGCTGGG TTGCGGGCCG ACACCGAGGC GGCGCGGCCT CGCGACCGCC 
-600  CTGGGCGGTC ACTGGCGAGT CACGGACTCG TTCCGCCAGC GGCCAATCCA 
-550  CCCCGAGTCC GAAACAGAAG ACGTCCCTGG GATGAAAGAC CCAGGCCTGG 
-500  GGCTTAAGGT GGAAAAACAA CTCATTCCTC GAGGCCCGGA GTCGGGCGTC 
-450  CCGGGAGAAC GGGAAAGGGA GATGAGCGCC CGCTGCGGGG AGAACGCGGT 
-400  CGGGTTCCTC TCCCCGAAGG TGGCAGCCGC AAAAACACGG CCTCGAAAGC 
-350  AGTTTCGAGG ACGATGGCTC CTGCGTCCCG GGAGTCGCCA TGACGCCGCG 
-300  GCCTGTCCCA GACCCGGCGA GGGAGGGGAC CAACCACCAT CTCCCCCTCA
-250  AGGCCCAAAC CGACAAAGAA CGGCCCCCGG TACCCCGGCC CCGCCACCAG
-200  GGCCACTCCG GGTCTCGCGA GACCCAAGGG CTGCGCCGCG AAGACCTCTG 
-150  GGAAAGGCGG GGGGAGGGGA GAGGAAGGAA GCGAGACCGG GGCTGGAGGC 
-100  GGGCCGAGGC CGCGAGTTGA GCCTCAGGAA GCAGAAGGGG CGCGGAAAGA 
-50   TGCGATTGAC GTCGCAAGCG AACCAATGAC GAGCGAGCTG TGGCAGGCCT
+1    ccagccaatg ggcagtgagg cctgacgcgg ggggcggacg ctggggccga
+50   gggtagcttg agcgcggcgg cggcgttgtt cagtcagagc gagaacattc
+100  cagagGTGAG TCCGGTGAAG GGGCGGCCCC CTGCCCGGTG CTTCCCGCCC 
+150  CCTCGACCCC TCGGGCCGCT GGCTGGCGGG GAAGGTGCAC TCCCCGACCG
141 
 
 
Figure 6.4. Effect of SIRT1 overexpression or SIRT1 knockdown by siRNA on A) percentage methylation at 
CpG sites within the EIF5 gene as measured by pyrosequencing and B) mRNA levels for EIF5 as measured 
by RT-qPCR. A – Methylation is expressed as the percentage of unmethylated cytosines converted to thymines as 
a result of bisulfite modification determined by pyrosequencing. Data are medians ± upper and lower quartile 
ranges for each CpG site (n = 9). For the set of data corresponding to each CpG site the first (left-hand-most) 
bar corresponds to SIRT1 overexpression, the second to control and the third to SIRT1 knockdown as indicated 
by the triangular symbols beneath each set to indicate a progressive decrease in SIRT1 expression. Outliers are 
represented by ○. *p < 0.05, **p < 0.01 compared with control (green); #p < 0.05, ##p < 0.01 compared with 
SIRT1 overexpression (blue), by Kruskal Wallis then Dunn’s multiple comparison. B – Gene expression is 
measured as the PCR cycle number at which the fluorescence signal increases above the background threshold 
(CT values). Data are mean ± SEM (n = 9) normalised to the CT value of the reference gene WNT11 measured in 
the same samples. *p < 0.05, **p < 0.01, ***p < 0.001 compared with control (green) or SIRT1 overexpression 
(blue) by one way ANOVA then Bonferroni's multiple comparison.  
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6.2.3 Effects of SIRT1 manipulation on IRX3 
Percentage DNA methylation was measured at three consecutive CpG sites within the PCR amplified 
IRX3 sequence spanning - 426 to + 11, occurring at - 64, - 19 and - 16 bp relative to the start of 
transcription of the IRX3 sequence (Figure 6.5 and Section 2.6.6). The first PCR generated a 993 bp 
product (IRX3YF#1 and IRX3YR#1) and the nested PCR generated a 437 bp product (IRX3F#2 and 
IRX3R#2). Pyrosequencing was carried out using the IRX3 sequencing primer (IRX3Seq). Standard 
curves for IRX3 can be found in Appendix C. 
 
Total RNA was used to assess IRX3 expression at the mRNA level by RT-qPCR using primers 
specific to a 150 bp region of the IRX3 gene (IRX3F and IRX3R) as described above. Primer 
sequences and annealing temperatures are outlined in Table 2.2D. Amplification and standard curves 
for IRX3 can be found in Appendix D. 
 
The 1st and 3rd CpG site upstream of the IRX3 transcript at positions -16 and -64 relative to the start 
of transcription showed altered levels of DNA methylation in response to SIRT1 manipulation (Figure 
6.6A). Table 6.1 summarises the data for CpG sites at which significant effects of SIRT1 expression 
level were measured. IRX3 gene expression changed in response to SIRT1 manipulation. SIRT1 
knockdown caused a decrease in levels of IRX3 transcript compared with SIRT1 overexpression (p < 
0.05) (Figure 6.6B).  
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Figure 6.5. The IRX3 sequence and related primers for use in the IRX3 pyrosequencing assay. The IRX3 
sequence taken from the human genome sequence is shown. Primers were designed for a PCR to a region in the 
IRX3 sequence (IRX3YF#1 – light blue and IRX3YR#1 – dark blue) and a nested PCR (IRX3F#2 – light green 
and IRX3R#2 – dark green) to focus in on three specific CpG sites (pink) within the IRX3 sequence. A 
sequencing primer was designed for use in the pyrosequencing reaction (IRX3Seq - range). Primers and 
annealing temperatures are given in Table 2.2C.   
IRX3 Sequence
-1000 CCAAACACTC CCTACAACTT CTTCAAGTCA AACTTGGGCA AGGTTGGCTG 
-950  GCTGACTGCG AGAGGAAAAA GAGGGCGCGG AGGGGGCGCG GCGCGCGGCC 
-900  GGGTGTAGAG GCCACGGAGG CGAGGCGCCG AGCGTCCCCT TTGTCCTGTA 
-850  GAGGGAGCTC CAGCCCCAAA TTTCCCTGCT GCCTCCCCCG GCCCGCCCAC
-800  CCCAGGCCCG CCTGGAGCCG GAATCCCGGC TGGAAAGGTG CGGCGGTCTG 
-750  ACACCCCCGC AACCCCCGCG CCGGGGCCTT AGCAGGATGC CTCTTCTAGG
-700  GCACGTGGGA AAACCCACCA GGGTGCCAAG ACGCACAGAT GCTCCCAGGA 
-650  CCCGGGCTCC CCAACTCTCA ACTAGAGCTG GGCAGTCACA CATCATCTAG 
-600  AGGATTATGT ACCCCTAGGC GACCCTCTTC TCCATATCCG CCTCCACCGT 
-550  CACCCCACAC CCTGGCATCT ATAAAGAGGG AAGGGGGGCA ACCGGGTTGG 
-500  AAGGAGGATG GAATCTGGGC TTGCACAGCC TCTTATAGGT AACAGTGAGA 
-450  AAGCCTCAAC TGTGTCGATC AAAGAATGGG GACGAAGGGA GTGATGAGAA
-400  CACGACCCCG CCACCCGCGC AGGCTAACCC CGTTGTGTCC AGACCCTTCT 
-350  CTAAATCTCT TGGCAAGGTC ACCAGAGAAG GATCCAAGCC CCCGCGGTTG 
-300  CTCCCGTAGA CAAGCGGGTC GGGCCCAGAT TCCCGGCTCT CAGCAAAGAA 
-250  GCTTGCCGGG GTCTCCCACC TGTCTCCTGC TCCCGTTTTC TCGGCCGCCC 
-200  CAGGTACTTT TCCAGCCACC TCTCCTGCTG CGGCGCCCCC AGCCCCGCCA 
-150  CTTCTGCGCC TCCTCAGCTA TTGCTGTCCT TTGACTACTC GGTCCCGATT 
-100  CGTCTCTCGT CCTTTCCCGC GAATTCTTCA AACAACCGAG GGGAGAAAAA 
-50   ACCCAAAAAA CAAAAAACCA CCAAACAGAT CCGTCGAGGG GGCAGACAGG
+1    cgggttatag tcaaagtggc agcagctcat ttatttagcc aaaaatagat
+50   actttctcgt acaatttggt tcacacatat gtacatttct ctgtatatat
+100  acacacacac aaaggcagac acgtttattc tcactgaaac tccacccccc
+150  aaaatcaacc ggacaaacaa acctcacagc gaatgcgggg tgccacagaa
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Figure 6.6. Effect of SIRT1 overexpression or SIRT1 knockdown by siRNA on A) percentage methylation at 
CpG sites within the IRX3 gene as measured by pyrosequencing and B) mRNA levels for IRX3 as measured 
by RT-qPCR. A – Methylation is expressed as the percentage of unmethylated cytosines converted to thymines as 
a result of bisulfite modification determined by pyrosequencing. Data are medians ± upper and lower quartile 
ranges for each CpG site (n = 9). For the set of data corresponding to each CpG site the first (left-hand-most) 
bar corresponds to SIRT1 overexpression, the second to control and the third to SIRT1 knockdown as indicated 
by the triangular symbols beneath each set to indicate a progressive decrease in SIRT1 expression. Outliers are 
represented by ○. *p < 0.05, **p < 0.01 compared with control (green); #p < 0.05, ##p < 0.01 compared with 
SIRT1 overexpression (blue), by Kruskal Wallis then Dunn’s multiple comparison. B – Gene expression is 
measured as the PCR cycle number at which the fluorescence signal increases above the background threshold 
(CT values). Data are mean ± SEM (n = 9) normalised to the CT value of the reference gene WNT11 measured in 
the same samples. *p< 0.05 compared with SIRT1 overexpression (blue) by one way ANOVA then Bonferroni's 
multiple comparison.  
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6.2.4 Effects of SIRT1 manipulation on KLF3 
Percentage DNA methylation was measured at six consecutive CpG sites within the PCR amplified 
KLF3 sequence spanning - 238 to + 71, occurring at -69, -60, -56, -52, -50 and -47 bp relative to the 
start of transcription of the KLF3 sequence (Figure 6.7 and Section 2.6.7). The first PCR generated a 
904 bp product (KLF3YF#1 and KLF3YR#1) and the nested PCR generated a 309 bp product 
(KLF3F#2 and KLF3R#2). Pyrosequencing was carried out using the KLF3 sequencing primer 
(KLF3Seq). Standard curves for KLF3 can be found in Appendix C. 
 
Total RNA was used to assess KLF3 expression at the mRNA level by RT-qPCR using primers 
specific to a 166 bp region of the KLF3 gene (KLF3F and KLF3R) as described above. Primer 
sequences and annealing temperatures are outlined in Table 2.2D. Amplification and standard curves 
for KLF3 can be found in Appendix D. 
 
The 3rd CpG site upstream of the KLF3 transcript at position -52 relative to the start of transcription 
showed altered levels of DNA methylation in response to SIRT1 overexpression compared with 
control (Figure 6.8A). Table 6.1 summarises the data for CpG sites at which significant effects of 
SIRT1 expression level were measured. KLF3 gene expression was also changed in response to SIRT1 
manipulation. SIRT1 overexpression caused an increase in levels of KLF3 transcript compared with 
the control (p < 0.001) and SIRT1 knockdown elicited the opposite response causing a decrease in 
levels of KLF3 transcript compared with the control (p < 0.05); the data for the two extremes 
(overexpression and knockdown) also showed a statistically significant difference (p < 0.001) (Figure 
6.8B).  
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Figure 6.7. The KLF3 sequence and related primers for use in the KLF3 pyrosequencing assay. The KLF3 
sequence taken from the human genome sequence is shown. Primers were designed for a PCR to a region in the 
KLF3 sequence (KLF3YF#1 – light blue and KLF3YR#1 – dark blue) and a nested PCR (KLF3F#2 – light green 
and KLF3R#2 – dark green) to focus in on six specific CpG sites (pink) within the KLF3 sequence. A sequencing 
primer was designed for use in the pyrosequencing reaction (KLF3Seq - orange). Primers and annealing 
temperatures are given in Table 2.2C.   
KLF3 Sequence
-1000 GTTTGCCAAG TTTCCAGGCA AGCCCAACTG CGCAAATGCC GCTTTTTAGC 
-950  TCCAGCGGCA GGCCTGGCCC GTGGGAGTTT TGCCCCAGGG GTCTCCGGGC 
-900  CTTCAAAGAA AAGTCCCACG AGGTGGGGGG CGCCGCCTGG GCCGCCGGCC 
-850  AGGGGGACCC GTCGCCCCAG GGCACAAAGA AAGAGCGCGC CTACAGGGTG 
-800  TCCCCTGACC CCGGCGACTC GGGGCCAGGG AGGCTCGGCG CGCCCCAGCG
-750  GCCGCTCTTC CCCTCCCGAA CCCGCCCGGC CCACTCGCTC CTGCACCGCG 
-700  GCCGCCTCGG CTCGGCTTTT CTCTTGCAGT GAGCTGAGTG CGCTCAGCCG 
-650  AGGAGGGGCC GCGCCGCGCC GCGCCGGCCG CGGGGCCCAG CCCTTCCCGC 
-600  CGCGCCCGGG GCCGCCCTTC CCGCTGGAGC CGGCTGATCG ATGGCCCTGG 
-550  CAGCCCGCGC CCCCCGCCTC GGCTCGCCCG CGAGCCCGGC TGTGTGTTTT 
-500  GGAAGCAGCG CAGCGGGCCG CAGCCGTGTG ACGCCCGGAG CGGGCAGCGC
-450  CGCCCTTCCT TCCCCCCGGG CTCGGGCGGC GGCGCGGCGG CTGGGCCGGG 
-400  CGGGAGGGCT GGCGGGGCGC GGACTCCGGG GAGGAGGGCG CGGGGAGGGG
-350  ACGCGGGCGG GGACGCGGGC GGGGGGCGGA GGCCGCGCCG CGCACGCCCA 
-300  GCCCCACGGC CGCGCCGCGC CTCGTGGGAC AGGTTGGGCC GGCGGGGCGG
-250  CGCCCGGCTC CGGGGAATAA TGAGTGTCTG TCAGGCCGTC CCCGGGTGAC
-200  TGGGCGGGGC GGGGCGGAGG CGGCGCGGGA GGCGGGGGTG GCGGGGGAAG 
-150  GGCGCAGGGC GGGGTGCGTG TTTGCGCGAG TGACTCGGCC GACCCCTCCG 
-100  GCGGCTGCCT CCACCCAAGT GGGTGGGGAC CCGCCCAGCC CGGGCGGCCG
-50   CGGCGGCTCC CTCTCCCCTC CCTGACCCTC CCACCCCGGG TCCCAGCCTC
+1    tacttacccc gccagccccg ggaggctcgc agagcgagcg gcgccggcgt
+50   catgtgactg cccggagttg gtgccaggag ccagagggga gccaggagcg
+100  gagccgcgcg gagccggggc ccgagccgga gcgcagcgag agcgcccgcc
+150  gcacgcgcgc ccgtccccgt cccctgcggc cgccaacgcc gcccggactg
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Figure 6.8. Effect of SIRT1 overexpression or SIRT1 knockdown by siRNA on A) percentage methylation at 
CpG sites within the KLF3 gene as measured by pyrosequencing and B) mRNA levels for KLF3 as measured 
by RT-qPCR. A – Methylation is expressed as the percentage of unmethylated cytosines converted to thymines as 
a result of bisulfite modification determined by pyrosequencing. Data are medians ± upper and lower quartile 
ranges for each CpG site (n = 9). For the set of data corresponding to each CpG site the first (left-hand-most) 
bar corresponds to SIRT1 overexpression, the second to control and the third to SIRT1 knockdown as indicated 
by the triangular symbols beneath each set to indicate a progressive decrease in SIRT1 expression. Outliers are 
represented by ○.*p < 0.05, **p < 0.01 compared with control (green); #p < 0.05, ##p < 0.01 compared with 
SIRT1 overexpression (blue), by Kruskal Wallis then Dunn’s multiple comparison. B – Gene expression is 
measured as the PCR cycle number at which the fluorescence signal increases above the background threshold 
(CT values). Data are mean ± SEM (n = 9) normalised to the CT value of the reference gene WNT11 measured in 
the same samples. *p < 0.05, ***p < 0.001 compared with control (green) or SIRT1 overexpression (blue) by 
one way ANOVA then Bonferroni's multiple comparison.  
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6.2.5 Effects of SIRT1 manipulation on PCTY1A 
Percentage DNA methylation was measured at two consecutive CpG sites within the PCR amplified 
PCYT1A sequence spanning - 369 to + 64, occurring at - 88 and - 21 bp relative to the start of 
transcription of the PCYT1A sequence (Figure 6.9 and Section 2.6.10). The first PCR generated a 939 
bp product (PCYT1AYF#1 and PCYT1AYR#1) and the nested PCR generated a 433 bp product 
(PCYT1A F#2 and PCYT1A R#2). Pyrosequencing was carried out using the PCYT1A sequencing 
primer (PCYT1A Seq). Standard curves for PCYT1A can be found in Appendix C. 
 
Total RNA was used to assess PCYT1A expression at the mRNA level by RT-qPCR using primers 
specific to a 168 bp region of the PCYT1A gene (PCYT1A F and PCYT1A R) as described above. 
Primer sequences and annealing temperatures are outlined in Table 2.2D. Amplification and standard 
curves for PCYT1A can be found in Appendix D. 
 
No statistically significant effect was measured in DNA methylation levels at either of the 2 CpG site 
assayed upstream of the PCYT1A transcript in response to altered SIRT1 expression levels (p > 0.05) 
(Figure 6.10A). Table 6.1 summarises the data for CpG sites at which significant effects of SIRT1 
expression level were measured. PCYT1A gene expression was changed in response to SIRT1 
manipulation. SIRT1 knockdown caused a decrease in levels of PCYT1A transcript compared with the 
control (p < 0.01), the difference between the two extremes (overexpression and knockdown) was also 
statistically significant (p < 0.001) (Figure 6.10B).  
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Figure 6.9. The PCYT1A sequence and related primers for use in the PCYT1A pyrosequencing assay. The 
PCYT1A sequence taken from the human genome sequence is shown. Primers were designed for a PCR to a 
region in the PCYT1A sequence (PCYT1AYF#1 – light blue and PCYT1AYR#1 – dark blue) and a nested PCR 
(PCYT1AF#2 – light green and PCYT1AR#2 – dark green) to focus in on two specific CpG sites (pink) within the 
PCYT1A sequence. A sequencing primer was designed for use in the pyrosequencing reaction (PCYT1ASeq - 
orange). Primers and annealing temperatures are given in Table 2.2C.   
PCYT1A Sequence
-1000 GAGGAGCAGC AGAGGGAGGT CCCTGCCAGC TGCAGCTCTC AGAGGAAAAG 
-950  AAAGATGTGG AGCACTGGTT CCAGGGAAGA ATGTTCTGAA GAGGGACAGA 
-900  GGTCAAGGTG ATAAGGCTGT TGCTTTAGAA AGGAAGGTGT TTCCTATGCT 
-850  TTTGCCTTTA CATTCTGTGC AAATCTCTCT AATATGGCTA TGACCAAAAT
-800  GGATTAACAT CAAGTTCCAA CAGCAGACAT TTACAAAGTA TCCTTTGTAA 
-750  AAGGCTAGGT AATATTAATA GCATTCAAAT AGGAGTAGCA GGGCCAGGCA 
-700  CTTACTCCCA GTAGGAAACT AATCTCAATC GACTTGGTAT AGGATTGAGT 
-650  ATTGTCCCGC TCCTCTCCTC ATCATTGTAA CTCTAAAAGT GTTCCTTCCT 
-600  TCGAAGGTAG ATGGCACGAA AGAGACTGAC AAAAGCTCCC AAAGAACTGG 
-550  GTCACAGAGT TTTCTGAGAA GATGAACACA GCAGAAACAC TGCAGTTGAT 
-500  GCCATGGGTC TGCTTCCATC CCCATCAGTG TCTTCATGGA CCCCATTGGG
-450  TCCAACAAGA AACTCCTCAG GGAGTAAGAA AAGTTAGGTT CAGATCTCCT 
-400  TCCCGCAGCC ACAATGACAC TGGTGACAGC AGTACGTTCA GGGGATTTGT 
-350  GACTGTAACT CTGCTTTTCG CTTTTCCTTA AGGAAATCAA AATTAAGATA 
-300  TTTCTCCACA AATTACCCAT CAGCGTGGCT CATTTCGTGA AGGACTTGGC 
-150  AAGCCACATA GCTTCAGAAC GGAAGGCAAA TGCTATAGTA TACCGGGAAG 
-100  AAAAGGCCTC TGCGTATTAC ACTACCTCCT TCTTCTGCCC ACTCCTCAGG 
-50   GGCAAAAAAT TAGTTCTACA TTTGAAAGAC GAATTTTTTA AAAAATTAAT
+1    gaaaatgaca atttccctgt tgagatcacg tgaacataaa cagtgaaaca
+50   aagcccttgg gggggggtaa atggatgcag agcaggcttc taaggtgcag
+100  tccccctcct tcgtgtgggt gagtgatgtc acttgcagga caggctgttt
+150  gggttccccc agtcctaggt cttctttccc cagttgtctt tcctttgtag
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Figure 6.10. Effect of SIRT1 overexpression or SIRT1 knockdown by siRNA on A) percentage methylation at 
CpG sites within the PCYT1A gene as measured by pyrosequencing and B) mRNA levels for PCTY1A as 
measured by RT-qPCR. A – Methylation is expressed as the percentage of unmethylated cytosines converted to 
thymines as a result of bisulfite modification determined by pyrosequencing. Data are medians ± upper and 
lower quartile ranges for each CpG site (n = 9). For the set of data corresponding to each CpG site the first 
(left-hand-most) bar corresponds to SIRT1 overexpression, the second to control and the third to SIRT1 
knockdown as indicated by the triangular symbols beneath each set to indicate a progressive decrease in SIRT1 
expression. Outliers are represented by ○. p > 0.05 compared between SIRT1 overexpression, control and SIRT1 
knockdown by Kruskal Wallis then Dunn’s multiple comparison. B – Gene expression is measured as the PCR 
cycle number at which the fluorescence signal increases above the background threshold (CT values). Data are 
mean ± SEM (n = 9) normalised to the CT value of the reference gene WNT11 measured in the same samples. 
**p < 0.01, ***p < 0.001 compared with control (green) or SIRT1 overexpression (blue) by one way ANOVA 
then Bonferroni's multiple comparison.  
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6.2.6 Effects of SIRT1 manipulation on PTPRG 
Percentage DNA methylation was measured at nine consecutive CpG sites within the PCR amplified 
PTPRG sequence spanning - 472 to + 29, occurring at - 72, - 66, - 64, - 62, - 51, - 47, - 39, - 35 and - 
32 bp relative to the start of transcription of the PTPRG sequence (Figure 6.11 and Section 2.6.11). 
The first PCR generated a 917 bp product (PTPRGYF#1 and PTPRGYR#1) and the second, nested 
PCR generated PCR generating a 501 bp product, (PTPRGF#2 and PTPRGR#2). Pyrosequencing was 
carried out using the PTPRG sequencing primer (PTPRGSeq). Standard curves for PTPRG can be 
found in Appendix C. 
 
Total RNA was used to assess PTPRG expression at the mRNA level by RT-qPCR using primers 
specific to a 205 bp region of the PTPRG gene (PTPRG F and PTPRG R) as described above. Primer 
sequences and annealing temperatures are outlined in Table 2.2D. Amplification and standard curves 
for PTPRG can be found in Appendix D.  
 
The 9th CpG site upstream of the PTPRG transcript at position -72 relative to the start of transcription 
showed altered levels of DNA methylation in response to SIRT1 manipulation (Figure 6.12A). Table 
6.1 summarises the data for CpG sites at which significant effects of SIRT1 expression level were 
measured. PTPRG gene expression was also changed in response to SIRT1 manipulation. SIRT1 
overexpression caused an increase in levels of PTPRG transcript compared with the control (p < 0.05) 
and SIRT1 knockdown elicited the opposite response causing a decrease in levels of PTPRG transcript 
compared with the control (p < 0.05); the data for the two extremes (overexpression and knockdown) 
also showed a statistically significant difference (p < 0.001) (Figure 6.12B).  
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Figure 6.11. The PTPRG sequence and related primers for use in the PTPRG pyrosequencing assay. The 
PTPRG sequence taken from the human genome sequence is shown. Primers were designed for a PCR to a 
region in the PTPRG sequence (PTPRGYF#1 – light blue and PTPRGYR#1 – dark blue) and a nested PCR 
(PTPRGF#2 – light green and PTPRGR#2 – dark green) to focus in on nine specific CpG sites (pink) within the 
PTPRG sequence. A sequencing primer was designed for use in the pyrosequencing reaction (PTPRGSeq - 
orange). Primers and annealing temperatures are given in Table 2.2C.   
PTPRG Sequence
-1000 CTTAGAAGTC TAAGCGATAA AGATCTTCTT ACCGAGAGCC AAGGGACAAA 
-950  ACTCATTACA GATAAGCCTA GTCCTCCCAT TTCCCCCGGA CGCCTCTCCC 
-900  CGATTGCTAA AGAAGCAGCC GCTCCCCGGG TAGCTGCCAG GAAATCAGTC
-850  CGGCCCCGCG GCGCTGCTTT CACCCTGCAG GGTGTAAGAG GCGCACTTCC 
-800  TGCGCCCTCC CCGCGGCCAA ACCGGGGTGC GGGAACCTTC TCCAGAGAAG 
-750  CTGCGAGTTG GGGAAACTCC GCCACCGATC CATCGTGGCG CCGGGAAAGG 
-700  GGATGCGGGG CTCGGAAGGG CTAGATTTCG CAATCCTGGG ATCGACATTC 
-650  CTCCCCTCCC CCACTTTCCC CAGCCTTGGA CTGGGCCAAT GAAAGCCCGA 
-600  AAAAGAAAAA AAAAAAAAAT TAAATCTCAA TGTAGCCGGA GTGCAAAGGC 
-550  CGCTCGGCTT TGTTTCCCGG CGGGGGAATG CGCTGTGTTG GAGGCGCGAA 
-500  CAGGAGCCGC AGACGGTGAG CCTCACCGCT GCAAATGCCA GGGCAGTGAA 
-450  GCCGAACAGA AAACCCCATC GCTTTAAAAA GGCAGCTGTC CGCCCTCCCC 
-400  CTTTCCCCTC GCCAGGGCGA GGGGCCCCTC AAGTCCGGGA TCCGCGAGCT 
-350  GCGCGGAGGA TCTCGCCAAA CCCGAGCACC GTGCGGCGTC TTTTAAGAGC 
-300  TCGAACAACG GGAATCCAGC AAAAAACAAG CCGGCCCCAG AAGGCAGCCT 
-250  CCCTCCTCTC TCCGCGCACG GGCTACAATC GCCCCCAGTC CCCAAACTGT 
-200  CCCAGTAGAG GCCGCGCGGA GAGAGCAGAG CCGAGGGACC CAGCGCAAGG 
-150  CGGGAGCCAA GCGCGGCTGC TTTAAGAACG CGGAGAGCGC GCGCCCGCCG 
-100  CCAGCTGGCC CGGGCTGCGC GCCCCCGCCG CCACCGCGCG CCCCCTGTTC
-50   GCTCGCTCCT TCGCTCGCCG GCTTTAAAGT CTCTGCCAGG ATCCATGCTC
+1    acatgttact tcctgtatgg aggcatggcc agtttccagc cccgcgctct
+50   tcgttccttc ccagcctgcg ccggagccac aactttcagg agcatggact
+100  gaaggcgccc tcgccccagc gcccctctga gatcctttgt gttttcctcc
+150  gtttcctccg gccgtttcta ttttgggggg ctctccgctc cccctgcctc
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Figure 6.12. Effect of SIRT1 overexpression or SIRT1 knockdown by siRNA on A) percentage methylation at 
CpG sites within the PTPRG gene as measured by pyrosequencing and B) mRNA levels for PTPRG as 
measured by RT-qPCR. A – Methylation is expressed as the percentage of unmethylated cytosines converted to 
thymines as a result of bisulfite modification determined by pyrosequencing. Data are medians ± upper and 
lower quartile ranges for each CpG site (n = 9). For the set of data corresponding to each CpG site the first 
(left-hand-most) bar corresponds to SIRT1 overexpression, the second to control and the third to SIRT1 
knockdown as indicated by the triangular symbols beneath each set to indicate a progressive decrease in SIRT1 
expression. Outliers are represented by ○. *p < 0.05, **p < 0.01 compared with control (green); #p < 0.05, ##p 
< 0.01 compared with SIRT1 overexpression (blue), by Kruskal Wallis then Dunn’s multiple comparison. B – 
Gene expression is measured as the PCR cycle number at which the fluorescence signal increases above the 
background threshold (CT values). Data are mean ± SEM (n = 9) normalised to the CT value of the reference 
gene WNT11 measured in the same samples. *p < 0.05, **p < 0.01, ***p < 0.001 compared with control 
(green) or SIRT1 overexpression (blue) by one way ANOVA then Bonferroni's multiple comparison.  
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6.2.7 Effects of SIRT1 manipulation on SLC39A4 
Percentage DNA methylation was measured at three consecutive CpG sites within the PCR amplified 
SLC39A4 sequence spanning - 242 to + 39, occurring at - 91, - 81 and - 61 bp relative to the start of 
transcription of the SLC39A4 sequence (Figure 6.13 and Section 2.6.12). The first PCR generated a 
900 bp product (SLC39A4YF#1 and SLC39A4YR#1) and the nested PCR generated PCR generating 
a 281 bp product, (SLC39A4F#2 and SLC39A4R#2). Pyrosequencing was carried out using the 
SLC39A4 sequencing primer (SLC39A4Seq). Standard curves for SLC39A4 can be found in 
Appendix C. 
 
Total RNA was used to assess SLC39A4 expression at the mRNA level by RT-qPCR using primers 
specific to a 171 bp region of the SLC39A4 gene (SLC39A4F and SLC39A4R) as described above. 
Primer sequences and annealing temperatures are outlined in Table 2.2D. Amplification and standard 
curves for SLC39A4 can be found in Appendix D. 
 
No statistically significant effect was measured in DNA methylation levels at any of the 3 CpG site 
assayed upstream of the SLC39A4 transcript in response to altered SIRT1 expression levels (p > 0.05) 
(Figure 6.14A). Table 6.1 summarises the data for CpG sites at which significant effects of SIRT1 
expression level were measured. SLC39A4 gene expression changed in response to SIRT1 
manipulation. SIRT1 knockdown caused a decrease in levels of SLC39A4 transcript compared with 
SIRT1 overexpression (p < 0.01) (Figure 6.14B).  
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Figure 6.13. The SLC39A4 sequence and related primers for use in the SLC39A4 pyrosequencing assay. The 
SLC39A4 sequence taken from the human genome sequence is shown. Primers were designed for a PCR to a 
region in the SLC39A4 sequence (SLC39A4YF#1 – light blue and SLC39A4YR#1 – dark blue) and a nested PCR 
(SLC39A4F#2 – light green and SLC39A4R#2 – dark green) to focus in on three specific CpG sites (pink) within 
the SLC39A4 sequence. A sequencing primer was designed for use in the pyrosequencing reaction (SLC39A4Seq 
- orange). Primers and annealing temperatures are given in Table 2.2C.   
SLC39A4 Sequence
-1000 AATGGCTCAC ACCTGTAATC CTAGCACTTT GGGAGATCGA GGTGGGTGGA 
-950  TTACCTGAGG TCAGGAGATC GAGACCAGCC TGGCCAACAT GGTGAAACCC 
-900  CGTCCTACTA AAAATATAAA AATTAACTGG GCGTGGTGGC GGGTGCCTGT 
-800  AATCCCAGCT ACTCGGGAGG CTGATGCAGA ATTGCTTGAA CCTGGGAGGC 
-750  AGAGGTTGCA GTGAGCCGAG ATGGTGCCAC TGTACTCCAG CCGGGGCGAC 
-700  AGAGTGAAGC TCTGTCTCAA AAGAAGAAAG AAAAGAAAAG GGGAGGGGAT 
-650  GGGAGGGAAG GTCATGTGAA GACAAAGGCA GGGATTGGAG TCATACTGCC 
-600  CACAAACCAA GGAACACCTG GGGCCACCAG TAGCCAGGAA AGGCTCATGG 
-550  AACAGACTGT TTCCTAGAGA CTTCAGAGAG AGCATTGCTC TCCTGACACT 
-500  TTGATTCCTA ACTTTCAGCC TCCAGAACTG TGAGAATAAG TTTCTGGTTT 
-450  TAAGGCACTC AGTTTATGGT AGGCTTTGTT AAGGTAGCCC TAGGAGGCCA 
-400  CCACACAGGC ACTCAGGATT AACGCCTCAG AGTCAGAAGA GGCTGGCGTC 
-350  CCAGGAACCG TGGGCTGCCA CACACTCTGG TCTGACGATC TCCAGGTTTG 
-300  CTTTCCATGA CAGAGAAATA AGCCCTCGGC TGTGTAAGCA GTTATAGGTA 
-250  AGCAAGTTTG ATTCCTGTTT GGGGACAGGT CCCACCTGCT GCCCACACAC 
-200  CCGGGTGAAT TTCCCTGACC CCACTCCTCA GGCAGGCAGG GTCTCCATAT 
-150  CAAAGAGGGG GCACCTGAGG CTGGCTGCCT GGGGGTCCTG AGTGCAGCTC 
-100  TCCTGGCTTC GAGGCACCCC GATGGGGAGA AGGCAGTGCC GCAATTGTCC
-50   TTTCTCAGCT GAGGGCCCTT CCCACCCAGC AAGGAGAGCA CAGCCATGCT
+1    ccaaggacaa gagtgtcttt actggagttg ggactggggc ctctataggg
+50   gcttctggtt tctgggctgt aggtttgtga ggtgtgggat cttaagtcaa
+100  aggtggggga ctagggcagg gtatcagaag gtgatgtcat cctcgtacag
+150  ggacagcagc agcaggacgg tccagccgcc cagcaggccc acgttgtgca
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Figure 6.14. Effect of SIRT1 overexpression or SIRT1 knockdown by siRNA on A) percentage methylation at 
CpG sites within the SLC39A4 gene as measured by pyrosequencing and B) mRNA levels for SLC39A4 as 
measured by RT-qPCR. A – Methylation is expressed as the percentage of unmethylated cytosines converted to 
thymines as a result of bisulfite modification determined by pyrosequencing. Data are medians ± upper and 
lower quartile ranges for each CpG site (n = 9). For the set of data corresponding to each CpG site the first 
(left-hand-most) bar corresponds to SIRT1 overexpression, the second to control and the third to SIRT1 
knockdown as indicated by the triangular symbols beneath each set to indicate a progressive decrease in SIRT1 
expression. Outliers are represented by ○. p > 0.05 compared between SIRT1 overexpression, control and SIRT1 
knockdown by Kruskal Wallis then Dunn’s multiple comparisons test. B – Gene expression is measured as the 
PCR cycle number at which the fluorescence signal increases above the background threshold (CT values). Data 
are mean ± SEM (n = 9) normalised to the CT value of the reference gene WNT11 measured in the same samples. 
**p < 0.01 compared with SIRT1 overexpression (blue) by one way ANOVA then Bonferroni's multiple 
comparison.  
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6.2.8 Effects of SIRT1 manipulation on TBX3 
Percentage DNA methylation was measured at three consecutive CpG sites within the PCR amplified 
TBX3 sequence spanning - 187 to + 53, occurring at - 137, - 125 and - 105 bp relative to the start of 
transcription of the TBX3 sequence (Figure 6.15 and Section 2.6.13). The first PCR generated a 912 bp 
product (TBX3YF#1 and TBX3YR#1) and the nested PCR generated a 440 bp product (TBX3F#2 and 
TBX3R#2). Pyrosequencing was carried out using the TBX3 sequencing primer (TBX3Seq). Standard 
curves for TBX3 can be found in Appendix C. 
 
Total RNA was used to assess TBX3 expression at the mRNA level by RT-qPCR using primers 
specific to a 198 bp region of the TBX3 gene (TBX3F and TBX3R) as described above. Primer 
sequences and annealing temperatures are outlined in Table 2.2D. Amplification and standard curves 
for TBX3 can be found in Appendix D. 
 
The 1st, 2nd and 3rd CpG site upstream of the TBX3 transcript at positions -105, -125 and -137 
relative to the start of transcription showed altered levels of DNA methylation in response to SIRT1 
manipulation (Figure 6.16A). Table 6.1 summarises the data for CpG sites at which significant effects 
of SIRT1 expression level were measured. TBX3 gene expression was also changed in response to 
SIRT1 manipulation. SIRT1 overexpression caused an increase in levels of TBX3 transcript compared 
with the control (p < 0.001) and SIRT1 knockdown had the opposite response causing a decrease in 
levels of TBX3 transcript compared with the control (p < 0.05); the data for the two extremes 
(overexpression and knockdown) also showed a statistically significant difference (p < 0.001) (Figure 
6.16B).  
158 
 
 
Figure 6.15. The TBX3 sequence and related primers for use in the TBX3 pyrosequencing assay. The TBX3 
sequence taken from the human genome sequence is shown. Primers were designed for a PCR to a region in the 
TBX3 sequence (TBX3YF#1 – light blue and TBX3YR#1 – dark blue) and a nested PCR (TBX3F#2 – light green 
and TBX3R#2 – dark green) to focus in on three specific CpG sites (pink) within the TBX3 sequence. A 
sequencing primer was designed for use in the pyrosequencing reaction (TBX3Seq - orange). Primers and 
annealing temperatures are given in Table 2.2C.   
TBX3 Sequence
-1000 CCTTCCCGTG CCGCCCCCGC CCCCCAACAG ACACACACCT CGGAGGCGAG 
-950  GCTGGGGGTC GGGAGACCAA AAGACTGACA GTGCCTCATC ATTTTTTATT
-900  GAATGTTTCA AAGATAAATT GAACTTCAAA AGGCAACTCC CCGAACAGCC 
-850  TGGAGACGGG TTTGAAGGGG AGACTAGGGG AGGATGTCAG CCTCCTGGGT
-800  GACTTTTGCC GTGGAGGGGG TGAAATGTGC ACCCTGGAAT TACCTTTCCC 
-750  CTTTCGGGGA TAATTTCCCT CCTCCCTCGC GTGACACAGC TAAGTTTTCG 
-700  CGGAGCTGGC CGCGCTTTGC ACGCACAACT CGGGATGGAT GGGGCCTCGT 
-650  AGGGGCGCCT TGGGCCAGCC GGGTTCAATT TGAGGCACCA GGGACTGCAG 
-600  GCTGTGTGGG GGGTTGCCGA GTGGAAAGGC GTTGCGTCTT GTCCACTTCT 
-550  ACAACCTGGA GGGTTGCTGC CTAGCCAAGC CCGCTCGGAC TGCTGGGGCA 
-500  TTCTGCTGGC CTTTTCCCCG AGCCAAACAC ACTGGTGCAA GAAGGTATTT 
-450  TCGACTTGGA TTCGCCAGAT TGATGTCAAA ACTGAGGGCG AGCTTAAAAC 
-400  GAAAAACATT CGTACTTGCC GAGCTTACTT TTGGTCGGAT TCGGGTGGGA 
-350  AAACCTGACT TAGGGAGCAC ATCAGTCTTT TTCCATTAAA ACTTAAAAGT 
-300  ATCTGAAATT ACCCTTCTTT CTGTATTCTC ATCAGGCCCC TTTCCGTCTC 
-250  CCTGCTTTGC TCCCTAATTT AAAGGAAAAG TAATTTCAGA TTGAAGTGGC 
-200  TCCCTTCGCT CAAGTAAGGG ACTTTTGTTT TTAGCTTTGT AACTTGAGTG 
-150  ACATCTCATT TTGGTTCGCT GGGGGCGGTC TTAATTATTT AAAGGCGAAG 
-100  GGAAGGGGGT AAACTCAGAA CAAGAAGATA CTAAACCCTC CCCTGACTGT 
-50   CCATCTTCAG GAAAGGTTCC CAAAGAAAAA ACATTTAACA CAAGGCCCAA
+1    agacatttca ataaaaattt attgaaattt cagtgatgtt ttaaagagag
+50   ggggaaaaat acagaaaacc aaagaactca tcaacaacta taacacaaaa
+100  tataccttca tgaatttgtc tttaaaccat ctctcagcac ctgacttttg
+150  aactgtgaat atatctctat aggcaggcac caattcaaaa caccgatact
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Figure 6.16. Effect of SIRT1 overexpression or SIRT1 knockdown by siRNA on A) percentage methylation at 
CpG sites within the TBX3 gene as measured by pyrosequencing and B) mRNA levels for TBX3 as measured 
by RT-qPCR. A – Methylation is expressed as the percentage of unmethylated cytosines converted to thymines as 
a result of bisulfite modification determined by pyrosequencing. Data are medians ± upper and lower quartile 
ranges for each CpG site (n = 9). For the set of data corresponding to each CpG site the first (left-hand-most) 
bar corresponds to SIRT1 overexpression, the second to control and the third to SIRT1 knockdown as indicated 
by the triangular symbols beneath each set to indicate a progressive decrease in SIRT1 expression. Outliers are 
represented by ○. *p < 0.05, **p < 0.01 compared with control (green); #p < 0.05, ##p < 0.01 compared with 
SIRT1 overexpression (blue), by Kruskal Wallis then Dunn’s multiple comparison. B – Gene expression is 
measured as the PCR cycle number at which the fluorescence signal increases above the background threshold 
(CT values). Data are mean ± SEM (n = 9) normalised to the CT value of the reference gene WNT11 measured in 
the same samples. *p < 0.05, ***p < 0.001 compared with control (green) or SIRT1 overexpression (blue) by 
one way ANOVA then Bonferroni's multiple comparison.  
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6.2.9 Summary of the effects of SIRT1 manipulation on gene-specific DNA methylation 
The effects of SIRT1 manipulation on DNA methylation levels on each target gene as measured by 
pyrosequencing is summarised in Table 6.1.
  
 CpG sites affected by manipulating level of SIRT1 expression 
Gene 
Region analysed 
(relative to tss) 
Number of CpG 
sites analysed 
CpG number 
(relative to tss) 
Methylation ( %) in cells 
with SIRT1 o/e 
(median (Q1,Q3); n = 9) 
Methylation ( %) in control 
cells 
(median (Q1,Q3); n = 9) 
Methylation ( %) in cells with 
reduced SIRT1 expression 
(median (Q1,Q3); n = 18) 
       
CDC7 -59 to +1 8 8 2 (1.5, 2) 2 (2, 2) 1.5 (0, 2) * 
       
EIF5 -61 to +1 8 1 
2 
4 
1 (1, 1.5) ** 
1 (0, 1.5) * 
2 (1, 2.5) 
0 (0, 0.25) 
0 (0, 1) 
2 (2, 3.25) 
0 (0, 0.25) ## 
0 (0, 0) ## 
5 (2, 8) *## 
       
IRX3 -65 to +1 3 1 
3 
92 (91.5, 97) 
83 (82, 87) 
94 (91.75, 95) 
86.5 (85, 91) 
91.5 (88.7, 93) * 
90 (87.75, 91) ## 
       
KLF3 -70 to -45 6 3 0 (0, 1.5) * 0 (0, 0) 0 (0, 0) 
       
PCYT1A -89 to +1 2 none affected    
       
PTPRG -73 to +1 9 9 7 (5.5, 11.5) 8 (5, 12.25) 5 (4, 6) **# 
       
SLC39A4 -92 to +1 3 none affected    
       
TBX3 -135 to +1 3 1 
2 
3 
96 (93.5, 96.5) 
84 (83, 87) 
91 (86.5, 95) 
95 (85, 98) 
83 (76.75, 86) 
87 (79.75, 90) 
84.5 (64.75, 92) **## 
78.5 (61.75, 81) **## 
77 (59.5, 82.25) **## 
       
Table 6.1. Summary of the effects of SIRT1 overexpression or SIRT1 knockdown by siRNA on percentage methylation at CpG sites in Caco-2 cells. Data are stated only for CpG 
sites at which significant effects of SIRT1 expression level were measured. tss – transcription start site; o/e – overexpression; Q1 – first quartile; Q3 – third quartile.*p < 0.05, **p 
< 0.01 compared with control (green); 
#
p < 0.05, 
##
p < 0.01 compared with SIRT1 overexpression (blue), by Kruskal Wallis then Dunn’s multiple comparisons tests. 
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6.3 Relationship between CpG site density and DNA methylation levels 
Inspection of values for gene-specific CpG site methylation across the eight genes studied revealed an 
apparent relationship between the intervals separating CpG sites and the percentage methylation, such 
that CpG sites clustered close together within a sequence appeared to have lower levels of 
methylation. Collating the data for mean DNA methylation at CpG sites at each of the eight loci 
revealed a linear relationship with the density at which they occurred (p = 0.0046) (Figure 6.17). This 
preliminary observation was confirmed by publication of a whole-genome study, where through a 
novel method – Methyl-MAPS (methylation mapping analysis by paired-end sequencing) using 
methyl sensitive and methyl dependent enzyme digestion followed by deep sequencing – it was 
established that overall CpG methylation increased with CpG site density until density reached 0.07 
(indicating there is a cytosine at least once every 15 nucleotides) after which CpG site methylation 
decreased rapidly (Edwards et al., 2010).  
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Figure 6.17. Relationship between CpG site density and average percentage DNA methylation. CpG site 
density was calculated by dividing the number of CpG sites in a sequence by the length of the sequence and 
plotted against the average % DNA methylation measured in the sequence. The R
2
 and p values are indicated.  
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6.4 Discussion 
The effects of SIRT1 overexpression or knockdown in Caco-2 cells on DNA methylation was 
investigated and changes in methylation were detected at CpG sites in the promoter regions for six of 
the eight genes (CDC7, EIF5, IRX3, KLF3, PTPRG, TBX3) in the ‘three way’ overlap highlighted by 
the in silico analysis presented in Chapter 5. Significant effects of SIRT1 manipulation on methylation 
were observed on at least 1 site in six of the eight promoter regions examined. No effects of SIRT1 
manipulation on DNA methylation was measured at the CpG sites of PCYT1A and SLC39A4. 
Methylation was measured at specific CpG sites within the promoter regions within a 50 - 100 bp 
region, so there is the chance that SIRT1 manipulation may have affected methylation status of CpG 
sites not captured in the assays for PCYT1A and SLC39A4. Expression at the mRNA level of all of the 
eight genes was affected significantly by SIRT1 overexpression and/or knockdown (CDC7, EIF5, 
KLF3, PCYT1A, PTPRG, TBX3) or when SIRT1 overexpression and knockdown were compared 
(IRX3 and SLC39A4). These experiments thus provide proof of concept that changes in SIRT1 
expression, such as is reported to occur under conditions of DR, can influence both gene-specific 
DNA methylation and corresponding gene expression. A relationship between CpG site density and 
percentage methylation was also observed. 
 
A limitation of the observations thus far is that we have established no causal link between the SIRT1-
dependent changes in gene methylation and expression that we observe. Approaches to establishing 
such a relationship could include utilising the methylated promoter reporter construct model, described 
in Section 4.3, to investigate the effects of in vitro methylation on the promoters of CDC7, EIF5, 
IRX3, KLF3, PCYT1A, PTPRG, SLC39A4 and TBX3 when driving expression of β galactosidase in a 
transfected cell line. Other evidence that would establish a causal link between promoter methylation 
and gene expression would be to show that those genes with highly methylated promoter regions 
(IRX3, PCYT1A, SLC39A4 and TBX3) have altered gene expression in Caco-2 cells treated with a 
DNA-demethylating agent such as 5-aza-2’-deoxycytidine. There is an opportunity – based on the 
existing data – to carry out analysis using a tool to predict transcription factor binding sites such as 
RegionMiner (Genomatix, Germany) to determine if sites methylated differentially by changed SIRT1 
levels lie within transcription factor binding sites which would provide some indirect evidence of a 
likely causal link between DNA methylation and gene expression. 
 
Speculative suggestions concerning the downstream consequences of the SIRT1-mediated changes in 
DNA methylation or expression of the genes studied here can be made but would require experimental 
investigation, since none of the genes highlighted through the in silico analysis (Chapter 5) and thus 
studied here have any specific, clear links to the ageing process or modification of lifespan. Beneficial 
effects of DR on lifespan could feasibly involve these genes however through maintenance of cell 
cycle control (CDC7 and EIF5), cellular structure (MYH10 and PCYT1A) and signalling (PTPRG), 
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control of gene expression (IRX3, KLF3 and TBX3) and regulation of dietary components (LDLR and 
SLC39A4). 
 
As determination of DNA methylation status of CpG sites by pyrosequencing is limited to only a small 
region of the gene, a criticism may be that the measurements provided are only a snapshot of the 
methylation pattern across the entire promoter region. Analysis of CpG sites in a much larger region of 
each promoter may reveal more complex patterns and relationships, as demonstrated by the gene 
suppression caused by methylation in CpG islands (Saxonov et al., 2006) and CpG shores (Irizarry et 
al., 2009) which have been described as CpG dense regions up to 2 kb upstream of genes affected by 
their methylation status. A second obvious limitation relating to the targeted CpG site methylation 
measurements made thus far is that, given we have now established proof of principle that SIRT1 can 
affect gene-specific DNA methylation, effects across the entire genome (i.e. effects at the level of the 
‘methylome’) should be considered. Chapter 7 describes experiments that investigate these more 
global effects using a microarray-based approach to assess effects of SIRT1 manipulation on DNA 
methylation and gene expression across the genome. 
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7 An investigation of genome-wide effects of SIRT1 on DNA methylation 
and gene expression 
7.1 Outline 
Chapter 3 reported investigation of the levels of global DNA methylation using the LINE-1 
retrotransposon as a surrogate marker, which we found did not change in response to SIRT1 
manipulation but revealed some effects of dietary polyphenols that were influenced by SIRT1 
expression levels. We also investigated in work which was presented in Chapter 6 changes in gene-
specific DNA methylation but only assayed a small number of the CpG sites that could theoretically 
be methylated and undergo changes in methylation in response to altered SIRT1 expression. To gain a 
more comprehensive view of the extent to which DNA methylation at specific loci may be affected by 
SIRT1 expression levels we carried out microarray-based analysis of the methylation pattern across 
the genome under conditions where SIRT1 was expressed at different levels. In parallel we measured 
the response to expressing SIRT1 at different levels at the level of the transcriptome. 
 
To investigate the effect of levels of SIRT1 expression on genome-wide DNA methylation and gene 
expression, SIRT1 was overexpressed and knocked down in the Caco-2 cell line. SIRT1 
overexpression and knockdown in Caco-2 cells was confirmed at the mRNA level by RT-qPCR and at 
the protein level by western blot. Genome-wide DNA methylation changes were measured by 
Methylated DNA Immunoprecipitation (MeDIP) followed by co-hybridisation of differential dye-
labelled input and methylation-enriched DNA samples to microarrays. Genome-wide transcript levels 
were compared at different levels of SIRT1 expression by hybridisation of RNA to microarrays. 
7.2 Investigating the genome-wide effects of SIRT1 on DNA methylation 
We tested our overarching hypothesis that changes in SIRT1 expression levels (as occurs under 
conditions of DR) can influence DNA methylation (which may mediate some of the beneficial effects 
of DR) on a genome-wide scale by manipulating the levels of SIRT1 within Caco-2 cells by 
overexpression from a transgene or siRNA-mediated knockdown then investigating the effects of 
DNA methylation at specific sites across the genome via hybridisation of input and methylation-
enriched DNA to microarrays. 
 
The MeDIP protocol, through which the methylated fraction of DNA is immunoprecipitated using an 
anti-5-methylcytidine antibody was initially described by (Weber et al., 2005) and further developed 
to include internal positive and negative controls to assess the reproducibility of enrichment within a 
sample set (S Lisanti, Newcastle University, Personal Communication) as described in Section 1.5.5 
and 2.6.14. 
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7.2.1 Experimental design 
Caco-2 cells seeded 24 hours previously at 3.5 x 10
5
 cells/well in a six well plate (area = 9.6 cm
2
/well) 
were transfected transiently with 100 pmol SIRT1-targeting siRNA or with 100 pmol of a Stealth 
RNAi
™
 siRNA negative control of similar GC content to achieve SIRT1 knockdown or with 2 μg 
SIRT1 expression construct (pCMV6-ENTRYSIRT1) to achieve SIRT1 overexpression or with 2 μg 
control vector with no SIRT1 insert (pCMV6-Neo). After 72 hours cells were lysed and DNA and 
total cell lysate were extracted from parallel experiments. Total cell lysate was used to assess SIRT1 
manipulation at the protein level by western blot as described in Section 2.8. Total cell lysate was 
extracted (Section 2.8.2.2) and protein concentration determined by Bradford assay (Section 2.8.1.4). 
Ten micrograms of total cell lysate was separated by SDS-PAGE (Section 2.8.1.5) and blotted onto a 
polyvinylidene difluride (PVDF) membrane (Section 2.8.1.6), which was then probed with antibodies 
to SIRT1 and the loading control protein alpha tubulin. Changes in SIRT1 protein levels were 
confirmed by differences in signal intensity when blots were probed with SIRT1 antibody. Typical 
western blot confirmation of SIRT1 knockdown or overexpression is shown in Figure 3.4 and Figure 
3.8 (Chapter 3) respectively. DNA for methylation analysis was prepared from three independent 
experiments pooled to produce three biological repeats for each condition (SIRT1 overexpression; 
SIRT1 knockdown and corresponding controls), of which those with the highest quality were selected 
for MeDIP. 
 
Having obtained DNA samples with confirmed SIRT1 knockdown and overexpression, a profile of 
DNA methylation across the genome was obtained using the DNA Methylation Service provided by 
NimbleGen Roche (Reykjavik, Iceland) as described in Section 2.6.14. Each DNA sample was 
subjected to MeDIP before site-specific DNA methylation across the genome was analysed by 
hybridisation to microarrays. 
 
To prepare samples for MeDIP DNA was sonicated using an ultrasonic homogeniser and purified as 
described in Section 2.6.14.2 to produce DNA fragments ranging from 200 – 1000 bp in length, 
confirmed by agarose gel electrophoresis (Figure 7.1A). Purified fragmented DNA (4.4 µg) was then 
spiked with unmethylated and methylated internal controls generated from Lambda phage dam dcm- 
genomic DNA (Figure 7.1B) and denatured at 95 °C as described in Section 2.6.14.3 and 2.6.14.4. 
Forty five microlitres of spiked fragmented DNA was stored at 4 °C to act as the input; the remaining 
spiked fragmented DNA was incubated with mouse anti-5-methylcytidine then with sheep anti-mouse 
IgG-coated superparamagnetic polystyrene beads, which were captured using a magnetic rack (Section 
2.6.14.4). 
 
Whole genome amplification of 2 ng/µl input or immunoprecipitated DNA was performed using the 
GenomePlex
®
 Complete Whole Genome Amplification kit (Sigma) to increase the yield of each DNA 
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sample (Section 2.6.15.5). The retention of the fragmentation size was confirmed by agarose gel 
electrophoresis (Figure 7.1C).  
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Figure 7.1. Confirmation of (A) DNA fragmentation by ultrasonic homogenisation, (B) methylation status of 
lambda phage internal controls and (C) retained DNA fragmentation after Whole Genome Amplification 
(WGA). A – Sonication products were analysed by agarose gel electrophoresis. B – Methylation status of in 
vitro methylated (i IVM; closed circles) and unmethylated (ii UM; open circles) internal controls for MeDIP was 
analysed by agarose gel electrophoresis before adding to the sonicated DNA. Two fragments (i and ii) were 
generated from Lambda phage dam dcm- genomic DNA (λ) by PCR amplification of two 500 bp regions, one of 
which was then in vitro methylated (i). Methylation status was confirmed by digestion with the methylation 
sensitive restriction enzyme AciI. A comparison of band size after digestion between unmethylated and 
methylated fragment i (i UM and i IVM) or between methylated fragment i and the unmethylated internal control 
fragment ii (ii UM) confirmed methylation. C – Sonicated WGA products (immunoprecipitated with an anti-5-
methylcytidine antibody in the case of the enriched sample) were analysed by agarose gel electrophoresis to 
confirm retention of DNA fragmentation. As indicated for A and C, lanes contained products generated from 
Caco-2 cells transfected transiently with either SIRT1-targeting siRNA or with a Stealth RNAi
™
 siRNA negative 
control of similar GC content or the SIRT1 expression construct pCMV6-ENTRYSIRT1or control vector 
pCMV6-Neo at 72 hours after transfection. M – DNA molecular weight marker (Hyperladder I, Bioline; sites 
indicated). The double-headed arrow on the right hand side of panel A and C indicates the range of DNA 
fragment sizes required for downstream array hybridisation.  
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Enrichment analysis was performed by qPCR to assess the efficiency of MeDIP enrichment using 
primers to the internal spike controls (Figure 7.2A) and known endogenous sequences of high (H19 
and L1.2) and low (UBE2B) levels of methylation (Figure 7.2B and Figure 7.2C). qPCR analysis of 
these genes was performed using the Roche LightCycler
®
 480 (Section 2.7.2.4). Primer sequences and 
annealing temperatures are stated in Table 2.2D. Amplification curves for the unmethylated and 
methylated Lambda Phage fragments, H19, L1.2 and UBE2B are shown in Appendix D. Enrichment 
was calculated using the CT values generated for each input and methylation-enriched sample by 
subtraction of negative control values from the value for each input or methylation-enriched sample, 
then subtraction of the corrected CT value of the enriched from the input sample giving a value   for 
which enrichment was calculated as 2  . Enrichment results using the comparison of the internal spike 
controls or the highly methylated sequences H19 and L1.2 versus the low methylation of UBE2B are 
shown in Figure 7.2A-C respectively. Enrichment values varied substantially across the ten samples 
analysed (two biological repeats for each of the five test conditions) and this variability was as 
substantial between biological duplicates of the same condition as between different conditions, so 
was not related to the manipulations in SIRT1 applied. However, all enrichments values exceeded the 
10-fold criteria required for further analysis. As each input and enriched sample are compared directly 
these variable levels of enrichment should not affect the analysis in a fundamental way, but may lead 
to difference in the sensitivity with which differences in DNA can be detected on the individual 
microarrays.  
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Figure 7.2. Enrichment of methylated DNA after MeDIP compared to input DNA. Levels of enrichment were 
calculated in each sample using CT values for negative controls subtracted from values for samples. Enriched 
sample values were subtracted from input values     and enrichment expressed as 2  . A – Lambda Phage 
controls. B – H19/UBE2B. C – L1.2/UBE2B. Data for the two biological replicates prepared and analysed for 
each condition are shown.  
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7.2.2 Array design and hybridisation by NimbleGen 
After confirmation of enrichment and quality assessment by retention of fragmentation and acceptable 
measures of absorbance (A260/A280), DNA samples were sent to NimbleGen Roche for analysis by 
hybridisation to the NimbleGen 3x720K CpG Island Plus RefSeq Promoter Array. This array consists 
of 3 identical arrays per chip targeting 720,000 probes covering 30,848 transcripts, 22,532 promoters 
and 27,728 CpG Islands. DNA samples from cells overexpressing SIRT1 and corresponding vector 
only controls or cells in which SIRT1 expression was reduced by siRNA and corresponding controls 
were hybridised as biological duplicates over three chips. DNA from cells transfected with a second 
SIRT1-targeting siRNA was hybridised to a fourth array. Input DNA was labelled with Cy3 and 
immunoprecipitated DNA with Cy5 and samples were co-hybridised to the arrays. 
7.2.3 Data analysis 
The raw data scanned from the array chips was supplied electronically. The summary report of the 
peak data mapped to the transcription start site of genes was imported into Excel (Microsoft) and 
duplicates were removed. Genes were supplied with Entrez identifiers. A stringent two-step approach 
was then taken to identify genes that were methylated at different levels under conditions of SIRT1 
knockdown or overexpression compared to control. In the first instance sequences enriched by MeDIP 
were identified as being represented on both biological duplicates and in the case of the SIRT1-
targetting siRNAs were required to appear in the list for both siRNAs. The resulting list of methylated 
genes whose signal intensity met the minimum p-value cut-off consisted of 4707 genes under control 
conditions (pCMV6-Neo), 5080 genes under conditions of SIRT1 overexpression (pCMV6-
ENTRYSIRT1), 5385 genes under control siRNA conditions (negative scrambled control) and 4766 
genes under conditions of SIRT1 knockdown (SIRT1-targeting siRNAs #1 & #2). Genes that 
underwent a change in methylation in response to either SIRT1 overexpression or SIRT1 knockdown 
were identified as those for which enrichment of methylation was detected on the array under only one 
of the two conditions being compared. A total of 4102 genes appeared on the lists of methylated genes 
for both separate control conditions suggesting the DNA methylation status was relatively unaffected 
by the transfection procedure alone. A total of 1555 genes were found to be differentially methylated 
under conditions of SIRT1 overexpression compared with control (Appendix E.II). A total of 1681 
genes were found to be differentially methylated under conditions of SIRT1 knockdown compared 
with control (Appendix E.II). A total of 490 genes were present on the lists of genes whose 
methylation changed in response to both SIRT1 overexpression and knockdown (Figure 7.3A and 
Appendix E.II).  
 
A total of 356 of the 490 genes whose methylation status was affected by SIRT1 manipulation in 
Caco-2 cells could be assigned mouse Ensembl identifiers and were present on the MM5 ‘Universe’ 
allowing comparisons with the previous in silico lists of genes that bound SIRT1 and genes responsive 
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to DR used for the in silico analysis presented in Chapter 5. Overlaps were observed of 12 (r.f. 1.34; p 
= 0.18) and 56 (r.f. 1.02; p = 0.43) genes respectively (Figure 7.3A and Appendix E.II) and were not 
statistically significant. Thus the overlap between genes whose methylation status was found to be 
affected by SIRT1 and those found to bind with SIRT1 or respond to DR did not exceed the number 
expected by chance. A total of 1051 of the 1219 mouse genes that showed an ageing related change in 
methylation status (Maegawa et al., 2010), used in the in silico analysis present in Chapter 5 and to 
guide selection of genes studied in the work presented in Chapter 6, could be represented by a 
comparable human Entrez identifier and were present on the ‘Universe’ of 11407 genes that were 
methylated in our DNA methylation microarray or the list generated by (Maegawa et al., 2010) 
(Figure 7.3A and Appendix E.II). Of these genes, 38 appeared on the list of 490 human genes that 
showed an SIRT1 manipulation-related change in methylation status, giving a representation factor of 
0.84 and hypergeometric probability of 0.89 (Figure 7.3B). Thus the overlap between genes whose 
methylation status was found to be affected by SIRT1 and those showing a change in methylation in 
older compared with younger mouse intestine did not exceed the number expected by chance. 
 
The less stringent lists composed of genes whose DNA methylation changed in response to SIRT1 
overexpression only (Appendix E.II) or SIRT1 knockdown only (Appendix E.II) were also 
investigated for the significance of the overlap with the gene expression data when only manipulating 
SIRT1 one way.  
 
Of the 1555 genes that showed a change in DNA methylation status in response to SIRT1 
overexpression 1060 could be converted to mouse Ensembl identifiers and were present on MM5 
allowing comparisons with the previous in silico lists of genes that bound SIRT1 and genes responsive 
to DR used for the in silico analysis presented in Chapter 5. Overlaps were observed of 15 (r.f. 0.56; p 
= 0.99) and 157 (r.f. 0.96; p = 0.68) genes respectively (Appendix E.II) and were not statistically 
significant. Thus the overlap between genes whose methylation status was found to be affected by 
SIRT1 overexpression and those found to bind with SIRT1 or respond to DR did not exceed the 
number expected by chance. Comparing the 1555 genes that showed a change in DNA methylation 
status in response to SIRT1 overexpression with the list of 1051 genes from the (Maegawa et al., 
2010) paper that could be represented by a human Entrez identifier and were present on the ‘Universe’ 
of genes that could be methylated an overlap of 103 genes was observed (r.f. 0.72; p = 0.99). Thus the 
overlap between genes whose methylation status was found to be affected by SIRT1 and those 
showing a change in methylation in older compared with younger mouse intestine did not exceed the 
number expected by chance. 
 
Of the 1681 genes that showed a change in DNA methylation status in response to SIRT1 knockdown 
1163 could be converted to mouse Ensembl identifiers and were present on MM5 allowing 
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comparisons with the lists of genes that bound SIRT1 and genes responsive to DR used for the in 
silico analysis presented in Chapter 5. Overlaps were observed of 35 (r.f. 1.19; p = 0.155) and 200 (r.f. 
1.12; p = 0.035) genes respectively (Appendix E.II). Thus the overlap between genes whose 
methylation status was found to be affected by SIRT1 knockdown and those found to bind with SIRT1 
did not exceed the number expected by chance. However, the gene methylation profile of Caco-2 cells 
affected by SIRT1 knockdown matches, to an extent greater than expected by chance, genes that 
respond to DR across a range of different mouse tissues, suggesting that changes in the level of SIRT1 
has an effect on the methylation status of some of the genes that are responsive to DR (Figure 7.3B). 
Comparing the 1681 genes that showed a change in DNA methylation status in response to SIRT1 
knockdown with the list of 1051 genes from the (Maegawa et al., 2010) paper that could be 
represented by a human Entrez identifier and were present on the ‘Universe’ of genes that could be 
methylated an overlap of 102 genes was observed (r.f. 0.77; p = 0.99).  
 
The lists of genes that changed either in response to SIRT1 overexpression or SIRT1 knockdown 
showed much the same trend in results as the list of 490 genes that changed in response to SIRT1 
overexpression and knockdown when overlapped in the same way, however, only genes whose 
methylation changed under conditions of SIRT1 knockdown were over represented on the list of genes 
found to be responsive to DR complied from the in silico in Chapter 5.  
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Genes affected by SIRT1 manipulation  
 
Continued… 
Human Gene 
Symbol 
Human Entrez 
ID   
Mouse Ensembl ID 
 
Human Gene 
Symbol 
Human Entrez 
ID   
Mouse Ensembl ID 
AAMP 14 † ENSMUSG00000006299 
 
C19orf53 28974 
 
ENSMUSG00000019362 
AKAP12 9590   ENSMUSG00000038587 
 
C20orf165 128497 
 
ENSMUSG00000017767 
APOBR 55911   ENSMUSG00000042759 
 
C20orf24 55969 † ENSMUSG00000027637 
CA10 56934   ENSMUSG00000056158 
 
C22orf43 51233 
  CADM3 57863   ENSMUSG00000005338 
 
C2orf18 54978 
 
ENSMUSG00000029175 
CBLN2 147381   ENSMUSG00000024647 
 
C4orf42 92070 
  CBLN4 140689   ENSMUSG00000067578 
 
C8orf56 157556 
  CDK5 1020 † ENSMUSG00000028969 
 
C9orf140 89958 
 
ENSMUSG00000026955 
CHRM1 1128   ENSMUSG00000032773 
 
C9orf142 286257 † ENSMUSG00000047617 
CLN3 1201   ENSMUSG00000030720 
 
C9orf163 158055 
  FBN2 2201   ENSMUSG00000024598 
 
C9orf37 85026 
  FGF2 2247   ENSMUSG00000037225 
 
CADPS 8618 
 
ENSMUSG00000054423 
FOXL1 2300   ENSMUSG00000043867 
 
CALCA 796 
 
ENSMUSG00000030669 
FZD5 7855   ENSMUSG00000045005 
 
CAMK1 8536 
 
ENSMUSG00000030272 
GATA3 2625   ENSMUSG00000015619 
 
CAPN13 92291 
 
ENSMUSG00000043705 
GBX1 2636   ENSMUSG00000067724 
 
CASP9 842 † ENSMUSG00000028914 
GLI3 2737   ENSMUSG00000021318 
 
CCDC147 159686 
 
ENSMUSG00000046585 
HOXD13 3239   ENSMUSG00000001819 
 
CCDC65 85478 
 
ENSMUSG00000003354 
IL23A 51561   ENSMUSG00000025383 
 
CCDC82 79780 
 
ENSMUSG00000079084 
ISL2 64843   ENSMUSG00000032318 
 
CCL22 6367 
 
ENSMUSG00000031779 
KCNMA1 3778   ENSMUSG00000063142 
 
CCT6P1 643253 
  LRRC14 9684   ENSMUSG00000033728 
 
CD22 933 
 
ENSMUSG00000030577 
MEGF11 84465   ENSMUSG00000036466 
 
CD63 967 
 
ENSMUSG00000025351 
ODZ4 26011   ENSMUSG00000048078 
 
CDC45 8318 
 
ENSMUSG00000000028 
PAN2 9924   ENSMUSG00000005682 
 
CDH15 1013 
 
ENSMUSG00000031962 
PAPLN 89932   ENSMUSG00000021223 
 
CDK5RAP1 51654 
 
ENSMUSG00000027487 
REEP2 51308   ENSMUSG00000038555 
 
CELA2A 63036 
 
ENSMUSG00000058579 
RORC 6097 † ENSMUSG00000028150 
 
CELF2 10659 
 
ENSMUSG00000002107 
RSPO3 84870   ENSMUSG00000019880 
 
CEP57L1 285753 
 
ENSMUSG00000019813 
SALL1 6299   ENSMUSG00000031665 
 
CGNL1 84952 
 
ENSMUSG00000032232 
SCUBE1 80274   ENSMUSG00000016763 
 
CHGA 1113 
 
ENSMUSG00000021194 
SHC3 53358   ENSMUSG00000021448 
 
CHRNA4 1137 
 
ENSMUSG00000027577 
SLC31A2 1318   ENSMUSG00000066152 
 
CILP2 148113 
 
ENSMUSG00000044006 
ST8SIA4 7903   ENSMUSG00000040710 
 
CLDN9 9080 
 
ENSMUSG00000066720 
SYNC 81493   ENSMUSG00000001333 
 
CLEC2L 154790 
 
ENSMUSG00000079598 
TBX15 6913   ENSMUSG00000027868 
 
CLN5 1203 † ENSMUSG00000022125 
ZDHHC24 254359   ENSMUSG00000006463 
 
CLU 1191 † ENSMUSG00000022037 
ZER1 10444   ENSMUSG00000039686 
 
CNTN4 152330 
 
ENSMUSG00000064293 
AADACL3 126767 
 
ENSMUSG00000078507 
 
COL11A1 1301 
 
ENSMUSG00000027966 
ABCC3 8714 
 
ENSMUSG00000020865 
 
COL4A2 1284 
 
ENSMUSG00000031503 
ABTB1 80325 
 
ENSMUSG00000030083 
 
COL9A3 1299 
 
ENSMUSG00000027570 
ACP5 54 
 
ENSMUSG00000001348 
 
COX19 90639 † ENSMUSG00000045438 
ACRBP 84519 
 
ENSMUSG00000072770 
 
CRYBA1 1411 
 
ENSMUSG00000000724 
ADAMTS3 9508 
 
ENSMUSG00000043635 
 
CSNK2B 1460 
 
ENSMUSG00000024387 
ADHFE1 137872 
 
ENSMUSG00000025911 
 
CSTB 1476 
 
ENSMUSG00000005054 
ADRA2C 152 
 
ENSMUSG00000045318 
 
CTBP1 1487 
 
ENSMUSG00000037373 
AES 166 
 
ENSMUSG00000054452 
 
CTCF 10664 * ENSMUSG00000005698 
AGER 177 
 
ENSMUSG00000015452 
 
CTLA4 1493 
 
ENSMUSG00000026011 
AGFG1 3267 
 
ENSMUSG00000026159 
 
CTRB2 440387 
 
ENSMUSG00000031957 
AIM1 202 
 
ENSMUSG00000019866 
 
CTRL 1506 
 
ENSMUSG00000031896 
AIRE 326 
 
ENSMUSG00000000731 
 
CTSA 5476 
 
ENSMUSG00000017760 
AK4 205 † ENSMUSG00000028527 
 
CTU2 348180 
 
ENSMUSG00000049482 
ALOX15B 247 
 
ENSMUSG00000020891 
 
DBF4B 80174 
  ALPK3 57538 
 
ENSMUSG00000038763 
 
DCAF4L1 285429 
  ALS2CR11 151254 
   
DCBLD2 131566 
 
ENSMUSG00000035107 
ALX1 8092 
 
ENSMUSG00000036602 
 
DDI1 414301 
 
ENSMUSG00000047619 
ANKRD11 29123 
 
ENSMUSG00000035569 
 
DERL2 51009 † ENSMUSG00000018442 
ANKRD9 122416 
 
ENSMUSG00000037904 
 
DIRC2 84925 
 
ENSMUSG00000022848 
APOL1 8542 
   
DKK4 27121 
 
ENSMUSG00000031535 
ARL17A 51326 
   
DNAJB12 54788 
 
ENSMUSG00000020109 
ARMC7 79637 
 
ENSMUSG00000057219 
 
DNAJC16 23341 
 
ENSMUSG00000040697 
ASCL2 430 
 
ENSMUSG00000009248 
 
DOCK2 1794 
 
ENSMUSG00000020143 
ASF1A 25842 † ENSMUSG00000019857 
 
DPP6 1804 
 
ENSMUSG00000061576 
ASMTL-AS1 80161 
   
DUSP21 63904 
 
ENSMUSG00000025043 
ATP10A 57194 
 
ENSMUSG00000025324 
 
ECHDC2 55268 
 
ENSMUSG00000028601 
ATP11A 23250 † ENSMUSG00000031441 
 
EFNA3 1944 
 
ENSMUSG00000028039 
B4GALNT4 338707 
 
ENSMUSG00000055629 
 
EHD1 10938 
 
ENSMUSG00000024772 
BAALC 79870 
 
ENSMUSG00000022296 
 
EPB41L4B 54566 
 
ENSMUSG00000028434 
BAHCC1 57597 
 
ENSMUSG00000039741 
 
EPHA1 2041 
 
ENSMUSG00000029859 
BANP 54971 
 
ENSMUSG00000025316 
 
EPN2 22905 
 
ENSMUSG00000001036 
BCAS4 55653 
   
EPPK1 83481 
  BID 637 † ENSMUSG00000004446 
 
ERAS 3266 
 
ENSMUSG00000031160 
BMP3 651 
 
ENSMUSG00000029335 
 
ERCC1 2067 
 
ENSMUSG00000003549 
BUB1 699 † ENSMUSG00000027379 
 
ERCC4 2072 
 
ENSMUSG00000022545 
BUB3 9184 
 
ENSMUSG00000066979 
 
ESYT3 83850 
 
ENSMUSG00000037681 
BZW1P2 151579 
   
ETNK2 55224 
 
ENSMUSG00000070644 
C10orf93 255352 
   
ETV3L 440695 
  C11orf66 220004 
 
ENSMUSG00000035179 
 
FAM173A 65990 
 
ENSMUSG00000057411 
C12orf10 60314 
 
ENSMUSG00000001285 
 
FAM193B 54540 † ENSMUSG00000021495 
C14orf48 256369 
   
FAM22A 728118 
  C15orf24 56851 
 
ENSMUSG00000055943 
 
FAM48B2 170067 
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FAM57B 83723 
 
ENSMUSG00000058966 
 
LACRT 90070 
  FAM86C2P 645332 
   
LAT2 7462 
 
ENSMUSG00000040751 
FAM86EP 348926 
   
LCA10 643736 
 
ENSMUSG00000019971 
FAM89A 375061 † ENSMUSG00000043068 
 
LDHAL6A 160287 
  FBL 2091 
 
ENSMUSG00000046865 
 
LEPREL4 10609 
 
ENSMUSG00000006931 
FBLL1 345630 
 
ENSMUSG00000051062 
 
LGI3 203190 
 
ENSMUSG00000033595 
FBP2 8789 † ENSMUSG00000021456 
 
LIFR 3977 
 
ENSMUSG00000054263 
FBXW8 26259 
 
ENSMUSG00000032867 
 
LIMK1 3984 
 
ENSMUSG00000029674 
FEM1B 10116 
 
ENSMUSG00000032244 
 
LOC100192378 100192378 
  FERMT1 55612 
 
ENSMUSG00000027356 
 
LOC100270710 100270710 
  FKBP1A 2280 † ENSMUSG00000032966 
 
LOC219347 219347 
 
ENSMUSG00000072678 
FLJ32063 150538 
   
LOC729020 729020 
  FLJ45983 399717 
   
LYRM1 57149 
 
ENSMUSG00000030922 
FOLR1 2348 
 
ENSMUSG00000001827 
 
LYSMD1 388695 
 
ENSMUSG00000053769 
FZR1 51343 
 
ENSMUSG00000020235 
 
MAGEF1 64110 
  GDAP2 54834 
 
ENSMUSG00000027865 
 
MAN2B1 4125 
 
ENSMUSG00000005142 
GGT5 2687 
 
ENSMUSG00000006344 
 
MAP4 4134 
 
ENSMUSG00000032479 
GHDC 84514 
 
ENSMUSG00000017747 
 
MAPK9 5601 
 
ENSMUSG00000020366 
GNB3 2784 
 
ENSMUSG00000023439 
 
MAST4 375449 
 
ENSMUSG00000034751 
GNG2 54331 
 
ENSMUSG00000043004 
 
MC1R 4157 * ENSMUSG00000074037 
GORAB 92344 
 
ENSMUSG00000040124 
 
MCHR1 2847 * ENSMUSG00000050164 
GP1BB 2812 † ENSMUSG00000050761 
 
METTL10 399818 
 
ENSMUSG00000030960 
GPCPD1 56261 
 
ENSMUSG00000027346 
 
METTL19 152992 
 
ENSMUSG00000029097 
GPER 2852 
 
ENSMUSG00000053647 
 
METTL21B 25895 
  GPR161 23432 
 
ENSMUSG00000040836 
 
MGAT3 4248 * ENSMUSG00000042428 
GPR179 440435 
 
ENSMUSG00000070337 
 
MGAT4B 11282 † ENSMUSG00000036620 
GPR32 2854 
   
MGC14436 84983 
  GPR89C 728932 
   
MGC16121 84848 
  GPRASP1 9737 
 
ENSMUSG00000043384 
 
MLXIPL 51085 † ENSMUSG00000005373 
GPRC5D 55507 
 
ENSMUSG00000030205 
 
MMGT1 93380 
 
ENSMUSG00000061273 
GPT2 84706 † ENSMUSG00000031700 
 
MORF4 10934 
  GRIA3 2892 
 
ENSMUSG00000001986 
 
MORN3 283385 
 
ENSMUSG00000029477 
GRIK4 2900 
 
ENSMUSG00000032017 
 
MSH4 4438 
 
ENSMUSG00000005493 
GRK7 131890 
   
MTMR11 10903 
 
ENSMUSG00000045934 
GRM2 2912 
 
ENSMUSG00000023192 
 
MTMR7 9108 
 
ENSMUSG00000039431 
GTF2I 2969 † ENSMUSG00000060261 
 
NAT9 26151 
 
ENSMUSG00000015542 
H2BFXP 767811 
   
NAV1 89796 
 
ENSMUSG00000009418 
HDAC7 51564 
 
ENSMUSG00000022475 
 
NCRNA00245 100131213 
  HDGFL1 154150 
 
ENSMUSG00000045835 
 
NDUFA4 4697 
 
ENSMUSG00000029632 
HIBCH 26275 † ENSMUSG00000041426 
 
NDUFV1 4723 † ENSMUSG00000037916 
HIC2 23119 
 
ENSMUSG00000050240 
 
NFKBIB 4793 
 
ENSMUSG00000030595 
HIST1H2BH 8345 
 
ENSMUSG00000064168 
 
NKAPL 222698 
 
ENSMUSG00000059395 
HIST1H4G 8369 
   
NKG7 4818 
 
ENSMUSG00000004612 
HIVEP3 59269 
 
ENSMUSG00000028634 
 
NLRP12 91662 
 
ENSMUSG00000078817 
HMGN2 3151 
 
ENSMUSG00000090620 
 
NLRX1 79671 
 
ENSMUSG00000032109 
HPR 3250 
 
ENSMUSG00000031722 
 
NOB1 28987 
 
ENSMUSG00000003848 
HS3ST2 9956 
 
ENSMUSG00000046321 
 
NPR1 4881 
 
ENSMUSG00000027931 
HSD17B3 3293 
 
ENSMUSG00000033122 
 
NR1D2 9975 † ENSMUSG00000021775 
HSPBAP1 79663 
 
ENSMUSG00000022849 
 
NR1H4 9971 † ENSMUSG00000047638 
HTRA1 5654 † ENSMUSG00000006205 
 
NR2C2 7182 
 
ENSMUSG00000005893 
IER5L 389792 
 
ENSMUSG00000089762 
 
NUDT8 254552 
 
ENSMUSG00000024869 
IGF2BP2 10644 
 
ENSMUSG00000033581 
 
NUDT9P1 119369 
  IL34 146433 
 
ENSMUSG00000031750 
 
NUP153 9972 
 
ENSMUSG00000021374 
INSC 387755 † ENSMUSG00000048782 
 
NUP214 8021 
 
ENSMUSG00000001855 
ITGAV 3685 
 
ENSMUSG00000027087 
 
ODZ3 55714 † ENSMUSG00000031561 
ITGB4 3691 
 
ENSMUSG00000020758 
 
OPCML 4978 
 
ENSMUSG00000062257 
ITPKA 3706 † ENSMUSG00000027296 
 
OR1F1 4992 
  JMJD8 339123 
 
ENSMUSG00000025736 
 
OR1L8 138881 
 
ENSMUSG00000075380 
JRKL 8690 
   
OR2A4 79541 
 
ENSMUSG00000043605 
KAL1 3730 
   
OR2T33 391195 
 
ENSMUSG00000056959 
KATNAL2 83473 
 
ENSMUSG00000025420 
 
OR5P3 120066 
 
ENSMUSG00000063764 
KCNE4 23704 
 
ENSMUSG00000047330 
 
OR6B1 135946 
 
ENSMUSG00000049168 
KCNF1 3754 
 
ENSMUSG00000051726 
 
OSCP1 127700 
 
ENSMUSG00000042616 
KCNMB2 10242 
 
ENSMUSG00000037610 
 
PABPC1P2 728773 
  KCTD10 83892 * ENSMUSG00000001098 
 
PAGE2B 389860 
  KIAA1609 57707 
 
ENSMUSG00000034105 
 
PAK4 10298 
 
ENSMUSG00000030602 
KIAA1671 85379 
 
ENSMUSG00000051339 
 
PANX1 24145 
 
ENSMUSG00000031934 
KIRREL 55243 
 
ENSMUSG00000041734 
 
PAQR8 85315 
 
ENSMUSG00000025931 
KLC3 147700 
 
ENSMUSG00000040714 
 
PARVA 55742 
 
ENSMUSG00000030770 
KLHDC5 57542 
 
ENSMUSG00000040102 
 
PARVG 64098 
 
ENSMUSG00000022439 
KLHL34 257240 
 
ENSMUSG00000047485 
 
PCDHGA10 56106 
  KLK10 5655 
 
ENSMUSG00000030693 
 
PCDHGB5 56101 
  KLK12 43849 
 
ENSMUSG00000044430 
 
PCDHGB6 56100 
 
ENSMUSG00000023036 
KLK7 5650 
 
ENSMUSG00000030713 
 
PCNXL2 80003 
 
ENSMUSG00000060212 
KRT24 192666 
 
ENSMUSG00000020913 
 
PDE11A 50940 
 
ENSMUSG00000075270 
KRT31 3881 
 
ENSMUSG00000048981 
 
PGAM4 441531 
  KRTAP5-5 439915 
   
PGBD3 267004 
  KRTCAP3 200634 
 
ENSMUSG00000029149 
 
PHKA1 5255 
 
ENSMUSG00000034055 
L1CAM 3897 
 
ENSMUSG00000031391 
 
PHYHD1 254295 
 
ENSMUSG00000079484 
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PIM1 5292 † ENSMUSG00000024014 
 
SNAPC2 6618 
 
ENSMUSG00000011837 
PIP5KL1 138429 
 
ENSMUSG00000046854 
 
SNORA12 677800 
  PKDCC 91461 † ENSMUSG00000024247 
 
SNORA62 6044 
 
ENSMUSG00000064925 
PKIG 11142 † ENSMUSG00000035268 
 
SNORA84 100124534 
  PKN1 5585 
 
ENSMUSG00000057672 
 
SNORD116-16 100033428 
  PLAT 5327 *† ENSMUSG00000031538 
 
SNORD63 26785 
  PLEKHN1 84069 
 
ENSMUSG00000078485 
 
SNX29 92017 
 
ENSMUSG00000071669 
PLK5 126520 
 
ENSMUSG00000035486 
 
SOX14 8403 
  PLXND1 23129 
 
ENSMUSG00000030123 
 
SPARC 6678 † ENSMUSG00000018593 
PNKD 25953 † ENSMUSG00000026179 
 
SRL 6345 
 
ENSMUSG00000022519 
PRDX2 7001 *† ENSMUSG00000005161 
 
SSTR2 6752 
 
ENSMUSG00000047904 
PRDX4 10549 
 
ENSMUSG00000025289 
 
STAC2 342667 
 
ENSMUSG00000017400 
PRNP 5621 
 
ENSMUSG00000079037 
 
STOX2 56977 † ENSMUSG00000038143 
ProSAPiP1 9762 
 
ENSMUSG00000037703 
 
SULT1A2 6799 
  PRR22 163154 
   
SURF6 6838 
 
ENSMUSG00000036160 
PSIMCT-1 100101490 
   
SUSD1 64420 
 
ENSMUSG00000038578 
PSMB9 5698 † ENSMUSG00000024337 
 
SV2B 9899 
 
ENSMUSG00000053025 
PSMD5 5711 
 
ENSMUSG00000026869 
 
SYCP1 6847 * ENSMUSG00000027855 
PTGDS 5730 
 
ENSMUSG00000015090 
 
SYNGR2 9144 
 
ENSMUSG00000048277 
PTP4A3 11156 † ENSMUSG00000059895 
 
T 6862 
 
ENSMUSG00000062327 
PTPRJ 5795 
 
ENSMUSG00000025314 
 
TAC3 6866 
 
ENSMUSG00000025400 
PTPRVP 148713 
 
ENSMUSG00000066885 
 
TAOK2 9344 
 
ENSMUSG00000059981 
RAB36 9609 
 
ENSMUSG00000020175 
 
TBCA 6902 † ENSMUSG00000042043 
RAD23A 5886 † ENSMUSG00000003813 
 
TBL2 26608 † ENSMUSG00000005374 
RAMP1 10267 † ENSMUSG00000034353 
 
TBX1 6899 † ENSMUSG00000009097 
RCC2 55920 
 
ENSMUSG00000040945 
 
TCEAL2 140597 
  RETN 56729 † ENSMUSG00000012705 
 
TCEB3B 51224 
  RFWD2 64326 
 
ENSMUSG00000040782 
 
TEAD4 7004 
 
ENSMUSG00000030353 
RG9MTD3 158234 
 
ENSMUSG00000035601 
 
TGM3 7053 
 
ENSMUSG00000027401 
RGS14 10636 
 
ENSMUSG00000052087 
 
TGM6 343641 
 
ENSMUSG00000027403 
RHOC 389 
 
ENSMUSG00000002233 
 
TM6SF2 53345 
 
ENSMUSG00000036151 
RMND5B 64777 
 
ENSMUSG00000001054 
 
TMEFF1 8577 
 
ENSMUSG00000028347 
RNASEH2A 10535 * ENSMUSG00000052926 
 
TMEM104 54868 
 
ENSMUSG00000045980 
RNF39 80352 
 
ENSMUSG00000036492 
 
TMEM151B 441151 
 
ENSMUSG00000050405 
RPH3AL 9501 
 
ENSMUSG00000020847 
 
TMEM173 340061 
 
ENSMUSG00000024349 
RPL12 6136 
 
ENSMUSG00000080054 
 
TMEM176A 55365 
 
ENSMUSG00000023367 
RPL8 6132 
 
ENSMUSG00000003970 
 
TMEM176B 28959 
 
ENSMUSG00000029810 
RPS27A 6233 
 
ENSMUSG00000055093 
 
TMEM223 79064 
 
ENSMUSG00000075043 
RRAS2 22800 
 
ENSMUSG00000055723 
 
TMEM31 203562 
  RSPH10B 222967 
   
TMEM81 388730 
 
ENSMUSG00000048174 
RSPH10B2 728194 
 
ENSMUSG00000075569 
 
TMEM87B 84910 
 
ENSMUSG00000014353 
RSPH6A 81492 
 
ENSMUSG00000040866 
 
TNFRSF8 943 
 
ENSMUSG00000028602 
RTDR1 27156 
 
ENSMUSG00000009070 
 
TNFSF12 8742 
 
ENSMUSG00000090170 
RUSC1-AS1 284618 
   
TNFSF13 407977 
 
ENSMUSG00000090170 
RUVBL2 10856 * ENSMUSG00000003868 
 
TNNC2 7125 
 
ENSMUSG00000017300 
S100A16 140576 
 
ENSMUSG00000074457 
 
TRAF5 7188 
  SAE1 10055 † ENSMUSG00000052833 
 
TSPO2 222642 
 
ENSMUSG00000023995 
SCNM1 79005 
 
ENSMUSG00000005629 
 
TTC24 164118 
 
ENSMUSG00000051036 
SCTR 6344 
 
ENSMUSG00000026387 
 
TTLL10 254173 
 
ENSMUSG00000029074 
SCXA 100129885 
 
ENSMUSG00000034161 
 
TUBB1 81027 
 
ENSMUSG00000016255 
SCXB 642658 † ENSMUSG00000034161 
 
UAP1L1 91373 
 
ENSMUSG00000026956 
SEMA6D 80031 
 
ENSMUSG00000027200 
 
UBE2L3 7332 † ENSMUSG00000038965 
SERP2 387923 
 
ENSMUSG00000052584 
 
UBE2V1 7335 
 
ENSMUSG00000078923 
SERPINB13 5275 
 
ENSMUSG00000048775 
 
UBE3B 89910 * ENSMUSG00000029577 
SERPINE2 5270 
 
ENSMUSG00000026249 
 
UCMA 221044 
 
ENSMUSG00000026668 
SFRP2 6423 
 
ENSMUSG00000027996 
 
UFSP1 402682 
 
ENSMUSG00000051502 
SFTA3 253970 
   
UGCG 7357 
 
ENSMUSG00000028381 
SFTPC 6440 
 
ENSMUSG00000022097 
 
UNC5CL 222643 
 
ENSMUSG00000043592 
SGCD 6444 
 
ENSMUSG00000020354 
 
UPK1A 11045 
 
ENSMUSG00000006313 
SGSH 6448 
 
ENSMUSG00000005043 
 
UQCR10 29796 
 
ENSMUSG00000059534 
SIAH3 283514 
 
ENSMUSG00000091722 
 
USF2 7392 
 
ENSMUSG00000058239 
SIGLEC10 89790 
 
ENSMUSG00000030468 
 
VPS13B 157680 
 
ENSMUSG00000037646 
SIGLEC15 284266 
 
ENSMUSG00000091055 
 
VRK1 7443 
 
ENSMUSG00000021115 
SIGLEC5 8778 
 
ENSMUSG00000039013 
 
VWF 7450 † ENSMUSG00000001930 
SIRT2 22933 
 
ENSMUSG00000015149 
 
WDR3 10885 
 
ENSMUSG00000033285 
SLC11A1 6556 
 
ENSMUSG00000026177 
 
WIF1 11197 
 
ENSMUSG00000020218 
SLC12A8 84561 
 
ENSMUSG00000035506 
 
XBP1 7494 † ENSMUSG00000020484 
SLC22A13 9390 
 
ENSMUSG00000074028 
 
XPA 7507 
 
ENSMUSG00000028329 
SLC25A10 1468 
 
ENSMUSG00000025792 
 
XRCC2 7516 
 
ENSMUSG00000028933 
SLC25A16 8034 
 
ENSMUSG00000071253 
 
YY2 404281 
 
ENSMUSG00000091736 
SLC27A1 376497 † ENSMUSG00000031808 
 
ZFAND2A 90637 † ENSMUSG00000053581 
SLC29A4 222962 
 
ENSMUSG00000050822 
 
ZFP57 346171 
 
ENSMUSG00000036036 
SLC2A9 56606 
 
ENSMUSG00000005107 
 
ZFP90 146198 
 
ENSMUSG00000031907 
SLC39A14 23516 
 
ENSMUSG00000022094 
 
ZMAT1 84460 
 
ENSMUSG00000052676 
SLC41A1 254428 † ENSMUSG00000013275 
 
ZNF286B 729288 
  SLC4A2 6522 
 
ENSMUSG00000028962 
 
ZNF30 90075 
  SLC4A5 57835 
 
ENSMUSG00000068323 
 
ZNF304 57343 
  SLC5A7 60482 
 
ENSMUSG00000023945 
 
ZNF323 64288 
  SMPD3 55512 
 
ENSMUSG00000031906 
 
ZNF567 163081 
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ZNF580 51157 * ENSMUSG00000055633 
ZNF581 51545 
 
ENSMUSG00000035228 
ZNF605 100289635 
 
ENSMUSG00000023284 
ZNF628 89887 
 
ENSMUSG00000074406 
ZNF646 9726 
 
ENSMUSG00000049739 
ZNF652 22834 
 
ENSMUSG00000075595 
ZNF668 79759 
 
ENSMUSG00000049728 
ZNF670 93474 
  ZNF705D 728957 
  ZNF721 170960 
  ZNF83 55769 
  ZW10 9183 
 
ENSMUSG00000032264 
 
 
 
 
Figure 7.3. Analysis by the ‘most stringent pathway’ of DNA methylation affected by SIRT1 manipulation 
(siRNA or overexpression construct) and by ageing. A – Genes with changed methylation over 72 hours in 
response to manipulated SIRT1 expression in Caco-2 cells by siRNA and overexpression are listed. Genes 
identified through the in silico analysis as differentially methylated in older tissue are in shaded cells. Genes 
identified through the in silico analysis as sites of SIRT1-binding (*) or as responsive to DR (†) are highlighted 
by dashed underlining. Human gene symbols and Entrez identifiers and mouse Ensembl identifiers are stated. B 
– Overlaps between genes identified as responsive to DR and genes differently methylated under conditions of 
SIRT1 knockdown are represented in a Venn diagram. ‘n’ indicates the number of genes common to both group; 
‘p’ indicates the cumulative hypergeometric probability..  
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7.3 Investigating the genome-wide effects of SIRT1 on gene expression 
To complement investigations into our hypothesis that SIRT1 may be mediating the beneficial effects 
of DR on gene regulation via DNA methylation we investigated the direct effects of SIRT1 
manipulation on gene expression. Microarray-based techniques allowed for the genome-wide effects 
of SIRT1 manipulation to be probed, profiling global gene expression changes in response to SIRT1 
levels. Such approaches would detect changes in gene expression brought about by changing the level 
of SIRT1 expression through all active mechanisms – not only effect on gene methylation. For 
example, multiple cellular substrates undergo SIRT1-mediated deacetylation, including transcription 
factors and co-regulators that are required for gene expression. For example, the forkhead transcription 
factors are down regulated by SIRT1 preventing the activation of gene transcription and subsequent 
downstream processes such as cell differentiation and apoptosis (Brunet et al., 2004; Motta et al., 
2004). 
 
The approach to data analysis to address our hypothesis that some effects of SIRT1 on gene expression 
are through DNA methylation was to compare the list of genes we found to be differentially 
methylated in response to changing levels of SIRT1 expression (as described in the preceding sections 
of this chapter) with the list of genes we found to be differentially expression in response to changing 
levels of SIRT1 expression. 
7.3.1 Experimental design 
RNA for transcriptome analysis under conditions of SIRT1 overexpression or knockdown was 
obtained from cells treated exactly as described for preparation of DNA for methylome analysis 
(Section 7.2.1). Samples for DNA methylome analysis and transcriptome analysis were obtained from 
cells processed in parallel. RNA for expression analysis was prepared from three independent 
experiments pooled to produce 3 biological repeats for each condition (SIRT1 overexpression; SIRT1 
knockdown and corresponding controls), of which all three biological replicates for SIRT1 
overexpression and controls and two biological replicates for each of the SIRT1 siRNAs and control 
were hybridised to the expression array. 
 
Having obtained RNA samples with confirmed SIRT1 knockdown and overexpression, gene 
expression was measured using the Illumina Gene Expression Service provided by Service XS 
(Leiden, The Netherlands) as described in Section 2.7.3. Each RNA sample was subjected to quality 
and integrity checks before global gene expression was measured by microarray analysis. RNA quality 
was assessed by spectrophotometry (Section 2.4.4) and integrity was assessed using the Bioanalyser 
(Section 2.4.5); the integrity output of the Bioanalyser for the samples analysed by microarray 
hybridisation is shown in Figure 7.4.   
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Figure 7.4. RNA integrity. A – Gel-like image generated from bioanalyser electropherogram output.                 
B – Typical bioanalyser electropherogram output. A RIN of 7 or more indicates RNA of sufficient quality.  
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7.3.2 Microarray design and hybridisation by Service XS 
After confirmation of integrity and quality, RNA samples were sent to Service XS for analysis. The 
Illumina HumanHT-12 v4 Expression BeadChip consists of 12 identical arrays targeting over 47,000 
probes covering genes, gene candidates and splice variants from the 2009 NCBI RefSeq Release 38. 
RNA samples were reverse transcribed to produce a cDNA template that was then in vitro transcribed 
amplified to incorporate biotin-labelled nucleotides. RNA samples from cells overexpressing SIRT1 
and corresponding vector only controls were hybridised as biological triplicates onto individual arrays, 
RNA samples from cells in which SIRT1 expression was reduced by one of two siRNAs and the 
corresponding control were hybridised as biological duplicates onto individual arrays within the 
HumanHT-12 v4 Expression BeadChip (Illumina), then the signal was developed with Streptavidin-
Cy3 and the BeadChip scanned. Gene expression data from the scan images and the intensity value for 
each probe was calculated. 
7.3.3 Data analysis 
The raw data scanned from the array chips was supplied electronically and was deposited in GEO 
(accession GSE30486). Using RankProd analysis (Hong et al., 2006) on a quality filtered subset of 
microarray probes (Section 2.7.3.3), 95 genes were identified whose expression was reduced (Figure 
7.5A and Appendix E.III) and 62 genes identified whose expression was increased (Figure 7.5B and 
Appendix E.III) by a factor of 1.5-fold or greater under conditions of SIRT1 knockdown. Under 
conditions of SIRT1 overexpression there was no statistically significant difference between gene 
expression in samples where SIRT1 was overexpressed compared with the control. The absence of any 
deviation, even to the extent that would be expected between biological replicates, suggested that an 
element of the gene expression profiling had failed and the experiment should be repeated, which time 
constraints did not permit. To allow comparison with the previous mouse data sets of genes that bound 
SIRT1 and genes responsive to DR used for the in silico analysis presented in Chapter 5, the genes 
differentially expressed under conditions of SIRT1 knockdown were assigned equivalent mouse 
Ensembl identifiers. A total of 107 of the 119 genes that were differentially expressed under 
conditions of SIRT1 knockdown were present on the MM5 microarray (Figure 7.5A and Figure 7.5B 
and Appendix E.III). Of these genes, 39 appeared on the list of 2613 mouse genes that respond to DR 
(Figure 7.5A and Figure 7.5B; shaded cells), giving a representation factor of 1.98 and hypergeometric 
probability of 2.67 x 10
-5 
(Figure 7.5C). Thus the gene profile of Caco-2 cells affected by SIRT1 
manipulation matches, to an extent substantially greater than expected by chance, genes that respond 
to DR across a range of different mouse tissues, both providing validity to Caco-2 cells with altered 
SIRT1 expression as an in vitro model of DR and lending support to the view that SIRT1 is a key 
mediator of the response of mammalian cells to DR. Overlaps between the 107 genes assigned mouse 
Ensembl identifiers affected by SIRT1 knockdown in Caco-2 cells and genes identified through the in 
silico analysis as binding SIRT1 (3 genes; r.f. 1.11; p = 0.507) or between these 107 genes and the set 
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of genes reported to show ageing-related changes in methylation status used for the in silico analysis 
(7 genes; r.f. 1.07; p = 0.478) (Figure 7.5A and Figure 7.5B; denoted by * or # respectively and 
Appendix E.III) did not exceed the level expected by chance.  
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Genes affected by reduced SIRT1 expression (siRNA) 
 
Continued... 
Human Gene 
Symbol 
Human 
Entrez ID 
  Mouse Ensembl ID Fc ↓ 
 
Human Gene 
Symbol 
Human 
Entrez ID 
  Mouse Ensembl ID Fc ↓ 
ISG15 9636 
  
ENSMUSG00000035692 2.28 
 
NDUFA7 4701 
 
ENSMUSG00000041881 1.60 
IFIT1 3434   ENSMUSG00000034459 2.25 
 
REEP1 65055  ENSMUSG00000052852 1.59 
NPPB 4879   ENSMUSG00000029019 2.19 
 
IRF9 10379  ENSMUSG00000002325 1.59 
IFI27 3429   ENSMUSG00000064215 2.01 
 
VAMP8 8673  ENSMUSG00000050732 1.58 
P4HA2 8974   ENSMUSG00000018906 1.95 
 
ANAPC1 64682  ENSMUSG00000014355 1.58 
RCN2 5955   ENSMUSG00000032320 1.93 
 
RPL8 6132  ENSMUSG00000003970 1.57 
PRIC285 85441   ENSMUSG00000027580 1.80 
 
GGCT 79017  ENSMUSG00000002797 1.57 
SIVA 10572   ENSMUSG00000064326 1.79 
 
CALM1 801  ENSMUSG00000001175 1.57 
FAM96A 84191   ENSMUSG00000032381 1.79 
 
RYBP 23429  ENSMUSG00000072872 1.56 
LAMP2 3920   ENSMUSG00000016534 1.77 
 
SCARNA18 677765  
 
1.56 
TXNIP 10628   ENSMUSG00000038393 1.76 
 
HDHD1A 8226  ENSMUSG00000048875 1.55 
PRODH 5625   ENSMUSG00000003526 1.76 
 
CCND1 595  ENSMUSG00000070348 1.55 
UGT1A6 54578   ENSMUSG00000054545 1.75 
 
TFDP1 7027  ENSMUSG00000038482 1.52 
TMED10 10972   ENSMUSG00000021248 1.74 
  
  
  GSTA2 2939   ENSMUSG00000057933 1.70 
  
  
  IGFBP6 3489   ENSMUSG00000023046 1.62 
  
  
  CIDEC 63924   ENSMUSG00000030278 1.61 
  
  
  CDKN1A 1026 * ENSMUSG00000023067 1.60 
  
  
  UQCRQ 27089   ENSMUSG00000044894 1.59 
  
  
  PTEN 5728   ENSMUSG00000013663 1.57 
  
  
  ERGIC1 57222   ENSMUSG00000001576 1.57 
  
  
  ACSL5 51703   ENSMUSG00000024981 1.57 
  
  
  TPT1 7178 * ENSMUSG00000060126 1.56 
  
  
  LOX 4015  ENSMUSG00000024529 2.47 
  
  
  ANKRD37 353322  ENSMUSG00000050914 2.43 
  
  
  APOA4 337  ENSMUSG00000032080 2.34 
  
  
  CSF1R 1436  ENSMUSG00000024621 2.34 
  
  
  CEACAM6 4680  
 
2.30 
  
  
  IFITM1 8519  ENSMUSG00000025491 2.26 
  
  
  AQP10 89872  
 
2.19 
  
  
 
 APOC3 345  ENSMUSG00000032081 2.10 
  
  
  GNRH2 2797  ENSMUSG00000015812 2.09 
  
  
  GPX2 2877 * ENSMUSG00000042808 2.05 
  
  
  SIRT1 23411  ENSMUSG00000020063 2.00 
  
  
  MORF4L1 10933  ENSMUSG00000062270 1.97 
  
  
  NQO1 1728  ENSMUSG00000003849 1.97 
  
  
  AKR1C2 1646  ENSMUSG00000021207 1.96 
  
  
  NDRG4 65009  ENSMUSG00000036564 1.92 
  
  
  CEACAM1 634  ENSMUSG00000074272 1.91 
  
  
  GSTA1 2938  ENSMUSG00000074183 1.90 
  
  
  OAS3 4940  ENSMUSG00000032661 1.89 
  
  
  MYPOP 339344  ENSMUSG00000048481 1.89 
  
  
  WSB1 26118  ENSMUSG00000017677 1.89 
  
  
  EEF1A2 1917  ENSMUSG00000016349 1.88 
  
  
  LOC644799 644799  
 
1.88 
  
  
  LGALS14 56891  
 
1.87 
  
  
  RPS29 6235  ENSMUSG00000034892 1.87 
  
  
  C5orf28 64417  
 
1.86 
  
  
  ALB 213  ENSMUSG00000029368 1.85 
  
  
  PRKRIR 5612  ENSMUSG00000030753 1.84 
  
  
  HN1 51155  ENSMUSG00000020737 1.83 
  
  
  B3GNT1 11041  ENSMUSG00000047379 1.83 
  
  
  OKL38 29948  ENSMUSG00000074063 1.80 
  
  
  FOXQ1 94234  ENSMUSG00000038415 1.80 
  
  
  LOC644363 644363  
 
1.78 
  
  
  MIR1978 100302173  
 
1.78 
  
  
  GAST 2520  ENSMUSG00000017165 1.76 
  
  
  CANX 821  ENSMUSG00000020368 1.76 
  
  
  MX1 4599  ENSMUSG00000000386 1.76 
  
  
  TMED10P 286102  
 
1.75 
  
  
  ITGA2 3673  ENSMUSG00000015533 1.75 
  
  
  ISG20 3669  ENSMUSG00000039236 1.72 
  
  
  WBSCR22 114049  ENSMUSG00000005378 1.70 
  
  
  IFRD2 7866  ENSMUSG00000010048 1.69 
  
  
  IL13RA1 3597  ENSMUSG00000017057 1.69 
  
  
  LOC440145 440145  
 
1.68 
  
  
  CDK2 1017  ENSMUSG00000025358 1.68 
  
  
  NAT13 80218  ENSMUSG00000022698 1.68 
  
  
  CD68 968  ENSMUSG00000018774 1.68 
  
  
  UTS2 10911  ENSMUSG00000028963 1.68 
  
  
  TMBIM6 7009 # ENSMUSG00000023010 1.68 
  
  
  N-PAC 84656  ENSMUSG00000022536 1.67 
  
  
  OSBPL8 114882  ENSMUSG00000020189 1.66 
  
  
  IPO11 51194  ENSMUSG00000042590 1.66 
  
  
  SCARNA14 692149  
 
1.65 
  
  
  MAL2 114569 * ENSMUSG00000024479 1.65 
  
  
  LOC644844 644844  
 
1.65 
  
  
  LOC285074 285074  
 
1.62 
  
  
  RAB32 10981  ENSMUSG00000019832 1.62 
  
  
  SEPHS2 22928  ENSMUSG00000049091 1.61 
  
  
  CDC2L6 23097  ENSMUSG00000038481 1.61 
  
  
  TM4SF5 9032  ENSMUSG00000018919 1.61 
  
  
  
A 
184 
 
Genes affected by reduced SIRT1 expression (siRNA) 
Human Gene 
Symbol 
Human 
Entrez ID 
  Mouse Ensembl ID Fc ↑ 
UGP2 7360 # ENSMUSG00000001891 1.90 
FABP5 2171   ENSMUSG00000027533 1.90 
GGH 8836   ENSMUSG00000073987 1.86 
CYP51A1 1595 * ENSMUSG00000001467 1.73 
LAPTM4B 55353   ENSMUSG00000022257 1.69 
VIM 7431   ENSMUSG00000026728 1.69 
COL3A1 1281   ENSMUSG00000026043 1.68 
SERPINI1 5274   ENSMUSG00000027834 1.67 
CA2 760   ENSMUSG00000027562 1.66 
CTSZ 1522   ENSMUSG00000016256 1.65 
FAM98A 25940   ENSMUSG00000002017 1.59 
TUBA3D 113457   ENSMUSG00000067338 1.59 
BNIP3L 665   ENSMUSG00000022051 1.57 
TAGLN 6876   ENSMUSG00000032085 1.55 
PDGFRA 5156   ENSMUSG00000029231 1.54 
HRSP12 10247   ENSMUSG00000022323 1.53 
LOC387934 387934  
 
2.09 
UBD 10537  ENSMUSG00000035186 2.08 
UQCRH 7388 * ENSMUSG00000063882 1.93 
CLEC2D 29121 # ENSMUSG00000030157 1.93 
LOC100131672 100131672  
 
1.91 
LOC653737 653737  
 
1.87 
RPLP1 6176 * ENSMUSG00000007892 1.85 
LOC441743 441743  
 
1.85 
RGS4 5999  ENSMUSG00000038530 1.84 
KIAA1199 57214  ENSMUSG00000052353 1.79 
LOC645231 645231  
 
1.75 
LOC642738 642738  
 
1.75 
CCNO 10309  ENSMUSG00000042417 1.73 
FGG 2266  ENSMUSG00000033860 1.69 
OSTCL 202459  
 
1.69 
ANXA2P1 303  
 
1.69 
LOC730996 730996  
 
1.68 
FGA 2243  ENSMUSG00000028001 1.67 
ARL6IP1 23204  ENSMUSG00000030654 1.67 
LOC100134273 100134273  
 
1.66 
KCNJ8 3764  ENSMUSG00000030247 1.66 
LOC727984 727984  
 
1.64 
TULP3 7289  ENSMUSG00000001521 1.64 
MYO1D 4642  ENSMUSG00000035441 1.64 
PI3 5266  
 
1.64 
LOC646527 646527  
 
1.62 
ZNF738 148203  
 
1.62 
LOC646966 646966  
 
1.61 
YY1 7528  ENSMUSG00000021264 1.61 
LOC390735 390735  
 
1.60 
LOC100133803 100133803  
 
1.60 
LOC727821 727821  
 
1.60 
LOC653631 653631  
 
1.59 
RPL12P6 440176  
 
1.59 
LOC100131905 100131905  
 
1.59 
LOC644937 644937  
 
1.59 
UBE2E1 7324  ENSMUSG00000021774 1.59 
LOC389322 389322  
 
1.58 
TRMT11 60487  ENSMUSG00000019792 1.57 
ODAM 54959  ENSMUSG00000009580 1.56 
LOC647307 647307  
 
1.56 
ANKRD1 27063  ENSMUSG00000024803 1.55 
LOC100129599 100129599  
 
1.53 
PRPS1 5631  ENSMUSG00000031432 1.53 
AIDA 64853  ENSMUSG00000042901 1.53 
TAF15 8148  ENSMUSG00000020680 1.51 
 
Figure 7.5. Analysis of genes affected by reduced SIRT1 expression (siRNA) and by DR. Genes with 
expression reduced (A) or increased (B) by 1.5-fold or greater (ranked) over 72 hours in response to reducing 
SIRT1 expression in Caco-2 cells by siRNA are listed. Genes identified through the in silico analysis as 
responsive to DR are in shaded cells. Genes identified through the in silico analysis as sites of SIRT1-binding (*) 
or as differentially methylated in older tissue (#) are highlighted by dashed underlining. Human gene symbols 
and Entrez identifiers and mouse Ensembl identifiers are stated. Overlaps between genes identified as responsive 
to DR and genes affected by SIRT1 knockdown are represented in a Venn diagram (C).‘n’ indicates the number 
of genes common to both groups; ‘p’ indicates the cumulative hypergeometric probability.  
B 
C 
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7.4 Relationship between the genome-wide effects of SIRT1 on DNA methylation and 
gene expression 
One of the primary goals of obtaining parallel data on gene methylation and expression in Caco-2 cells 
in response to changed levels of SIRT1 expression was to investigate the relationship between the two 
measures. The two data sets were overlapped using the Entrez gene identifier annotations provided 
(Appendix E.IV). For the purpose statistical analysis by calculation of hypogeometric probability, a 
universal list of genes was generated by identifying all of the 9838 that were enriched for methylation 
under any of our experimental conditions that were represented also on the transcriptome (Illumina) 
array. The rationale for excluding any genes on the transcriptome array that were not identified as 
methylated under any of our conditions was to avoid a statistical bias in favour of a significant overlap 
between genes undergoing both a change in methylation and expression in response to SIRT1 
manipulation by virtue of using a universal gene set that included genes for which there was no 
evidence of methylation per se. Of the 9838 genes, 9659 were also on the transcriptome array 
(Appendix E.IV). Of the 1555 genes for which we detected changes in methylation under conditions 
of SIRT1 overexpression (compared with control) 1524 were on the transcriptome array (gene list ‘A’ 
– Appendix E.IV). Of the 1681 genes for which we detected changes in methylation under conditions 
of SIRT1 knockdown (compared with control) 1657 were on the transcriptome array (gene list ‘B’ – 
Appendix E.IV). Of the 490 genes (Figure 7.4) for which we detected changes in methylation under 
conditions of both SIRT1 overexpression and knockdown (compared with control), 482 were on the 
transcriptome array (gene list ‘C’ – Appendix E.IV). Of the 157 genes that we found to be expressed 
differentially in response to SIRT1 knockdown, 53 (Figure 7.6) were represented within the pool of 
9659 genes that showed enrichment for methylation under any of our experimental conditions (and 
were represented on the transcriptome array). None of the overlaps between these 53 genes and gene 
lists ‘A’, ‘B’ or ‘C’ as defined above were statistically significant (for gene list ‘A’: 9 genes, r.f. 1.08, 
p = 0.46; for gene list ‘B’: 7 genes, r.f. 0.77, p = 0.82; for gene list ‘C’: 1 gene, r.f. 0.38, p  = 0.93; for 
gene lists and overlaps see Appendix E.IV). A possible explanation is that whilst SIRT1 affects both 
gene methylation and expression, there is no causal relationship; rather SIRT1 acts through 
independent mechanisms to bring about both effects. However, as discussed in more depth in the 
following section, analysis of the methylome data is still at a preliminary stage and refinement of the 
data analysed may uncover large overlaps.  
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Figure 7.6. Analysis of gene expression and DNA methylation affected by SIRT1 manipulation. 
Diagrammatic representation of the overlaps between genes identified as affected by SIRT1 manipulation either 
in expression levels or DNA methylation status. ‘n’ indicates the number of genes common to both groups.  
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7.5 Discussion 
The effects of SIRT1 manipulation on DNA methylation and gene expression on a genome-wide scale 
were investigated. Genes whose expression changed in response to SIRT1 knockdown were 
represented to an extent greater than would be expected by chance on the list of genes previously 
generated through work presented in Chapter 5 whose expression changed in response to DR. This 
observation supports the view that manipulation of SIRT1 in the Caco-2 cell line provides a model of 
DR. Genes whose DNA methylation changed in response to SIRT1 manipulation (siRNA knockdown 
or overexpression) were not represented to an extent greater than would be expected by chance on the 
list genes generated whose DNA methylation status changed with age.  
 
The criteria applied to identify differentially methylated loci were particularly stringent. Genes were 
considered as methylated only if enrichment peaks were reported based on analysis of hybridisation to 
all replicate arrays and were identified as undergoing a SIRT1-dependent change in methylation only 
if a peak became absent under the condition being compared. Thus, in this preliminary analysis we did 
not take into account any quantitative difference in peak enrichment intensity between conditions 
being compared; rather we took an ‘all or none’ approach. Application of a more quantitative approach 
is likely to increase the list of genes identified as differentially methylated in response to changing 
levels of SIRT1 expression and may uncover other significant associations with other data sets. Such 
changes will be undertaken through research beyond the scope or available timescale of the current 
project.  
 
The large number of candidate gene targets generated through analysis presented in this chapter open 
many avenues for further exploration. Follow up investigations could focus on the broad analysis of 
separating responses according to the direction of the methylation change in response to an increase in 
SIRT1 from knockdown to endogenous levels or endogenous to overexpressed levels. More specific 
analysis could focus in on select gene targets generated from the above directional studies and, as 
discussed previously in Chapter 6, effects of SIRT1 on expression of target genes could be measured 
by RT-qPCR and effects on DNA methylation measured by pyrosequencing. Additionally, a causal 
link between DNA methylation and gene expression could be addressed using in vitro methylation of 
promoter-reporter constructs and/or by the treatment of cells with demethylating agents such as 5-aza-
2’-deoxycytidine, followed by RT-qPCR to examine effects on target gene expression.  
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8 Discussion and conclusions 
This study set out to investigate effects of the SIRT1 histone deacetylase and dietary compounds on 
DNA methylation in the context of dietary restriction (DR) and longevity. The SIRT1 protein acts to 
remove acetyl groups from the lysine residues on histone tails, as well as an array of other protein 
substrates and this action may be a mechanism through which some of the beneficial effects of DR are 
mediated. DNA methylation changes with ageing and is associated with histone deacetylation, the two 
mechanisms working in juxtaposed roles to regulate gene expression. The work outlined in this thesis 
investigated in detail the relationship between manipulation of SIRT1 expression and DNA 
methylation at global and site-specific levels in the human intestinal cell line Caco-2. 
 
The role of SIRT1 in lifespan extension received much attention after initial discoveries in yeast 
(Kaeberlein, 1999), worms (Tissenbaum and Guarente, 2001) and flies (Rogina and Helfand, 2004) 
showed that increasing the levels of the equivalent SIRT1 homologue (Sir2) resulted in longer 
lifespan. The response to increasing the levels of Sir2 showed many other parallels with the response 
of these organisms to DR, including a reduction in fertility. 
 
DR also increases lifespan in rodents, and parallel observed increases in SIRT1 levels (Barger et al., 
2008; Kanfi et al., 2008; Nisoli et al., 2005; Cohen et al., 2004) suggest that SIRT1 may also play a 
role in this response in mammals. Such observations further fuelled interest in SIRT1, and in particular 
if activating SIRT1 would mimic some of the beneficial responses associated with the DR. Our initial 
studies, presented in Chapter 3, aimed to determine if SIRT1, alone or in combination with, specific 
dietary compounds, reported previously in the literature to activate SIRT1 (resveratrol) or that had a 
similar structure and were implicated in DNA methylation (genistein/daidzein), could alter DNA 
methylation levels, indicating a possible mechanism through which healthspan-enhancing aspects of 
DR might be mediated. Several cell lines derived from a variety of tissues were assessed for the levels 
of global DNA methylation with the aim of identifying cell models with a range of endogenous levels 
of DNA methylation and select cell lines with very high and low levels of methylation to investigate 
the effects of SIRT1 expression at these extremes. No significant differences were found in levels of 
global DNA methylation measured by the LINE-1 and LUMA pyrosequencing assays. The human 
intestinal Caco-2 cell line was therefore selected as a model for testing the effects dietary polyphenols 
on DNA methylation. This cell line has the morphological and physiological properties of enterocytes, 
the absorptive cell in the epithelial lining of the intestine, and so provided, in part, a suitable model for 
the intestinal response to DR, or, in the case of this study, potential dietary mimetics of DR whose first 
encounter upon consumption would be with the intestinal epithelial barrier. The major limitation with 
using a tumour-derived cell line model in any scientific investigation, (excluding those into the related 
189 
 
cancer from which the cell line was derived) is that changes associated with oncogenesis may 
influence findings. This limitation must be borne in mind particularly in studies involving 
measurement of DNA methylation, because it is well established that changes in DNA methylation 
occur with oncogenesis (Cheung et al., 2009). Thus a limitation of the current study is that observed 
changes in DNA methylation would be against a background that was already different from normal 
enterocytes. Nonetheless, we reasoned that the model was adequate at least to demonstrate proof of 
concept that SIRT1 and/or dietary polyphenols can influence DNA methylation and also identify 
affected genes for more targeted investigations, ultimately (beyond the scope of this project) in normal 
tissues. 
 
We established that SIRT1 manipulation alone in the Caco-2 cell line had no effect on global DNA 
methylation levels. This perhaps was unsurprising as the LINE-1 element used as a surrogate marker 
of global DNA methylation was not identified as a site at which SIRT1 bound to the genome (in 
mouse embryonic stem cells) (Oberdoerffer et al., 2008). Subsequent investigations into the effects of 
polyphenols alone or in combination with SIRT1 manipulation yielded complex results, though only 
when assessed by gel-based LINE-1 COBRA. Specifically, resveratrol (10µM, 48 hours) caused an 
increase in DNA methylation at the LINE-1 element. This response was abrogated when SIRT1 
overexpression was combined with resveratrol treatment returning DNA methylation levels back to 
baseline. SIRT1 overexpression in the presence of genistein or daidzein (50 µM, 48 hours) caused a 
decrease in DNA methylation, suggesting that polyphenols can interact with SIRT1 to have effects on 
mechanisms involved in the process of methylating and demethylating cytosine residues. The nature of 
such possible interactions is unclear, but the complexity in the pattern observed may indicate effects 
through multiple pathways, some of which become predominant at particular ratios of SIRT1 to 
specific polyphenols. 
 
Measurement of global DNA methylation with a surrogate marker such as the LINE-1 element also 
has drawbacks in terms of coverage of only one sequence (albeit frequent) and its possible altered 
methylation status in the Caco-2 cell line compared with normal tissue. Comparisons with values for 
methylation of the LINE-1 element in normal tissue reported in the literature are difficult because 
levels of methylation at specific, adjacent CpG sites appear to be substantially different. For example 
in the assay we applied values at the different CpG sites varied from ~30 % to ~70 % in the Caco-2 
cell line. Reports of methylation at individual CpG sites in the LINE-1 element are frequently not 
available for comparison as CpG site methylation is reported as an average of the individual values. 
Comparison is further complicated by the fact that different investigations have measured methylation 
at different CpG sites within the LINE-1 sequence. A further possible limitation associated with use of 
the LINE-1 element to probe effects on global DNA methylation is that the sequence may be 
particularly refractory to methylation changes. For example, although reports in the literature show 
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many changes in DNA methylation across different sites as individuals grow older (Maegawa et al., 
2010; Rakyan et al., 2010; Teschendorff et al., 2010; Christensen et al., 2009; Kwabi-Addo et al., 
2007), a longitudinal study in humans aged between 55 and 92 years showed no change in the levels 
of LINE-1 DNA methylation observed in individuals over an 8 year period (Bollati et al., 2009) and 
no change was measured in the levels of LINE-1 methylation levels between different age groups in 
biopsied normal human colon (Figueiredo et al., 2009).  
 
As the number of reported investigations into the possible ability of SIRT1 and its homologues to 
increase lifespan have increased, so has the level of discordance within the published literature as to 
the exact role, if any, it plays in determining lifespan different species. In 2010, a review article on the 
role played by nutrient sensing pathways in the longevity response to DR by Fontana et al (Fontana et 
al., 2010) sparked a series of communications in the journal Science after the failure to include 
consideration of the role of sirtuins. Thirty-three scientists involved in research on sirtuins argued that 
the numerous observations that have implicated the sirtuin family in nutrient-sensing and life 
extension pathways, backed up by a large body of peer reviewed evidence, warranted inclusion in the 
review. However, the authors countered that effects of SIRT1 on lifespan extension in mammals had 
yet to be demonstrated and so did not fit into the discussion of conserved pathways. The ability of the 
SIRT1 homologues to extend lifespan in worms and flies has recently been questioned as procurement 
and study of strains with Sir2 overexpression, originally reported to have extended lifespan, showed 
that these effected were not reproduced when specific genetic crosses were made (Burnett et al; 
Nature, 2011; in press). This genetic approach led to identification of the Dyf gene in C. elegans, and 
not Sir2, as co-segregating with the extended-lifespan phenotype. Observations that SIRT1 protein 
increased with DR in rodents have not been unchallenged. Moreover SIRT1-overexpressing transgenic 
mice do not appear to live longer than control animals. However, numerous beneficial effects 
mimicking those seen in DR, including reduced fasting levels of insulin, glucose and cholesterol and 
improved glucose homeostasis (Bordone et al., 2007), are commensurate with better health in older 
age which is highly pertinent to our ageing society. 
 
Further controversy surrounding sirtuins arose in the debate over activation of SIRT1 by resveratrol 
and related synthetic compounds. Multiple publications based observations of increased SIRT1 
deacetylase activity in response to resveratrol treatment appear to have been based on a flawed 
fluorescence activity assay, where resveratrol-mediated activation of SIRT1 was only observed when 
SIRT1 was attached to the fluorescent moiety. In our own investigation we encountered different 
problems with the assay in that fluorescence emission was completely independent of the addition of 
recombinant SIRT1 or cell lysate. While there may have been an opportunity to further optimise the 
assay – perhaps to obtain fluorescence emission above this ‘background’ level – the accumulating 
evidence concerning the lack of robustness of the assay led us to abandon this approach. A limitation 
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of several aspects of the present study, therefore, is that although we established unequivocally that 
SIRT1 mRNA and protein levels were affected substantially in the Caco-2 cell line model of SIRT1 
overexpression and knockdown that we employed to measure effect on both DNA methylation and 
gene expression, we did not demonstrate that these changes resulted in the (expected) altered level of 
SIRT1 enzymatic activity. Other reports of studies that did not rely on the fluorescence-based assay of 
SIRT1 activation do support the view that this polyphenol can activate SIRT1. For example, 
resveratrol was shown to change the levels of SIRT1 mRNA and protein in coronary arterial 
endothelial cells and cultured arteries, promoting mitochondrial biogenesis (Csiszar et al., 2009), and 
the Krüppel-like factor 2 (KLF2), whose deficiency has been show to induce atherosclerosis, is 
upregulated by resveratrol in a SIRT1-dependent manner (Gracia-Sancho et al., 2010), suggesting that 
some of the beneficial effects of resveratrol are through SIRT1. 
 
To better understand mechanisms through which SIRT1 expression could be regulated, the 
transcriptional activity of the SIRT1 promoter was investigated in response to polyphenols and 
changes in promoter methylation. We also aimed to determine if there are changes in expression of 
SIRT1 with increased age. We established that the plant polyphenols investigated did not affect SIRT1 
activity at the transcriptional level. Caco-2 cells transfected with a promoter-reporter construct 
containing the SIRT1 promoter then treated with the polyphenols resveratrol, genistein and daidzein 
showed no change in reporter gene expression. The generation of the SIRT1 promoter-reporter 
construct allowed further investigations into effects on SIRT1 transcriptional activity with respect to 
the influence of promoter methylation. Caco-2 cells transfected with a methylated SIRT1 promoter 
report construct had significantly reduced levels of reporter gene activity compared with an 
unmethylated control, suggesting SIRT1 activity can be regulated through the methylation status of the 
promoter region upstream of the SIRT1 gene. 
 
Our hypothesis proposes that the increased levels of SIRT1 seen under DR affect levels of DNA 
methylation to mediate the beneficial effects of reduced dietary intake. There is documented evidence 
of levels of SIRT1 fluctuating with age (Alcendor et al., 2007; Sasaki et al., 2006; Michishita et al., 
2005; Sakamoto et al., 2004) though to our knowledge there is currently no literature that reports the 
effects of age in the gut, a tissue which, if dietary intake was effecting healthy lifespan – potentially 
through SIRT1 levels – would be the first barrier responsible for regulating the downstream response 
of the body to dietary restriction. We addressed the possibility that an increase in SIRT1 expression 
may oppose an age-related decline in expression using mouse intestinal tissue. We found no effect of 
age on the expression of SIRT1 at the protein level in mouse intestinal tissue extracted from young 
and old mice. These measurements were made in a small sample set, so increased sample numbers, as 
well as exploring SIRT1 levels in various tissue types, would be required to draw a more robust 
conclusion.  
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Having obtained only very limited data supporting possible effects of SIRT1 (in combination with 
polyphenols) on methylation at the LINE-1 element in our cell line model, we proposed that it was 
important to address the possibility that effects of SIRT1 on DNA methylation may be predominantly 
at other sites, particularly at specific gene loci. Targets to investigate for site-specific methylation 
changes in response to SIRT1 manipulation were identified through use of published resources to 
identify genes that bind to SIRT1 but also show a response to DR and change in methylation status 
with ageing, as described in Chapter 5. Ten genes (CDC7, EIF5, IRX3, KLF3, LDLR, MYH10, 
PCYT1A, PTPRG, SLC39A4, and TBX3) were found to fit all three of these criteria and were involved 
in a diverse range of cellular processes. To our knowledge, these genes have not previously been 
highlighted in the context of lifespan, DR or SIRT1 function. In addition to identifying specific genes 
for further study this in silico analysis also lent support to our hypothesis because overlaps between all 
pairs of gene lists, as well as the ‘three way’ overlap, were all significantly greater than expected by 
chance. Further investigation of promoter DNA methylation and gene expression of these genes 
highlighted by the in silico analysis in response to SIRT1 manipulation, described in Chapter 6, 
revealed that changing the level of SIRT1 expressed in Caco-2 cells for six of the eight genes for 
which we measured promoter DNA methylation resulted in a significant change at at least one of the 
CpG sites captured in the assay and also had an effect on the expression, at the mRNA level, of all 
eight of these genes. These data support our hypothesis that some effects of DR mediated by SIRT1 
are through effects on DNA methylation resulting in altered gene expression. A major limitation of 
these observations, however, is that a causal link between the observed changes in DNA methylation 
and gene expression is not established. The changes in DNA methylation observed, although 
statistically significant, were small. In some cases these differences were at CpG sites that showed low 
levels of methylation (e.g. EIF5: 2 % to 5 %) and in other instances at CpG sites that showed high 
levels of methylation (e.g. TBX3: 77 % to 91 %). There is wide discussion about whether or not such 
changes, which are typical responses to other dietary manipulations or changes seen in ageing, are 
likely to have functional consequences with respect to gene expression. Because DNA methylation is a 
binary phenomenon (a CpG site is methylated or not methylated in a single cell) then any change 
within a single cell is a large change, and differences in percentage methylation reflect a shift in cell 
population, so may have biological consequences at the level of tissue function. 
 
Evidence for direct causal links between changes in promoter methylation of these genes and their 
expression could be sought though the use of promoter-reporter constructs; comparison of the level of 
reporter gene expression between unmethylated and in vitro-methylated constructs, as presented in 
Chapter 4 for a SIRT1-promoter-reporter construct, could provide evidence that gene expression is 
affected by the methylation status of the promoter region. However, a major limitation of this 
approach is that it does not easily allow manipulation of the methylation status of selected CpG sites. 
Another approach to link changes in promoter methylation with gene expression could be to use the 
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demethylating agent 5-aza-2’-deoxycytidine in those genes with highly methylated promoter regions 
(IRX3, PCYT1A, SLC39A4 and TBX3) then measure the effects of this treatment on gene expression. 
 
The analysis of the response of surrogate global and selected site-specific levels of DNA methylation 
in response to SIRT1 manipulation was logically preceded by the use of micro-array based 
technology, described in Chapter 7, to investigate the DNA methylation pattern across the genome 
under conditions of SIRT1 manipulation. We aimed to gain through this approach a more extensive 
understanding of the effects of SIRT1 levels on DNA methylation. In parallel, we measured the 
response to altering the SIRT1 expression at the level of the transcriptome. Genes whose expression 
changed in response to SIRT1 knockdown were represented to an extent greater than would be 
expected by chance on the list of genes previously generated through the work presented in Chapter 5 
whose expression changed in response to DR. Moreover, genes whose methylation status changed in 
response to SIRT1 knockdown were also represented to an extent greater than would be expect by 
change in this same list of DR-responsive genes. These exciting observations provide firstly evidence 
in support of the view that SIRT1 plays a role (at least in mammals) in the response to DR. As noted 
above in this chapter, this premise is the topic of recent vigorous challenge. The observations also 
support our overarching hypothesis that some of the functional consequences of DR are mediated via 
SIRT1 through effect at the level of DNA methylation. The data reveal a large number of gene targets 
for which causal links between these modifications and roles in modulating the ageing process could 
be investigated. Future lines of investigation should, include a more detailed bioinformatics analysis of 
the gene lists generated through the methylomic and transcriptomic studies and identified gene targets 
with likely roles in modifying aspects of the ageing process should be investigated using basic and 
advanced molecular biology to uncover the mechanisms directly linking the change in SIRT1 with 
changes at the level of transcription and epigenetic modifications. 
 
The ageing processes is a vastly complex series of physiological changes from the cell to whole 
organism level stemming from multiple changes in cellular pathways causing aberrant functional 
changes and ultimately, diminished health. The multiple deacetylation targets of SIRT1, some 
involved in other nutrient-sensing pathways, suggest a complex network of pathway changes and cell 
regulation would be affected by DR-altered SIRT1 levels. We propose effects on DNA methylation to 
be only one mechanism through which SIRT1 can affect the ageing process. A full understanding of 
the role of SIRT1 in ageing requires that this full network of interactions is studied in more detail and 
taken into account. Systems biology approaches may provide a means to better understand the 
functions of SIRT1 at this level of complexity. In light of the roles played by other members of the 
sirtuin family in healthy ageing, as discussed in Chapter 1, SIRT1 could be working in concert with 
other sirtuins, and such interactions should also be included. 
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In conclusion, the work presented in this thesis has indicated that effects of SIRT1 on methylation of 
specific genes may correspond with altered expression under conditions of dietary restriction and that 
many of the same genes undergo a change in methylation level with increased age. The data reveal a 
large number of gene targets for which causal links between these modifications roles in modulating 
the ageing process could be investigated. 
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Appendix A: Plasmid Maps 
I. pBLUE-TOPO® (Invitrogen) 
 
Comments for pBLUE-TOPO
® 
7793 nucleotides 
 
T7 promoter/priming site: bases 17-36 
TOPO
®
 Cloning site: bases 116-117 
ATG initiation codon: bases 143-145 
Polyhistidine region: bases 155-172 
LacZ Reverse priming site: bases 173-191 
Xpress
™
 epitope: bases 212-235  
Enterokinase recognition site: bases 211-235 
LacZ ORF: bases 264-3313 
BGH polyadenylation sequence: bases 3386-3613 
F1 origin: bases 3659-4087 
SV40 promoter and origin: bases 4141-4423 
Neomycin resistance gene: bases 4498-5292 
SV40 polyadenylation sequence: bases 5466-5596 
pUC origin: bases 5979-6652 (complimentary strand) 
Ampicillin resistance gene: bases 6797-7657 (complementary strand) 
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II. pCMV6-Neo (Origene) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comments for pCMV6-Neo
 
5838 nucleotides 
 
CMV promoter: bases 201-926 
T7 promoter: bases 953-971 
Multiple Cloning Sites: bases 972-1030 
Poly-A signal: bases 1063-1648 
SV40 origin: bases 1740-2047 
Neomycin resistance gene: bases 2120-2904 
ColE1 origin: bases 3588-4206 
Ampicillin resistance gene: bases 4405-5256 
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III. pCMV6-ENTRY (Origene) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comments for pCMV6-ENTRY
 
4929 nucleotides 
 
CMV promoter: bases 201-926 
T7 promoter: bases 953-971 
Multiple Cloning Sites: bases 978-1153 
Poly-A signal: bases 1206-2739 
ColE1 origin: bases 2067-2739 
SV40 origin: bases 3998-4300 
Kanamycin/Neomycin resistance gene: bases 3169-3963 
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Appendix B: Composition of cell culture medium  
DMEM – Dulbecco’s Modified Eagle Medium (Caco-2, HeLa, HepG2, MDA) 
 
Components Concentration (mg/L) Molarity (mM) 
Amino Acids: 
  
Glycine 30 0.4 
L-Alanyl-L-Glutamine 862 3.97 
L-Arginine hydrochloride 84 0.398 
L-Cystine 2HCl 63 0.201 
L-Histidine hydrochloride-H2O 42 0.2 
L-Isoleucine 105 0.802 
L-Leucine 105 0.802 
L-Lysine hydrochloride 146 0.798 
L-Methionine 30 0.201 
L-Phenylalanine 66 0.4 
L-Serine 42 0.4 
L-Threonine 95 0.798 
L-Tryptophan 16 0.0784 
L-Tyrosine 72 0.398 
L-Valine 94 0.803 
 
Vitamins   
Choline chloride 4 0.0286 
D-Calcium pantothenate 4 0.00839 
Folic Acid 4 0.00907 
Niacinamide 4 0.0328 
Pyridoxine hydrochloride 4 0.0196 
Riboflavin 0.4 0.00106 
Thiamine hydrochloride 4 0.0119 
i-Inositol 7.2 0.04 
 
Inorganic Salts:   
Calcium Chloride (CaCl2-2H2O) 264 1.8 
Ferric Nitrate (Fe(NO3)3-9H2O) 0.1 0.000248 
Magnesium Sulfate (MgSO4-7H2O) 200 0.813 
Potassium Chloride (KCl) 400 5.33 
Sodium Bicarbonate (NaHCO3) 3700 44.05 
Sodium Chloride (NaCl) 6400 110.34 
Sodium Phosphate monobasic (NaH2PO4-2H2O) 141 0.916 
 
Other Components:   
D-Glucose (Dextrose) 4500 25 
Phenol Red 15 0.0399 
Sodium Pyruvate 110 1 
 
DMEM – Dulbecco’s Modified Eagle Medium no phenol red (Caco-2 polyphenol treatment) 
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Components Concentration (mg/L) Molarity (mM) 
Amino Acids: 
  
Glycine 30 0.4 
L-Arginine hydrochloride 84 0.398 
L-Cystine 2HCl 63 0.201 
L-Histidine hydrochloride-H2O 42 0.2 
L-Isoleucine 105 0.802 
L-Leucine 105 0.802 
L-Lysine hydrochloride 146 0.798 
L-Methionine 30 0.201 
L-Phenylalanine 66 0.4 
L-Serine 42 0.4 
L-Threonine 95 0.798 
L-Tryptophan 16 0.0784 
L-Tyrosine disodium salt dihydrate 104 0.398 
L-Valine 94 0.803 
 
Vitamins   
Choline chloride 4 0.0286 
D-Calcium pantothenate 4 0.00839 
Folic Acid 4 0.00907 
Niacinamide 4 0.0328 
Pyridoxine hydrochloride 4 0.0196 
Riboflavin 0.4 0.00106 
Thiamine hydrochloride 4 0.0119 
i-Inositol 7.2 0.04 
 
Inorganic Salts:   
Calcium Chloride (CaCl2-2H2O) 200 1.8 
Ferric Nitrate (Fe(NO3)3-9H2O) 0.1 0.000248 
Magnesium Sulfate (MgSO4-7H2O) 97.67 0.813 
Potassium Chloride (KCl) 400 5.33 
Sodium Bicarbonate (NaHCO3) 3700 44.05 
Sodium Chloride (NaCl) 6400 110.34 
Sodium Phosphate monobasic (NaH2PO4-2H2O) 125 0.906 
 
Other Components:   
D-Glucose (Dextrose) 4500 25 
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DMEM/F12 1:1 – Dulbecco’s Modified Eagle Medium (SHSY-5Y) 
 
Components Concentration (mg/L) Molarity (mM) 
Amino Acids: 
  
Glycine 18.75 0.25 
L-Alanine 4.45 0.05 
L-Alanyl-L-Glutamine 542 2.5 
L-Arginine hydrochloride 147.5 0.699 
L-Asparagine-H2O 7.5 0.05 
L-Aspartic acid 6.65 0.05 
L-Cysteine hydrochloride-H2O 17.56 0.0998 
L-Cystine 2HCl 31.29 0.1 
L-Glutamic Acid 7.35 0.05 
L-Histidine hydrochloride-H2O 31.48 0.15 
L-Isoleucine 54.47 0.416 
L-Leucine 59.05 0.451 
L-Lysine hydrochloride 91.25 0.499 
L-Methionine 17.24 0.116 
L-Phenylalanine 35.48 0.215 
L-Proline 17.25 0.15 
L-Serine 26.25 0.25 
L-Threonine 53.45 0.449 
L-Tryptophan 9.02 0.0442 
L-Tyrosine disodium salt dihydrate 55.79 0.214 
L-Valine 25.85 0.221 
 
Vitamins:   
Biotin 0.0035 0.0000143 
Choline chloride 8.98 0.0641 
D-Calcium pantothenate 2.24 0.0047 
Folic Acid 2.65 0.00601 
Niacinamide 2.02 0.0166 
Pyridoxine hydrochloride 2 0.00971 
Riboflavin 0.219 0.000582 
Thiamine hydrochloride 2.17 0.00644 
Vitamin B12 0.68 0.000502 
i-Inositol 12.6 0.07 
  
225 
 
Continued 
Components Concentration (mg/L) Molarity (mM) 
Inorganic Salts: 
  
Calcium Chloride (CaCl2) (anhydrous) 116.6 1.05 
Cupric sulfate (CuSO4-5H2O) 0.0013 0.0000052 
Ferric Nitrate (Fe(NO3)3-9H2O) 0.05 0.000124 
Ferric sulfate (FeSO4-7H2O) 0.417 0.0015 
Magnesium Chloride (MgCl2-6H2O) 61 0.3 
Magnesium Sulfate (MgSO4-7H2O) 100 0.407 
Potassium Chloride (KCl) 311.8 4.16 
Sodium Bicarbonate (NaHCO3) 1200 14.29 
Sodium Chloride (NaCl) 6995.5 120.61 
Sodium Phosphate dibasic (Na2HPO4-7H2O) 134 0.5 
Sodium Phosphate monobasic (NaH2PO4-H2O) 62.5 0.453 
Zinc sulfate (ZnSO4-7H2O) 0.432 0.0015 
 
Other Components:  
D-Glucose (Dextrose) 3151 17.51 
Hypoxanthine Na 2.39 0.015 
Linoleic Acid 0.042 0.00015 
Lipoic Acid 0.105 0.00051 
Phenol Red 8.1 0.0215 
Putrescine 2HCl 0.081 0.000503 
Sodium Pyruvate 55 0.5 
Thymidine 0.365 0.00151 
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Leibovitz’s L15 Medium (SW480) 
 
Components Concentration (mg/L) Molarity (mM) 
Amino Acids:   
Glycine 200 2.67 
L-Alanine 225 2.53 
L-Arginine 500 2.87 
L-Asparagine 250 1.89 
L-Cysteine 120 0.992 
L-Glutamine 300 2.05 
L-Histidine 250 1.61 
L-Isoleucine 250 1.91 
L-Leucine 125 0.954 
L-Lysine 75 0.514 
L-Methionine 75 0.503 
L-Phenylalanine 125 0.758 
L-Serine 200 1.9 
L-Threonine 300 2.52 
L-Tryptophan 20 0.098 
L-Tyrosine 300 1.66 
L-Valine 100 0.855 
 
Vitamins: 
  
Choline chloride 1 0.00714 
D-Calcium pantothenate 1 0.0021 
Folic Acid 1 0.00227 
Niacinamide 1 0.0082 
Pyridoxine hydrochloride 1 0.00485 
Riboflavin 5'-phosphate Na 0.1 0.000209 
Thiamine monophosphate 1 0.00226 
i-Inositol 2 0.0111 
 
Inorganic Salts: 
  
Calcium Chloride (CaCl2) (anhydrous) 140 1.26 
Magnesium Chloride (anhydrous) 93.7 0.986 
Magnesium Sulfate (MgSO4) (anhydrous) 97.67 0.814 
Potassium Chloride (KCl) 400 5.33 
Potassium Phosphate monobasic (KH2PO4) 60 0.441 
Sodium Chloride (NaCl) 8000 137.93 
Sodium Phosphate dibasic (Na2HPO4) 
anhydrous 
190 1.34 
 
Other Components: 
  
D+ Galactose 900 5 
Phenol Red 10 0.0266 
Sodium Pyruvate 550 5 
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MEM – Minimum Essential Medium (MCF-7) 
 
Components Concentration (mg/L) Molarity (mM) 
Amino Acids: 
  
L-Arginine hydrochloride 126 0.597 
L-Cystine 24 0.1 
L-Glutamine 292 2 
L-Histidine hydrochloride-H2O 42 0.2 
L-Isoleucine 52 0.397 
L-Leucine 52 0.397 
L-Lysine hydrochloride 73 0.399 
L-Methionine 15 0.101 
L-Phenylalanine 32 0.194 
L-Threonine 48 0.403 
L-Tryptophan 10 0.049 
L-Tyrosine 36 0.199 
L-Valine 46 0.393 
 
Vitamins:   
Choline chloride 1 0.00714 
D-Calcium pantothenate 1 0.0021 
Folic Acid 1 0.00227 
Niacinamide 1 0.0082 
Pyridoxal hydrochloride 1 0.0049 
Riboflavin 0.1 0.000266 
Thiamine hydrochloride 1 0.00297 
i-Inositol 2 0.0111 
 
Inorganic Salts:   
Calcium Chloride (CaCl2-2H2O) 264 1.8 
Magnesium Sulfate (MgSO4-7H2O) 200 0.813 
Potassium Chloride (KCl) 400 5.33 
Sodium Bicarbonate (NaHCO3) 2200 26.19 
Sodium Chloride (NaCl) 6800 117.24 
Sodium Phosphate monobasic (NaH2PO4-2H2O) 158 1.01 
 
Other Components:   
D-Glucose (Dextrose) 1000 5.56 
Phenol Red 10 0.0266 
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Appendix C: Methylation standard curves for pyrosequencing  
 
 
 
 
 
Figure C.1. Standard curves generated for the CDC7 PCR product to confirm linear amplification 
of the methylated and unmethylated DNA. Linear amplification of methylated and unmethylated DNA 
for CpG sites at positions -58, -51, -49, -43, -27, -10, -7 and -4 bp relative to the start of transcription 
of the CDC7 sequence are shown in A – H respectively and R2 values are indicated.  
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Figure C.2. Standard curves generated for the EIF5 PCR product to confirm linear amplification of the 
methylated and unmethylated DNA. Linear amplification of methylated and unmethylated DNA for CpG sites at 
positions -60, -58, -48, -41, -38, -32, -21 and -17 bp relative to the start of transcription of the EIF5 sequence 
are shown in A – H respectively and R2 values are indicated.   
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Figure C.3. Standard curves generated for the IRX3 PCR product to confirm linear amplification of the 
methylated and unmethylated DNA. Linear amplification of methylated and unmethylated DNA for CpG sites at 
positions -64, -19 and -16 bp relative to the start of transcription of the IRX3 sequence are shown in A – C 
respectively and R
2
 values are indicated.  
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Figure C.4. Standard curves generated for the KLF3 PCR product to confirm linear amplification of the 
methylated and unmethylated DNA. Linear amplification of methylated and unmethylated DNA for CpG sites at 
positions -69, -60, -56, -52, -50 and -47 bp relative to the start of transcription of the KLF3 sequence are shown 
in A – F respectively and R2 values are indicated.  
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Figure C.5. Standard curves generated for LINE-1 PCR product to confirm linear amplification of 
methylated and unmethylated DNA. Linear amplification of methylated and unmethylated DNA for CpG sites at 
positions 232, 252, 256 and 270 bp into the LINE-1 sequence are shown in A – D respectively and R2 values are 
indicated.  
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Figure C.6. Standard curves generated for the PCYT1A PCR product to confirm linear amplification of the 
methylated and unmethylated DNA. Linear amplification of methylated and unmethylated DNA for CpG sites at 
positions -88 and -21 bp relative to the start of transcription of the PCYT1A sequence are shown in A and B 
respectively and R
2
 values are indicated.  
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Figure C.7. Standard curves generated for the PTPRG PCR product to confirm linear amplification of the 
methylated and unmethylated DNA. Linear amplification of methylated and unmethylated DNA for CpG sites at 
positions -72, -66, -64, -62, -51, -47, -39, -35 and -32 bp relative to the start of transcription of the PTPRG 
sequence are shown in A – I respectively and R2 values are indicated.  
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Figure C.8. Standard curves generated for the SLC39A4 PCR product to confirm linear amplification of the 
methylated and unmethylated DNA. Linear amplification of methylated and unmethylated DNA for CpG sites at 
positions -91, -81 and -61 bp relative to the start of transcription of the SLC39A4 sequence are shown in A – C 
respectively and R
2
 values are indicated.  
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Figure C.9. Standard curves generated for the TBX3 PCR product to confirm linear amplification of the 
methylated and unmethylated DNA. Linear amplification of methylated and unmethylated DNA for CpG sites at 
positions -137, -125 and -105 bp relative to the start of transcription of the TBX3 sequence are shown in A – C 
respectively and R
2
 values are indicated. 
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Appendix D: Amplification and Standard Curves for qPCR 
 
 
Figure D.1. RT-qPCR amplification (A) and standard (B) curves using primers for β ACTIN on reverse-
transcribed Caco-2 cell RNA. A – Typical amplification curves generated using primers for β ACTIN. 
Fluorescence intensity generated by amplification of cDNA of unknown concentration was measured and plotted 
against PCR cycle number to determine the threshold crossing point (CT values). Each sample was measured in 
duplicate. B – Typical standard curve generated for β ACTIN. The mean log concentration of each cDNA sample 
within a two-fold dilution series was plotted against the CT value. The standard curve was then used to calculate 
the relative levels of β ACTIN in each unknown sample.  
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Figure D.2. RT-qPCR amplification (A) and standard (B) curves using primers for CDC7 on reverse-
transcribed Caco-2 cell RNA. A – Typical amplification curves generated using primers for CDC7. 
Fluorescence intensity generated by amplification of cDNA of unknown concentration was measured and plotted 
against PCR cycle number to determine the threshold crossing point (CT values). Each sample was measured in 
duplicate. B – Typical standard curve generated for CDC7. The mean log concentration of each cDNA sample 
within a two-fold dilution series was plotted against the CT value. The standard curve was then used to calculate 
the relative levels of CDC7 in each unknown sample.  
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Figure D.3. RT-qPCR amplification (A) and standard (B) curves using primers for EIF5 on reverse-
transcribed Caco-2 cell RNA. A – Typical amplification curves generated using primers for EIF5. Fluorescence 
intensity generated by amplification of cDNA of unknown concentration was measured and plotted against PCR 
cycle number to determine the threshold crossing point (CT values). Each sample was measured in duplicate. B – 
Typical standard curve generated for EIF5. The mean log concentration of each cDNA sample within a two-fold 
dilution series was plotted against the CT value. The standard curve was then used to calculate the relative levels 
of EIF5 in each unknown sample.   
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Figure D.4. qPCR amplification curve using primers for H19 on Caco-2 cell DNA. A – Typical amplification 
curves generated using primers for H19. Fluorescence intensity generated by amplification of DNA of unknown 
concentration was measured and plotted against PCR cycle number to determine the threshold crossing point 
(CT values). Each sample was measured in duplicate. 
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Figure D.5. RT-qPCR amplification (A) and standard (B) curves using primers for IRX3 on reverse-
transcribed Caco-2 cell RNA. A – Typical amplification curves generated using primers for IRX3. Fluorescence 
intensity generated by amplification of cDNA of unknown concentration was measured and plotted against PCR 
cycle number to determine the threshold crossing point (CT values). Each sample was measured in duplicate. B – 
Typical standard curve generated for IRX3. The mean log concentration of each cDNA sample within a two-fold 
dilution series was plotted against the CT value. The standard curve was then used to calculate the relative levels 
of IRX3 in each unknown sample.  
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Figure D.6. RT-qPCR amplification (A) and standard (B) curves using primers for KLF3 on reverse-
transcribed Caco-2 cell RNA. A – Typical amplification curves generated using primers for KLF3. Fluorescence 
intensity generated by amplification of cDNA of unknown concentration was measured and plotted against PCR 
cycle number to determine the threshold crossing point (CT values). Each sample was measured in duplicate. B – 
Typical standard curve generated for KLF3. The mean log concentration of each cDNA sample within a two-fold 
dilution series was plotted against the CT value. The standard curve was then used to calculate the relative levels 
of KLF3 in each unknown sample. 
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Figure D.7. qPCR amplification curve using primers for L1.2 on Caco-2 cell DNA. A – Typical amplification 
curves generated using primers for L1.2. Fluorescence intensity generated by amplification of DNA of unknown 
concentration was measured and plotted against PCR cycle number to determine the threshold crossing point 
(CT values). Each sample was measured in duplicate. 
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Figure D.8. qPCR amplification curve using primers for the Lambda Phage ‘methylated’ fragment spiked 
into Caco-2 cell DNA. A – Typical amplification curves generated using primers for methylated Lambda Phage. 
Fluorescence intensity generated by amplification of DNA of unknown concentration was measured and plotted 
against PCR cycle number to determine the threshold crossing point (CT values). Each sample was measured in 
duplicate. 
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Figure D.9. qPCR amplification curve using primers for the Lambda Phage ‘unmethylated’ fragment spiked 
into Caco-2 cell DNA. A – Typical amplification curves generated using primers for unmethylated Lambda 
Phage. Fluorescence intensity generated by amplification of DNA of unknown concentration was measured and 
plotted against PCR cycle number to determine the threshold crossing point (CT values). Each sample was 
measured in duplicate. 
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Figure D.10. RT-qPCR amplification (A) and standard (B) curves using primers for PCYT1A on reverse-
transcribed Caco-2 cell RNA. A – Typical amplification curves generated using primers for PCYT1A. 
Fluorescence intensity generated by amplification of cDNA of unknown concentration was measured and plotted 
against PCR cycle number to determine the threshold crossing point (CT values). Each sample was measured in 
duplicate. B – Typical standard curve generated for PCYT1A. The mean log concentration of each cDNA sample 
within a two-fold dilution series was plotted against the CT value. The standard curve was then used to calculate 
the relative levels of PCYT1A in each unknown sample.  
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Figure D.11. RT-qPCR amplification (A) and standard (B) curves using primers for PTPRG on reverse-
transcribed Caco-2 cell RNA. A – Typical amplification curves generated using primers for PTPRG. 
Fluorescence intensity generated by amplification of cDNA of unknown concentration was measured and plotted 
against PCR cycle number to determine the threshold crossing point (CT values). Each sample was measured in 
duplicate. B – Typical standard curve generated for PTPRG. The mean log concentration of each cDNA sample 
within a two-fold dilution series was plotted against the CT value. The standard curve was then used to calculate 
the relative levels of PTPRG in each unknown sample.  
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Figure D.12. RT-qPCR amplification (A) and standard (B) using primers for SIRT1 on reverse-transcribed 
Caco-2 cell RNA. A – Typical amplification curves generated using primers for SIRT1. Fluorescence intensity 
generated by amplification of cDNA of unknown concentration was measured and plotted against PCR cycle 
number to determine the threshold crossing point (CT values). Each sample was measured in duplicate. B – 
Typical standard curve generated for SIRT1. The mean log concentration of each cDNA sample within a two-
fold dilution series was plotted against the CT value. The standard curve was then used to calculate the relative 
levels of SIRT1 in each unknown sample.  
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Figure D.13. RT-qPCR amplification (A) and standard (B) curves using primers for SLC39A4 on reverse-
transcribed Caco-2 cell RNA. A – Typical amplification curves generated using primers for SLC39A4. 
Fluorescence intensity generated by amplification of cDNA of unknown concentration was measured and plotted 
against PCR cycle number to determine the threshold crossing point (CT values). Each sample was measured in 
duplicate. B – Typical standard curve generated for SLC39A4. The mean log concentration of each cDNA 
sample within a two-fold dilution series was plotted against the CT value. The standard curve was then used to 
calculate the relative levels of SLC39A4 in each unknown sample.  
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Figure D.14. RT-qPCR amplification (A) and standard (B) curves using primers for TBX3 on reverse-
transcribed Caco-2 cell RNA. A – Typical amplification curves generated using primers for TBX3. Fluorescence 
intensity generated by amplification of cDNA of unknown concentration was measured and plotted against PCR 
cycle number to determine the threshold crossing point (CT values). Each sample was measured in duplicate. B – 
Typical standard curve generated for TBX3. The mean log concentration of each cDNA sample within a two-fold 
dilution series was plotted against the CT value. The standard curve was then used to calculate the relative levels 
of TBX3 in each unknown sample.  
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Figure D.15. qPCR amplification curve using primers for UBE2B in Caco-2 cell DNA. A – Typical 
amplification curves generated using primers for UBE2B. Fluorescence intensity generated by amplification of 
DNA of unknown concentration was measured and plotted against PCR cycle number to determine the threshold 
crossing point (CT values). Each sample was measured in duplicate. 
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Figure D.16. RT-qPCR amplification (A) and standard (B) curves using primers for WNT11 on reverse-
transcribed Caco-2 cell RNA. A – Typical amplification curves generated using primers for WNT11 (accession 
number: NM_004626.2). Fluorescence intensity generated by amplification of cDNA of unknown concentration 
was measured and plotted against PCR cycle number to determine the threshold crossing point (CT values). 
Each sample was measured in duplicate. B – Typical standard curve generated for WNT11. The mean log 
concentration of each cDNA sample within a two-fold dilution series was plotted against the CT value. The 
standard curve was then used to calculate the relative levels of WNT11 in each unknown sample.  
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Appendix E: Gene identifiers  
(See CD insert) 
I. from published sources 
II. for genes whose methylation changed with SIRT1 manipulation 
III. for genes whose expression changed with SIRT1 knockdown 
IV. for genes whose methylation and expression changed with SIRT1 manipulation 
 
 
Locations of the above gene lists are denoted on the spreadsheet tabs. 
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